

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:38:00 ; Search time 4864 Seconds
(without alignments)
10461.497 Million cell updates/sec

Title: US-09-978-299A-329
Perfect score: 1174
Sequence: 1 cggacgcgtgggggaaaccc.....taaagttactcaaatctgtg 1174

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 22

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database :

GenEmbl:*

- 1: gb_ba:*
- 2: gb_htg:*
- 3: gb_in:*
- 4: gb_cm:*
- 5: gb_ov:*
- 6: gb_pat:*
- 7: gb_ph:*
- 8: gb_pl:*
- 9: gb_pr:*
- 10: gb_ro:*
- 11: gb_sts:*
- 12: gb_sy:*
- 13: gb_un:*
- 14: gb_vi:*
- 15: em_ba:*
- 16: em_fun:*
- 17: em_hum:*
- 18: em_in:*
- 19: em_mu:*
- 20: em_om:*
- 21: em_or:*
- 22: em_ov:*
- 23: em_pat:*
- 24: em_ph:*
- 25: em_pl:*
- 26: em_ro:*
- 27: em_sts:*
- 28: em_un:*
- 29: em_vi:*
- 30: em_htg_hum:*
- 31: em_htg_inv:*
- 32: em_htg_other:*
- 33: em_htg_mus:*
- 34: em_htg_pln:*
- 35: em_htg_rod:*
- 36: em_htg_mam:*
- 37: em_htg_vrt:*
- 38: em_sy:*
- 39: em_htgo_hum:*
- 40: em_htgo_mus:*
- 41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	1174	100.0	1174	6	AX454422	AX454422 Sequence
2	1174	100.0	1174	6	AX464138	AX464138 Sequence
3	1174	100.0	1174	6	AX490900	AX490900 Sequence
4	1174	100.0	1174	9	AY359029	AY359029 Homo sapi
5	1163.8	99.1	1634	6	BD127562	BD127562 Primer fo
6	1163.8	99.1	1634	9	AK075187	AK075187 Homo sapi
7	1163.8	99.1	1696	6	AX775907	AX775907 Sequence
8	1163.8	99.1	1704	6	BD210070	BD210070 Human tra
9	1163.8	99.1	1709	9	AF290615	AF290615 Homo sapi
10	1151.8	98.1	1695	6	BD191327	BD191327 186 human
11	1121	95.5	1121	6	BD233468	BD233468 Human pro
12	1118	95.2	1457	6	AX136301	AX136301 Sequence
13	1118	95.2	1457	6	BD123603	BD123603 Secretory
14	1118	95.2	1457	9	AK075505	AK075505 Homo sapi
15	1106	94.2	1138	6	AX683269	AX683269 Sequence
16	1106	94.2	1138	6	AX779812	AX779812 Sequence
17	1105	94.1	1466	6	AX775909	AX775909 Sequence
18	1105	94.1	1515	9	BC016374	BC016374 Homo sapi
19	1104	94.0	1130	9	BC003106	BC003106 Homo sapi
20	1049	89.4	1816	6	BD191202	BD191202 186 human
21	974	83.0	1742	6	AR379540	AR379540 Sequence
22	969	82.5	969	6	BD233458	BD233458 Human pro

ALIGNMENTS

RESULT 1
AX454422
LOCUS AX454422 1174 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 7 from Patent WO0208284.
ACCESSION AX454422
VERSION AX454422.1 GI:21713835
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A.,
Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J.,
Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I.
and Ye,W.
TITLE Compositions and methods for the diagnosis and treatment of
disorders involving angiogenesis
JOURNAL Patent: WO 0208284-A 7 31-JAN-2002;
Genentech, Inc. (US) ; Baker, Kevin P. (US) ; Ferrara, Napoleone
(US) ; Gerber, Hanspeter (US) ; Gerritsen, Mary E. (US) ; Goddard,
Audrey (US) ; Godowski, Paul J. (US) ; Gurney, Austin L. (US) ;
Hillan, Kenneth J. (US) ; Marsters, Scot A. (US) ; Pan, James (US)
; Paoni, Nicholas F. (US) ; Stephan, Jean-Philippe F. (US) ;
Watanabe, Colin K. (US) ; Williams, P. Mickey (US) ; Wood, William
I. (US)

FEATURES
source

Location/Qualifiers
1..1174
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 CGGACGCGTGGGGAAACCCITCCGAGAAACAGCAACAGCTGAGCTGCTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCCGGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTGGGTGATACGGCGCTTGGCCACCGGCGCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTGGGTGATACGGCGCTTGGCCACCGGCGCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
Db 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCAATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCAATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGPATTTGTTGGATTGT 840
Db 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGPATTTGTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
RESULT 2
AX464138
LOCUS AX464138 1174 bp DNA linear PAT 16-JUL-2002
DEFINITION Sequence 271 from Patent WO0140466.
ACCESSION AX464138
VERSION AX464138.1 GI:21899085
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Baker,K.P., Beresini,M., Deforge,L., Desnoyers,L., Filvaroff,E.,
Gao,W.Q., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L.,
Sherwood,S., Smith,V., Stewart,T.A., Tumas,D., Watanabe,C.K.,
Wood,W.L. and Zhang,Z.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL Patent: WO 0140466-A 271 07-JUN-2001;
Genentech Inc. (US)
FEATURES
source
1..1174
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGCGCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGCGCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
Db 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGACCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGACCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTTGAAGATGGAGAAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
DB 721 CACAGGAATTTCTTTGAAGATGGAGAAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
DB 901 GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATFAGACATCTAA 1080
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATFAGACATCTAA 1080
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAAGAAATCA 1140
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 3
LOCUS AX490900 1174 bp DNA linear PAT 16-AUG-2002
DEFINITION Sequence 7 from Patent WO0200690.
ACCESSION AX490900
VERSION AX490900.1 GI:22323787
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Baker,K.P., Ferrara,N., Gerber,H., Gerritsen,M.E., Goddard,A., Godowski,P.J., Gurney,A.L., Hillan,K.J., Marsters,S.A., Pan,J., Paoni,N.F., Stephan,J.P., Watanabe,C.K., Williams,P.M., Wood,W.I. and Ye,W.
TITLE Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JOURNAL Patent: WO 0200690-A 7 03-JAN-2002; Genentech, Inc. (US)
FEATURES
 source location/Qualifiers
 1. .1174
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
ORIGIN

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCGACCGCTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
DB 1 CCGACCGCTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGCGGGCGCCGAAAGGGAGCCCTCTGCGGTGAGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGCGGGCGCCGAAAGGGAGCCCTCTGCGGTGAGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCTTTGGCCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGCTGACCATGGCTTTGGCCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCTTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCACTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
DB 301 TCAATTTGTCACTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTAGAGCAATATGTTGCCATCTTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTAGAGCAATATGTTGCCATCTTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAATGAGACAAGAAACAATTTATGTCCTGATGCCAAAAA 480
DB 421 CAGAATCAGCTGCCATTCGCTGAATGAGACAAGAAACAATTTATGTCCTGATGCCAAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATTTCTGGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080

```
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 4
AY359029 1174 bp mRNA linear PRI 03-OCT-2003
LOCUS Homo sapiens clone DNA26847 Clorf8 (UNQ169) mRNA, complete cds.
DEFINITION
ACCESSION AY359029
VERSION AY359029.1 GI:37183175
KEYWORDS FLI CDNA.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1174)
AUTHORS Clark,H.F., Gurney,A.L., Abaya,E., Baker,K., Baldwin,D., Brush,J.,
Chen,J., Chow,B., Chui,C., Crowley,C., Currell,B., Deuel,B.,
Dowd,P., Eaton,D., Foster,J., Grimaldi,C., Gu,Q., Hass,P.E.,
Heldens,S., Huang,A., Kim,H.S., Klimowski,L., Jin,Y., Johnson,S.,
Lee,J., Lewis,L., Liao,D., Mark,M., Robbie,E., Sanchez,C.,
Schoenfeld,J., Seehagiri,S., Simmons,L., Singh,J., Smith,V.,
Stinson,J., Vagts,A., Vandlen,R., Watanabe,C., Wieand,D., Woods,K.,
Xie,M.H., Yansura,D., Yi,S., Yu,G., Yuan,J., Zhang,M., Zhang,Z.,
Goddard,A., Wood,W.I. and Godowski,P.
The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
JOURNAL Genome Res. 13 (10), 2265-2270 (2003)
PUBMED 12975309
REFERENCE 2 (bases 1 to 1174)
AUTHORS Clark,H.F.
DIRECT SUBMISSION
JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA
FEATURES
source
1..1174
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="DNA26847"
1..1174
/locus_tag="UNQ169"
70..1041
/locus_tag="UNQ169"
/note="PRO195"
/codon_start=1
/product="Clorf8"
/protein_id="AAQ89388.1"
/db_xref="GI:37183176"
translation="MAAPKGSLSWVRLQGLPPLLLLTALAGSGTASAEAPDSVLGD
TASCHRAQLTYPLHTYPKEEELYACQRCRLFSICQFVDDGIDLNRTKLECESACTE
AYSQDEQYACHLGCQNQLPFAELRQQLMSLMPKMHLLFPLTLVRSFWSNMDSQAQ
FITSSWFYQLQDDGKIVIFQSKPEIQYAPHLEQEPNLRSSLSKMSYLMQNSQAH
RNFLDGESEDFLRCLSLNSGWLITTLVLSVMVLLWICATVATAVEQYVPSEKLSI
YGDLEFMNEQKLNRYPASSLVVRSKTEDHEEAGPLPTKYNLAHSEI"

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 2.1e-274;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGTGTGACAGAG 60
```

```
QY 61 GGGAAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTTCGGGGACCGTTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTTCGGGGACCGTTTCGGCTGAAGCA 180
QY 181 TTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGATCAGCTGCCATTCCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGATCAGCTGCCATTCCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATCTCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATCTCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATAGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATAGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTCGTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTCGTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCCCTTAAGAAATCA 1140
```

```
QY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174
|||||
Db 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 5
BD127562 1634 bp DNA linear PAT 18-SEP-2002
LOCUS
DEFINITION
Primer for synthesizing full-length cDNA and use thereof.
ACCESSION
BD127562
VERSION
BD127562.1 GI:232222507
KEYWORDS
JP 2002017375-A/2993.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1634)
Ota,T., Nishikawa,T., Isogai,T., Hayashi,K., Ishii,S., Kawai,Y.,
Wakamatsu,A., Sugiyama,T., Nagai,K., Kojima,S., Otsuki,T. and
Koga,H.
Primer for synthesizing full-length cDNA and use thereof
Patent: JP 2002017375-A 2993 22-JAN-2002;
HELIX RESEARCH INSTITUTE
OS Homo sapiens (human)
PN JP 2002017375-A/2993
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253172
PI TOSHIO OTA, TETSUO NISHIKAWA, TAKAO ISOGAI, KOJI HAYASHI, SHIZUKO
PI ISHII,
PI YURI KAWAI, AI WAKAMATSU, TOMOYASU SUGIYAMA, KEIICHI NAGAI, PI
SHINICHI KOJIMA,
PI TETSUJI OTSUKI, HISASHI KOGA
PC
C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
10,
PC C12P21/02, C12Q1/68//C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
Primer for synthesizing full-length cDNA and use thereof FH key
Location/Qualifiers
(191)..(1159).
FT CDS
Location/Qualifiers
1..1634
source
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN
Query Match 99.1%; Score 1163.8; DB 6; Length 1634;
Best Local Similarity 99.8%; Pred. No. 6.5e-272;
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 8 GTGGGGAAACCCCTCCGAGAAACAGCAAAAGCTGCTGCTGACAGAGGGGAACA 67
|||
Db 129 GAGGAGAAACCCCTCCGAGAAACAGCAAAAGCTGCTGCTGACAGAGGGGAACA 188
|||

QY 68 AGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCGCGCTGC 127
|||
Db 189 AGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCGCGCTGC 248
|||

QY 128 TGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACT 187
|||
Db 249 TGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACT 308
|||

QY 188 CGGTCTTGGGTGATACGGCTCTTGGCCACCGGSCCTGTGCTGCTGACCTACCCCTTGCA 247
|||
Db 309 CGGTCTTGGGTGATACGGCTCTTGGCCACCGGSCCTGTGCTGCTGACCTACCCCTTGCA 368
|||

QY 248 CCTACCCTAAGGAAGAGGAGTGTACGCATGTACAGAGGTTGCAGGCTGTTTCAATT 307
|||
Db 369 CCTACCCTAAGGAAGAGGAGTGTACGCATGTACAGAGGTTGCAGGCTGTTTCAATT 428
|||

QY 308 GTCAAGTTTGTGGATGATGAATGACTTAATCGAACTAAATGGAATGTGAATCTGCAT 367
|||
Db 429 GTCAAGTTTGTGGATGATGAATGACTTAATCGAACTAAATGGAATGTGAATCTGCAT 488
|||
```

```
QY 368 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAATC 427
|||||
Db 489 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGCCAATC 548
|||||

QY 428 AGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGCTCCTGATGCCAAAATGCACC 487
|||||
Db 549 AGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGCTCCTGATGCCAAAATGCACC 608
|||||

QY 488 TACTCTTTCTCTAACTCTGGTGAGTCACTTCTGGAGTGACATGATGGACTCCGCACAGA 547
|||||
Db 609 TACTCTTTCTCTAACTCTGGTGAGTCACTTCTGGAGTGACATGATGGACTCCGCACAGA 668
|||||

QY 548 GCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGAAATAAGTTATAT 607
|||||
Db 669 GCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGAAATAAGTTATAT 728
|||||

QY 608 TCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCCTACAAATTGA 667
|||||
Db 729 TCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCCTACAAATTGA 788
|||||

QY 668 GAGAATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCCGACAGGA 727
|||||
Db 789 GAGAATCATCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCCGACAGGA 848
|||||

QY 728 ATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAACTCTGGGT 787
|||||
Db 849 ATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAACTCTGGGT 908
|||||

QY 788 GGATTTTAACTAAGTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTCAA 847
|||||
Db 909 GGATTTTAACTAAGTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTTGTTGTCAA 968
|||||

QY 848 CTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATATCTATGGTGACT 907
|||||
Db 969 CTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATATCTATGGTGACT 1028
|||||

QY 908 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGTTCTTCTTGTGGTTGTTA 967
|||||
Db 1029 TGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGTTCTTCTTGTGGTTGTTA 1088
|||||

QY 968 GATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1027
|||||
Db 1089 GATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTC 1148
|||||

QY 1028 ATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAAAATTC 1087
|||||
Db 1149 ATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAAAATTC 1208
|||||

QY 1088 CTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCTTAAAGAAATCACTATAAA 1147
|||||
Db 1209 CTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCTTAAAGAAATCACTATAAA 1268
|||||

QY 1148 ATGCAATAAAGTTACTCAAAATCTGTG 1174
|||||
Db 1269 ATGCAATAAAGTTACTCAAAATCTGTG 1295
|||||

RESULT 6
AK075187 1634 bp mRNA linear PRI 03-SEP-2002
LOCUS
DEFINITION
Homo sapiens cDNA FLJ90706 fis, clone PLACE1007626.
ACCESSION
AK075187
VERSION
AK075187.1 GI:22761112
KEYWORDS
oligo capping; fis (full insert sequence).
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Isogai,T., Ota,T., Nishikawa,T., Hayashi,K., Otsuki,T.,
Sugiyama,T., Suzuki,Y., Nagai,K., Sugano,S., Ishii,S.,
Kawai-Hio,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y.,
```


Kojima,S., Nagahari,K., Masuho,Y., Ono,T., Okano,K., Yoshikawa,Y.,
Aotsuka,S., Sasaki,N., Hattori,A., Okumura,K., Iwayanagi,T. and
Ninomiya,K.
NEDO human cDNA sequencing project
Unpublished
2 (bases 1 to 1634)
Isogai,T. and Otsuki,T.
Direct Submission
Submitted (25-MAR-2002) Takao Isogai, Helix Research Institute,
Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan
(E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
NEDO human cDNA sequencing project supported by Ministry of
Economy, Trade and Industry of Japan; cDNA full insert sequencing:
Research Association for Biotechnology; cDNA library construction:
Institute of Medical Science, University of Tokyo, Laboratory of
Genome Structure, Human Genome Center; cDNA 5'- & 3'-end one pass
sequencing and clone selection: Helix Research Institute (supported
by Japan Key Technology Center etc.).

FEATURES

Location/Qualifiers
1..1634
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="PLACE1007626"
/tissue type="placenta"
/clone_lib="PLACE1"
/note="cloning vector: pME189FL3"

ORIGIN

Query Match 99.1%; Score 1163.8; DB 9; Length 1634;
Best Local Similarity 99.8%; Pred. No. 6.5e-272;
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 8 GTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGAACA 67
DB 129 GAGGAGGAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAGGGAACA 188
QY 68 AGATGGCGGCCCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCGCGCTGC 127
DB 189 AGATGGCGGCCCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCGCGCTGC 248
QY 128 TGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCAATTGACT 187
DB 249 TGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCAATTGACT 308
QY 188 CGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCCTTGACA 247
DB 309 CGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCCTTGACA 368
QY 248 CCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTTTCAATTT 307
DB 369 CCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTTTCAATTT 428
QY 308 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATACTAAATGGAATGTGAATCTGCAT 367
DB 429 GTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATACTAAATGGAATGTGAATCTGCAT 488
QY 368 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTGGCCAGATC 427
DB 489 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTGGCCAGATC 548
QY 428 AGCTGCCATTTCGCTGAATGAGACAAGAACTTATGTCCTGATGTCCTGATGTCCTGATGTC 487
DB 549 AGCTGCCATTTCGCTGAATGAGACAAGAACTTATGTCCTGATGTCCTGATGTCCTGATGTC 608
QY 488 TACTCTTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGATGAGTCCGACACAGA 547
DB 609 TACTCTTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGATGAGTCCGACACAGA 668
QY 548 GCTTCATAAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
DB 669 GCTTCATAAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 728

QY 608 TCCAGTCTTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACAAATTTGA 667
DB 729 TCCAGTCTTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACAAATTTGA 788
QY 668 GAGAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGA 727
DB 789 GAGAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGA 848
QY 728 ATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGGCTCTCTCTTAACTCTGGGT 787
DB 849 ATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGGCTCTCTCTTAACTCTGGGT 908
QY 788 GGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGTTGTCAA 847
DB 909 GGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGTTGTCAA 968
QY 848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGTGAATCTATGTTGACT 907
DB 969 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGTGAATCTATGTTGACT 1028
QY 908 TGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTGGTTGTTA 967
DB 1029 TGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTGGTTGTTA 1088
QY 968 GATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGTCTC 1027
DB 1089 GATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGTCTC 1148
QY 1028 ATTCCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTTAAATTTCA 1087
DB 1149 ATTCCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTTAAATTTCA 1208
QY 1088 CTCCTCATAGAGCTTTTAAATGTTTTCATTTGATATAGGCTTAAAGAAATCAGTATAA 1147
DB 1209 CTCCTCATAGAGCTTTTAAATGTTTTCATTTGATATAGGCTTAAAGAAATCAGTATAA 1268
QY 1148 ATGCAATAAAGTTACTCAATCTGTG 1174
DB 1269 ATGCAATAAAGTTACTCAATCTGTG 1295

RESULT 7

AX775907
LOCUS AX775907 1696 bp mRNA linear PAT 14-JUL-2003
DEFINITION Sequence 177 from Patent WO03048202.
ACCESSION AX775907
VERSION AX775907.1 GI:32693625
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Matsuda,A. and Muramatsu,S.
TITLE NF-kB activating gene
JOURNAL Patent: WO 03048202-A 177 12-JUN-2003;
Asahi Kasei Kabushiki Kaisha (JP)
FEATURES
source Location/Qualifiers
1..1696
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
251..1222
/note="unnamed protein product"
/codon_start=1
/protein_id="CAE11653.1"
/db_xref="GI:32693626"
/translation="MAAPKGLWVRLQGLPPLLLTLMALAGSGTASAEAFDSVLGD
TASCHRAQCLTYPLHTYPKEELYACQRCRLFSICQVDDGIDLNRKLECEACTE
AYSQSDQYACHLGCQNLPEAELRQELMSLMPKMLLPPLTLVRSFWSDMMDSAQS
FITSSWTFYLDQDDKIVIFQSKPEIQYAPHLEQFTNLRSSLSKMSYLOMRNSQAH
RNPLEDGEDSGFLKLSLNSGWILTTTLVLVSVMLLWICCATAVATAVEQYVPSEKLSI
YGDLEFMNEQKLNRYPASSLVVRSKTEDHEEAGPLPTKVNLAHSEI"

QY 128 TGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCATTTGACT 187
Db 303 TGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAGCATTTGACT 362
QY 188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTTCAGTTGACCTACCCCTTGACCA 247
Db 363 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTTCAGTTGACCTACCCCTTGACCA 422
QY 248 CCTACCCCTAAGGAAGAGGAGTTGACGATGTACGAGAGGTTGACGCTGTTTCAATTT 307
Db 423 CCTACCCCTAAGGAAGAGGAGTTGACGATGTACGAGAGGTTGACGCTGTTTCAATTT 482
QY 308 GTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGGAATCTGCAT 367
Db 483 GTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGGAATCTGCAT 542
QY 368 GTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGCCAGAATC 427
Db 543 GTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGCCAGAATC 602
QY 428 AGCTGCCATTCGCTGAACCTGAGCAAGAACTTATGCTCCCTGATGCCAAAATGCACC 487
Db 603 AGCTGCCATTCGCTGAACCTGAGCAAGAACTTATGCTCCCTGATGCCAAAATGCACC 662
QY 488 TACTCTTTCTTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCCGCACAGA 547
Db 663 TACTCTTTCTTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCCGCACAGA 722
QY 548 GCTTCATTAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 607
Db 723 GCTTCATTAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 782
QY 608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCCTACAAATTGA 667
Db 783 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCCTACAAATTGA 842
QY 668 GAGAATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCCACAGGA 727
Db 843 GAGAATCATCTTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCCACAGGA 902
QY 728 ATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAACTCTGGGT 787
Db 903 ATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAACTCTGGGT 962
QY 788 GGATTTTAACTACAACTCTTGCTCTCTCGGTGATGGTATGCTTTGGATTGTTGTGCAA 847
Db 963 GGATTTTAACTACAACTCTTGCTCTCTCGGTGATGGTATGCTTTGGATTGTTGTGCAA 1022
QY 848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGGTGACT 907
Db 1023 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGGTGACT 1082
QY 908 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTTGGTTGTTA 967
Db 1083 TGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTTGGTTGTTA 1142
QY 968 GATCTAAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAATCTTGCTC 1027
Db 1143 GATCTAAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAATCTTGCTC 1202
QY 1028 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAAAATTTCCA 1087
Db 1203 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAAAATTTCCA 1262
QY 1088 CTCCTCATAGAGCTTTTAAATGTTTCATTGGATATAGGCTTTAAGAAATCACTATATAA 1147
Db 1263 CTCCTCATAGAGCTTTTAAATGTTTCATTGGATATAGGCTTTAAGAAATCACTATATAA 1322
QY 1148 ATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1323 ATGCAATAAAGTTACTCAAAATCTGTG 1349

RESULT 9
AF290615
LOCUS
DEFINITION
1709 bp mRNA linear PRI 01-APR-2001
Homo sapiens clone E9271 liver membrane-bound protein mRNA,
complete cds.
AF290615
AF290615.1 GI:13491977
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1709)
Qu,X., Zhang,C., Zhai,Y., Wu,S., Yu,Y., Wei,H., Xing,G., Lu,C.,
Zhou,G., Dong,C. and He,F.
Homo sapiens liver membrane-bound protein mRNA
Unpublished
2 (bases 1 to 1709)
Qu,X., Zhang,C., Yu,Y., Wu,S., Wei,H., Xing,G., Zhai,Y., Lu,C.,
Wang,M. and He,F.
Direct Submission
Submitted (28-JUL-2000) Department of Genomics and Proteomics,
Institute of Radiation Medicine, Beijing Taiping Road 27, Beijing
100850, P. R. China
Location/Qualifiers
1. 1709
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="1"
/map="lp33-p32.1"
/clone="E9271"
/tissue_type="liver"
/dev_stage="fetus"
251..1222
/note="LMBP; similar to mouse thymic dendritic
cell-derived factor 1"
/codon_start=1
/product="liver membrane-bound protein"
/protein_id="AAK28026.1"
/db_xref="GI:13491978"
/translation="MAAPKGSILWVLTOLGLPPLLLTALAGSGTASABAFDSVLGD
TASCHRAQLTYPLHTYPEEELYACQRCRLFSICQFVDDGIDINRTKLEESACTE
AYSQDEQYACHLGCONQLPFAELRQELMLPKMHLPLTLVRSFWSMDMDSAQ
FITSWTFYLOADDGKIVIFQSKPEIQYAPHEPNTNRESLSKMSYLOMRNSQAH
RNFLDESDGFLRCLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"

ORIGIN

Query Match 99.1%; Score 1163.8; DB 9; Length 1709;
Best Local Similarity 99.8%; Pred. No. 6.5e-272;
Matches 1165; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 8 GTGGGGAAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 67
Db 189 GAGGAGGAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAGGGGAACA 248
QY 68 AGATGGCGCGCGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCGCGCTGC 127
Db 249 AGATGGCGCGCGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCGCGCTGC 308
QY 128 TGCTGCTGACCATGGCCCTTGCCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCATTTGACT 187
Db 309 TGCTGCTGACCATGGCCCTTGCCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCATTTGACT 368
QY 188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCCTTGACCA 247
Db 369 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCCTTGACCA 428
QY 248 CCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGCAGGCTGTTTCAATTT 307
Db 429 CCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGCAGGCTGTTTCAATTT 488

```
QY 308 GTCAAGTTGTGGATGATGGAATGACTTAATCGAACTAAATTTGGAATGTGAATCTGCAT 367
Db 489 GTCAAGTTGTGGATGATGGAATGACTTAATCGAACTAAATTTGGAATGTGAATCTGCAT 548
QY 368 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTCCAGAATC 427
Db 549 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTCCAGAATC 608
QY 428 AGTGGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCTGATGCCAAAATGCACC 487
Db 609 AGTGGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCTGATGCCAAAATGCACC 668
QY 488 TACTCTTTCTCTAACTCTGGTGGGTCAATCTTGAGTGACATGATGACTCCGCACAGA 547
Db 669 TACTCTTTCTCTAACTCTGGTGGGTCAATCTTGAGTGACATGATGACTCCGCACAGA 728
QY 548 GCTTCATAAACCCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 607
Db 729 GCTTCATAAACCCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATAGTTATAT 788
QY 608 TCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACAAATTTGA 667
Db 789 TCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACAAATTTGA 848
QY 668 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGA 727
Db 849 GAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGA 908
QY 728 ATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTAACTCTGGGT 787
Db 909 ATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTAACTCTGGGT 968
QY 788 GGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGTTGTCAA 847
Db 969 GGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGTTGTCAA 1028
QY 848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGTTGACT 907
Db 1029 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTATGTTGACT 1088
QY 908 TGGAGTTTATGAATGAACCAAAGCTAAACAGATATCCAGCTTCTTCTCTTGGTTGTTA 967
Db 1089 TGGAGTTTATGAATGAACCAAAGCTAAACAGATATCCAGCTTCTTCTCTTGGTTGTTA 1148
QY 968 GATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACTACAAAAGTGAATCTTGCTC 1027
Db 1149 GATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACTACAAAAGTGAATCTTGCTC 1208
QY 1028 ATTCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCCA 1087
Db 1209 ATTCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAAATTTCCA 1268
QY 1088 CTCCTCATAGAGTTTAAATGTTTCAATGGATATAGGCTTAAGAAATCACTATAAA 1147
Db 1269 CTCCTCATAGAGTTTAAATGTTTCAATGGATATAGGCTTAAGAAATCACTATAAA 1328
QY 1148 ATGCAATAAAGTTACTCAAATCTGTG 1174
Db 1329 ATGCAATAAAGTTACTCAAATCTGTG 1355

RESULT 10
BD191327
LOCUS BD191327 1695 bp DNA linear PAT 17-JUL-2003
DEFINITION 186 human secreted proteins.
ACCESSION BD191327
VERSION BD191327.1 GI:33001066
KEYWORDS JP 2002510192-A/291.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1695)
AUTHORS Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,
```

```
Bednarik,D.P., Endress,G.A., Yu,G.L., N.J., Feng,P., Young,P.E.,
Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.S., Florence,K.A.,
Olson,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,
Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.
186 human secreted proteins
Patent: JP 2002510192-A 291 02-APR-2002;
HUMAN GENOME SCIENCES INC
PN JP 2002510192-A/291
PD 02-APR-2002
PF 06-MAR-1998 JP 1998538883
PR 07-MAR-1997 US 60/040162,07-MAR-1997 US 60/040333 PR
07-MAR-1997 US 60/038621,07-MAR-1997 US 60/040161 PR
07-MAR-1997 US 60/040626,07-MAR-1997 US 60/040334 PR
07-MAR-1997 US 60/040336,07-MAR-1997 US 60/040163 PR
11-APR-1997 US 60/043580,11-APR-1997 US 60/043568 PI STEVEN
M RUBEN, CRAIG A ROSEN, CARRIE L FISCHER, DANIEL R SOPPET, PI
KENNETH C CARTER, DANIEL P BEDNARIK, GREGORY
A ENDRESS, GUO LIANG
PI YU, JIAN NI,
PI PING FENG, PAUL E YOUNG, JOHN M GREENE, ANN
M FERRIE, ROXANNE DUAN,
PI JING SHAN HU, KIMBERLY A FLORENCE, HENRIK
S OLSEN, REINHARD EBNER,
PI LAURIE A BREWER, PAUL A MOORE, YANGGU SHI, DAVID W LAFLEUR PI
,YI LI, ZHI ZHEN ZENG,
PI HLA KYAW
PC C12N15/12, C12N5/10, C12N1/21, C07K14/47, C07K16/18, C12Q1/68, PC
G01N33/50,
PC G01N33/53, G01N33/68, A61K38/17
CC Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers.
Location/Qualifiers
1.1695
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 98.1%; Score 1151.8; DB 6; Length 1695;
Best Local Similarity 99.7%; Pred. No. 5.4e-269;
Matches 1164; Conservative 0; Mismatches 2; Indels 1; Gaps 1;

QY 8 GTGGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGACAGAGGGGAACA 67
Db 167 GAGGAGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGACAGAGGGGAACA 226
QY 68 AGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 127
Db 227 AGATGGCGGCGCGGAA-GGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCTGC 285
QY 128 TGCTGCTGACCATGGCCTTGCGGAGGTTGCGGGGACCGCTTCGGCTGAAGCATTTGACT 187
Db 286 TGCTGCTGACCATGGCCTTGCGGAGGTTGCGGGGACCGCTTCGGCTGAAGCATTTGACT 345
QY 188 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCCTTGACCA 247
Db 346 CGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCCTTGACCA 405
QY 248 CCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGACGCTGTTTCAATTT 307
Db 406 CCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGACGCTGTTTCAATTT 465
QY 308 GTCAGTTTGTGGATGATGGAATTTGACTTAATCGAACTAAATTTGGAATGTGAATCTGCAT 367
Db 466 GTCAGTTTGTGGATGATGGAATTTGACTTAATCGAACTAAATTTGGAATGTGAATCTGCAT 525
QY 368 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTCAGAAATC 427
Db 526 GTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTCAGAAATC 585
QY 428 AGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCTGATGCCAAAATGCACC 487
```


Db 586 AGCTGCCATCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCCAAAATGCACC 645

QY 488 TACTCTTTCTCTAACTCTGGTGAAGTCAATCTTGGAGTGACATGATGGACTCCGCACAGA 547

Db 646 TACTCTTTCTCTAACTCTGGTGAAGTCAATCTTGGAGTGACATGATGGACTCCGCACAGA 705

QY 548 GCTTCATAAACCCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607

Db 706 GCTTCATAAACCCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 765

QY 608 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCCTACAAATTTGA 667

Db 766 TCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCCTACAAATTTGA 825

QY 668 GAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATAGAGAAATTCACAAGCCACAGGA 727

Db 826 GAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATAGAGAAATTCACAAGCCACAGGA 885

QY 728 ATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCCTCTCTCTTAATCTGGGT 787

Db 886 ATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCCTCTCTCTTAATCTGGGT 945

QY 788 GGATTTTAACTPACAACTCTTGCTCTCGGTGATGGTATGCTTTGGATTTGTGTGCAA 847

Db 946 GGATTTTAACTPACAACTCTTGCTCTCGGTGATGGTATGCTTTGGATTTGTGTGCAA 1005

QY 848 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTATGGTGACT 907

Db 1006 CTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTATGGTGACT 1065

QY 908 TGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTTGGTTGTTA 967

Db 1066 TGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTTGGTTGTTA 1125

QY 968 GATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGCTC 1027

Db 1126 GATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAATCTTGCTC 1185

QY 1028 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAATAGACATCTAAAATTTCCA 1087

Db 1186 ATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAATAGACATCTAAAATTTCCA 1245

QY 1088 CTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCACTATAAA 1147

Db 1246 CTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCACTATAAA 1305

QY 1148 ATGCAATAAAGTTACTCAAATCTGTG 1174

Db 1306 ATGCAATAAAGTTACTCAAATCTGTG 1332

RESULT 11

BD233468

LOCUS BD233468 1121 bp DNA linear PAT 17-JUL-2003

DEFINITION Human protein having hydrophobic domain and DNA encoding the same.

ACCESSION BD233468

VERSION BD233468.1 GI:33043238

KEYWORDS JP 2002519016-A/14.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 1121)

Kato,S. and Kimura,T.

Human protein having hydrophobic domain and DNA encoding the same

Patent: JP 2002519016-A 14 02-JUL-2002;

JOURNAL SAGAMI CHEMICAL RESEARCH CENTER, PROTEGENE INC

COMMENT OS Homo sapiens (human)

PN JP 2002519016-A/14

PD 02-JUL-2002

PF 18-JUN-1999 JP 2000557267

PI SEISHI KATO,TOMOKO KIMURA

PC

C12N15/09,C07K14/47,C12N1/15,C12N1/19,C12N5/10,C12N15/00,C12N5/ PC

00

CC Human protein having hydrophobic domain and DNA encoding the

CC same

PH Key Location/Qualifiers

FT source 1..1121

FT /organism='Homo sapiens (human)'.
Location/Qualifiers
1..1121
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

FEATURES

source

ORIGIN

Query Match 95.5%; Score 1121; DB 6; Length 1121;
Best Local Similarity 100.0%; Pred.No. 1.6e-261;
Matches 1121; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 GACAGAGGGGAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGG 113

Db 1 GACAGAGGGGAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGG 60

QY 114 GCTCCCGCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGC 173

Db 61 GCTCCCGCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGC 120

QY 174 TGAAGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCAATTGAC 233

Db 121 TGAAGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCAATTGAC 180

QY 234 CTACCCCTTGCAACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAG 293

Db 181 CTACCCCTTGCAACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAG 240

QY 294 GCTGTTTTCAATTTGTGAGTTTGTGGATGATGGAATTGACTTTAAATCGAAATTAATTGGA 353

Db 241 GCTGTTTTCAATTTGTGAGTTTGTGGATGATGGAATTGACTTTAAATCGAAATTAATTGGA 300

QY 354 ATGTGAATCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCT 413

Db 301 ATGTGAATCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCT 360

QY 414 TGGTTGCCAGAAATCAGTGCCCATTCGCTGAATGAGACAAGAACTATGTCCCTGAT 473

Db 361 TGGTTGCCAGAAATCAGTGCCCATTCGCTGAATGAGACAAGAACTATGTCCCTGAT 420

QY 474 GCCAAAAATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGAT 533

Db 421 GCCAAAAATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGAT 480

QY 534 GGACTCCGCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGG 593

Db 481 GGACTCCGCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGG 540

QY 594 AAAAATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCATTTGGAGCAGGA 653

Db 541 AAAAATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCATTTGGAGCAGGA 600

QY 654 GCCTACAAAATTTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTC 713

Db 601 GCCTACAAAATTTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTC 660

QY 714 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTC 773

Db 661 ACAAGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTC 720

QY 774 TCTTAATCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTG 833

Db 721 TCTTAATCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTG 780

QY 834 GATTTGTTGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 893

Db 781 GATTTGTTGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 840

QY 894 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 953
Db 841 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTC 900
QY 954 TCITGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 1013
Db 901 TCITGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAA 960
QY 1014 AGTGAATCTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGA 1073
Db 961 AGTGAATCTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGA 1020
QY 1074 CATCTAAAAATCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCCTTAA 1133
Db 1021 CATCTAAAAATCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCCTTAA 1080
QY 1134 GAATCACTATAAAATGCAATAAAAGTTACTCAATCTGTG 1174
Db 1081 GAATCACTATAAAATGCAATAAAAGTTACTCAATCTGTG 1121
RESULT 12
AX136301
LOCUS AX136301 1457 bp DNA linear PAT 30-MAY-2001
DEFINITION Sequence 223 from Patent EP1067182.
ACCESSION AX136301
VERSION AX136301.1 GI:14272707
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Ota,T.; Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and Hayashi,X.
TITLE Secretory protein or membrane protein
JOURNAL Patent: EP 1067182-A 223 10-JAN-2001;
Helix Research Institute (JP)
FEATURES
source location/Qualifiers
1..1457 /organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
14..985
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC39792.1"
/db_xref="GI:14272708"
/db_xref="REMTREMBL:CAC39792"
/translation="MAAPKGSLSWVRTQLGLPPLLLLTALAGSGTASAEAFDSVLGD
TASCHRAQLTYPLHTYPKEELYACORGRLFSICQFVDDGIDLNRTKLECESACTE
AYSQSDQYACHLGCQNQLPPAELRQELSLMPKMHLLFPLILVRSFWSDMDSQAS
FITSSWTFYLOADDGKIVIFQSKPEIQYAPHLEQEPNLRRESSLSKMSYLOMRNSQAH
RNFLDGEDSGDFLRCLSLNSGWILTTTLVLSVMVLLWICCATVATAVEQYVPSEKLSI
YGDLEFMNEQKLNRYPASSLVVVRSKTEDHEEAGPLPTKVNLAHSEI"
ORIGIN
Query Match 95.2%; Score 1118; DB 6; Length 1457;
Best Local Similarity 100.0%; Pred. No. 8.8e-261;
Matches 1118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 57 AGAGGGGAACAAGATGGCGGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCT 116
Db 1 AGAGGGGAACAAGATGGCGGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCT 60
QY 117 CCCGCCGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGACCGCTTCGGCTGA 176
Db 61 CCCGCCGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCGGGACCGCTTCGGCTGA 120
QY 177 AGCATTTGACTCGGCTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCAAGTGACCTA 236
Db 121 AGCATTTGACTCGGCTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCAAGTGACCTA 180

QY 237 CCCCTTGCAACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTACAGAGGTTGCAGGCT 296
Db 181 CCCCTTGCAACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTACAGAGGTTGCAGGCT 240
QY 297 GTTTTCAATTTGTTCAGTTTGTGGATGATGGAATTCGCTTAAATCGAACTAAATTCGAATG 356
Db 241 GTTTTCAATTTGTTCAGTTTGTGGATGATGGAATTCGCTTAAATCGAACTAAATTCGAATG 300
QY 357 TGAATCTGCATGTACAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGG 416
Db 301 TGAATCTGCATGTACAGAAGCATATTCCTCAATCTGTATGAGCAATATGCTTGCCATCTTGG 360
QY 417 TTGCCAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCC 476
Db 361 TTGCCAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCC 420
QY 477 AAAAAATGCACCTACTCTTTTCCTCTAACTCTGGTGAGGTCAATCTTGGAGTGACATGATGGA 536
Db 421 AAAAAATGCACCTACTCTTTTCCTCTAACTCTGGTGAGGTCAATCTTGGAGTGACATGATGGA 480
QY 537 CTCCGCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAA 596
Db 481 CTCCGCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAA 540
QY 597 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCC 656
Db 541 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCC 600
QY 657 TACAAATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACA 716
Db 601 TACAAATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACA 660
QY 717 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGTATGGCTTTTAAAGATGCCTCTCTCT 776
Db 661 AGCGCACAGGAATTTTCTTGAAGATGGAGAAAGTGTATGGCTTTTAAAGATGCCTCTCTCT 720
QY 777 TAACTCTGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 836
Db 721 TAACTCTGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 780
QY 837 TTGTTGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTAT 896
Db 781 TTGTTGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTAT 840
QY 897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
Db 841 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 900
QY 957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 1016
Db 901 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGT 960
QY 1017 GAATCTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACAT 1076
Db 961 GAATCTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACAT 1020
QY 1077 CTAAAAATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAA 1136
Db 1021 CTAAAAATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAA 1080
QY 1137 ATCACTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1081 ATCACTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1118

RESULT 13
BD123603
LOCUS BD123603 1457 bp DNA linear PAT 18-SEP-2002
DEFINITION Secretory protein or membrane protein.
ACCESSION BD123603
VERSION BD123603.1 GI:23218548
KEYWORDS JP 2002017376-A/112.

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1457)
AUTHORS Ota,T., Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and Hayashi,K.
TITLE Secretory protein or membrane protein
JOURNAL Patent: JP 2002017376-A 112 22-JAN-2002;
HELIX RESEARCH INSTITUTE
COMMENT OS Homo sapiens (human)
PN JP 2002017376-A/112
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253173
PI TOSHIO OTA,TAKAO ISOGAI,TETSUO NISHIKAWA,YURI KAWAI,TOMOYASU
PI SUGIYAMA,
PI KOJI HAYASHI
PC
C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10,
PC C12P21/02,C12Q1/68//C12P21/08,C12N15/00,C12N5/00 CC
Secretory protein or membrane protein
FH Key Location/Qualifiers
FT CDS (14)..(982).
FEATURES
source
1..1457
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 95.2%; Score 1118; DB 6; Length 1457;
Best Local Similarity 100.0%; Pred. No. 8.8e-261;
Matches 1118; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 57 AGAGGGGAACAAGATGGCGGCGCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCT 116
DB 1 AGAGGGGAACAAGATGGCGGCGCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCT 60
QY 117 CCCGCCGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGA 176
DB 61 CCCGCCGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGA 120
QY 177 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTA 236
DB 121 AGCATTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTA 180
QY 237 CCCCTTGACACACCTAACCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCGAGGCT 296
DB 181 CCCCTTGACACACCTAACCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCGAGGCT 240
QY 297 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATG 356
DB 241 GTTTTCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATG 300
QY 357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGG 416
DB 301 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGG 360
QY 417 TTGCCAGAATCAGCTGCCATTGCTGAACTGAGACACAAGAACAACTATGTCCCTGATGCC 476
DB 361 TTGCCAGAATCAGCTGCCATTGCTGAACTGAGACACAAGAACAACTATGTCCCTGATGCC 420
QY 477 AAAAAATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATTCGAGTGACATGATGGA 536
DB 421 AAAAAATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATTCGAGTGACATGATGGA 480
QY 537 CTCGGCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAA 596
DB 481 CTCGGCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAA 540
QY 597 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCC 656

Db 541 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCC 600
Qy 657 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 716
Db 601 TACAAATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 660
Qy 717 AGGCACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCT 776
Db 661 AGGCACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCT 720
Qy 777 TAACTCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 836
Db 721 TAACTCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 780
Qy 837 TTGTTGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTAT 896
Db 781 TTGTTGTGCAACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTAT 840
Qy 897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 956
Db 841 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCT 900
Qy 957 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGT 1016
Db 901 TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGT 960
Qy 1017 GAATCTTGTCTATTCTGAAAATTTAAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACAT 1076
Db 961 GAATCTTGTCTATTCTGAAAATTTAAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACAT 1020
Qy 1077 CTAAAAATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAA 1136
Db 1021 CTAAAAATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAA 1080
Qy 1137 ATCACTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1081 ATCACTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1118
RESULT 14
AK075505
LOCUS Homo sapiens cDNA PSEC0203 fis, clone HEMBA1002441. linear PRI 03-SEP-2002
DEFINITION AK075505
ACCESSION AK075505
VERSION AK075505.1 GI:22761691
KEYWORDS oligo capping; fis (full insert sequence).
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Ota,T., Nishikawa,T., Suzuki,Y., Kawai-Hio,Y., Hayashi,K., Ishii,S., Saito,K., Yamamoto,J., Wakamatsu,A., Nagai,T., Nakamura,Y., Nagahara,K., Sugano,S. and Isogai,T.
TITLE HRI human cDNA sequencing project
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1457)
AUTHORS Isogai,T. and Yamamoto,J.
TITLE Direct Submission
JOURNAL Submitted (20-MAR-2002) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)
COMMENT HRI human cDNA sequencing project; cDNA 5'- & 3'-end one pass sequencing, clone selection and full insert sequencing; Helix Research Institute (supported by Japan Key Technology Center etc.); cDNA library construction; Institute of Medical Science, University of Tokyo, Laboratory of Genome Structure, Human Genome Center.
FEATURES
source
1..1457
/organism="Homo sapiens"
/mol_type="mrna"
/db_xref="taxon:9606"
/clone="HEMBA1002441"

||||| 302 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 361
QY 417 TTGCCAGAAATCAGCTGCCATTCGCTGAATCAGACAAAGAACAATCTATGTCCCTGATGCC 476
Db 362 TTGCCAGAAATCAGCTGCCATTCGCTGAATCAGACAAAGAACAATCTATGTCCCTGATGCC 421
QY 477 AAAAAATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 536
Db 422 AAAAAATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 481
QY 537 CTCGCGACAGAGCTTCATAACCTCTTCAATGACATTTTATCTTCAAGCCGATGACGGA 596
Db 482 CTCGCGACAGAGCTTCATAACCTCTTCAATGACATTTTATCTTCAAGCCGATGACGGA 541
QY 597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCC 656
Db 542 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCC 601
QY 657 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACA 716
Db 602 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACA 661
QY 717 AGCGCACAGGAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCCCTCTCTCT 776
Db 662 AGCGCACAGGAATTTCTTGAAGATGGAAGATGATGGCTTTTAAAGATGCCCTCTCTCT 721
QY 777 TAACTCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGAT 836
Db 722 TAACTCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGAT 781
QY 837 TTGTTGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896
Db 782 TTGTTGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 841
QY 897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCT 956
Db 842 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCT 901
QY 957 TGTGGTTGTTAGATCTAAAACCTGAAGATCATGAAGAGCAGGAGCTCTACCTACAAAAGT 1016
Db 902 TGTGGTTGTTAGATCTAAAACCTGAAGATCATGAAGAGCAGGAGCTCTACCTACAAAAGT 961
QY 1017 GAATCTTGCTCAITCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACAT 1076
Db 962 GAATCTTGCTCAITCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACAT 1021
QY 1077 CTAAATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTTAAGAA 1136
Db 1022 CTAAATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTTAAGAA 1081
QY 1137 ATCACTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1082 ATCACTATAAATGCAATAAAGTTACTCAAAATCTGTG 1119

RESULT 16
AX779812
LOCUS AX779812 1138 bp DNA linear PAT 14-JUL-2003
DEFINITION Sequence 1969 from Patent WO03039443.
ACCESSION AX779812
VERSION AX779812.1 GI:32696806
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Haferlach,T., Schoch,C., Kern,W., Kohlmann,A., Schnittger,S.,
Dugas,M., Eils,R., Brors,B. and Mergenthaler,S.
TITLE Novel genetic markers for leukemias
JOURNAL Patent: WO 03039443-A 1969 15-MAY-2003;
Deutsches Krebsforschungszentrum (DE) ;

Ludwig-Maximilian-Universitaet Muenchen (DE) ; Haferlach, Torsten,
PD Dr. Dr. (DE) ; Schoch, Claudia (DE) ; Kern, Wolfgang (DE)
FEATURES
source 1. .1138
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
ORIGIN
Query Match 94.2%; Score 1106; DB 6; Length 1138;
Best Local Similarity 99.9%; Pred. No. 7.1e-258;
Matches 1117; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
QY 57 AGAGGGGAACAAGATGGCGCGCCGAGGGAGAGCTCTGGGTGAGGACCCCAACTGGGGCT 116
Db 3 AGAGGGGAACAAGATGGCGCGCCGAGGGAGAGCTCTGGGTGAGGACCCCAACTGGGGCT 61
QY 117 CCGCGCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGA 176
Db 62 CCGCGCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGA 121
QY 177 AGCAATTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGCGCTGTCAAGTTGACCTA 236
Db 122 AGCAATTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGCGCTGTCAAGTTGACCTA 181
QY 237 CCCCTTGACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTCAAGAGAGTTGCAGGCT 296
Db 182 CCCCTTGACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTCAAGAGAGTTGCAGGCT 241
QY 297 GTTTTCAATTTGTCAAGTTTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATG 356
Db 242 GTTTTCAATTTGTCAAGTTTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATG 301
QY 357 TGAATCTGCATGTACAGAAGCATATTCCCCTTCTGATGAGCAATATGCTGCCATCTTGG 416
Db 302 TGAATCTGCATGTACAGAAGCATATTCCCCTTCTGATGAGCAATATGCTGCCATCTTGG 361
QY 417 TTGCCAGAAATCAGCTGCCATTCGCTGAATCAGACAAAGAACTTATGTCCTGATGCC 476
Db 362 TTGCCAGAAATCAGCTGCCATTCGCTGAATCAGACAAAGAACTTATGTCCTGATGCC 421
QY 477 AAAAAATGCACCTACTCTTCTCTCTAACTCTGGTGAGGTCAATCTGAGAGTGACATGATGGA 536
Db 422 AAAAAATGCACCTACTCTTCTCTCTAACTCTGGTGAGGTCAATCTGAGAGTGACATGATGGA 481
QY 537 CTCGCGACAGAGCTTCATAAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGA 596
Db 482 CTCGCGACAGAGCTTCATAAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGA 541
QY 597 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCC 656
Db 542 AATAGTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCC 601
QY 657 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 716
Db 602 TACAAATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACA 661
QY 717 AGCGCACAGGAATTTTCTTGAAGATGGAAGAGTATGGCTTTTAAAGATGCCCTCTCTCT 776
Db 662 AGCGCACAGGAATTTTCTTGAAGATGGAAGAGTATGGCTTTTAAAGATGCCCTCTCTCT 721
QY 777 TAACTCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 836
Db 722 TAACTCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGAT 781
QY 837 TTGTTGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 896
Db 782 TTGTTGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTAT 841
QY 897 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCT 956
Db 842 CTATGGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCT 901

QY	957	TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGT	1016
Db	902	TGTGGTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGT	961
QY	1017	GAATCTTGCTCATCTCGAAATTTAAGCATTTTTCTTTAAAAAGACAAGTGTAAATAGACAT	1076
Db	962	GAATCTTGCTCATCTCGAAATTTAAGCATTTTTCTTTAAAAAGACAAGTGTAAATAGACAT	1021
QY	1077	CTAAAAATCCACTCCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCCTTAAAGAA	1136
Db	1022	CTAAAAATCCACTCCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCCTTAAAGAA	1081
QY	1137	ATCAGCTATAAAATGCAAAATAAAAGTTACTCAAAATCTGTG	1174
Db	1082	ATCAGCTATAAAATGCAAAATAAAAGTTACTCAAAATCTGTG	1119

RESULT	17
AX775909	
LOCUS	AX775909
DEFINITION	Sequence 179 from Patent WO03048202.
ACCESSION	AX775909
VERSION	AX775909.1 GI:32693627
KEYWORDS	.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

CDS
18_.992
/locus_tag="taxon:9808
/note="unnamed protein product"
/codon_start=1
/protein_id="CAE11654.1"
/db_xref="GI:32693628"
/translation="MAAPKGSLSWVRLTGLPPLLLLTALAGSGTASAEAFDSVLGD
TASCHRAQLTYPLHTYPKEELYACQRCLEFSICQVDDGIDLNRITKLECESACTE
AYSQSDQYACHLCQCNQLPFAELRQEQMLMPKWHLLFPLTLVRSFSDMMDSQAQS
FITSSWTFYLQADDGKIVIFQSKPEIQYAPHLEQPTNRESSLSKMSSDLQMRNSQA
HRNFLEDGESDGLRCLSLNSGWILTTTLVLVSMVLLWICCATVATAVEQYVVPSEKLS
IYGDLEFMNEOKLNRYPASSLVVRSKTEDEHEEAGPLPTKYNLAHSEI"

```

ORIGIN		Query Match 94.1%; Score 1105; DB 6; Length 1466; Best Local Similarity 99.7%; Pred. No. 1.3e-257; Matches 1118; Conservative 0; Mismatches 0; Indels 3; Gaps 1;
QY	57 AGAGGGGAACAAGATGCGGCCCCGAAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT	116
Dd	5 AGAGGGGAACAAGATGCGGCCCCGAAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCT	64
QY	117 CCCGCCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGGGGGACCCTTCGGCTGA	176
Dd	65 CCCGCCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGGGGGACCCTTCGGCTGA	124
QY	177 AGCATTTGACTCGGCTCTTGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTA	236
Dd	125 AGCATTTGACTCGGCTCTTGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTA	184
QY	237 CCCCTTGACACACTACCTTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGCT	296
Dd	185 CCCCTTGACACACTACCTTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGCT	244
QY	297 GTTTTCAAATTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATG	356

Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,
Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Fahey,J., Helton,E., Kettelman,M., Madan,A., Rodrigues,S.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E.,
Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
12477932
2 (bases 1 to 1515)
Strausberg,R.
Direct Submission
Submitted (29-OCT-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgabs-r@mail.nih.gov
Tissue Procurement: CLONTECH
cDNA Library Preparation: CLONTECH Laboratories, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
<http://www.systemsbio.org>
contact: amadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAL Plate: 38 Row: e Column: 10.
Location/Qualifiers
1..1515
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:27259 IMAGE:4618034"
/tissue_type="Lung"
/clone_lib="NIH MGC_77"
/lab_host="DH10B"
/note="vector: pDNR-LIB"
1..1515
/gene="Clorf8"
/note="synonym: HSPC001"
/db_xref="LocusID:9528"
18..992
/codon_start=1
/product="thymic dendritic cell-derived factor 1"
/protein_id="AAH16374.1"
/db_xref="GI:16741048"
/db_xref="LocusID:9528"
/translation="WAAPKGLWVRTQLGLPPLLLLTALAGSGGTASAEAFDSVLGD
TASCRACQLTYPLHTYPKBEELYACORGLFSICQFVDDGIDLNRTRKCESACTE
AYSQDEQYACHLGCQNQLPPFAELRQEQQLMSLMPKMLLFLTLVRSFWSDMMDSAQS
FITSSWTFYLOADDGKIVIFOSKPEIQYAPHLEQEPNLRSSLSKMSDDLQWNSQA
HRNFLEDGESDGLRCLSLNSGWILTTLLVLSVMLLVICCATVATAVEQYVPSEKLS
IYGDLEFMNEQKLNRYPASSLVVRSKTEDHEEAGPLPTKVNLAHSEI"

ORIGIN

Query Match

94.1%; Score 1105; DB 9; Length 1515;

Best Local Similarity 99.7%; Pred. No. 1.3e-257;
Matches 1118; Conservative 0; Mismatches 0; Indels 3; Gaps 1;
QY 57 AGAGGGGAACAAGATGGCGCGCGCCGAAAGGGAGCCTCTGGGTGAGACCCAACTGGGCT 116
|||||
Db 5 AGAGGGGAACAAGATGGCGCGCGCCGAAAGGGAGCCTCTGGGTGAGACCCAACTGGGCT 64
|||||
QY 117 CCGCCGCTGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGA 176
|||||
Db 65 CCGCCGCTGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGA 124
|||||
QY 177 AGCAATTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCTCAGTTGACCTA 236
|||||
Db 125 AGCAATTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTCTCAGTTGACCTA 184
|||||
QY 237 CCCCTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCT 296
|||||
Db 185 CCCCTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCT 244
|||||
QY 297 GTTTTCAATTGTGCTGCTGCTGCTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATG 356
|||||
Db 245 GTTTTCAATTGTGCTGCTGCTGCTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATG 304
|||||
QY 357 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 416
|||||
Db 305 TGAATCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGG 364
|||||
QY 417 TTGCCAGAATCAGCTGCCATTCGCTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCC 476
|||||
Db 365 TTGCCAGAATCAGCTGCCATTCGCTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCC 424
|||||
QY 477 AAAATGACACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 536
|||||
Db 425 AAAATGACACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGA 484
|||||
QY 537 CTCGCGACAGAGCTTCATAAACCTCTTCAAGGACTTTTATCTTCAAGCCGATGACGGAAA 596
|||||
Db 485 CTCGCGACAGAGCTTCATAAACCTCTTCAAGGACTTTTATCTTCAAGCCGATGACGGAAA 544
|||||
QY 597 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACCAATTTGGAGCAGGAGCC 656
|||||
Db 545 AATAGTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACCAATTTGGAGCAGGAGCC 604
|||||
QY 657 TACAAATTTGAGAGAATCATCTCTTAAGCAAAATGTCCT--ATCTGCAAAATGAGAAATTC 713
|||||
Db 605 TACAAATTTGAGAGAATCATCTCTTAAGCAAAATGTCCTCAGATCTGCAAAATGAGAAATTC 664
|||||
QY 714 ACAAGCCGACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTC 773
|||||
Db 665 ACAAGCCGACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTC 724
|||||
QY 774 TCTTAACCTCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTG 833
|||||
Db 725 TCTTAACCTCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTG 784
|||||
QY 834 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 893
|||||
Db 785 GATTTGTTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAG 844
|||||
QY 894 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTC 953
|||||
Db 845 TATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTC 904
|||||
QY 954 TCTTGTGTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAA 1013
|||||
Db 905 TCTTGTGTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAA 964
|||||
QY 1014 AGTGAATCTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGA 1073
|||||
Db 965 AGTGAATCTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGA 1024
|||||
QY 1074 CATCTAAATTCCTCTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGCCCTTAA 1133
|||||

Db	1025	CATCTAAATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTCGGATATAGGCCTTAA	1084
QY	1134	GAATCACTATAAAATGCAAAATAAAAGTTTACTCAAATCTGTG	1174
Db	1085	GAATCACTATAAAATGCAAAATAAAAGTTTACTCAAATCTGTG	1125
RESULT 19			
BC003106			
LOCUS			
DEFINITION	Homo sapiens chromosome 1 open reading frame 8, mRNA (cDNA clone MGC:1961 IMAGE:3501639), complete cds.		
ACCESSION	BC003106		
VERSION	BC003106.1	GI:13111876	
KEYWORDS	MGC.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
AUTHORS	1 (bases 1 to 1130)		
	Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G., Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D., Altschul,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K., Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F., Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L., Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L., Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S., Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J., Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J., McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S., Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W., Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A., Fahey,J., Helton,E., Kettman,M., Madan,A., Young,A.C., Shevchenko,Y., Sanchez,A., Whiting,M., Madan,A., Touchman,J.W., Green,E.D., Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D., Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M., Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smailus,D.E., Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.		
TITLE	Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences		
JOURNAL	Proc. Natl. Acad. Sci. U.S.A.	99 (26), 16899-16903	(2002)
MEDLINE	22388257		
PUBMED	12477932		
REFERENCE	2	(bases 1 to 1130)	
AUTHORS	Strausberg,R.		
TITLE	Direct Submission		
JOURNAL	Submitted (13-FEB-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA		
REMARK	NIH-MGC Project URL: http://mgc.nci.nih.gov		
COMMENT	Contact: MGC help desk Email: cgabbs-r@mail.nih.gov Tissue Procurement: ATCC cDNA Library Preparation: Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Genome Sequence Centre, BC Cancer Agency, Vancouver, BC, Canada info@bcgsc.bc.ca Steven Jones, Jennifer Asano, Ian Bosdet, Yaron Butterfield, Susanna Chan, Readman Chiu, Chris Fjell, Erin Garland, Ran Guin, Letticia Hsiao, Martin Krzywinski, Reta Kutsche, Oliver Lee, Soo Sen Lee, Victor Ling, Carrie Mathewson, Candice McLeavy, Steven Ness, Pawan Pandoh, Anna-Liisa Prabhu, Parvaneh Saeedi, Jacqueline Schein, Duane Smailus, Michael Smith, Lorraine Spence, Jeff Stott, Michael Thorne, Miranada Tsai, Natasja van den Bosch, Jill Vardy, George Yang, Scott Zuyderduyn, Marco Marra.		
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov Series: IRAL Plate: 6 Row: j Column: 2 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 20070190.			

FEATURES		Location/Qualifiers
source		1..1130
		/organism="Homo sapiens"
		/mol_type="mRNA"
		/db_xref="taxon:9606"
		/clone="MGC:1961 IMAGE:3501639"
		/tissue_type="Brain, neuroblastoma"
		/clone_lib="NIH MGC 19"
		/lab_host="DH10B-R"
		/note="Vector: pOTB7"
gene		1..1130
		/gene="Clorf8"
		/note="synonym: HSPC001"
		/db_xref="LocusID:9528"
CDS		69..971
		/codon_start=1
		/product="Clorf8 protein"
		/protein_id="AAH03106.1"
		/db_xref="GI:13111877"
		/db_xref="LocusID:9528"
		/translation="MALAGSGTASAEAFDSVLGDTASCHRAQLTYPLHTYPKSEEL YACQRCRLFSICQFVDDGIDLNRTKLECSACTEAYSQSDEQYACHLGCQNQLPFAE LRQELMSLMPKMHLLFPLTLVRSFWSMDMSAQHSRTSWTFYLDQDDGKIVIFQSK PEIQYAPHLEQEPNLRSSLSKMSYLOWNSQAHNFLEDGESDGLRCLSLNSGWI LTTTLVLSVMVLLTTCATVATAVEQYVPSEKLSIYGDLEFMNEQKLNRYRPASSLVVV RSKTEDHEEAGPLPIKVNLAHSEI"
ORIGIN		
		Query Match 94.0%; Score 1104; DB 9; Length 1130;
		Best Local Similarity 100.0%; Pred. No. 2.2e-257;
		Matches 1104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	71	TGGCGGCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGCTGC 130
Db	1	TGGCGGCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGCTGC 60
Qy	131	TGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACTCGG 190
Db	61	TGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACTCGG 120
Qy	191	TCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCACTTGACCTACCCCTTGACACACT 250
Db	121	TCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCACTTGACCTACCCCTTGACACACT 180
Qy	251	ACCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTTCAATTGTGTC 310
Db	181	ACCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTTCAATTGTGTC 240
Qy	311	AGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAATCTGCATGTA 370
Db	241	AGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAATCTGCATGTA 300
Qy	371	CAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGCCAGAAATCAGC 430
Db	301	CAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGCCAGAAATCAGC 360
Qy	431	TGCCATTCCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAATGCACCTAC 490
Db	361	TGCCATTCCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAATGCACCTAC 420
Qy	491	TCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCCGCCACAGAGCT 550
Db	421	TCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCCGCCACAGAGCT 480
Qy	551	TCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATCC 610
Db	481	TCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATCC 540
Qy	611	AGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGAG 670
Db	541	AGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACAAATTTGAGAG 600
Qy	671	AATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAGCGCACAGGAATT 730

Db 601 AATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGAATT 660
QY 731 TTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAACTCTGGGTGGA 790
Db 661 TTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAACTCTGGGTGGA 720
QY 791 TTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATGCTTTGGATTGTTGTGCAACTG 850
Db 721 TTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATGCTTTGGATTGTTGTGCAACTG 780
QY 851 TTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTATGCTGACTTGG 910
Db 781 TTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTATGCTGACTTGG 840
QY 911 AGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTGGTTGTAGAT 970
Db 841 AGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTGGTTGTAGAT 900
QY 971 CTAATACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCATT 1030
Db 901 CTAATACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAATCTTGCTCATT 960
QY 1031 CTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAAATTCCACTC 1090
Db 961 CTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAAATTCCACTC 1020
QY 1091 CTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCACTATAAAATG 1150
Db 1021 CTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCACTATAAAATG 1080
QY 1151 CAAATAAAGTTACTCAAAATCTGTG 1174
Db 1081 CAAATAAAGTTACTCAAAATCTGTG 1104

RESULT 20
BD191202
LOCUS 186 human secreted proteins.
DEFINITION 186 human secreted proteins.
ACCESSION BD191202
VERSION BD191202.1 GI:33000941
KEYWORDS JP 2002510192-A/166.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1816)
AUTHORS Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,
Bednarik,D.P., Endress,G.A., Yu,G.L., N.J., Feng,P., Young,P.E.,
Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.S., Florence,K.A.,
Olsen,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,
Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.
186 human secreted proteins
Patent: JP 2002510192-A 166 02-APR-2002;
HUMAN GENOME SCIENCES INC
PN JP 2002510192-A/166
PD 02-APR-2002
PF 06-MAR-1998 JP 1998538883
PR 07-MAR-1997 US 60/040162,07-MAR-1997 US 60/040333 PR
07-MAR-1997 US 60/038621,07-MAR-1997 US 60/040161 PR
07-MAR-1997 US 60/040626,07-MAR-1997 US 60/040334 PR
07-MAR-1997 US 60/040336,07-MAR-1997 US 60/040163 PR
11-APR-1997 US 60/043580,11-APR-1997 US 60/043568 PI STEVEN
M RUBEN,CRAIG A ROSEN,CARRIE L FISCHER,DANIEL R SOPPET, PI
KENNETH C CARTER,DANIEL P BEDNARIK,GREGORY
A ENDRESS, GUO LIANG
PI YU, JIAN NI.
PI PING FENG, PAUL E YOUNG, JOHN M GREENE, ANN
M FERRIE, ROXANNE DUAN,
PI JING SHAN HU, KIMBERLY A FLORENCE, HENRIK
S OLSEN, REINHARD EBNER,
PI LAURIE A BREWER, PAUL A MOORE, YANGGU SHI, DAVID W LAFLEUR PI
YI LI, ZHIZHEN ZENG,

PI HLA KYAW
PC C12N15/12,C12N5/10,C12N1/21,C07K14/47,C07K16/18,C12Q1/68, PC
G01N33/50,
PC G01N33/53,G01N33/68,A61K38/17
CC Strandedness: Double;
CC Topology: Linear;
PH Key Location/Qualifiers.
FEATURES
source
1. 1816
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
ORIGIN
Query Match 89.4%; Score 1049; DB 6; Length 1816;
Best Local Similarity 94.7%; Pred. No. 5.3e-244;
Matches 1119; Conservative 11; Mismatches 37; Indels 15; Gaps 4;
QY 8 GTGGGGAAACCCCTTCCGAGAAACACAGCAACAAAGCTGAGCTGTGTGACAGAGGGGAACA 67
Db 222 GAGGAGGAAACCCCTTCCGAGAAACACAGCAACAAAGCTGAGCTGTGTGACAGAGGGGAACA 281
QY 68 AGATGGCGGGCGCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 127
Db 282 AGATGGCGGGCGCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGC 341
QY 128 TGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCATTTGACT 187
Db 342 TGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCATTTGACT 401
QY 188 CGGTCTTGGGTGATACGGCGCTCTTGGCCACCGGGCCTGTCTAGTTGACCTACCCCTTGCA 247
Db 402 CGGTCTTGGGTGATACGGCGCTCTTGGCCACCGGGCCTGTCTAGTTGACCTACCCCTTGCA 461
QY 248 CCTACCCCTAAGGAAGAGGAGTTGTACCATGTCTAGAGAGGTTTCAGGCTGTTTTCATTT 307
Db 462 CCTACCCCTAAGGAAGAGGAGTTGTACCATGTCTAGAGAGGTTTCAGGCTGTTTTCATTT 521
QY 308 GTCAGTTTGTGGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAATCTGCAT 367
Db 522 GTCAGTTTGTGGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAATCTGCAT 581
QY 368 GTACAGAAAGCATATTCCTAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGCCAGATC 427
Db 582 GTACAGAAAGCATATTCCTAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGCCAGATC 641
QY 428 AGCTGCCATTGCTGAACTGAGACAAGAACTTATGTCCTCTGATGCCAAAATGCACC 487
Db 642 AGCTGCCATTGCTGAACTGAGACAAGAACTTATGTCCTCTGATGCCAAAATGCACC 701
QY 488 TACTCTTTCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCCGGCAGAGA 547
Db 702 TACTCTTTCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCCGGCAGAGA 761
QY 548 GCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 607
Db 762 GCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATAT 821
QY 608 TCCAGTCTAAGCC---AGAAATCCAGTACGCCACCACTTTGGAGC---AGGAGCCTACAA 661
Db 822 TCCAGTCTAAGCCCAAGAAATCCAGGTACGCCACCACTTTGGAGCCAGGAGCCCTACCAA 881
QY 662 ATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCT---GCAATGAGAAATTCACAAG 718
Db 882 ATTTGGRGRGAWCMTCTCTAAGCAAAATGTCNTCAKMTCGSMAATGAGAAATTCACAAG 941
QY 719 CGCACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTA 778
Db 942 CGCACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTA 1001
QY 779 ACTCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATGCTTTGGATTT 838
Db 1002 ACTCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATGCTTTGGATTT 1061

QY 839 GTTGTGCAACTGTTGTACAGCTGTGGAGCA-----GTATGTTCCCTCTGAGAAAGCTGA 892
Db 1062 GTTGTGCAACTGTTGTACAGCTGTGGAGCAAGTATAGTTTCCCTCTGAGAAAGCTGA 1121
QY 893 GTATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTT 952
Db 1122 GTATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTT 1181
QY 953 CTCTGTGGTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAA 1012
Db 1182 CTCTGTGGTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAA 1241
QY 1013 AAGTGAATCTTGTCTCAATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAG 1072
Db 1242 AAGTGAATCTTGTCTCAATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAG 1301
QY 1073 ACATCTAAAAATCCACTCCCTCATAGAGCTTTTAAAAATGGTTTCAATGGATATAGGCCCTTA 1132
Db 1302 ACATCTAAAAATCCACTCCCTCATAGAGCTTTTAAAAATGGTTTCAATGGATATAGGCCCTTA 1361
QY 1133 AGAAATCACTATAAAATGCAAAATGCAAAATGCTCAATCTGTG 1174
Db 1362 AGAAATCACTATAAAATGCAAAATGCAAAATGCTCAATCTGTG 1403

RESULT 21
AR379540
LOCUS AR379540 1742 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 85 from patent US 6607879.
ACCESSION AR379540
VERSION AR379540.1 GI:40087174
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1742)
AUTHORS Cocks,B.G., Stuart,S.G. and Seilhamer,J.J.
TITLE Compositions for the detection of blood cell and immunological response gene expression
JOURNAL Patent: US 6607879-A 85 19-AUG-2003;
FEATURES Location/Qualifiers
source 1..1742
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 83.0%; Score 974; DB 6; Length 1742;
Best Local Similarity 97.1%; Pred.No. 9e-226;
Matches 1152; Conservative 0; Mismatches 15; Indels 19; Gaps 15;
QY 8 GTGGGGAAACCTTCCGAGAAACAGCAACAAGCTGAGTGC-TGTGACAGAGGGAAAC 66
Db 154 GAGGAGGAAACCTTCCGAGAAACAGCAACAAGCTGAGTGC-TGTGACAGAGGGAAAC 213
QY 67 AAGATGGCGGCGCGGAAGGG-GAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCT 125
Db 214 AAGATGGCGGCGCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCCGCT 273
QY 126 GCTGCTGCTGACCATGGCCTTGGCCGAGG-TTCGGGGACCGCTTCGGCTGAAGCATTTG 184
Db 274 GCTGCTGCTGACCATGGCCTTGGCCGAGGTTTCGGGGACCGCTTCGGCTGAAGCATTTG 333
QY 185 ACTCGGTCTTGGGTGATACGGCGTCTTGGC-ACCGGGCCTGTCAGTTGACCTACCCCTTG 243
Db 334 ACTCGGTCTTGGGTGATACGGCGTCTTGGCAACCGGGCCTGTCAGTTGACCTACCCCTTG 393
QY 244 CACACCTACCCCTAA-GGAAGAGGAGTTGTCAGCATGTTCAGAGAGGTTGC-AGGCTGTTTT 301
Db 394 CACACCTACCCCTAAGGAAGAGGAGTTGTCAGCATGTTCAGAGAGGTTTCAAGGCTGTTTT 453
QY 302 CAA--TTTGTGAGTTTGTGGATGATGGA-TTGACTTAAATCGAACTAAATGGAAATGTG 358

Db 454 CAAATTTGTCAAGTTTCTGGATGATGGAATTTGACTTAAATCGAACTAAATGGAAATGTG 513
QY 359 AATCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTT--GCCATCTTGG 416
Db 514 AATCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTTGCCAACTTGGT 573
QY 417 TTGCCAGAATCAGCTGCCAATTCGCTGAACTGAGACAAAGAACTTATGTCCCTGATGCC 476
Db 574 TTGCCAGAATCAGCTGCCAATTCGCTGAACTGAGACAAAGAACTTATGTCCCTGATGCC 633
QY 477 AAAAAATGCACCTACTCTTTTCCCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGA 536
Db 634 AAAAAATGCACCTACTCTTTTCCCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGA 693
QY 537 CTCCGCACAGAGCTTTCATAACCTC-TTCATGGACTTTTATCTTCAAGCCGATGACGGAA 595
Db 694 CTCCGCACAGAGCTTTCATAACCTC-TTCATGGACTTTTATCTTCAAGCCGATGACGGAA 753
QY 596 AAATAGTTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGC 655
Db 754 AAATAGTTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGC 813
QY 656 CTACAAAATTTGAGA-GAATCATCTCTAAGCAAAATGTCCT---ATCTGCAAAATGA-GAAA 710
Db 814 CTACAAAATTTGAGAGGAATCATCTCTAAGCAAAATGTCCTCAGATCTGCAAAATGAGGAAA 873
QY 711 TTCACAAGCGCACAGGAATTTTCTTGAAG-ATGGAGAAAGTGAATGGCTTTTAAAGATGCC 769
Db 874 TTCACAAGCGCACAGGAATTTTCTTGAAGTATGGAGAAAGTGAATGGCTTTTAAAGATGCC 933
QY 770 TCTCTCTTAACTCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATATGC 829
Db 934 TCTCTCTTAACTCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATATGC 993
QY 830 TTT-GGATTTGTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAG 888
Db 994 TTTGGGATTTGTGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAG 1053
QY 889 CTGAGTATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCT 948
Db 1054 CTGAGTATCTATGGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCT 1113
QY 949 TCTTCTCTTGTGTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCT 1008
Db 1114 TCTTCTCTTGTGTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCT 1173
QY 1009 ACAAAAGTGAATCTGCTCATTTCTGAAATTTAAGCATTTTTCTTTAAAGACAAGTGA 1068
Db 1174 ACAAAAGTGAATCTGCTCATTTCTGAAATTTAAGCATTTTTCTTTAAAGACAAGTGA 1233
QY 1069 ATAGACATCTAAATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGC 1128
Db 1234 ATAGACATCTAAATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGC 1293
QY 1129 CTTAAGAAATCACTATAAAATGCAAAATGAAGTTACTCAAAATCTGTG 1174
Db 1294 CTTAAGAAATCACTATAAAATGCAAAATGAAGTTACTCAAAATCTGTG 1339

RESULT 22
BD233458
LOCUS BD233458 969 bp DNA linear PAT 17-JUL-2003
DEFINITION Human protein having hydrophobic domain and DNA encoding the same.
ACCESSION BD233458
VERSION BD233458.1 GI:33043228
KEYWORDS JP 2002519016-A/4.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 969)
Rato,S. and Kimura,T.
Human protein having hydrophobic domain and DNA encoding the same

JOURNAL Patent: JP 2002519016-A 4 02-JUL-2002;
SAGAMI CHEMICAL RESEARCH CENTER, PROTEGENE INC
COMMENT OS Homo sapiens (human)
PN JP 2002519016-A/4
PD 02-JUL-2002
PF 18-JUN-1999 JP 2000557267
PI SEISHI KATO, TOMOKO KIMURA
PC

C12N15/09, C07K14/47, C12N1/15, C12N1/19, C12N5/10, C12N5/00, C12N5/ PC
00
CC Human protein having hydrophobic domain and DNA encoding the
CC same
FH Key Location/Qualifiers
FT source 1..969
FT /organism='Homo sapiens (human)'.
FEATURES Location/Qualifiers
source 1..969
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

ORIGIN

Query Match 82.5%; Score 969; DB 6; Length 969;
Best Local Similarity 100.0%; Pred. No. 1.4e-224;
Matches 969; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 70 ATGGCGGCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGCTG 129
Db 1 ATGGCGGCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCGCGCTGCTG 60
Qy 130 CTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACTCG 189
Db 61 CTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCATTTGACTCG 120
Qy 190 GTCTTGGGTGATACGGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCCTTGACACC 249
Db 121 GTCTTGGGTGATACGGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCCTTGACACC 180
Qy 250 TACCCTAAGGAAGAGAGTTGTACGCATGTCAGAGAGGTTGAGGCTGTTTCAATTGT 309
Db 181 TACCCTAAGGAAGAGAGTTGTACGCATGTCAGAGAGGTTGAGGCTGTTTCAATTGT 240
Qy 310 CAGTTTGTGGATGGAATTGACTTAAATCGAACTAAATGGAAATGGAATGTAATCTGCATGT 369
Db 241 CAGTTTGTGGATGGAATTGACTTAAATCGAACTAAATGGAAATGGAATGTAATCTGCATGT 300
Qy 370 ACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGCCAGAAFCAG 429
Db 301 ACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTGGTTGCCAGAAFCAG 360
Qy 430 CTGCCATTCGCTGAACCTGAGACAAGAACACTTATGTCCCTGATGCCAAAAATGCACCTA 489
Db 361 CTGCCATTCGCTGAACCTGAGACAAGAACACTTATGTCCCTGATGCCAAAAATGCACCTA 420
Qy 490 CTCCTTCCCTCTAACTCTGGTGAGGTCATTCGGAGTGACATGATGAGACTCCGCACAGAGC 549
Db 421 CTCCTTCCCTCTAACTCTGGTGAGGTCATTCGGAGTGACATGATGAGACTCCGCACAGAGC 480
Qy 550 TTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTC 609
Db 481 TTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATAGTTATATTC 540
Qy 610 CAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACAAATTTGAGA 669
Db 541 CAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACAAATTTGAGA 600
Qy 670 GAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGAAT 729
Db 601 GAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCGCACAGGAAT 660
Qy 730 TTTCTTTGAAGATGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTCTTAACTCTGGGTGG 789
Db 661 TTTCTTTGAAGATGGAGAAAGTATGGCTTTTTTAAGATGCCCTCTCTCTTAACTCTGGGTGG 720

Qy 790 ATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTTGCTTTGGAATTTGTTGTGCAACT 849
Db 721 ATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTTGCTTTGGAATTTGTTGTGCAACT 780
Qy 850 GTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTATGGTGACTTG 909
Db 781 GTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTATGGTGACTTG 840
Qy 910 GAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTGTGGTTGTTAGA 969
Db 841 GAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTGTGGTTGTTAGA 900
Qy 970 TCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGTCTCAT 1029
Db 901 TCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAATCTTGTCTCAT 960
Qy 1030 TCTGAAATTT 1038
Db 961 TCTGAAATTT 969

Search completed: June 15, 2004, 05:14:15
Job time : 4881 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 15, 2004, 03:37:20 ; Search time 538 Seconds
(without alignments)
9270.232 Million cell updates/sec

Title: US-09-978-299A-329
Perfect score: 1174
Sequence: 1 cggacgcgtggggaaaccc.....taaaagtactcaaatctgtg 1174

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 210

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 80%
Maximum Match 100%
Listing first 65000 summaries

Database : N_Geneseq_29Jan04:*
1: Geneseqn1980s:*
2: Geneseqn1990s:*
3: Geneseqn2000s:*
4: Geneseqn2001as:*
5: Geneseqn2001bs:*
6: Geneseqn2002s:*
7: Geneseqn2003as:*
8: Geneseqn2003bs:*
9: Geneseqn2003cs:*
10: Geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %		DB ID	Description
		Match	Length		
1	1174	100.0	1174	2	Aaz34171 Human PRO
2	1174	100.0	1174	3	Aac78540 Human PRO
3	1174	100.0	1174	3	Aaa77533 Human PRO
4	1174	100.0	1174	4	Aas21379 Human CDN
5	1174	100.0	1174	4	Aac97400 Human ang
6	1174	100.0	1174	6	AbL88075 Human PRO
7	1174	100.0	1174	6	AbL95564 Human ang
8	1174	100.0	1174	7	AcD23988 Novel hum
9	1174	100.0	1174	7	AcD42704 Novel hum
10	1174	100.0	1174	7	AcA67129 CDNA enco
11	1174	100.0	1174	7	AcA63739 Novel hum
12	1174	100.0	1174	7	AcA03738 CDNA enco
13	1174	100.0	1174	7	AcA71903 Human sec
14	1174	100.0	1174	7	AbX89276 DNA encod
15	1174	100.0	1174	7	AbX92543 CDNA enco
16	1174	100.0	1174	7	AcD41930 Human sec
17	1174	100.0	1174	7	AcA66284 Human cDN
18	1174	100.0	1174	7	AcA04159 Human cDN
19	1174	100.0	1174	8	Ada45790 Novel hum
20	1174	100.0	1174	8	Ada76221 Human PRO
21	1174	100.0	1174	8	Ada18871 Human PRO
22	1174	100.0	1174	8	Ada61494 Homo sapi
23	1174	100.0	1174	8	Adb19279 Novel hum

24	1174	100.0	1174	8	ADB27820	Adb27820 cDNA enco
25	1174	100.0	1174	8	ADA86299	Ada86299 Novel hum
26	1174	100.0	1174	8	ADB15863	Adb15863 Human PRO
27	1174	100.0	1174	8	ADA47649	Ada47649 Human PRO
28	1174	100.0	1174	8	ADA67444	Ada67444 Human PRO
29	1174	100.0	1174	8	ADB30451	Adb30451 cDNA enco
30	1174	100.0	1174	8	ADA85747	Ada85747 Novel hum
31	1174	100.0	1174	8	ADA96959	Ada96959 Human PRO
32	1174	100.0	1174	8	ADA79263	Ada79263 Human PRO
33	1174	100.0	1174	8	ADA87402	Ada87402 Novel hum
34	1174	100.0	1174	8	ADB16604	Adb16604 Human PRO
35	1174	100.0	1174	8	ADA91696	Ada91696 Novel hum
36	1174	100.0	1174	8	ADB14759	Adb14759 Human PRO
37	1174	100.0	1174	8	ADA24868	Ada24868 Novel hum
38	1174	100.0	1174	8	ADB18720	Adb18720 Novel hum
39	1174	100.0	1174	8	ADA93935	Ada93935 Human PRO
40	1174	100.0	1174	8	ADB19831	Adb19831 Novel hum
41	1174	100.0	1174	8	ADB13143	Adb13143 Human PRO
42	1174	100.0	1174	8	ACD98559	AcD98559 Novel hum
43	1174	100.0	1174	8	ACD29885	AcD29885 Novel hum
44	1174	100.0	1174	8	ADA12529	Ada12529 Human cDN
45	1174	100.0	1174	8	ADA74397	Ada74397 Human PRO
46	1174	100.0	1174	8	ADB24630	Adb24630 Human PRO
47	1174	100.0	1174	8	ADA82154	Ada82154 Human PRO
48	1174	100.0	1174	8	ADA75117	Ada75117 Human PRO
49	1174	100.0	1174	8	ADA85195	Ada85195 Novel hum
50	1174	100.0	1174	8	ADA84643	Ada84643 Novel hum
51	1174	100.0	1174	8	ADB29899	Adb29899 cDNA enco
52	1174	100.0	1174	8	ADA80427	Ada80427 Human PRO
53	1174	100.0	1174	8	ADA75669	Ada75669 Human PRO
54	1174	100.0	1174	8	ADA46894	Ada46894 Human PRO
55	1174	100.0	1174	8	ADB25190	Adb25190 Human PRO
56	1174	100.0	1174	8	ADA93366	Ada93366 Human PRO
57	1174	100.0	1174	8	ADB26716	Adb26716 cDNA enco
58	1174	100.0	1174	8	ADB31003	Adb31003 cDNA enco
59	1174	100.0	1174	8	ADA60931	Ada60931 Homo sapi
60	1174	100.0	1174	8	ADB24078	Adb24078 Human PRO
61	1174	100.0	1174	8	ADA96407	Ada96407 Human PRO
62	1174	100.0	1174	8	ADA80979	Ada80979 Human PRO
63	1174	100.0	1174	8	ADA95855	Ada95855 Human PRO
64	1174	100.0	1174	8	ADB26164	Adb26164 cDNA enco
65	1174	100.0	1174	8	ADB21649	Adb21649 Novel hum
66	1174	100.0	1174	8	ACD29300	AcD29300 Novel hum
67	1174	100.0	1174	8	ADA77428	Ada77428 Human PRO
68	1174	100.0	1174	8	ADB18168	Adb18168 cDNA enco
69	1174	100.0	1174	8	ADA86851	Ada86851 Novel hum
70	1174	100.0	1174	8	ADA87954	Ada87954 Novel hum
71	1174	100.0	1174	8	ADA46342	Ada46342 Novel hum
72	1174	100.0	1174	8	ADB28372	Adb28372 cDNA enco
73	1174	100.0	1174	8	ADB28924	Adb28924 cDNA enco
74	1174	100.0	1174	8	ADA76876	Ada76876 Human PRO
75	1174	100.0	1174	8	ADA88506	Ada88506 Novel hum
76	1174	100.0	1174	8	ADA97511	Ada97511 Human PRO
77	1174	100.0	1174	8	ADB27268	Adb27268 cDNA enco
78	1174	100.0	1174	8	ADB22201	Adb22201 Novel hum
79	1174	100.0	1174	8	ADA66892	Ada66892 Human PRO
80	1174	100.0	1174	8	ADB22753	Adb22753 Human PRO
81	1174	100.0	1174	8	ADB23526	Adb23526 Human PRO
82	1174	100.0	1174	8	ADA92248	Ada92248 Novel hum
83	1174	100.0	1174	8	ADB15311	Adb15311 Human PRO
84	1174	100.0	1174	8	ADB38563	Adb38563 Novel hum
85	1174	100.0	1174	8	ADB38011	Adb38011 Novel hum
86	1174	100.0	1174	9	ADB66483	Adb66483 Novel hum
87	1174	100.0	1174	9	ADB89563	Adb89563 Human PRO
88	1174	100.0	1174	9	ADB90295	Adb90295 Human PRO
89	1174	100.0	1174	9	ADB39396	Adb39396 Novel hum
90	1174	100.0	1174	9	ADB73835	Adb73835 Human PRO
91	1174	100.0	1174	9	ADB47019	Adb47019 Novel hum
92	1174	100.0	1174	9	ADB86626	Adb86626 Human PRO
93	1174	100.0	1174	9	ADB76551	Adb76551 Human PRO
94	1174	100.0	1174	9	ADB77231	Adb77231 Novel hum
95	1174	100.0	1174	9	ADB34388	Adb34388 Human PRO
96	1174	100.0	1174	9	ADB35492	Adb35492 Human PRO

97	1174	100.0	1174	9	ADB33836	Human PRO
98	1174	100.0	1174	9	ADB34940	Human PRO
99	1174	100.0	1174	9	ADB36044	Human PRO
100	1174	100.0	1174	9	ADB46439	Novel hum
101	1174	100.0	1174	9	ADC43977	Human cDN
102	1174	100.0	1174	9	ADC61737	Human cDN
103	1174	100.0	1174	9	ADC63701	Human cDN
104	1174	100.0	1174	9	ADC66801	Human cDN
105	1174	100.0	1174	9	ADC68925	Human cDN
106	1174	100.0	1174	9	ADC62985	Human cDN
107	1174	100.0	1174	9	ADC68050	Human cDN
108	1174	100.0	1174	9	ADC41370	Human cDN
109	1174	100.0	1174	9	ADC67425	Human cDN
110	1174	100.0	1174	9	ADC62361	Human cDN
111	1174	100.0	1174	9	ADC41994	Human cDN
112	1174	100.0	1174	9	ADC50312	Novel hum
113	1174	100.0	1174	9	ADC71859	Novel hum
114	1174	100.0	1174	9	ADC59838	Novel hum
115	1174	100.0	1174	9	ADC52845	Novel hum
116	1174	100.0	1174	9	ADC57199	Novel hum
117	1174	100.0	1174	9	ADC60390	Novel hum
118	1174	100.0	1174	9	ADC50865	Novel hum
119	1174	100.0	1174	9	ADC65392	Human PRO
120	1174	100.0	1174	9	ADC54490	Novel hum
121	1174	100.0	1174	9	ADC53451	Novel hum
122	1174	100.0	1174	9	ADC58974	Novel hum
123	1174	100.0	1174	9	ADC55852	Novel hum
124	1174	100.0	1174	9	ADC58422	Novel hum
125	1174	100.0	1174	9	ADD03096	Novel hum
126	1174	100.0	1174	9	ADC90088	Novel hum
127	1174	100.0	1174	9	ADC69507	CDNA enco
128	1174	100.0	1174	9	ADC48396	Human PRO
129	1174	100.0	1174	9	ADD09925	Human PRO
130	1174	100.0	1174	9	ADD04500	Novel hum
131	1174	100.0	1174	9	ADC80456	Novel hum
132	1174	100.0	1174	9	ADD10963	Human PRO
133	1174	100.0	1174	9	ADD10296	Human sec
134	1174	100.0	1174	9	ADC47844	Human PRO
135	1174	100.0	1174	9	ADC79904	Novel hum
136	1174	100.0	1174	9	ADD11256	Human sec
137	1174	100.0	1174	9	ADD09373	Human PRO
138	1174	100.0	1174	9	ADD41086	Novel hum
139	1174	100.0	1174	9	ADD52225	CDNA enco
140	1174	100.0	1174	9	ADD52965	CDNA enco
141	1174	100.0	1174	9	ADD53517	Novel hum
142	1174	100.0	1174	9	ADD37049	Human sec
143	1174	100.0	1174	9	ADD51673	CDNA enco
144	1174	100.0	1174	9	ADD02472	Human PRO
145	1174	100.0	1174	9	ADD01906	Human PRO
146	1174	100.0	1174	9	ADD54088	Novel hum
147	1174	100.0	1174	9	ADe49363	Human cDN
148	1174	100.0	1174	9	ADD92405	Human PRO
149	1174	100.0	1174	9	ADD91301	Human PRO
150	1174	100.0	1174	9	ADe03915	Human PRO
151	1174	100.0	1174	9	ADe32212	Novel hum
152	1174	100.0	1174	9	ADe22144	CDNA enco
153	1174	100.0	1174	9	ADD79368	CDNA enco
154	1174	100.0	1174	9	ADe35417	Human cDN
155	1174	100.0	1174	9	ADe16531	Human cDN
156	1174	100.0	1174	9	ADD73146	Human cDN
157	1174	100.0	1174	9	ADe41904	Human PRO
158	1174	100.0	1174	9	ADe17721	Human PRO
159	1174	100.0	1174	9	ADD91853	Human PRO
160	1174	100.0	1174	9	ADe33316	Novel hum
161	1174	100.0	1174	9	ADe33868	Novel hum
162	1174	100.0	1174	9	ADD79920	CDNA enco
163	1174	100.0	1174	9	ADD92957	Human PRO
164	1174	100.0	1174	9	ADD72504	Human cDN
165	1174	100.0	1174	9	ADe19377	Human PRO
166	1174	100.0	1174	9	ADe18825	Human PRO
167	1174	100.0	1174	9	ADe43021	Human PRO
168	1174	100.0	1174	9	ADD95810	Human PRO
169	1174	100.0	1174	9	ADe22696	CDNA enco

170	1174	100.0	1174	9	ADD78814	CDNA enco
171	1174	100.0	1174	9	ADe32764	Novel hum
172	1174	100.0	1174	9	ADe42456	Human PRO
173	1174	100.0	1174	9	ADe17155	Human cDN
174	1174	100.0	1174	9	ADD80472	CDNA enco
175	1174	100.0	1174	9	ADD89500	Human PRO
176	1174	100.0	1174	9	ADe40784	Human PRO
177	1174	100.0	1174	9	ADe04583	Human PRO
178	1174	100.0	1174	10	ADC81008	Novel hum
179	1174	100.0	1174	10	ADD76456	Human PRO
180	1174	100.0	1174	10	ADD87820	Human PRO
181	1174	100.0	1174	10	ADD86224	Human PRO
182	1174	100.0	1174	10	ADe75672	Human PRO
183	1174	100.0	1174	10	ADe48663	Human cDN
184	1174	100.0	1174	10	ADe41257	Human sec
185	1174	100.0	1174	10	ADe23248	CDNA enco
186	1174	100.0	1174	10	ADe23800	CDNA enco
187	1174	100.0	1174	10	ADe24443	CDNA enco
188	1174	100.0	1174	10	ADD87268	Human PRO
189	1174	100.0	1174	10	ADe89134	Human PRO
190	1174	100.0	1174	10	ADe18273	Human PRO
191	1174	100.0	1174	10	ADe88582	Human PRO
192	1174	100.0	1174	10	ADe89764	Human cDN
193	1163.8	99.1	1634	4	AAK94533	Human ful
194	1163.8	99.1	1696	9	ADC37344	Nuclear f
195	1163.8	99.1	1704	3	AAZ56760	Human tra
196	1151.8	98.1	1695	2	AAV59792	Human sec
197	1151.8	98.1	1695	6	ABS73786	Human cDN
198	1151.8	98.1	1695	8	ACD82929	CDNA sequ
199	1121	95.5	1121	3	AAZ90051	Hydrophob
200	1118	95.2	1457	5	AAF93855	Human cDN
201	1106	94.2	1138	2	AAZ82075	Human CBC
202	1106	94.2	1138	7	ABZ72012	Human unk
203	1106	94.2	1138	7	ABZ75896	Heart dis
204	1105	94.1	1466	9	ADC37346	Nuclear f
205	1103	94.0	1109	6	ABK35662	CDNA sequ
206	1097	93.4	1472	2	AAZ35556	Secreted
207	1049	89.4	1756	2	AAV59667	Human sec
208	1049	89.4	1816	6	ABS73654	Human cDN
209	1049	89.4	1816	8	ACD82797	CDNA sequ
210	969	82.5	969	3	AAZ90041	Hydrophob

ALIGNMENTS

RESULT 1	
AAZ34171	
ID	AAZ34171 standard; cDNA; 1174 BP.
XX	
AC	AAZ34171;
XX	
DT	07-DEC-1999 (first entry)
XX	
DE	Human PRO195 nucleotide sequence.
XX	
KW	Human; PRO; EST; expressed sequence tag; PCR primer; hybridisation;
KW	probe; blood coagulation disorder; cancer; cellular adhesion disorder;
KW	secreted protein; transmembrane protein; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO9946281-A2.
XX	
PD	16-SEP-1999.
XX	
PF	08-MAR-1999; 99WO-US005028.
XX	
PR	10-MAR-1998; 98US-0077450P.
PR	11-MAR-1998; 98US-0077632P.
PR	11-MAR-1998; 98US-0077641P.
PR	11-MAR-1998; 98US-0077649P.
PR	12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080155P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082767P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
XX
PA (GETH) GENENTECH INC.
XX
PI Wood WI, Goddard A, Gurney A, Yuan J, Baker KP, Chen J;
XX
XX WPI; 1999-551358/46.
DR P-PSDB; AAY41733.
DR
XX
PT New secreted and transmembrane polypeptides and their polynucleotides,
PT useful for treating blood coagulation disorders, cancers and cellular
PT adhesion disorders.
XX
PS Claim 2; Fig 131; 530pp; English.
XX
CC The present invention describes secreted and transmembrane polypeptides
CC and their polynucleotides. The nucleotide sequences are useful as sources
CC of probes, primers, for chromosome mapping, and for generation of
CC antisense sequences. They can also be used to create transgenic animals.
CC The proteins can be used to treat a variety of diseases and disorders,
CC depending on their function. Diseases that may be treated include blood
CC coagulation disorders, cancers and cellular adhesion disorders. They may
CC also be used to raise antibodies. AAZ33891 to AAZ34338, and AAY41685 to
CC AAY41774 represent polynucleotide and polypeptide sequence given in the
CC exemplification of the present invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 2; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||
Db 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
|||
Db 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
|||
QY 121 CCGCTGCTGCTGCTGACCATGCGCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
|||
Db 121 CCGCTGCTGCTGCTGACCATGCGCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
|||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCCTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
|||
Db 181 TTTGACTCGGTCTTGGGTGATACGGCCTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
|||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
|||
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
|||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
|||
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
|||
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420
|||
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420
|||
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGCAAGAAACAACATTATGTCCTGATGCCAAAA 480
|||
Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGCAAGAAACAACATTATGTCCTGATGCCAAAA 480
|||

QY	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCA	TTCTGGAGTGCATGATGGACTCC	540
DB				
QY	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCA	TTCTGGAGTGCATGATGGACTCC	540
DB				
QY	541	GCACAGAGCTTCATAAACCTCTTCA	TGGAGCTTTTATCTTCAAGCCGATGACGGA	600
DB				
QY	541	GCACAGAGCTTCATAAACCTCTTCA	TGGAGCTTTTATCTTCAAGCCGATGACGGA	600
DB				
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAG	TACGACCAACACATTTGGAGCAGGACCTACA	660
DB				
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAG	TACGACCAACACATTTGGAGCAGGACCTACA	660
DB				
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATG	CTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB				
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATG	CTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB				
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTG	AGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
DB				
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTG	AGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
DB				
QY	781	TCTGGTGGATTTTAACTACAACTCTTTGT	CTCCTCGGTGATGGTATTGCTTTGGATTGT	840
DB				
QY	781	TCTGGTGGATTTTAACTACAACTCTTTGT	CTCCTCGGTGATGGTATTGCTTTGGATTGT	840
DB				
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAG	TATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
DB				
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAG	TATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
DB				
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAG	CTAAACAGATATCCAGCTTCTTCTTTGTG	960
DB				
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAG	CTAAACAGATATCCAGCTTCTTCTTTGTG	960
DB				
QY	961	GTTGTTAGATCTAAAAC	TGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
DB				
QY	961	GTTGTTAGATCTAAAAC	TGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
DB				
QY	1021	CTTGTCTCATCTGAAATTTAAGCATTTTCT	TTTAAAGACAAGTGTAATAGACATCTAA	1080
DB				
QY	1021	CTTGTCTCATCTGAAATTTAAGCATTTTCT	TTTAAAGACAAGTGTAATAGACATCTAA	1080
DB				
QY	1081	AATCCACTCCTCATAGAGCTTTTAAAAATG	GTGTTTCATTTCGATATAGGCCTTAAGAAATCA	1140
DB				
QY	1081	AATCCACTCCTCATAGAGCTTTTAAAAATG	GTGTTTCATTTCGATATAGGCCTTAAGAAATCA	1140
DB				
QY	1141	CTATAAAATGCAAAATAAAGTTTACTCAAAT	CTGTG	1174
DB				
QY	1141	CTATAAAATGCAAAATAAAGTTTACTCAAAT	CTGTG	1174
DB				

RESULT, T. 2

AAC78540
ID AAC78540 standard; cDNA; 1174 BP.

AAC78540:

DT 08-FEB-2001 (first entry)

Human PRO195 (UN0169) nucleotide sequence SEQ ID NO:329.

Human; secreted protein; transmembrane protein; PRO; EST; cytosstatic;
KW expressed sequence tag; detection; cancer; ss.

AA Homo sapiens.

AA
PN WO200053756-A2.

14-SEP-2000.

18-FEB-2000; 2000WO-US004341.

PR 08-MAR-1999; 99WO-US005028.

PR 12-MAR-1999; 99US-0123957P.

PR 29-MAR-1999; 99US-0126773P.

21-APR-1999; 99US-0130232P.
28-APR-1999; 99US-0131445P.
14-MAY-1999; 99US-0134287P.
23-JUN-1999; 99US-0141037P.
26-JUL-1999; 99US-0145698P.
29-OCT-1999; 99US-0162506P.
30-NOV-1999; 99WO-US028313.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028565.
16-DEC-1999; 99WO-US030095.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.

(GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Pilvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillian KJ;
Klavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
Stewart TA, Tumas D, Williams PM, Wood WI;

WPI; 2000-611443/58.
P-PSDB; AAB44289.

Novel PRO polypeptides and polynucleotides used in detection methods, to target bioactive molecules to specific cells, and to modulate cellular activities.

Claim 2; Fig 131; 636pp; English.

AAC78458 to AAC78599 represent polynucleotide and EST (expressed sequence tag) sequences which encode secreted or transmembrane PRO polypeptides. The PRO polynucleotides and polypeptides have cytosolic activity. The polynucleotides and polypeptides can be used for detecting the presence of PRO polypeptides in samples, for linking bioactive molecules to cells and for modulating biological activities of cells, using the polypeptides for specific targeting. The polypeptide targeting can be used to kill the target cells, e.g. for the treatment of cancers. The polypeptide pairs provide specific targeting of bioactive molecules to cells. AAC78500 to AAC78987 represent PCR primers and probes used in the isolation of the PRO polynucleotide sequences

Sequence 1174 BP: 325 A: 250 C: 275 G: 324 T: 0 U: 0 Other: 1

Query Match 100.0%; Score 1174; DB 3; Length 1174;

Query Match	100.0%	100.0%
Best Local Similarity	100.0%	100.0%
Pred. No. 0;		

Matches 1174: Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

1 CCGACCGCTGGGGGAAACCCCTTCCGAGAAAACAGCAAACAAGCTGAGCTGCTGTGACAGAG 60

61 GGGAAACAAGATGGCGGGCGCCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

5' ACCACCAACATGCGCGCGGAGGGGAGCCCTCTGGTGAGGCCCACTGGGGCTCCCG 120

121 CCGCTCCTCCTGCTGACCATGGCCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

180

CGGGGACCGCTTCCCGGAGGTTCGGGACCGCTGAAGCA

C-
101 TTTTCTACATCCCTCCTTCCTGCTGTATACCGGGCTTGTCAGTTGACCTACCCCC 240

107 TTTTGGGCGCTGTCCTGTAGTGAACATCCCC 240

0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.0

300

Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGCACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAATAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTCCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAAATCAGCTGCCATTCCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAAGCTTCTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCAAGCTTCTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGTCTTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGTCTTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGAAATTTCTTGAAGATGGAGAAAGTGATGCGTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGAAATTTCTTGAAGATGGAGAAAGTGATGCGTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTCCTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTCCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 3
AAA77533
ID AAA77533 standard; cDNA; 1174 BP.

XX
AC AAA77533;
XX
DT 07-NOV-2000 (first entry)
XX
DE Human PRO195 cDNA sequence SEQ ID NO:30.
XX
KW Human; PRO; promotion; inhibition; angiogenesis; cardiovascularisation;
KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;
KW cytostatic; gene therapy; vaccine; ss.

XX Homo sapiens.
OS
XX WO200032221-A2.
PN
XX
XX
PD 08-JUN-2000.
XX
PF 30-NOV-1999; 99WO-US028313.
XX
PR 01-DEC-1998; 98WO-US025108.
PR 16-DEC-1998; 98US-0112850P.
PR 12-JAN-1999; 99US-0115554P.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-OCT-1999; 99US-0162506P.
XX
PA (GEITH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ;
PI Goddard A, Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF;
PI Smith V, Watanabe CK, Williams PM, Wood WI;
XX
DR WPI; 2000-412154/35.
DR P-PSDB; AAB24394.
XX
PT Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing
PT and treating diagnosing a cardiovascular, endothelial or angiogenic
PT disorders in mammals.
XX
PS Claim 61; Fig 13; 315pp; English.
XX
CC The present invention describes nucleic acids encoding PRO polypeptides
CC useful for preventing, diagnosing and treating diagnosing a
CC cardiovascular, endothelial or angiogenic disorder in mammals by
CC modulating cell proliferation, angiogenesis and cardiovascularisation,
CC and for identifying agonists and antagonists of these processes. The
CC nucleic acids and the proteins they encode may be used in the prevention,
CC treatment and diagnosis of diseases associated with inappropriate PRO
CC expression such as cardiovascular, endothelial or angiogenic disorders in
CC mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For
CC example, the nucleic acids (NCs) and vectors containing them and the PRO
CC polypeptide may be used to treat disorders associated with decreased PRO
CC expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent
CC nucleotide and protein sequences used in the exemplification of the
CC present invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 3; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGACAAGATGGCGCGCCGAGGGAGCCCTCTGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGGACAAGATGGCGCGCCGAGGGAGCCCTCTGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180

ID XX ABL88075 standard; cDNA; 1174 BP.
AC XX ABL88075;
XX XX
DT 16-MAY-2002 (first entry)
XX XX
DE Human PRO195 cDNA sequence SEQ ID NO:7.
XX XX
KW Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW vulnery; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping; gene; ss.
XX XX
OS Homo sapiens.
XX XX
PN WO200200690-A2.
XX XX
PD 03-JAN-2002.
XX XX
PF 20-JUN-2001; 2001WO-US019692.
XX XX
PR 23-JUN-2000; 2000US-0213637P.
PR 20-JUL-2000; 2000US-0219556P.
PR 25-JUL-2000; 2000US-0220624P.
PR 25-JUL-2000; 2000US-0220664P.
PR 28-JUL-2000; 2000WO-US020710.
PR 02-AUG-2000; 2000US-0222695P.
PR 17-AUG-2000; 2000US-00643657.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 18-SEP-2000; 2000US-00664610.
PR 18-SEP-2000; 2000US-00665350.
PR 24-OCT-2000; 2000US-0242922P.
PR 08-NOV-2000; 2000US-00709238.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 22-JAN-2001; 2001US-00767609.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
XX XX
PA (GETH) GENENTECH INC.
XX XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX XX
DR WPI; 2002-090516/12.
DR P-PSDB; ABB84820.
XX XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal.

XX PS Claim 2; Fig 7; 565pp; English.
XX XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnery and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal, e.g.
CC cardiac hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The PRO polynucleotides have applications in molecular biology,
CC including use as hybridisation probes, and in chromosome and gene
CC mapping. ABL88259 to ABL88267 represent primers and probes used in the
CC exemplification of the present invention
XX XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 6; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
61 GGGAAACAAGATGGCGGCGCCGGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCTTGGCGCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
121 CCGCTGCTGCTGACCATGGCCTTGGCGCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCCTGGGTGATACGGCGCTTGGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
181 TTTGACTCGGTCCTGGGTGATACGGCGCTTGGCCACCGGGCCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGCTGTTT 300
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGA 360
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGA 360
QY 361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCCGTTGAACCTGAGACAAGAAACAACTTATGTCCCTGATGCCAAA 480
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
421 CAGAATCAGCTGCCATTCCGTTGAACCTGAGACAAGAAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGTTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
481 ATGCACCTACTCTTTCTCTAACTCTGTTGAGGTCATTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCTACA 660
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGAGGTATTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGAGGTATTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 7
ABL95564

ID ABL95564 standard; cDNA; 1174 BP.

AC ABL95564;

DT 19-JUL-2002 (first entry)

DE Human angiogenesis related cDNA PRO195 SEQ ID NO: 7.

XX Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiast; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic; gene; ss.

XX Homo sapiens.

OS WO200208284-A2.

XX 31-JAN-2002.

XX 09-JUL-2001; 2001WO-US021735.

XX 20-JUL-2000; 2000US-0219556P.

XX 25-JUL-2000; 2000US-0220624P.

XX 25-JUL-2000; 2000US-0220664P.

XX 28-JUL-2000; 2000WO-US020710.

XX 02-AUG-2000; 2000US-0222695P.

XX 17-AUG-2000; 2000US-00643657.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 07-SEP-2000; 2000US-0230978P.

XX 18-SEP-2000; 2000US-00664610.

XX 18-SEP-2000; 2000US-00665350.

XX 24-OCT-2000; 2000US-0242922P.

XX 08-NOV-2000; 2000US-00709238.

XX 08-NOV-2000; 2000WO-US030952.

XX 10-NOV-2000; 2000WO-US030873.

XX 01-DEC-2000; 2000WO-US032678.

XX 20-DEC-2000; 2000US-00747259.

XX 20-DEC-2000; 2000WO-US034956.

PR 22-JAN-2001; 2001US-00767609.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 30-MAY-2001; 2001US-00870574.
PR 30-MAY-2001; 2001WO-US017443.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.

XX (GETH) GENENTECH INC.

PA (BAKE/) BAKER K P.

PA (FERR/) FERRARA N.

PA (GERB/) GERBER H.

PA (GERR/) GERRITSEN M E.

PA (GODD/) GODDARD A.

PA (GODO/) GODOWSKI P J.

PA (GURN/) GURNEY A L.

PA (HILL/) HILLAN K J.

PA (MARS/) MARSTERS S A.

PA (PANJ/) PAN J.

PA (PAON/) PAONI N F.

PA (STEP/) STEPHAN J F.

PA (WATA/) WATANABE C K.

PA (WILL/) WILLIAMS P M.

PA (WOOD/) WOOD W I.

XX

XX

PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;

PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;

PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;

XX WPI; 2002-171999/22.

DR P-PSDB; ABB95426.

XX

PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,

PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial

PT infarction), endothelial or angiogenic disorders in a mammal.

XX

PS Claim 1; Fig 7; 567pp; English.

XX The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 6; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGACAAGATGGCGGCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGACAAGATGGCGGCGCGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGACCATGGCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCGCATGTCCAGAGGTTGCAGGCTGTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCGCATGTCCAGAGGTTGCAGGCTGTT 300
Qy 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Qy 421 CAGAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660
Qy 661 AATTTGAGAGAAATCATCTCTPAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAAATCATCTCTPAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCCTCTCGGTGATGGTATTTGGTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCCTCTCGGTGATGGTATTTGGTTGGATTGT 840
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Qy 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Qy 1081 AATTCACCTCCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Qy 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 8
ACD23988

ID XX ACD23988 standard; cDNA; 1174 BP.
AC XX ACD23988;
DT 26-AUG-2003 (first entry)
XX Novel human secreted and transmembrane protein PRO195 cDNA.
DE Human; secreted and transmembrane protein; PRO; antiinflammatory;
XX antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing; gene; ss.
XX Homo sapiens.
OS US2003032156-A1.
XX 13-FEB-2003.
PN 06-MAY-2002; 2002US-00140474.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-341980/32.
DR P-PSDB; ABO17751.

XX New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.

PS Claim 2; Fig 271; 660pp; English.

XX The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding

CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGTGTGACAGAG 60
DB |||||
1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB |||||
61 GGGAAACAAGATGGCGGCGCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB |||||
121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCACTGACCTACCCC 240
DB |||||
181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCACTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT 300
DB |||||
241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
DB |||||
301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB |||||
361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
DB |||||
421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTACTCTGGTGGGTCATTTCTGGAGTGACATGATGGACTCC 540
DB |||||
481 ATGCACCTACTCTTTCTCTACTCTGGTGGGTCATTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATTTTCAAGCCGATACCGGAAAAATA 600
DB |||||
541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATTTTCAAGCCGATACCGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCATTTTGGAGCAGGAGCCTACA 660
DB |||||
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCATTTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB |||||
661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
|||||
Db 721 CACAGGAATTTCTTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCGGTGATGGTATTCGTTTGGATTTGT 840
|||||
Db 781 TCTGGGTGGATTTTAACTACAACTCTTGTCCTCGGTGATGGTATTCGTTTGGATTTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900
|||||
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAACTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
|||||
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960

QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
|||||
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
|||||
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATGGATATAGGCCTTAAGAAATCA 1140
|||||
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATGGATATAGGCCTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
|||||
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 9

ACD42704
ID ACD42704 standard; cDNA; 1174 BP.
XX
AC ACD42704;
XX
DT 09-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; virucide; gene therapy;
KW cell death; growth induction cascade; blood coagulation cascade;
KW viral infection; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003050239-A1.
XX
PD 13-MAR-2003.
XX
PF 15-OCT-2001; 2001US-00978191.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-007886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.

PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.

PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAAGCTGAGCTGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCGGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCTGCTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCTGCTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCGCATGTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCGCATGTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTTGTGGATGATGGAAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
DB 301 TCAATTTGTGAGTTTGTGGATGATGGAAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTGCCATTTCGTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
DB 421 CAGAAATCAGCTGCCATTTCGTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480

QY 481 ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGAGACTCC 540
DB 481 ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGAGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTAGCACCACATTTTGGAGCAGGAGCTTACA 660
DB 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTAGCACCACATTTTGGAGCAGGAGCTTACA 660

QY 661 AATTGAGAGAATCATCTTAAGCAAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTTAAGCAAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

(GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-352836/33.
DR P-PSDB; ABU81005.

PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.

PS Claim 2; Fig 271; 643pp; English.

XX The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ACA66994-ACA67268 represent cDNA sequences encoding
CC the human PRO polypeptides of the invention. Note: The sequence data for
CC this patent was obtained in electronic format directly from the USPTO web
CC site at seqdata.uspto.gov/psipsDIDEntry.html

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGGGTGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTGAGAGAGGTTGACGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTGAGAGAGGTTGACGGCTGTTT 300
QY 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGCAATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGC 420

Db 361 TCTGCAATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTTAACCTCTGGTGGAGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTTAACCTCTGGTGGAGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGACTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGACTTACA 660
QY 661 AATTGAGAGATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAATCA 1140
Db 1081 AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 11

ACA63739

ID ACA63739 standard; cDNA; 1174 BP.

XX ACA63739;

AC ACA63739;

XX 16-JUN-2003 (first entry)

DT Novel human secreted and transmembrane protein PRO195 cDNA.

DE Human; secreted and transmembrane protein; PRO; antiinflammatory;
XX antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; inflammatory disease; organ failure;
KW atherosclerosis; cardiac injury; infertility; birth defect;
KW premature aging; AIDS; cancer; diabetic complication; chromosome mapping;
KW gene mapping; pharmaceutical; diagnostic; biosensor; bio reactor;
KW tissue typing; gene; ss.

OS	Homo sapiens.		
XX			
PN	US2002192706-A1.		
XX			
PD	19-DEC-2002.		
XX			
PF	24-OCT-2001; 2001US-00999832.		
XX			
PR	17-OCT-1997; 97US-0062250P.	PR	06-JAN-2000; 2000WO-US000376.
PR	03-NOV-1997; 97US-0064249P.	PR	11-FEB-2000; 2000WO-US003565.
PR	13-NOV-1997; 97US-0065311P.	PR	18-FEB-2000; 2000WO-US004341.
PR	21-NOV-1997; 97US-0066364P.	PR	24-FEB-2000; 2000WO-US005004.
PR	10-MAR-1998; 98US-0077450P.	PR	02-MAR-2000; 2000WO-US005841.
PR	11-MAR-1998; 98US-0077632P.	PR	10-MAR-2000; 2000WO-US006319.
PR	11-MAR-1998; 98US-0077641P.	PR	21-MAR-2000; 2000WO-US007532.
PR	11-MAR-1998; 98US-0077649P.	PR	30-MAR-2000; 2000WO-US008439.
PR	12-MAR-1998; 98US-0077791P.	PR	17-MAY-2000; 2000WO-US013705.
PR	13-MAR-1998; 98US-0078004P.	PR	22-MAY-2000; 2000WO-US014042.
PR	17-MAR-1998; 98US-00040220.	PR	30-MAY-2000; 2000WO-US014941.
PR	20-MAR-1998; 98US-0078886P.	PR	02-JUN-2000; 2000WO-US015264.
PR	20-MAR-1998; 98US-0078910P.	PR	28-JUL-2000; 2000WO-US020710.
PR	20-MAR-1998; 98US-0078936P.	PR	24-AUG-2000; 2000WO-US023328.
PR	20-MAR-1998; 98US-0078939P.	PR	01-DEC-2000; 2000WO-US032678.
PR	25-MAR-1998; 98US-0079294P.	PR	20-DEC-2000; 2000WO-US034956.
PR	26-MAR-1998; 98US-0079656P.	PR	28-FEB-2001; 2001WO-US006520.
PR	27-MAR-1998; 98US-0079663P.	PR	22-MAR-2001; 2001WO-US009552.
PR	27-MAR-1998; 98US-0079664P.	PR	25-MAY-2001; 2001WO-US017092.
PR	27-MAR-1998; 98US-0079689P.	PR	01-JUN-2001; 2001WO-US017800.
PR	27-MAR-1998; 98US-0079728P.	PR	20-JUN-2001; 2001WO-US019692.
PR	27-MAR-1998; 98US-0079786P.	PR	29-JUN-2001; 2001WO-US021066.
PR	30-MAR-1998; 98US-0079920P.	PR	09-JUL-2001; 2001WO-US021735.
PR	30-MAR-1998; 98US-0079923P.	XX	
PR	31-MAR-1998; 98US-0080105P.	DR	WPI; 2003-328860/31.
PR	31-MAR-1998; 98US-0080107P.	DR	P-PSDB; ABU72241.
PR	31-MAR-1998; 98US-0080165P.	XX	
PR	31-MAR-1998; 98US-0080194P.	PT	New secreted and transmembrane nucleic acids and polypeptides, designated
PR	01-APR-1998; 98US-0080327P.	PT	as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PR	01-APR-1998; 98US-0080328P.	PT	cardiac injury, infertility, birth defects, premature aging, AIDS, or
PR	01-APR-1998; 98US-0080333P.	PT	cancer.
PR	01-APR-1998; 98US-0080334P.	XX	
PR	08-APR-1998; 98US-0081049P.	PS	Claim 2; Fig 131; 453pp; English.
PR	08-APR-1998; 98US-0081070P.	XX	
PR	08-APR-1998; 98US-0081071P.	CC	The invention describes an isolated nucleic acid (I) comprising, or which
PR	09-APR-1998; 98US-0081195P.	CC	is at least 80 % sequence identity to, or the full-length coding sequence
PR	09-APR-1998; 98US-0081203P.	CC	of, any of 118 300-2100 nucleotide sequences, which encodes its
PR	09-APR-1998; 98US-0081229P.	CC	corresponding PRO polypeptide selected from 118 100-700 amino acid
PR	15-APR-1998; 98US-0081817P.	CC	sequences, all given in the specification. The nucleic acids and
PR	15-APR-1998; 98US-0081819P.	CC	polypeptides are useful for treating inflammatory diseases, organ
PR	15-APR-1998; 98US-0081952P.	CC	failure, atherosclerosis, cardiac injury, infertility, birth defects,
PR	15-APR-1998; 98US-0081955P.	CC	premature aging, AIDS, cancer, or diabetic complications. The nucleic
PR	15-APR-1998; 98US-0082568P.	CC	acids are useful as hybridisation probes, in chromosome and gene mapping,
PR	21-APR-1998; 98US-0082569P.	CC	and in generating antisense RNA or DNA. The polypeptides are useful as
PR	21-APR-1998; 98US-0082700P.	CC	pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful
PR	22-APR-1998; 98US-0082704P.	CC	in tissue typing. This sequence encodes a novel human secreted and
PR	22-APR-1998; 98US-0082797P.	XX	transmembrane PRO polypeptide
PR	22-APR-1998; 98US-0082804P.	SQ	Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
PR	23-APR-1998; 98US-0082796P.		
PR	07-OCT-1998; 98WO-US021141.		
PR	20-NOV-1998; 98WO-US024855.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	30-NOV-1999; 99WO-US028313.		
PR	02-DEC-1999; 99WO-US028551.		
PR	02-DEC-1999; 99WO-US028565.		
PR	16-DEC-1999; 99WO-US030095.		
PR	30-DEC-1999; 99WO-US031243.		
PR	30-DEC-1999; 99WO-US031274.		
PR	05-JAN-2000; 2000WO-US000219.		
PR	06-JAN-2000; 2000WO-US000277.		

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCGCGGAAGGGAGCCCTCTGCGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGGCGGCGCGGAAGGGAGCCCTCTGCGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CCGCTGCTGCTGCTGACCATGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180

QY 181 TTTGACTCGGTCCTTGGGTGATACGGCGTCTTGCCACGGGCTGTGCTCAGTTGACCTACCC 240
Db 181 TTTGACTCGGTCCTTGGGTGATACGGCGTCTTGCCACGGGCTGTGCTCAGTTGACCTACCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGAGTGTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGAGTGTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTAA 360
QY 361 TCTGCATGTACAGAACGATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAACGATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTTAACCTCTGGTGAGGTCACTCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTTAACCTCTGGTGAGGTCACTCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCAACCACTATTTGGAGCAGGACTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCAACCACTATTTGGAGCAGGACTACA 660
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTAACAACCTCTGCTCCTCTCGGTGATGGTATTTGATTTGT 840
Db 781 TCTGGGTGATTTTAACTAACAACCTCTGCTCCTCTCGGTGATGGTATTTGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAAGTTACTCAATCTGTG 1174

RESULT 12
ACA03738
ID ACA03738 standard; cDNA; 1174 BP.

XX ACA03738;
AC 23-MAY-2003 (first entry)
XX
DT
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;
KW ss.
XX
OS Homo sapiens.
XX
PN US2003036180-A1.
XX
PD 20-FEB-2003.
XX
PF 09-MAY-2002; 2002US-00143114.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geirritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-332040/31.

P-PSDB; ABU66705.

New secreted and transmembrane PRO nucleic acids, useful for gene
therapy, in chromosome and gene mapping, as chromosome markers, in tissue
typing, and in chromosome identification.

Claim 2; Fig 271; 660pp; English.

The present invention relates to the isolation of novel human PRO
polypeptides, and the polynucleotide sequences encoding them. The PRO
polypeptides are secreted and transmembrane proteins. The PRO
polypeptides are useful for detecting other PRO polypeptides, for linking
biological molecules to cells expressing PRO polypeptides, for modulating
biological activities of cells expressing PRO polypeptides, and for
identifying agonists or antagonists. The PRO polypeptides are useful for
for stimulating the release of tumour necrosis factor (TNF)-alpha from
human blood, for stimulating the proliferation or differentiation of
chondrocytes, and detecting the presence of tumours. The polynucleotide
sequences encoding PRO polypeptides are useful as hybridisation probes,

CC in chromosome and gene mapping, in the generation of antisense RNA and
CC DNA, in the preparation of PRO polypeptides, for generating transgenic
CC animals or knockout animals, for the genetic analysis of individuals with
CC genetic disorders, and in gene therapy. ACA03603-ACA03877 represent cDNAs
CC encoding the human PRO polypeptides of the invention. Note: The sequence
CC data for this patent was obtained in electronic format directly from the
CC USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCGCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCGCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTTCAGTTGACCTACCCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Qy 301 TCAATTTGTGAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAACCTATGTCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAACCTATGTCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTCTCTAACTCTGAGGAGTCACTTCTGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGAGGAGTCACTTCTGAGTGACATGATGGACTCC 540
Qy 541 GCACAGAGCTTCATAAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660
Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTTCTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Qy 781 TCTGGTGGATTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGTGGATTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Qy 841 TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db |||||||
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db |||||||
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||||
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db |||||||
QY 1141 CTATAAAATGCAATAAAAGTTACTCAATCTGTG 1174
Db |||||||

RESULT 13
ACA71903
ID ACA71903 standard; cDNA; 1174 BP.
AC ACA71903;
XX
XX 11-AUG-2003 (first entry)
DT Human secreted and transmembrane polypeptide PRO195 cDNA.
DE Human; ss; Gene; thrombolytic agent; interferon; interleukin; cytokine;
XX erythropoietin; colony stimulating factor; cancer; colorectal carcinoma;
KW apoptosis related condition; AIDS; amyotrophic lateral sclerosis;
KW inflammatory disease; asthma; atherosclerosis; neurodegenerative disease;
KW gastrointestinal disorder; Alzheimer's disease; Parkinson's disease;
KW hypertension; myocardial ischaemia; kidney disease; carcinogenesis;
KW glomerulonephritis; lung disease; pulmonary hypertension; preeclampsia;
KW bronchial asthma; gastric ulcer; renal failure; cardiovascular disease;
KW inflammatory bowel disease; reproductive disorder; premature labour.
XX
OS Homo sapiens.
XX
PN US2002177553-A1.
XX
PD 28-NOV-2002.
XX
PF 15-OCT-2001; 2001US-00978192.
XX
PR 17-OCT-1997; 97US-00632250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.

PR 30-MAR-1998; 98US-0079923P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Deanoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuc SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-328499/31.
DR P-PSDB; ABU84921.
XX
PT New isolated PRO polypeptides e.g. PRO213, PRO274 and PRO300, for use as
PT pharmaceuticals, diagnostics, biosensors and bioreactors, for identifying
PT modulators of receptor-ligand interactions.
XX
PS Claim 2; SEQ ID NO 329; 55pp; English.
XX
CC The invention relates to an isolated secreted and transmembrane
CC polypeptide, designated as PRO polypeptide. The PRO polypeptide is useful
CC in PRO polypeptide detection methods. The PRO polypeptide is useful for
CC linking a bioactive molecule to a cell. The PRO polypeptide or an
CC antibody against it is useful for modulating a biological activity of a
CC cell. The PRO polypeptide is useful in industrial applications including
CC pharmaceuticals, diagnostics, biosensors and bioreactors. The PRO
CC polypeptide is also useful as a thrombolytic agent, interferon,
CC interleukin, erythropoietin, colony stimulating factor and other
CC cytokines. The PRO polypeptide is useful for treating disease such as
CC cancer e.g. colorectal carcinoma; apoptosis related conditions e.g. AIDS,
CC amyotrophic lateral sclerosis; inflammatory disease e.g. asthma,
CC atherosclerosis; neurodegenerative disease e.g. Alzheimer's disease,
CC Parkinson's disease; cardiovascular disease e.g. hypertension and
CC myocardial ischaemia; kidney disease e.g. renal failure and
CC glomerulonephritis; lung disease e.g. pulmonary hypertension, bronchial
CC asthma; gastrointestinal disorders e.g. gastric ulcer and inflammatory
CC bowel disease; reproductive disorders e.g. premature labour and
CC pre-eclampsia; carcinogenesis. The present sequence represents a cDNA
CC encoding a PRO polypeptide of the invention. Note: The sequence data for
CC this patent did not form part of the printed specification but was
CC obtained in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20020177553

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. NO. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAAAAGCTGAGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAAAAGCTGAGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAAGGGGAGCCCTCGGGTGAGGACCCCAACTGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCGGAAGGGGAGCCCTCGGGTGAGGACCCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGCGCGGAGGTTGCGGGACCGCTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGCCCTTGCGCGGAGGTTGCGGGACCGCTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
DB 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
DB 421 CAGAAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCCCTTAACTCTGGTGAGGTCATTCTGGAGTGACATGAGACTCC 540

DB 481 ATGCACCTACTCTTTCCCTTAACTCTGGTGAGGTCATTCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
DB 541 GCACAGAGCTTCATAACCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
QY 601 GTTATATTCCAGTCTAAGCCAGAAAATCCAGTACGCCACCAATTGGAGCAGGACCTACA 660
DB 601 GTTATATTCCAGTCTAAGCCAGAAAATCCAGTACGCCACCAATTGGAGCAGGACCTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTCAACTGTTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTCCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
DB 1021 CTTCCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTTAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 14
ABX89276

ID ABX89276 standard; cDNA; 1174 BP.

XX ABX89276;

XX 13-MAY-2003 (first entry)

XX DNA encoding novel secreted and transmembrane protein PRO195.

DE Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
XX cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ss.

XX Homo sapiens.

OS US2003017563-A1.

PN

PD 23-JAN-2003.
XX
PF 07-MAY-2002; 2002US-00140808.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR P-PSDB; ABU59786.
XX
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are

CC thus useful for treating sports injuries, and arthritis. This sequence
CC encodes a novel human PRO protein
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTTACCCTAAGGAAGAGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTTACCCTAAGGAAGAGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTGCTGTAACCTGAGTGAAGCAAGCAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGTAACCTGAGTGAAGCAAGCAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTCTCTAATCTGCTGAGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAATCTGCTGAGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660

QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGGTGATTTTAACTACAACCTCTGTCCTCTCGGTGATGATTTGTTGGATTTGT 840
Db 781 TCTGGGTGATTTTAACTACAACCTCTGTCCTCTCGGTGATGATTTGTTGGATTTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTAGATCTAAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCTTGGATATAGGCTTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCTTGGATATAGGCTTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 15
ABX92543
ID ABX92543 standard; cDNA; 1174 BP.
XX
AC ABX92543;
XX
DT 08-MAY-2003 (first entry)
XX
DE cDNA encoding human PRO195 polypeptide.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW immune disorder; diabetes; hyper-insulinaemia; hypo-insulinaemia;
KW cardiac insufficiency; nervous system disorder; kidney disorder;
KW bone disorder; cartilage disorder; arthritis; tumour; wound healing;
KW genetic disorder; cytostatic; antidiabetic; antiinflammatory;
KW antiarthritic; anti-tumour; vulnerary; antianaemic; dermatological;
KW cardiant; gene; ss.
XX
OS Homo sapiens.
XX
PN US2002169284-A1.
XX
PD 14-NOV-2002.
XX
PF 16-OCT-2001; 2001US-00978697.
XX
PR 26-MAY-1981; 81US-00267213.
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.

PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 20-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.

XX Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton D;
PA Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
XX Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-288163/28.
DR P-PSDB; ABU61119.

XX Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating cancer, kidney diseases, bone,
PT cartilage disorders and immune deficiencies.

XX Claim 2; Fig 131; 459pp; English.
PS The present invention relates to the isolation of novel human PRO
XX polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The bioactive molecule maybe a
CC toxin, radiolabel or antibody, and causes apoptosis or death of the cell.
CC The PRO polypeptides are useful for treating immune disorders, diabetes
CC or hyper- or hypo-insulinaemia, cardiac insufficiency, nervous system
CC disorders, kidney disorders, bone and cartilage disorders or arthritis,
CC tumours, and wound healing. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and gene
CC mapping, in the generation of antisense RNA and DNA, in the preparation
CC of PRO polypeptides, for generating transgenic animals or knockout
CC animals, for the genetic analysis of individuals with genetic disorders,
CC and in gene therapy. The present sequence encodes a human PRO polypeptide
CC of the invention. Note: The sequence data for this patent was obtained in
CC electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDentry.html

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAACCCCTTCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60
Db |||||
QY 1 CGGACGCGTGGGGAACCCCTTCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGAACAAGATGGCGCGCGGAGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
Db |||||
QY 61 GGAACAAGATGGCGCGCGGAGGAGCCTCTGGGTGAGGAGCCTCTGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180
Db |||||
QY 121 CCGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGCTTCCACCGGCTGTGACCTACCC 240
Db |||||
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGCTTCCACCGGCTGTGACCTACCC 240
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGCAGGCTGTT 300
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGCAGGCTGTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGAAATGAA 360
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGAAATGAA 360
Db |||||
QY 361 TGTGCATGTACAGAAGCATATTTCCCATCTGATGAGCAATATGCTTGGTTC 420
Db |||||
QY 361 TGTGCATGTACAGAAGCATATTTCCCATCTGATGAGCAATATGCTTGGTTC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAAGTCACTTCTGGAGTGACATGATGGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAAGTCACTTCTGGAGTGACATGATGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATACCTCTTCTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
Db |||||
QY 541 GCACAGAGCTTCATACCTCTTCTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACCATTTGGAGCAGGAGCTTACA 660
Db |||||

QY	661	AAATTGAGAGATCATCTCTAAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661	AAATTGAGAGATCATCTCTAAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGCTCCTCGGTGATGGTATTGCTTTGGATTTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACCTCTTGCTCCTCGGTGATGGTATTGCTTTGGATTTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTGTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTGTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA	1080
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174
RESULT 16			
ACD41930			
ID	ACD41930 standard; cDNA; 1174 BP.		
XX			
AC	ACD41930;		
XX			
DT	05-SEP-2003 (first entry)		
XX			
DE	Human secreted/transmembrane protein (PRO) cDNA #136.		
XX			
KW	Human; ss; gene; PRO; secreted protein; transmembrane protein; tumour;		
KW	cytostatic; gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;		
KW	proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;		
KW	PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;		
KW	chondrocyte cell proliferation; chondrocyte cell differentiation;		
KW	pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell; A-peptide; factor VIIA.		
XX			
OS	Homo sapiens.		
PN			
XX	US2003036179-A1.		
PN			
XX	20-FEB-2003.		
PD			
XX			
PF	10-MAY-2002; 2002US-00142431.		
XX			
PR	31-MAR-1997; 97WO-US005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		

PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-466355/44.
P-PSDB; ABO24976.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 271; 659pp; English.

The invention relates to an isolated nucleic acid comprising at least 80%
sequence identity to a PRO (secreted and transmembrane protein) cDNA
comprising a nucleic acid (a) encoding a PRO polypeptide, or its
extracellular domain (with or without its associated signal peptide),
which comprises any of the 275 120-850 residue amino acid sequences,
given in the specification; (b) comprising any of the 275 300-3500
nucleotide sequences, given in the specification; or (c) comprising the
full-length coding sequence of the nucleotide sequences given in the
specification, or of the DNA deposited under any of the American Type
Culture Collection (ATCC) Accession Numbers listed in the specification.
Also included are a vector comprising the novel nucleic acid, a host cell
comprising the vector, producing a PRO polypeptide, the isolated PRO
polypeptides detailed above, a chimeric molecule comprising the PRO
polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
antibody, detecting a PRO polypeptide in a sample suspected of containing
the PRO polypeptide, linking a bioactive molecule to a cell expressing a
PRO polypeptide, modulating at least one biological activity of a cell
expressing a PRO polypeptide, stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
modulating the uptake of glucose or FFA by skeletal muscle cells or
adipocyte cells, stimulating the proliferation or differentiation of
chondrocyte cells (or proliferation of or gene expression in pericyte
cells), stimulating the proliferation of inner ear utricular supporting
cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
binding of A-peptide to factor VIIA, or differentiation of adipocyte
cells, detecting the presence of a tumour in a mammal and an
oligonucleotide probe derived from any of the nucleotide sequences given
in the specification. The polynucleotide is useful in molecular biology,
including uses as hybridisation probes, in chromosome and gene mapping,
in generating antisense RNA and DNA, and in gene therapy. The
polynucleotide may also be used in preparing PRO polypeptides by
recombinant techniques, and in generating either transgenic animals or
knock-out animals which, in turn, are useful in the development and
screening of therapeutically useful reagents. The PRO polypeptide or the
antibody is used in preparing a medicament for treating a condition
responsive to the polypeptide or antibody, such as tumours, and in
various diagnostic assays. The present sequence encodes a PRO polypeptide

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match		100.0%;	Score 1174;	DB 7;	Length 1174;
Best Local Similarity		100.0%;	Pred. No. 0;		
Matches 1174;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG	60		
Db	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG	60		
QY	61	GGGAACAAGATGGCGCGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG	120		
Db	61	GGGAACAAGATGGCGCGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG	120		
QY	121	CCGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180		
Db	121	CCGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGCGCTTGCAGTTGACCTACCCC	240		
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGCGCTTGCAGTTGACCTACCCC	240		
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT	300		
Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT	300		
QY	301	TCAATTTGTCAGTTTGTGGATGATGGATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360		
Db	301	TCAATTTGTCAGTTTGTGGATGATGGATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360		
QY	361	TTGCATGTACAGAACCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
Db	361	TTGCATGTACAGAACCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
QY	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480		
Db	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480		
QY	481	ATGCACCTACTCTTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGATGGACTCC	540		
Db	481	ATGCACCTACTCTTCTTAACTCTGCTGAGGTCATCTTGGAGTGACATGATGGACTCC	540		
QY	541	GCACAGAGCTTCATAAACCCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600		
Db	541	GCACAGAGCTTCATAAACCCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600		
QY	601	GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACCACATTTGGAGCAGGAGCTTACA	660		
Db	601	GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACCACATTTGGAGCAGGAGCTTACA	660		
QY	661	AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG	720		
Db	661	AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG	720		
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC	780		
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC	780		
QY	781	TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT	840		
Db	781	TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT	840		
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900		
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900		
QY	901	GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960		
Db	901	GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960		
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020		
Db	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020		

XX The invention relates to a new isolated nucleic acid molecule comprising a
CC sequence with at least 80% identity to: (a) a nucleotide encoding any of
CC 94 PRO polypeptides whose sequences are fully defined in the
CC specification; or (b) any of 94 nucleotide sequences fully defined in the
CC specification; or the full length coding sequence of any these 94
CC nucleotide sequences. Also included are an isolated PRO polypeptide
CC scoring at least 80% positives when compared to any of the PRO
CC polypeptide sequences cited above (or an isolated PRO polypeptide having
CC at least 80% amino acid sequence identity to: (a) an amino acid sequence
CC encoded by the nucleotide deposited with ATCC numbers listed in the
CC specification; (b) the PRO polypeptide, lacking its associated signal
CC peptide; or (c) an extracellular domain of the PRO polypeptide, with or
CC lacking its associated signal peptide), a vector comprising the nucleic
CC acid molecule, a host cell comprising the vector (and producing a PRO
CC polypeptide), a chimeric molecule comprising the PRO polypeptide fused
CC to a heterologous amino acid sequence and an anti-PRO antibody. The PRO
CC polypeptides or polynucleotides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. These are particularly useful for
CC detecting or treating e.g. malignancies or cancers (e.g. ovarian cancer,
CC colorectal cancer, sarcoma, leukaemia or lymphoma), inflammatory disease,
CC necrosis, atherosclerosis, infertility, premature aging, psoriasis,
CC inflammatory disease, renal disease, arthritis, immune-mediated alopecia,
CC stroke, encephalitis, hepatitis, or multiple sclerosis in mammals. The
CC PRO polypeptides are useful in drug screening, particularly as targets
CC for therapeutic intervention in these diseases, and in the diagnostic
CC determination of the presence of these diseases. The PRO polypeptides are
CC also useful as molecular weight markers, or for chromosome
CC identification. The PRO genes are useful as hybridisation probes, or for
CC screening libraries of human cDNA, genomic DNA or mRNA. The PRO genes may
CC also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence encodes a PRO polypeptide
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 7; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACCGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGTCTTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGCTCTGGGTGATACGGCGTCTTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTGTGGATGATGGAATTTGAACTTAAATCGAACTAAATTTGGAATGAA 360
DB 301 TCAATTTGTGAGTTGTGGATGATGGAATTTGAACTTAAATCGAACTAAATTTGGAATGAA 360
QY 361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAACCACTTATGTCCCTGATGCCAAA 480
DB 421 CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAACCACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTTCTTCTGAGTGACATGATGAGTCC 540

DB 481 ATGCACCTACTCTTCTCTAACTCTGGTGAAGTCACTTCTGGAGTGACATGAGTCC 540
QY 541 GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600
DB 541 GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGCTTACA 660
DB 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTGTTGGATTTGT 840
DB 781 TCTGGTGGATTTTAACTPACAACTCTTGTCTCTCGGTGATGTTGTTGGATTTGT 840
QY 841 TGTCAAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTCAAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGCTTTTCAATGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174
DB 1141 CTATAAATGCAATTAAGTTACTCAATCTGTG 1174

RESULT 18

ACA04159
ID ACA04159 standard; cDNA; 1174 BP.

XX ACA04159;

XX 27-MAY-2003 (first entry)

XX Human cDNA encoding a secreted/transmembrane protein, SEQ ID 271.

DE Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.

OS Homo sapiens.

XX US2003032155-A1.

XX 13-FEB-2003.

XX 03-MAY-2002; 2002US-00137865.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-331925/31.
P-PSDB; ABU66981.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 2; Fig 271; 659pp; English.

The invention relates to an isolated nucleic acid comprising, or which is at least 80% identical to, or the full-length coding sequence of, any of the 275 nucleotide sequences, encoding the corresponding PRO polypeptide (one of 275 secreted or transmembrane proteins). The nucleic acid further comprises the full-length coding sequence of the DNA deposited under American Type Culture Collection (ATCC) accession number in a list given in the specification. Also included are vectors and host cells for producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO extracellular domains and mature sequences, methods of detecting PRO proteins, methods for stimulating the release of TNF-alpha (tumour necrosis factor alpha) from human blood, (and the proliferation of differentiation of chondrocyte cells, the proliferation of, or gene expression in pericyte cells, the release or proteoglycans from cartilage, proliferation of inner ear urticular supporting cells, the proliferation of T-lymphocyte cells, the release of a cytokine from peripheral blood mononuclear cells (PBMC), or the proliferation of endothelial cells), a method for modulating the uptake of glucose or free fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the binding of A-peptide to factor VIIA, or the differentiation of adipocyte cells, a method for detecting the presence of a tumour in a mammal and an oligonucleotide probe derived from any of the nucleotide sequences cited above. The nucleic acids and polypeptides are useful for treating inflammatory diseases, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or diabetic complications. The nucleic acids are useful as hybridisation probes, in chromosome and gene mapping, and in generating antisense RNA or DNA. The polypeptides are useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both are useful in tissue typing. The present sequence encodes a PRO protein of the invention

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match									
Best Local Similarity 100.0%; Score 1174; DB 7; Length 1174;									
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAAAGTGTGCTGTGACAGAG	60						
Db	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAAAGTGTGCTGTGACAGAG	60						
QY	61	GGGAACAAGATGGCGGCGCCGAAGGGAGCCCTCTGGGTAGGACCCAACTGGGGTCCCG	120						
Db	61	GGGAACAAGATGGCGGCGCCGAAGGGAGCCCTCTGGGTAGGACCCAACTGGGGTCCCG	120						
QY	121	CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA	180						
Db	121	CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA	180						
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCACTTGACCTACCCC	240						
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCACTTGACCTACCCC	240						
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTGTACGCATGTACAGAGGTTGACGGTGT	300						
Db	241	TTGCACACCTACCTAAGGAAGAGGAGTGTACGCATGTACAGAGGTTGACGGTGT	300						
QY	301	TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGA	360						
Db	301	TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGA	360						
QY	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420						
Db	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420						
QY	421	CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTATGTCCCTGATGCCAAA	480						
Db	421	CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTATGTCCCTGATGCCAAA	480						
QY	481	ATGCACCTACTCTTCTCTTAACCTCTGCTGAGGTCATTTCTGGAGTGACATGATGACTCC	540						
Db	481	ATGCACCTACTCTTCTCTTAACCTCTGCTGAGGTCATTTCTGGAGTGACATGATGACTCC	540						
QY	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGGAAAATA	600						
Db	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGGAAAATA	600						
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA	660						
Db	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA	660						
QY	661	AATTTGAGAGATCACTCTTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAGCG	720						
Db	661	AATTTGAGAGATCACTCTTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAGCG	720						
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTAAC	780						
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTAAC	780						
QY	781	TCTGGTGGATTTTAACTACAACCTCTTCTCGGTGATGGTATGCTTTGGATTGT	840						
Db	781	TCTGGTGGATTTTAACTACAACCTCTTCTCGGTGATGGTATGCTTTGGATTGT	840						
QY	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900						
Db	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900						
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960						
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960						
QY	961	GTTGTTAGATCTAAACTGAAGATTCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT	1020						
Db	961	GTTGTTAGATCTAAACTGAAGATTCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT	1020						

QY	1021	CTTGCTCATCTCGAATTTAAGCAATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTCGAATTTAAGCAATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGCCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGCCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAATAAAGTTACTCAATCTGTG	1174
Db	1141	CTATAAAATGCAATAAAGTTACTCAATCTGTG	1174
RESULT 19			
ADA45790			
ID	ADA45790	standard; cDNA; 1174 BP.	
XX	ADA45790;		
AC	ADA45790;		
XX	20-NOV-2003	(first entry)	
DT	20-NOV-2003	(first entry)	
XX	Novel human secreted and transmembrane protein PRO195 cDNA.		
DE	Human; secreted and transmembrane protein; PRO; gene; ss;		
XX	Tumour necrosis factor alpha release; TNF-alpha release;		
KW	glucose uptake modulator; FFA uptake modulator;		
KW	cell proliferation stimulator; cell differentiation stimulator;		
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;		
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
KW	gene therapy; chromosome identification; chromosome marker.		
XX	Homo sapiens.		
OS	US2003022328-A1.		
XX	30-JAN-2003.		
PN	16-APR-2002; 2002US-00123904.		
XX	31-MAR-1997; 97WO-US005230.		
PF	12-JUN-1998; 98WO-US012456.		
XX	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		
PR	14-SEP-1998; 98WO-US019177.		
PR	16-SEP-1998; 98WO-US019330.		
PR	17-SEP-1998; 98WO-US019437.		
PR	07-OCT-1998; 98WO-US021141.		
PR	29-OCT-1998; 98WO-US022991.		
PR	29-OCT-1998; 98WO-US022992.		
PR	20-NOV-1998; 98WO-US024855.		
PR	01-DEC-1998; 98WO-US025108.		
PR	05-JAN-1999; 99WO-US000106.		
PR	08-MAR-1999; 99WO-US005028.		
PR	10-MAR-1999; 99WO-US005190.		
PR	20-APR-1999; 99WO-US008615.		
PR	14-MAY-1999; 99WO-US010733.		
PR	02-JUN-1999; 99WO-US012252.		
PR	01-SEP-1999; 99WO-US020111.		
PR	08-SEP-1999; 99WO-US020594.		
PR	13-SEP-1999; 99WO-US020944.		
PR	15-SEP-1999; 99WO-US021090.		
PR	15-SEP-1999; 99WO-US021547.		
PR	05-OCT-1999; 99WO-US023089.		
PR	29-NOV-1999; 99WO-US028214.		
PR	30-NOV-1999; 99WO-US028313.		
PR	30-NOV-1999; 99WO-US028409.		
PR	01-DEC-1999; 99WO-US028301.		
PR	01-DEC-1999; 99WO-US028634.		
PR	02-DEC-1999; 99WO-US028551.		

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-584997/55.
DR P-PSDE; ADA45791.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBM cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGACCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCCGGAGGTTCCGGGACCCGCTTCAGTTGACCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCCGGAGGTTCCGGGACCCGCTTCAGTTGACCA 180
Qy 181 TTTGACTCGGCTTGGGTGATACGGCGCTTGGCCCGGAGGTTCCGGGACCCGCTTCAGTTGACCA 240
Db 181 TTTGACTCGGCTTGGGTGATACGGCGCTTGGCCCGGAGGTTCCGGGACCCGCTTCAGTTGACCA 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGAGGTTGCAGGCTGTTT 300
Qy 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTGCGTGAACCTGAGACAAGACAACATTATGTCCTGATGCCAAAA 480

Db	421	CAGAAATCAGCTGCCATTGGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480	OS	Homo sapiens.
Qy	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC	540	XX	US2003073212-A1.
Db	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC	540	PD	17-APR-2003.
Qy	541	GCACAGAGCTTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA	600	XX	16-APR-2002; 2002US-00123903.
Db	541	GCACAGAGCTTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA	600	XX	31-MAR-1997; 97WO-US005230.
Qy	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA	660	PR	12-JUN-1998; 98WO-US012456.
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA	660	PR	14-JUL-1998; 98WO-US014552.
Qy	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720	PR	28-AUG-1998; 98WO-US017888.
Db	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720	PR	10-SEP-1998; 98WO-US018824.
Qy	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC	780	PR	14-SEP-1998; 98WO-US019093.
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC	780	PR	14-SEP-1998; 98WO-US019094.
Qy	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840	PR	14-SEP-1998; 98WO-US019177.
Db	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840	PR	16-SEP-1998; 98WO-US019330.
Qy	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900	PR	17-SEP-1998; 98WO-US019437.
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900	PR	07-OCT-1998; 98WO-US021141.
Qy	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960	PR	29-OCT-1998; 98WO-US022991.
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG	960	PR	29-OCT-1998; 98WO-US022992.
Qy	961	GTTGTTAGATCTAAAAGCTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT	1020	PR	20-NOV-1998; 98WO-US024855.
Db	961	GTTGTTAGATCTAAAAGCTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT	1020	PR	01-DEC-1998; 98WO-US025108.
Qy	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080	PR	05-JAN-1999; 99WO-US000106.
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080	PR	08-MAR-1999; 99WO-US005028.
Qy	1081	AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140	PR	10-MAR-1999; 99WO-US005190.
Db	1081	AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140	PR	20-APR-1999; 99WO-US008615.
Qy	1141	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174	PR	14-MAY-1999; 99WO-US010733.
Db	1141	CTATAAATGCAATAAAGTTACTCAAAATCTGTG	1174	PR	02-JUN-1999; 99WO-US012252.
RESULT 20					
ADA76221					
ID	ADA76221 standard; cDNA; 1174 BP.				
XX					
AC					
XX					
DT	20-NOV-2003 (first entry)				
XX					
DE	Human PRO polynucleotide #136.				
XX					
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;				
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;				
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;				
KW	liver; microvascular endothelial cell; glucose; FFA;				
KW	skeletal muscle cell; adipocyte cell; pericyte cell;				
KW	inner ear utricular supporting cell; T-lymphocyte cell;				
KW	endothelial cell tube formation; bone disorder; cartilage disorder;				
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;				
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;				
KW	immune system cell infiltration.				
XX					

24-AUG-2000; 200WO-US023328.
08-NOV-2000; 200WO-US030952.
10-NOV-2000; 200WO-US030873.
01-DEC-2000; 200WO-US032678.
20-DEC-2000; 200WO-US0747259.
20-DEC-2000; 200WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006666.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-687639/65.
P-PSDB; ADA76222.

New isolated nucleic acid encoding a secreted and transmembrane polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 271; 659pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Qy 61 GGGAAACAAGATGCGGGCGCCGAAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120
Db 61 GGGAAACAAGATGCGGGCGCCGAAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGAGCCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGAGCCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCAGTTGACCTACCCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Qy 301 TCAATTTGTGAGTTGTGGATGATGGAATGAACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTGTGGATGATGGAATGAACTTAAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAACCTTATGTCCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTTCTTAACCTCTGAGGAGGTCATTTCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCTTAACCTCTGAGGAGGTCATTTCTGGAGTGACATGAGACTCC 540
Qy 541 GCACAGAGCTTCATTAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATTAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTTGGAGCAGGAGCTTACA 660
Qy 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Qy 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGGTGATGATGATTTGATTTGT 840
Db 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGGTGATGATGATTTGATTTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATATAGACATCTAA 1080
DB 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174

RESULT 21

ADA18871

ID ADA18871 standard; cDNA; 1174 BP.

XX AC ADA18871;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.

XX OS Homo sapiens.

XX PN US2003054517-A1.

XX PD 20-MAR-2003.

XX PF 08-MAY-2002; 2002US-00141755.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.

PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-521854/49.
DR P-PSDE; ADA18872.
DR New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumors.
PT Claim 2; Fig 271; 660pp; English.
XX
PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO
CC polypeptides by recombinant techniques and in generating either
CC transgenic animals or knock-out animals which are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polypeptides or antibodies are used in preparing a medicament for
CC treating a condition responsive to the polypeptides or antibodies, such
CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC cells, for stimulating the proliferation of or gene expression in
CC pericyte cells, for stimulating the release of proteoglycans from
CC cartilage, for stimulating the proliferation of inner ear utricular
CC supporting cells, for stimulating the release of cytokines from PEMC
CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC inhibiting the differentiation of adipocyte cells and for stimulating the
CC proliferation of endothelial cells. This sequence represents a human PRO
CC polynucleotide of the invention. Note: The sequence data for this patent
CC is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
DB 1 CGGACCGCTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGCAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCCGCAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGSCCTTGGCCGAGGTTCCGGGACCCGCTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGSCCTTGGCCGAGGTTCCGGGACCCGCTCGGCTGAAGCA 180
QY 181 TTTGACTCGCTCTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGCTCTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCCAGAGAGGTTGAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCCAGAGAGGTTGAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGCAAGAAACAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGCAAGAAACAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGAGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGAGGACTCC 540
QY 541 GCACAGAGCTTCATAAACCCTTTTCATGGACTTTTATCTTCAAGCCGATGACGAAAAATA 600
Db 541 GCACAGAGCTTCATAAACCCTTTTCATGGACTTTTATCTTCAAGCCGATGACGAAAAATA 600
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTCAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTCAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
Db 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAFTGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAFTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 22
ADA61494
ID ADA61494 standard; cDNA; 1174 BP.
XX ADA61494;
AC ADA61494;
XX 20-NOV-2003 (first entry)
XX Homo sapiens.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;

cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCAACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCAACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGATGTTGGATGATGGAATTGACTTAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTGTGATGTTGGATGATGGAATTGACTTAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGGACTCC 540
Db 481 ATGCACCTACTCTTTCCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGATGGTATTTGGATTTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGATGGTATTTGGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 23
ADB19279
ID ADB19279 standard; cDNA; 1174 BP.
XX
AC ADB19279;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokin.
OS Homo sapiens.
XX
PN US2003068796-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123261.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.

Db 541 GCACAGAGCTTCATAACCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAATA 600
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTTACA 660
Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGTCAATAGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGTCAATAGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Qy 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGTCTCTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGTCTCTCTTTGTG 960
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTTCATTTAGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTTCATTTAGGATATAGGCTTAAAGAAATCA 1140
Qy 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 24
ADB27820
ID ADB27820 standard; cDNA; 1174 BP.
XX ADB27820;
AC ADB27820;
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #136.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003082704-A1.
PN
XX 01-MAY-2003.
PD
XX 24-APR-2002; 2002US-00131819.
XX

PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-765415/72.
DR P-PSDB; ADB27821.
DR
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTACCTACCCC 240

QY 241 TTGCACACCTACCTTAAGGAAGAGAGATTGTACGGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 241 TTGCACACCTACCTTAAGGAAGAGAGATTGTACGGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCACTTTGTTGC 420
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCACTTTGTTGC 420
Db |||||
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db |||||
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db |||||
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db |||||
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db |||||
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||

RESULT 25
ADA86299
ID ADA86299 standard; cDNA; 1174 BP.
XX
AC ADA86299;
XX
DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.
DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX US2003082711-A1.
PN
XX 01-MAY-2003.
PD
XX 16-MAY-2002; 2002US-00147508.
PF
XX 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI WPI; 2003-786914/74.
DR P-PSDB; ADA86300.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match		100.0%;	Score 1174;	DB 8;	Length 1174;		
Best Local Similarity		100.0%;	Pred. No. 0;				
Matches 1174;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;		
Qy	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60				
Db	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60				
Qy	61	GGGAACAAGATGGCGGCGCGCAAGGGAGCCCTCTGGGTGAGGACCAACTGGGGCTCCCG	120				
Db	61	GGGAACAAGATGGCGGCGCGCAAGGGAGCCCTCTGGGTGAGGACCAACTGGGGCTCCCG	120				
Qy	121	CCGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA	180				
Db	121	CCGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA	180				
Qy	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC	240				
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC	240				
Qy	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT	300				
Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT	300				
Qy	301	TCAATTTGTGATGATGGAATGGAATGACTTAAATCGAATTAATCGAATTTGGAATGTGAA	360				
Db	301	TCAATTTGTGATGATGGAATGGAATGACTTAAATCGAATTAATCGAATTTGGAATGTGAA	360				
Qy	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC	420				
Db	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTC	420				
Qy	421	CAGAATCAGCTGCCATTGCTGAACCTGAGACAAAGCAAACTTATGTCCCTGATGCCAAAA	480				
Db	421	CAGAATCAGCTGCCATTGCTGAACCTGAGACAAAGCAAACTTATGTCCCTGATGCCAAAA	480				
Qy	481	ATGCACCTACTCTTTCCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC	540				
Db	481	ATGCACCTACTCTTTCCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC	540				
Qy	541	GCAACAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600				
Db	541	GCAACAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600				
Qy	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGACCTACA	660				
Db	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGACCTACA	660				
Qy	661	AATTTGAGAGATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720				
Db	661	AATTTGAGAGATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720				
Qy	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780				
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780				
Qy	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCCTCTCGGTGATGGTATGCTTTGGATTGT	840				
Db	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCCTCTCGGTGATGGTATGCTTTGGATTGT	840				
Qy	841	TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAGCTGAGTATCTAT	900				
Db	841	TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAGCTGAGTATCTAT	900				
Qy	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGTTCTTCTTTGIG	960				
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGTTCTTCTTTGIG	960				
Qy	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACTACAAAAGTGAAT	1020				
Db	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACTACAAAAGTGAAT	1020				
Qy	1021	CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080				

Db	1021	CTTGCTCATCTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
QY	1081	AATTCACCTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081	AATTCACCTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG	1174
RESULT 26			
ADB15863			
ID	ADB15863 standard; cDNA; 1174 BP.		
XX	ADB15863;		
AC	ADB15863;		
XX	20-NOV-2003 (first entry)		
DT	20-NOV-2003 (first entry)		
XX	Human PRO polynucleotide #136.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
XX	Homo sapiens.		
OS	US2003087350-A1.		
XX	08-MAY-2003.		
PN	22-APR-2002; 2002US-00127821.		
PD	04-AUG-1998; 98US-0095301P.		
XX	02-JUN-1999; 99WO-US012252.		
PR	25-AUG-1999; 99US-00380137.		
PR	30-MAR-2000; 2000WO-US008439.		
PR	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX	(GETH) GENENTECH INC.		
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		
XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
PI	WPI; 2003-786941/74.		
XX	P-PSDB; ADB15864.		
DR	New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,		
DR	and for manufacturing a medicament for diagnosing or treating tumor.		
XX	Claim 2; Fig 271; 637pp; English.		
PS	The invention relates to isolated human PRO polypeptides (secreted and		
XX	transmembrane polypeptides) and the polynucleotides encoding them. The		
CC	invention also relates to an antibody which specifically binds to a PRO		
CC	polypeptide, a method for stimulating the release of tumour necrosis		
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the		
CC	proliferation or differentiation of chondrocyte cells and a method for		
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,		
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The		
CC	polynucleotides are useful in molecular biology, including uses as		
CC	hybridisation probes, in chromosome and gene mapping, in generating		
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also		

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGCGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGCGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATAGGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA	180
Db	121	CCGCTGCTGCTGCTGACCATAGGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA	180
QY	181	TTTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT	300
Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
Db	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCATATGCTTGCCATCTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCATATGCTTGCCATCTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
Db	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540
Db	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540
QY	541	GCACAGAGCTTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA	600
Db	541	GCACAGAGCTTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAATA	600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA	660
Db	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCTTACA	660

QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
QY	781	TCTGGGTGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTGTTGGATTGT	840
Db	781	TCTGGGTGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTGTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGTTTCATTGGATATAGGCTTAAAGAATCA	1140
Db	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGTTTCATTGGATATAGGCTTAAAGAATCA	1140
QY	1141	CTATAAAATGCAATAAAGTTACTCTCAATCTGTG	1174
Db	1141	CTATAAAATGCAATAAAGTTACTCTCAATCTGTG	1174

RESULT 27

ADA47649
ID ADA47649 standard; cDNA; 1174 BP.

ADA47649;

20-NOV-2003 (first entry)

Human PRO polynucleotide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.

US2003073215-A1.

17-APR-2003.

07-MAY-2002; 2002US-00140925.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-644801/61.
DR P-PSDB; ADA47650.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.

XX Claim 2; Fig 271; 659pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;				
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
QY	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG	60	
Db	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG	60	
QY	61	GGGAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120	
Db	61	GGGAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120	
QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGGTGAAGCA	180	
Db	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGGTGAAGCA	180	
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240	
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240	
QY	241	TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGACGCTGTTT	300	
Db	241	TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGACGCTGTTT	300	
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360	
Db	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360	
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGC	420	
Db	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGC	420	
QY	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480	
Db	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480	
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCGGAGTGACATGAGACTCC	540	
Db	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCGGAGTGACATGAGACTCC	540	
QY	541	GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAAATA	600	
Db	541	GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAAATA	600	
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA	660	
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA	660	
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720	
Db	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720	
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTGCTTTTAAAGATGCCTCTCTTTAAC	780	
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTGCTTTTAAAGATGCCTCTCTTTAAC	780	
QY	781	TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTTCCCTCTGAGAGCTGATCTAT	840	
Db	781	TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGTTTCCCTCTGAGAGCTGATCTAT	840	
QY	841	TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT	900	
Db	841	TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGATCTAT	900	
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960	
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960	
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT	1020	
Db	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT	1020	
QY	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080	
Db	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080	

Db	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080	
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA	1140	
Db	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA	1140	
QY	1141	CTATAAAATGCAATAAAAGTTTACTCAATCTGTG	1174	
Db	1141	CTATAAAATGCAATAAAAGTTTACTCAATCTGTG	1174	
RESULT 28				
ADA67444				
ID	ADA67444	standard; cDNA; 1174 BP.		
XX				
AC	ADA67444;			
XX				
DT	20-NOV-2003	(first entry)		
XX				
DE	Human PRO polynucleotide #136.			
XX				
KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;			
KW	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;			
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;			
KW	liver; microvascular endothelial cell; glucose; FFA;			
KW	skeletal muscle cell; adipocyte cell; pericyte cell;			
KW	inner ear utricular supporting cell; T-lymphocyte cell;			
KW	endothelial cell tube formation; bone disorder; cartilage disorder;			
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;			
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;			
KW	immune system cell infiltration.			
XX				
OS	Homo sapiens.			
XX				
PN	US2003068795-A1.			
XX				
PD	10-APR-2003.			
XX				
PF	15-APR-2002; 2002US-00123236.			
XX				
PR	31-MAR-1997; 97WO-US005230.			
PR	12-JUN-1998; 98WO-US012456.			
PR	14-JUL-1998; 98WO-US014552.			
PR	28-AUG-1998; 98WO-US017888.			
PR	10-SEP-1998; 98WO-US018824.			
PR	14-SEP-1998; 98WO-US019093.			
PR	14-SEP-1998; 98WO-US019094.			
PR	14-SEP-1998; 98WO-US019177.			
PR	16-SEP-1998; 98WO-US019330.			
PR	17-SEP-1998; 98WO-US019437.			
PR	07-OCT-1998; 98WO-US021141.			
PR	29-OCT-1998; 98WO-US022991.			
PR	29-OCT-1998; 98WO-US022992.			
PR	20-NOV-1998; 98WO-US024855.			
PR	01-DEC-1998; 98WO-US025108.			
PR	05-JAN-1999; 99WO-US000106.			
PR	08-MAR-1999; 99WO-US005028.			
PR	10-MAR-1999; 99WO-US005190.			
PR	20-APR-1999; 99WO-US008615.			
PR	14-MAY-1999; 99WO-US010733.			
PR	02-JUN-1999; 99WO-US012252.			
PR	01-SEP-1999; 99WO-US020111.			
PR	08-SEP-1999; 99WO-US020594.			
PR	13-SEP-1999; 99WO-US020944.			
PR	15-SEP-1999; 99WO-US021090.			
PR	15-SEP-1999; 99WO-US021547.			
PR	05-OCT-1999; 99WO-US023089.			
PR	29-NOV-1999; 99WO-US028214.			
PR	30-NOV-1999; 99WO-US028313.			
PR	30-NOV-1999; 99WO-US028409.			
PR	01-DEC-1999; 99WO-US028301.			
PR	01-DEC-1999; 99WO-US028634.			
PR	02-DEC-1999; 99WO-US028551.			

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-695926/66.
DR P-PSDB; ADA67445.
XX
PT Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
PS Claim 2; Fig 271; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCGCCGAGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCGCCGAGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACTACCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACTACCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGTTGCAGGTGTTT 300
Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCACTGACAGAGCAATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 361 TCTGCACTGACAGAGCAATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
Db |||||
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTGTCTCCTCTCGGFGATGGTATTTGCTTGGATTGT 840
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTGTCTCCTCTCGGFGATGGTATTTGCTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db |||||
QY 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db |||||
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db |||||
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db |||||

RESULT 29
ADB30451
ID ADB30451 standard; cDNA; 1174 BP.
XX
AC ADB30451;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX
PN US2003068794-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123155.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-708391/67.
DR P-PSDB; ADB30452.
XX

PT New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX

PS Claim 2; Fig 271; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db |||||
Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db |||||
Qy 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
Qy 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db |||||
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAGTTGACCTACCCC 240
Db |||||
Qy 241 TTGCACACCTACCTTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Db |||||
Qy 241 TTGCACACCTACCTTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Db |||||
Qy 301 TCAATTTGTAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db |||||
Qy 301 TCAATTTGTAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db |||||
Qy 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
Qy 421 CAGAAATCAGTCCCATTCGCTGAATGAGACAAGAAACAATTATGTCCTGATGCCAAAA 480
Db |||||
Qy 421 CAGAAATCAGTCCCATTCGCTGAATGAGACAAGAAACAATTATGTCCTGATGCCAAAA 480
Db |||||
Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db |||||
Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db |||||
Qy 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
Qy 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660
Db |||||
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660
Db |||||
Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db |||||
Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db |||||
Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||

QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGT 840
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGTGATCTAT 900
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGTGATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCGGGCTCTACCTACAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCGGGCTCTACCTACAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAATGCAANTAAAGTTACTCAATCTGTG 1174
Db |||||
QY 1141 CTATAAATGCAANTAAAGTTACTCAATCTGTG 1174
Db |||||

RESULT 30
ADA85747
ID ADA85747 standard; cDNA; 1174 BP.
XX
AC ADA85747;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082693-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127843.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786907/74.
DR P-PSDB; ADA85748.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX

PS
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGAGCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGAGCCGCTTCGGCTGAAGCA 180
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGAGCCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCTGTGAGTTGACCTACCC 240
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCTGTGAGTTGACCTACCC 240
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGAGAGAGGTTGCAGGCTGTT 300
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGAGAGAGGTTGCAGGCTGTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGA 360
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGA 360
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCATTCTGGAGTGACATGATGACTCC 540
Db |||||

Db 181 TTTGACTGGTCTTGGTGATACGGCGTCTTGCCACCGGCGCTGTCACTTGACCTACCCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Qy 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Qy 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Qy 481 ATGCACCTACTCTTTCTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Qy 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Qy 781 TCTGGGTGGAATTTAACTACAACCTCTGTCTCCTCGGTGATGGTATTTGCTTGGATTTGT 840
Db 781 TCTGGGTGGAATTTAACTACAACCTCTGTCTCCTCGGTGATGGTATTTGCTTGGATTTGT 840
Qy 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTCTCTTTGTG 960
Db 901 GGTGACTTGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTCTCTTTGTG 960
Qy 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAAGTGAAT 1020
Qy 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Qy 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140
Qy 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 32
ADA79263
ID ADA79263 standard; cDNA; 1174 BP.
XX
AC ADA79263;
XX

DT 20-NOV-2003 (first entry)
XX Human PRO polynucleotide #136.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS US2003082763-A1.
XX 01-MAY-2003.
PN 17-APR-2002; 2002US-00124818.
PD 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755116/71.
P-PSDB; ADA79264.

New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in detection and treatment of cancer and in modulating the uptake of
glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

Claim 2; Fig 27i; 659pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |||||
61 GGGAAACAAGATGGCGCGCGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTGCGGGGACCGCTTCGGTGAAGCA 180
Db |||||
121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTGCGGGGACCGCTTCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCGCTGTCAAGTTGACTACCCC 240
Db |||||
181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCGCTGTCAAGTTGACTACCCC 240
QY 241 TTGCACACCTACCTACCTAAGGAAGAGGAGTTGTACCGCATGTTCAGAGAGGTTGACGGCTGTTT 300
Db |||||
241 TTGCACACCTACCTACCTAAGGAAGAGGAGTTGTACCGCATGTTCAGAGAGGTTGACGGCTGTTT 300
QY 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |||||
301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCAATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
361 TCTGCAATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAACTTATGTCCCTGATGCCAAAA 480
Db |||||
421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTTCATCTCGGAGTGACATGATGGACTCC 540
Db |||||
481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTTCATCTCGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGGAAAAATA 600
Db |||||
541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGGAAAAATA 600
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTTGGAGCAGGAGCCTACA 660

Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTAGCCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAAAGTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAAGTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 33
ADA87402
ID ADA87402 standard; cDNA; 1174 BP.
AC ADA87402;
XX
DT 20-NOV-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.
XX
PN US2003087345-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.

PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001US-00866032.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001US-00872035.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001US-00886342.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001US-00887879.
PR	29-JUN-2001;	2001US-00901066.
PR	09-JUL-2001;	2001US-00901735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

New PRO nucleic acid, useful for manufacturing a medicament for diagnosing or treating tumor.

Claim 2; Fig 271; 638pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF- α from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match	100.0%;	Score 1174;	DB 8;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 CGGACGGCTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGGCTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

QY 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 34
ADBL6604
XX ADBL6604 standard; cDNA; 1174 BP.
AC ADBL6604;
XX 20-NOV-2003 (first entry)
DT Human PRO polynucleotide #136.
DE
XX

KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX

OS Homo sapiens.
XX
XX US2003087349-A1.
XX
PD 08-MAY-2003.
XX
XX 19-APR-2002; 2002US-00125928.
XX
PR 19-JUN-1998; 98US-0089947P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786940/74.
XX P-PSDB; ADBL6605.

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
Db 61 GGAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTGACGATGTGAGAGGTTGAGGCTGTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTGACGATGTGAGAGGTTGAGGCTGTT 300
QY 301 TCAATTTGTGCTGTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGCTGTGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACCAAGAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACCAAGAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTCTGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTCTGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAACGG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAACGG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
QY 781 TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||

RESULT 35

ADA91696

ID ADA91696 standard; cDNA; 1174 BP.

XX ADA91696;

AC ADA91696;

XX ADA91696;

DT 20-NOV-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX

OS Homo sapiens.

XX

XX US2003082694-A1.

PN

XX 01-MAY-2003.

PD

XX 22-APR-2002; 2002US-00127845.

XX

PF 03-MAR-2000; 2000US-0187202P.

XX

PR 01-DEC-2000; 2000WO-US032678.

PR

XX 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-786908/74.

DR

XX P-PSDB; ADA91697.

XX

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,

PT or a composition for treating e.g., tumor or for tissue typing.

XX

PS Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTACAGAG 60

Db |||||

QY 1 CGGACGGCTGGGGGAAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTACAGAG 60

Db |||||

QY 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db |||||

QY 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db |||||

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGGACCGCTTCGCTGAAGCA 180

Db |||||

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGGACCGCTTCGCTGAAGCA 180

Db |||||

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACGGGCGCTGTGAGTTGACCTACCCC 240

Db |||||

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACGGGCGCTGTGAGTTGACCTACCCC 240

Db |||||

QY 241 TTGCACACCTACCCCTAAGGAAGAGAGTGTGTACCGCATGTTCAGAGAGGTTGAGGCTGTTT 300

Db |||||

QY 241 TTGCACACCTACCCCTAAGGAAGAGAGTGTGTACCGCATGTTCAGAGAGGTTGAGGCTGTTT 300

Db |||||

QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db |||||

QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db |||||

QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db |||||

QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db |||||

QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCTGATGCCAAA 480

Db |||||

QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCTGATGCCAAA 480

Db |||||

QY 481 ATGCACCTACTCTTTTCTCTAACTCTTGGTGGGCTCATTTCTGGAGTGACATGAGGACTCC 540

Db |||||

QY 481 ATGCACCTACTCTTTTCTCTAACTCTTGGTGGGCTCATTTCTGGAGTGACATGAGGACTCC 540

Db |||||

QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTTGT 840
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
Db 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGCAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATATAGACATCTAA 1080
QY 1081 AATCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 36
ADBI4759
ID ADBI4759 standard; cDNA; 1174 BP.
XX
AC ADBI4759;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.

XX 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786942/74.
DR P-PSDB; ADBI4760.
DR
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
XX
PS Claim 2; Fig 271; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
the proliferation of or gene expression in pericyte cells, for stimulating
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence represents a human PRO polynucleotide of the invention. Note:
The sequence data for this patent is also available in electronic format
from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCTGGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db 1 CGGACGCTGGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGGCGGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGGCGGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGTGTGCTGTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGTGTGCTGTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCTCAGTTGACCTACCCC	240
Db	181		
QY	241	TTGCACACCTAACCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGTTTGCAGGCTGTTT	300
Db	241		
QY	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA	360
Db	301		
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
Db	361		
QY	421	CAGAATCAGCTGCAATTCGCTGAACCTGAGACAAAGAACAACTTATGTCCCTGATGCCAAA	480
Db	421		
QY	481	ATGCACCTACTCTTTCCTCTAACTCTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC	540
Db	481		
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541		
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGAGCCTACA	660
Db	601		
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661		
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC	780
Db	721		
QY	781	TCTGGGTGGAATTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTTGT	840
Db	781		
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
Db	841		
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901		
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
Db	961		
QY	1021	CTTTGCTCATTTCTGAAATTTAAGCATTTTTCTTTTAAAGACAAGTGTATAGACATCTAA	1080
Db	1021		
QY	1081	AATTCACCTCTCATAGAGCTTTTAAAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA	1140
Db	1081		
QY	1141	CTATAAAATGCAATAAAGTTACTCAAATCTGTG	1174
Db	1141		

RESULT 37
ADA24868
ID ADA2

XX	ADA24868;	
AC	20-NOV-2003	(first entry)
XX	Novel human secreted and transmembrane protein	
DE	Human; secreted and transmembrane protein	
XX	chromosome identification; various sports-related joint disorders	
KW	wound healing; obesity; diabetes	
KW	cardiac insufficiency disorders	
KW	haemoglobin associated disorders	
XX	Homo sapiens.	
OS	US2003050241-A1.	
XX	13-MAR-2003.	
PN	16-OCT-2001;	2001US-00978564.
XX	17-OCT-1997;	97US-0062250P.
PR	03-NOV-1997;	97US-0064249P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066364P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077641P.
PR	11-MAR-1998;	98US-0077649P.
PR	12-MAR-1998;	98US-0077791P.
PR	13-MAR-1998;	98US-0078004P.
PR	20-MAR-1998;	98US-0078886P.
PR	20-MAR-1998;	98US-0078910P.
PR	20-MAR-1998;	98US-0078936P.
PR	20-MAR-1998;	98US-0078939P.
PR	25-MAR-1998;	98US-0079294P.
PR	26-MAR-1998;	98US-0079656P.
PR	27-MAR-1998;	98US-0079663P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079689P.
PR	27-MAR-1998;	98US-0079728P.
PR	27-MAR-1998;	98US-0079786P.
PR	30-MAR-1998;	98US-0079920P.
PR	30-MAR-1998;	98US-0079923P.
PR	31-MAR-1998;	98US-0080105P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080165P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080328P.
PR	01-APR-1998;	98US-0080333P.
PR	01-APR-1998;	98US-0080334P.
PR	08-APR-1998;	98US-0081049P.
PR	08-APR-1998;	98US-0081070P.
PR	08-APR-1998;	98US-0081071P.
PR	09-APR-1998;	98US-0081195P.
PR	09-APR-1998;	98US-0081203P.
PR	09-APR-1998;	98US-0081229P.
PR	15-APR-1998;	98US-0081817P.
PR	15-APR-1998;	98US-0081819P.
PR	15-APR-1998;	98US-0081838P.
PR	15-APR-1998;	98US-0081952P.
PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082700P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082757P.
PR	22-APR-1998;	98US-0082804P.
PR	23-APR-1998;	98US-0082756P.
PR	27-APR-1998;	98US-0083336P.
PR	28-APR-1998;	98US-0083332P.

```
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083504P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH ) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL,
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-521814/49.
DR P-PSDB; ADA24869.
XX
PT New isolated PRO polypeptides for example extracellular, secreted and
PT membrane bound proteins, useful for modulating the biological activities
PT of cells and for treating, for example diabetes, cancer, rheumatoid
PT arthritis, and hearing loss.
XX
PS Claim 2; Fig 131; 461pp; English.
XX
CC The invention describes an isolated secreted and transmembrane (PRO)
CC polypeptide (I). PRO337 polypeptide is useful for detecting PRO4993
CC polypeptide in a sample, and vice versa. PRO725, PRO700 and PRO739 are
CC useful for detecting PRO1559 polypeptide in a sample, and PRO1559 is
CC useful for detecting PRO725, PRO700 and PRO739 in a sample. PRO4993 is
CC useful for linking a bioactive molecule to a cell expressing a PRO337
CC polypeptide, and PRO337 is useful for linking a bioactive molecule to a
CC cell expressing a PRO4993 polypeptide. PRO1559 is useful for linking a
CC bioactive molecule to a cell expressing a PRO735, PRO700 and PRO739

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180
Db 121 CCGCTGCTGCTGTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180
Qy 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTTCAGTTGACCTACCC 240
Db 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTTCAGTTGACCTACCC 240
```


QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACTGACACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACTGACACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACCGAAAAATA 600
Db 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACCGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGGAATTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAATAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAATAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTTCATTGGATATAGGCCTTAAGAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTTCATTGGATATAGGCCTTAAGAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAATCTGTG 1174

RESULT 38
ADB18720
ID ADB18720 standard; cDNA; 1174 BP.
XX
AC ADB18720;
XX
DT 20-NOV-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokin.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
PF 15-APR-2002; 2002US-00123292.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695954/66.
DR P-PSDB; ADB18721.
XX
PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PT diagnosis and treatment of cancer.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocytes
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGCGGAGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGACAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGACAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTCGAATGTGAA 360
DB 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTCGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
DB 421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGACTCC 540
DB 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGACCTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGACCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGATTTAACTACAACCTCTTCTCTCTCTCGGTGATGATGCTTTGGATTGT 840
DB 781 TCTGGGTGATTTAACTACAACCTCTTCTCTCTCTCGGTGATGATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTGATCTAATAAAGCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTGATCTAATAAAGCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
DB 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAAATCTGTG 1174

RESULT 39
ADA93935

ID ADA93935 standard; cDNA; 1174 BP.

XX ADA93935;

AC ADA93935;

DT 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US200307722-A1.

PN 24-APR-2003.

XX 03-MAY-2002; 2002US-00137872.

PF 03-MAR-2000; 2000US-0187202P.

XX 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755077/71.

DR P-PSDB; ADA93936.

XX New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.

PS Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA, and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

SQ Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGCGCCGGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCCGGGCTGTCACTGACCTACCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCCGGGCTGTCACTGACCTACCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAGGCTGTTT	300
DB	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTCGACTTAAATCGAACTAAATTTGGAATGTAA	360
DB	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTCGACTTAAATCGAACTAAATTTGGAATGTAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
DB	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480
DB	421	CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480
QY	481	ATGCACCTACTCTTTTCTCTAATCTTGGTGAGGTCATCTTGAGTGACATGATGGACTCC	540
DB	481	ATGCACCTACTCTTTTCTCTAATCTTGGTGAGGTCATCTTGAGTGACATGATGGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA	660
DB	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTAACTACAACCTCTGCTCTCGGTGATGGTATTGCTTTGGATTGT	840

Db 781 TCTGGTGGATTTAACTACAACTCTTGCTCCTCGGTGATGGTATGCTTTGGATTGT 840

Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGIG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGIG 960

Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGTCTATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

Db 1021 CTTGTCTATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCA 1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCA 1140

Qy 1141 CTATAAATGCAATAAAGTTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTTACTCAATCTGTG 1174

RESULT 40

ADB19831

ID ADB19831 standard; cDNA; 1174 BP.

XX AC ADB19831;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082691-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127838.

XX PR 17-NOV-1998; 98US-0108802P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 02-JUN-2000; 2000WO-US015264.

PR 23-AUG-2000; 2000WO-US023522.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

DR WPI; 2003-755108/71.

DR P-PSDB; ADB19832.

XX PT PRO nucleic acid, useful for preparing a composition for treating e.g.,

PT tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

CC The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

Qy 181 TTTGACTCGGTCTGGGTGATACGGGCTCTTGCCACCGGGCTGTTCAGTTGACCTACCCC 240

Db 181 TTTGACTCGGTCTGGGTGATACGGGCTCTTGCCACCGGGCTGTTCAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTACAGAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTACAGAGAGGTTGCAGGCTGTTT 300

Qy 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Qy 361 TCTGCATGTACAGAAGCATATTCCTAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAGCATATTCCTAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420

Qy 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACTATGTCCTGATGCCAAAA 480

Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACTATGTCCTGATGCCAAAA 480

Qy 481 ATGCACCTACTCTTCTTCTAATCTGCTGGAGGTCATCTCGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTCTCTAATCTCTGGTGGAGTCACTCTGGAGTGACATGAGTCC 540
QY 541 GCACAGAGCTTCATACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
Db 541 GCACAGAGCTTCATACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGCTTACA 660
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTANGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTANGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCACTTGAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 41

ADBI3143
ID ADBI3143 standard; cDNA; 1174 BP.

XX ADBI3143;

XX ADBI3143;

XX 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082710-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147484.
XX 09-DEC-1999; 99US-0170262P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786913/74.
XX P-PSDB; ADBI3144.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
XX preparing a composition for treating e.g., tumor, or for tissue typing.
XX Claim 2; Fig 271; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting the uptake of
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems,
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassaemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence represents a human PRO polynucleotide of the invention. Note:
XX The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAGGAGGAGCTCTGSGTGAGGACCCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAGGAGGAGCTCTGSGTGAGGACCCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGCATGTGAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGCATGTGAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAAGTAAATGGAATGTGAA 360
Db 301 TCAATTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAAGTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGCTCTCGGATGATGATTTGCTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACCTCTTGCTCTCGGATGATGATTTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCRAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCRAATCTGTG 1174

RESULT 42

ACD98559

ID ACD98559 standard; cDNA; 1174 BP.

XX

AC ACD98559;
XX
DT 26-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy;
KW chromosome identification; tissue typing; gene; ss.
XX Homo sapiens.
OS
PN US2003044945-A1.
XX
PD 06-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142419.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00865034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-492275/46.
P-PSDB; ABO43284.

New transmembrane polypeptides and nucleic acids encoding the
polypeptides, useful in gene therapy, in chromosome identification, as
chromosome markers, or in generating probes.

Claim 2; Fig 271; 660pp; English.

The invention describes an isolated nucleic acid encoding a PRO (secreted
and transmembrane) polypeptide. Nucleic acids which encode PRO can be
used to generate either transgenic animals or knock-out animals useful in
developing and screening of therapeutically useful reagents. The nucleic
acids may also be used in gene therapy, in chromosome identification, as
chromosome markers, or in generating probes. The PRO polypeptides are
useful as molecular markers for protein electrophoresis, and the isolated
nucleic acids may be used for recombinantly expressing those markers. The
PRO polypeptides and nucleic acids may also be used in tissue typing.
Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
affinity purification of PRO from recombinant cell culture or natural
sources. This sequence encodes a novel human secreted and transmembrane
PRO polypeptide

XX

SQ	Sequence	1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;	
	Query Match	100.0%; Score 1174; DB 8; Length 1174;	
	Best Local Similarity	100.0%; Pred. No. 0;	
	Matches 1174; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTTCAGTTGACCTACCCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTTCAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCTATGTCAGAGAGGTTGCAGGCTGTTT	300
DB	241	TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCTATGTCAGAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACCTTAAATCGAACTAAATGGAATGTGA	360
DB	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACCTTAAATCGAACTAAATGGAATGTGA	360
QY	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGCATGAGCAATATGCTTGCCATCTTGGTTGC	420
DB	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGCATGAGCAATATGCTTGCCATCTTGGTTGC	420
QY	421	CAGAAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAAA	480
DB	421	CAGAAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAAA	480
QY	481	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGGGACTCC	540
DB	481	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGGGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAATAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAATAATA	600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTGGAGAGAGCCTACA	660
DB	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTGGAGAGAGCCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTTCTCTCGGTGATGGTATTTGGATTGT	720
DB	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTTCTCTCGGTGATGGTATTTGGATTGT	720
QY	721	CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTGTG	960
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020

PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WL;
XX
DR WPI; 2003-503575/47.
DR P-PSDB; ABO19690.

XX Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.

PS Claim 2; Fig 131; 459pp; English.

XX The invention describes an isolated, secreted and transmembrane
CC polypeptide, termed PRO polypeptide (I). (I) is useful for detecting
CC PRO4993, PRO337, PRO1559, PRO725, PRO700 or PRO739 polypeptide, and for
CC linking a bioactive molecule to a cell expressing the above polypeptides.
CC The bioactive molecule is a toxin, radiolabel or an antibody and causes
CC cell death. (I) is useful as therapeutic agent, in medical and industrial
CC applications e.g. for treating neuropathy, especially peripheral
CC neuropathy, diabetic peripheral neuropathy, AIDS-associated neuropathy,
CC Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinaemia,

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCTTGGCCGGAGGTTCCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACTACCC 240
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACTACCC 240
Db |||||
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGATGTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGATGTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGATGATGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |||||
QY 301 TCAATTTGTCAGTTTGTGATGATGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGGTTC 420
Db |||||
QY 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGTTGCCATCTTGGTTC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGTAAGTGAAGCAAGCAAACTATGTCCTGATGCCAAAA 480
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGTAAGTGAAGCAAGCAAACTATGTCCTGATGCCAAAA 480
Db |||||
QY 481 ATGCACCTACTCTTCTTAACCTCTGAGTGGTGGTCACTCTGAGTGACATGAGGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTCTTAACCTCTGAGTGGTGGTCACTCTGAGTGACATGAGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCAAGCACTTTTATCTTCAAGCCGATGACGGAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCAAGCACTTTTATCTTCAAGCCGATGACGGAATA 600
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660
Db |||||
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db |||||
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db |||||
QY 781 TCTGGGTGGATTTTAACTACAACCTCTGCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
QY 781 TCTGGGTGGATTTTAACTACAACCTCTGCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCACTTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCACTTTTCTTTTAAAGACAGTGTAAATAGACATCTAA 1080
Db |||||

[illegible]

RESULT 44

ADA12529
ID ADA12529 standard; cDNA; 1174 BP.

AC ADA12529;

DT 06-NOV-2003 (first entry)

DE Human cDNA encoding secreted/transmembrane polypeptide PRO195.

ss; gene; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS; cancer;
KW diabetic complication; tissue typing; human.

OS Homo sapiens.

PN US2003055216-A1.

PD 20-MAR-2003.

17-OCT-2001: 2001US-00978824.

PR	21-MAY-1996;	96US-0018049P.
PR	17-OCT-1997;	97US-0062250P.
PR	03-NOV-1997;	97US-0064249P.
PR	13-NOV-1997;	97US-0065311P.
PR	21-NOV-1997;	97US-0066364P.
PR	10-MAR-1998;	98US-0077450P.
PR	11-MAR-1998;	98US-0077632P.
PR	11-MAR-1998;	98US-0077641P.
PR	11-MAR-1998;	98US-0077649P.
PR	12-MAR-1998;	98US-0077791P.
PR	13-MAR-1998;	98US-0078004P.
PR	17-MAR-1998;	98US-00040220.
PR	20-MAR-1998;	98US-0077886P.
PR	20-MAR-1998;	98US-0078910P.
PR	20-MAR-1998;	98US-0078936P.
PR	20-MAR-1998;	98US-0078939P.
PR	25-MAR-1998;	98US-0079294P.
PR	26-MAR-1998;	98US-0079656P.
PR	27-MAR-1998;	98US-0079663P.
PR	27-MAR-1998;	98US-0079664P.
PR	27-MAR-1998;	98US-0079689P.
PR	27-MAR-1998;	98US-0079728P.
PR	27-MAR-1998;	98US-0079786P.
PR	30-MAR-1998;	98US-0079920P.
PR	30-MAR-1998;	98US-0079923P.
PR	31-MAR-1998;	98US-0080105P.
PR	31-MAR-1998;	98US-0080107P.
PR	31-MAR-1998;	98US-0080165P.
PR	31-MAR-1998;	98US-0080194P.
PR	01-APR-1998;	98US-0080327P.
PR	01-APR-1998;	98US-0080328P.
PR	01-APR-1998;	98US-0080333P.
PR	01-APR-1998;	98US-0080334P.
PR	08-APR-1998;	98US-0081070P.
PR	08-APR-1998;	98US-0081071P.
PR	09-APR-1998;	98US-0081195P.
PR	09-APR-1998;	98US-0081203P.
PR	09-APR-1998;	98US-0081229P.
PR	15-APR-1998;	98US-0081817P.
PR	15-APR-1998;	98US-0081819P.
PR	15-APR-1998;	98US-0081838P.

PR	15-APR-1998;	98US-0081952P;
PR	15-APR-1998;	98US-0081955P;
PR	21-APR-1998;	98US-0082568P;
PR	21-APR-1998;	98US-0082569P;
PR	22-APR-1998;	98US-0082700P;
PR	22-APR-1998;	98US-0082704P;
PR	22-APR-1998;	98US-0082797P;
PR	22-APR-1998;	98US-0082804P;
PR	23-APR-1998;	98US-0082796P;
PR	27-APR-1998;	98US-0083336P;
PR	28-APR-1998;	98US-0083322P;
PR	29-APR-1998;	98US-0083392P;
PR	29-APR-1998;	98US-0083495P;
PR	29-APR-1998;	98US-0083496P;
PR	29-APR-1998;	98US-0083499P;
PR	29-APR-1998;	98US-0083500P;
PR	29-APR-1998;	98US-0083545P;
PR	29-APR-1998;	98US-0083554P;
PR	29-APR-1998;	98US-0083558P;
PR	29-APR-1998;	98US-0083559P;
PR	30-APR-1998;	98US-0083742P;
PR	05-MAY-1998;	98US-0084366P;
PR	06-MAY-1998;	98US-0084414P;
PR	06-MAY-1998;	98US-0084441P;
PR	07-MAY-1998;	98US-0084598P;
PR	07-MAY-1998;	98US-0084600P;
PR	07-MAY-1998;	98US-0084627P;
PR	07-MAY-1998;	98US-0084637P;
PR	07-MAY-1998;	98US-0084639P;
PR	07-MAY-1998;	98US-0084640P;
PR	07-MAY-1998;	98US-0084643P;
PR	13-MAY-1998;	98US-0085323P;
PR	13-MAY-1998;	98US-0085338P;
PR	13-MAY-1998;	98US-0085339P;
PR	15-MAY-1998;	98US-0085573P;
PR	15-MAY-1998;	98US-0085579P;
PR	15-MAY-1998;	98US-0085689P;
PR	15-MAY-1998;	98US-0085697P;
PR	15-MAY-1998;	98US-0085700P;
PR	15-MAY-1998;	98US-0085704P;
PR	18-MAY-1998;	98US-0086023P;
PR	22-MAY-1998;	98US-0086392P;
PR	22-MAY-1998;	98US-0086414P;
PR	22-MAY-1998;	98US-0086430P;
PR	22-MAY-1998;	98US-0086486P;
PR	28-MAY-1998;	98US-0087098P;
PR	28-MAY-1998;	98US-0087106P;
PR	28-MAY-1998;	98US-0087208P;
PR	26-JUN-1998;	98US-00105413;
PR	26-JUN-1998;	98US-0090863P;
PR	26-JUN-1998;	98US-0091010P;
PR	01-JUL-1998;	98US-0091359P;
PR	30-JUL-1998;	98US-0094651P;
PR	11-SEP-1998;	98US-01003304P;
PR	07-OCT-1998;	98US-01006978;
PR	07-OCT-1998;	98WO-US021141;
PR	02-NOV-1998;	98US-00184216;
PR	06-NOV-1998;	98US-00187368;
PR	20-NOV-1998;	98US-0103304P;
PR	20-NOV-1998;	98WO-US024855;
PR	07-DEC-1998;	98US-00202054;
PR	22-DEC-1998;	98US-00218517;
PR	22-DEC-1998;	98US-0113296P;
PR	23-DEC-1998;	98US-0113621P;
PR	05-JAN-1999;	99WO-US000106;
PR	05-MAR-1999;	98US-00254465;
PR	08-MAR-1999;	99WO-US005028;
PR	10-MAR-1999;	99US-00255686;
PR	10-MAR-1999;	99WO-US005190;
PR	12-MAR-1999;	99US-00267213;
PR	12-MAR-1999;	99US-00123957P;

PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 21-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCTTCCGAGAAACACGAAACGAGCTGAGCTGCTGTGACAGAG 60
|||||

Db 1 CGGACGCGTGGGGAAACCTTCCGAGAAACACGAAACGAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGCGCGCGCGAAGGGGAGCCTCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
|||
Db 61 GGGAAACAAGATGCGCGCGCGAAGGGGAGCCTCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
|||
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
|||
Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
|||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
|||
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
|||
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
|||
Db 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
|||
QY 301 TCAATTTGTGCTGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
|||
Db 301 TCAATTTGTGCTGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
|||
QY 361 TCTGCATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
|||
Db 361 TCTGCATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
|||
QY 421 CAGAATCAGCTGCCATTGCGTGAAGTGAAGCAAGAAACAATTATGTCCCTGATGCCAAAA 480
|||
Db 421 CAGAATCAGCTGCCATTGCGTGAAGTGAAGCAAGAAACAATTATGTCCCTGATGCCAAAA 480
|||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
|||
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
|||
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
|||
Db 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
|||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA 660
|||
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA 660
|||
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
|||
Db 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
|||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATCCCTCTCTCTTAAC 780
|||
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATCCCTCTCTCTTAAC 780
|||
QY 781 TCTGGGTGATTTTAACTACAACCTCTTCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
|||
Db 781 TCTGGGTGATTTTAACTACAACCTCTTCTCTCGGTGATGGTATTGCTTTGGATTTGT 840
|||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
|||
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
|||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
|||
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
|||
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
|||
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
|||
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
|||
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
|||
QY 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATATAGGCTTATAGGCTTAAAGAAATCA 1140
|||
Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATATAGGCTTATAGGCTTAAAGAAATCA 1140
|||

QY	1141	CTATAAAATGCAATATAAGTTACTCAAATCTGTG	1174
Db	1141	CTATAAAATGCAATATAAGTTACTCAAATCTGTG	1174
RESULT 45			
ID	ADA74397		
XX	ADA74397	standard; cDNA; 1174 BP.	
AC	ADA74397;		
DT	20-NOV-2003	(first entry)	
XX	Human PRO polynucleotide #136.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003068798-A1.		
XX			
PD	10-APR-2003.		
XX			
PF	07-MAY-2002; 2002US-00140928.		
XX			
PR	31-MAR-1997;	97WO-US005230.	
PR	12-JUN-1998;	98WO-US012456.	
PR	14-JUL-1998;	98WO-US014552.	
PR	28-AUG-1998;	98WO-US017888.	
PR	10-SEP-1998;	98WO-US018824.	
PR	14-SEP-1998;	98WO-US019093.	
PR	14-SEP-1998;	98WO-US019094.	
PR	14-SEP-1998;	98WO-US019177.	
PR	16-SEP-1998;	98WO-US019330.	
PR	17-SEP-1998;	98WO-US019437.	
PR	07-OCT-1998;	98WO-US021141.	
PR	29-OCT-1998;	98WO-US022991.	
PR	29-OCT-1998;	98WO-US022992.	
PR	20-NOV-1998;	98WO-US024855.	
PR	01-DEC-1998;	98WO-US025108.	
PR	05-JAN-1999;	99WO-US000106.	
PR	08-MAR-1999;	99WO-US005028.	
PR	10-MAR-1999;	99WO-US005190.	
PR	20-APR-1999;	99WO-US008615.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	01-SEP-1999;	99WO-US020111.	
PR	08-SEP-1999;	99WO-US020594.	
PR	13-SEP-1999;	99WO-US020944.	
PR	15-SEP-1999;	99WO-US021090.	
PR	15-SEP-1999;	99WO-US021547.	
PR	05-OCT-1999;	99WO-US023089.	
PR	29-NOV-1999;	99WO-US028214.	
PR	30-NOV-1999;	99WO-US028313.	
PR	30-NOV-1999;	99WO-US028409.	
PR	01-DEC-1999;	99WO-US028301.	
PR	01-DEC-1999;	99WO-US028634.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028564.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	20-DEC-1999;	99WO-US030911.	
PR	20-DEC-1999;	99WO-US030999.	

PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGCGAAGGGGAGCCTCTGGGTGAGACCCCACTGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGCGAAGGGGAGCCTCTGGGTGAGACCCCACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCAATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCAATGGCCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCCGGGCCTGTCACTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCCGGGCCTGTCACTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGATGTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGATGTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGTCAGTTTGGGTGATGGAATTGACTTAAATCGAATTAATTGGAATGTGAA 360
DB 301 TCAATTGTGTCAGTTTGGGTGATGGAATTGACTTAAATCGAATTAATTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
DB 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGGACTCC 540
DB 481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTACA 660
DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
DB 1021 CTTGCTCATCTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
RESULT 46
ADB24630
ID ADB24630 standard; cdna; 1174 BP.
XX
AC ADB24630;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
OS US2003077713-A1.
XX PD 24-APR-2003.
XX PF 22-APR-2002; 2002US-00127839.
XX PR 05-JUN-2000; 2000US-0209832P.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755068/71.
DR P-PSDB; ADB24631.
XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX Claim 2; Fig 271; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
SQ Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CGGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTCTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTCTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTGTTGGGTGATGGAATTCGACTTAAATCGAATGAAATTTGGAATGTGAA 360
DB 301 TCAATTTGTGCTGTTGGGTGATGGAATTCGACTTAAATCGAATGAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACCAAGAACAACTTATGTCCTGATGCCAAAA 480
DB 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACCAAGAACAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTTGGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCCACCACATTTGGAGCAGGAGCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCCACCACATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
DB 1021 CTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 47

ADA82154

ID ADA82154 standard; cDNA; 1174 BP.

XX

AC ADA82154;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human PRO polynucleotide #136.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003082701-A1.

XX

PD 01-MAY-2003.

XX

PF 23-APR-2002; 2002US-00128686.

XX

PR 31-AUG-1998; 98US-0098525P.

PR 16-SEP-1998; 98US-0100634P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.

PR 02-JUN-2000; 2000WO-US015264.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-755110/71.

DR P-PSDB; ADA82155.

XX

PT PRO nucleic acid, useful for preparing a composition for treating e.g.,

PT tumor or for tissue typing.

XX

PS Claim 2; Fig 271; 637pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCGCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTTCGGGGACCGCTTCGGTGAAGCA 180

DB 121 CCGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTTCGGGGACCGCTTCGGTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCTGTCACTTGACCTACCCC 240

DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCTGTCACTTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAGGCTGTTT 300

DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGAATGTAA 360

DB 301 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGAATGTAA 360

QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

DB 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCCTTAACCTTGGTGAGGTCATTTCTGGAGTGACATGEGACTCC 480

DB 421 CAGAATCAGCTGCCATTTCCTTAACCTTGGTGAGGTCATTTCTGGAGTGACATGEGACTCC 480

QY 481 ATGCACCTACTCTTTTCTTAACCTTGGTGAGGTCATTTCTGGAGTGACATGEGACTCC 540

DB 481 ATGCACCTACTCTTTTCTTAACCTTGGTGAGGTCATTTCTGGAGTGACATGEGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600

DB 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660

DB 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCCTACA 660

QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720

DB 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTTAAC 780

Db 721 CACAGCAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTGTTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCCTCTCGGTGATGGTATTGCTTTGGATTGTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 48
ADA75117
ID ADA75117 standard; cDNA; 1174 BP.
XX
AC
XX ADA75117;
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073216-A1.
XX
PD 17-APR-2003.
XX
PF 30-MAY-2002; 2002US-00160498.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX
DR WPI; 2003-765392/72.
DR P-PSDB; ADA75118.

XX
PT New secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha in human blood and detecting
PT the presence of tumor in a mammal.

XX
PS Claim 2; Fig 271; 638pp; English.

XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGGTGGGGAAACCCCTCCGAGAAAACAGCAACCAAGCTGAGTGTGTGACAGAG 60
DB 1 CGGACCGGTGGGGAAACCCCTCCGAGAAAACAGCAACCAAGCTGAGTGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGAGCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGAGTTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGAGTTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGIGAA 360
DB 301 TCAATTTGTGCTAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGIGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTAGTACGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTAGTACGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAAGAACTTATGTCCTGATGCCAAA 480
DB 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAAGAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACTCTTTCATGGACCTTTTATCTTCAAGCCCGATGACGGAAAATA 600
DB 541 GCACAGAGCTTCATAACTCTTTCATGGACCTTTTATCTTCAAGCCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAGATGGAGAAAGTATGCGCTTTTAAAGATGCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAGATGGAGAAAGTATGCGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
DB 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACCTAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 49

ADA85195
ID ADA85195 standard; cDNA; 1174 BP.

XX AC ADA85195;

XX DT 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.

DE Human; secreted and transmembrane protein; PRO; gene; ss;
XX Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003082695-A1.

PN 01-MAY-2003.

PD 22-APR-2002; 2002US-00127846.

PF 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786909/74.

DR P-PSDB; ADA85196.

XX New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT composition for treating e.g. tumor by gene therapy, or for tissue
PT typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCTGGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCGCGGAGGGGAGCCTCTGGGTAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCGCGGAGGGGAGCCTCTGGGTAGGACCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGAGGTTCCGGGACCCGCTTCGGTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGAGGTTCCGGGACCCGCTTCGGTGAAGCA 180
Qy 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTTGCCACCGGGCCCTGTCACTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTTGCCACCGGGCCCTGTCACTTGACCTACCCC 240
Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTTCAGGCTGTTT 300
Qy 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGTAGTGAAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCTCAATCTGTAGTGAAGCAATATGCTTGCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAAGCAAGCAAGCAAGCAAGCAAGCA 480
Qy 481 ATGCACCTACTCTTTTCTCAATCTGCTGAGGTTGAGGTTGAGGTTGAGGTTGAGGTTGAGG 540
Db 481 ATGCACCTACTCTTTTCTCAATCTGCTGAGGTTGAGGTTGAGGTTGAGGTTGAGGTTGAGG 540
Qy 541 GCACAGAGCTTCATAAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Qy 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Qy 781 TCTGGGTGGATTTTAACTACACTCTCTCTCTCGGTGATGATGATGATGATGATGATGATGAT 840
Db 781 TCTGGGTGGATTTTAACTACACTCTCTCTCTCGGTGATGATGATGATGATGATGATGATGAT 840
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTTACCTACAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTAAGCATTTTCTTTAAAGACAAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTAAGCATTTTCTTTAAAGACAAAGTGAATAGACATCTAA 1080
Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAATCA 1140
Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 50
ADA84643
ID ADA84643 standard; cDNA; 1174 BP.
XX
AC ADA84643;
XX
DT 20-NOV-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082708-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146729.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786911/74.
DR P-PSDB; ADA84644.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGACCATGCGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCACTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCCTGTCACTTGACCTACCCC 240
Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCAGAGAGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCAGAGAGTTGCAGGCTGTTT 300
Qy 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGA 360
Qy 361 TCTGCATGTACAGAAAGCATATTCCTAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCTAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTTATGTCCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTCTCTAATCTGGTGAGGTGAGTCAATCTGGAGTGACATGAGTACTCC 540
Db 481 ATGCACCTACTCTTCTCTAATCTGGTGAGGTGAGTCAATCTGGAGTGACATGAGTACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTACA 660
Qy 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAATGAGAAATTCACAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAATGAGAAATTCACAGCG 720

Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840

Db 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840

QY 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db 841 TGTGCAACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

Db 1021 CTTGCTCATCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 51

ADB29899

ID ADB29899 standard; cDNA; 1174 BP.

XX AC ADB29899;

DT 20-NOV-2003 (first entry)

DE cDNA encoding human PRO polypeptide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

OS Homo sapiens.

XX US2003073214-A1.

PN 17-APR-2003.

PD 17-APR-2002; 2002US-00124822.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 10-MAR-2000; 2000WO-US006319.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.

PR 24-AUG-2000; 2000WO-US023328.

PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.

PR 20-DEC-2000; 2000WO-US034956.

PR 28-FEB-2001; 2001US-00796498.

PR 28-FEB-2001; 2001WO-US006520.

PR 01-MAR-2001; 2001WO-US006666.

PR 09-MAR-2001; 2001US-00802706.

PR 14-MAR-2001; 2001US-00808689.

PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.

PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.

PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.

PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-720081/68.
DR P-PSDB; ADB29900.

XX
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT the release of tumor necrosis factor alpha and detecting the presence of
PT a tumor in a mammal.

XX
PS Claim 2; Fig 271; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGCGCGCGCGCGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGCGCGCGCGCGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CCGCTGCTGCTGCTGACCATGGCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGGCTGTCAAGTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTGGGTGATACGGCGTCTTGCCACCGGGCTGTCAAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGTCAGGCTGTTT	300
Db	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGTCAGGCTGTTT	300
QY	301	TCAATTTGTGCTGATGATGGAATTTGACTTAAATCGAATAAATTTGGAATGTGAA	360
Db	301	TCAATTTGTGCTGATGATGGAATTTGACTTAAATCGAATAAATTTGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC	420
QY	421	CAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
Db	421	CAGAAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC	540
Db	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC	540
QY	541	GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541	GCACAGAGCTTCAATACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA	660
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGAAATCACTCTAAGCAAAATGTCCTATCTGCAATAGAGAAATTCACAAGCG	720
Db	661	AATTTGAGAGAAATCACTCTAAGCAAAATGTCCTATCTGCAATAGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC	780
QY	781	TCGCGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840
Db	781	TCGCGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
QY	1081	AATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCGCTTAAGAAATCA	1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
RESULT 52
ADA80427
ID ADA80427 standard; cDNA; 1174 BP.
XX
AC ADA80427;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082761-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121061.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755115/71.
DR P-PSDB; ADA80428.
XX

New PRO polypeptides useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors.

Claim 2; Fig 271; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG	60
DB	1	CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCCGGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGGCCGGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGGCCACGGGCGCTGTCAAGTTGACCTACCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGGCCACGGGCGCTGTCAAGTTGACCTACCC	240
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGACGGCTGTTT	300
DB	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGACGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360
DB	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC	420
DB	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC	420

QY	421	CAGAAATCAGCTGCCATTTCCTGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
DB	421	CAGAAATCAGCTGCCATTTCCTGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGAGACTCC	540
DB	481	ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCAATTCGGAGTGACATGAGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTGGAGCAGGACCTACA	660
DB	601	GTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTGGAGCAGGACCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGCTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGAATCATCTCTAAGCAAAATGCTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
QY	781	TCTGGTGGATTTTAACTCAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTTGT	840
DB	781	TCTGGTGGATTTTAACTCAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTTGT	840
QY	841	TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
DB	841	TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCAATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
DB	1021	CTTGCTCAATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
DB	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
DB	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 53
ADA75669

ID ADA75669 standard; cDNA; 1174 BP.

XX ADA75669;

DT 20-NOV-2003 (first entry)

XX Human PRO polynucleotide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

immune system cell infiltration.

Homo sapiens.

US2003082703-A1.

01-MAY-2003.

23-APR-2002; 2002US-00128691.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z;

WPI; 2003-765414/72.

P-PSDB; ADA75670.

New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor or for tissue typing.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGGCTGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGGCTTTCGCCACCGGGCTGTTCAGTTGACCTACCCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGGGCTTTCGCCACCGGGCTGTTCAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAAGCAACTTATGTCCCTGATGCCAAA 480

Db 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGCAAGCAAGCAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTCTTAACCTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACCGGAAAAATA 600

Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACCGGAAAAATA 600

QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660

Db 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660

QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGAATTTGT 840

Db 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGAATTTGT 840

QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAAGTGAAT 1020

Db 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAAGTGAAT 1020

QY 1021 CTTGCTCATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAATAGACATCTAA 1080

Db 1021 CTTGCTCATTCTGAAATTTAAGCAATTTTCTTTTAAAGCAAGTGTAATAGACATCTAA 1080

QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 54
ADA46894

ID ADA46894 standard; cDNA; 1174 BP.

XX AC ADA46894;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #136.

XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.

XX PN US2003073210-A1.

XX PD 17-APR-2003.

XX PF 11-APR-2002; 2002US-00121045.

XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-644800/61.
P-PSDB; ADA46895.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 271; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other; ; SQ

Query Match	100.0%	Score 1174;	DB 8;	Length 1174;
Best Local Similarity	100.0%	Pred. No. 0;		
Matches 1174; Conservative	0;	Mismatches	0;	Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGCGTGGGGAAACCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG	120
Db	61	GGGAACAAGATGGCGGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGCTCCCG	120
QY	121	CCGCTGCTGCTGTGACCATGGCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CCGCTGCTGCTGTGACCATGGCCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCCGGGCCCTGTCACTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCCGGGCCCTGTCACTTGACCTACCCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT	300
Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA	360
Db	301	TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGGCATCTTGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGGCATCTTGTTGC	420
QY	421	CAGAAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACCTTATGTCCCTGATGCCAAAA	480
Db	421	CAGAAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACCTTATGTCCCTGATGCCAAAA	480

QY	481	ATGCACCTACTCTTTCCCTTAACCTCTGGTGGAGGTCAATCTGGAGTGACATGATGGACTCC	540
Db	481		
QY	541	GCACAGAGCTTCATAAACCTCTTTCATGGACTTTTTATCTTCAAGCCCGATGACGGAAAAATA	600
Db	541		
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA	660
Db	601		
QY	661	AATTTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661		
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
Db	721		
QY	781	TCTGGGTGGAATTTAACTACAACTCTTGTCTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
Db	781		
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
Db	841		
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG	960
Db	901		
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
Db	961		
QY	1021	CTTGCTCATTCAGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA	1080
Db	1021		
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081		
QY	1141	CTATAAAATGCAATAAAGTTACTCAAATCTGTG	1174
Db	1141		

RESULT 55

ADB25190
ID ADB25190 standard; cDNA: 1174 BP.

AC ADB25190;

DT 20-NOV-2003 (first entry)

Human PRO polynucleotide SEQ ID NO 271.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.

PN US2003077715-A1.

Db 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174
RESULT 56
ADA93366
ID ADA93366 standard; cDNA, 1174 BP.
XX
AC ADA93366;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077721-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131837.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoysers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755076/71.
DR P-PSDB; ADA93367.
XX
PT New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT tumor.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGTGTCTGCTGTGACCATGGCCTTGGCCGAGAGTTTCGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGTGTCTGCTGTGACCATGGCCTTGGCCGAGAGTTTCGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGGCCCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGGCCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTTCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTTCAGGCTGTTT 300
QY 301 TCATTTGTTCAGTTTGTGATGATGGAATGTGACTTAAATCGAATGGAATGGAATGTGAA 360
DB 301 TCATTTGTTCAGTTTGTGATGATGGAATGTGACTTAAATCGAATGGAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480
DB 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTTGGAGTGACATGAGGACTCC 540
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTTGGAGTGACATGAGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
DB 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTGGATTTGT 840

Db 781 TCTGGGTGGATTAACTACAACCTCTTGCTCCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGACGAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGACGAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAATCA 1140
QY 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174

RESULT 57
ADB26716
ID ADB26716 standard; cDNA; 1174 BP.
XX
AC ADB26716;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092147-A1.
XX
PD 15-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121051.
XX

PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020394.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.

RESULT 58
ADB31003
ID ADB31003 standard; cDNA; 1174 BP.
XX
AC ADB31003;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US015264.
PR 02-JUN-2000; 2000WO-US020710.
PR 28-JUL-2000; 2000WO-US022031.
PR 11-AUG-2000; 2000WO-US023522.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US030952.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-786990/74.
P-PSDB; ADB31004.

Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
hypo-insulinemia, sports injuries, arthritis, obesity, heart
attack, various coagulation disorders, tumors.

Claim 2; Fig 271; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.

```

SQ      Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match      100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY	541	GCACGAGCTTCATAAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541	GCACGAGCTTCATAAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTGGAGCAGGACCTTACA	660
Db	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCACCAATTGGAGCAGGACCTTACA	660
QY	661	AAATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661	AAATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTTAAGATGCCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTTTAAGATGCCCTCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTGTG	960
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
QY	1081	AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081	AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAAATCTGTG	1174
Db	1141	CTATAAATGCAATAAAGTTACTCAAATCTGTG	1174
RESULT 59			
ADA60931			
ID	ADA60931 standard; cDNA; 1174 BP.		
XX			
AC	ADA60931;		
XX			
DT	20-NOV-2003 (first entry)		
XX			
DE	Homo sapiens.		
XX			
KW	Human; secreted and transmembrane protein; PRO; gene; ss;		
KW	Tumour necrosis factor alpha release; TNF-alpha release;		
KW	glucose uptake modulator; FFA uptake modulator;		
KW	cell proliferation stimulator; cell differentiation stimulator;		
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;		
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
KW	gene therapy; chromosome identification; chromosome marker.		
XX			
OS	Novel.		
OS	human.		
OS	secreted.		
OS	and.		
OS	transmembrane.		
OS	protein.		
OS	PRO195.		
OS	cDNA.		

XX US2003049817-A1.
PN
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US005884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR 10-MAR-2009; 2000WO-US006319.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-695893/66.
P-PSDB; ADA60932.

New secreted and transmembrane PRO polypeptide and nucleic acid, useful
for manufacturing a medicament for diagnosing or treating tumor.

Claim 2; Fig 271; 658pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACCGCTGGGGAAACCCCTCCGAGAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGGCATGTGACAGAGGTTGACGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGGCATGTGACAGAGGTTGACGGCTGTTT 300
QY 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCAATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAAATTCACAAGCG 720
Db 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGAGTGGCTTTTAAAGATGCTCTCTTAAAC 780
QY 781 TCTGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGTTGATTTGATTTGT 840
Db 781 TCTGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGTTGATTTGATTTGT 840
QY 841 TGTGCACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGATGAACAAAAGCTTAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTGGAGTTTATGATGAACAAAAGCTTAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTAGATCTAAACTGAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174
RESULT 60
ADB24078
ID ADB24078 standard; cDNA; 1174 BP.
XX
AC ADB24078;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077714-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127901.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755069/71.
DR P-PSDB; ADB24078.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The

invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTGACAGAG	60
DB	1	CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240
DB	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCAAGGCTGTTT	300
DB	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGGTTGCAAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
DB	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGC	420
DB	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
DB	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCGGAGTGACATGATGACTCC	540
DB	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCGGAGTGACATGATGACTCC	540

QY	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATACGGAATAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATACGGAATAATA	600
QY	601	GTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTGGAGCAGGAGCTACA	660
DB	601	GTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCAACACATTTGGAGCAGGAGCTACA	660
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT	900
DB	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT	900
QY	901	GGTGACTTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960
DB	901	GGTGACTTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960
QY	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
DB	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
QY	1081	AATTCACACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCTTAAAGAAATCA	1140
DB	1081	AATTCACACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174
DB	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174

RESULT 61

ADA96407
ID ADA96407 standard; cDNA; 1174 BP.

XX
AC ADA96407;

XX
DT 20-NOV-2003 (first entry)

XX
DE Human PRO polynucleotide #136.

XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

OS Homo sapiens.

XX
FN US2003082690-A1.

XX
PD 01-MAY-2003.

XX

PF 22-APR-2002; 2002US-00127837.
XX
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755107/71.
DR P-PSDB; ADA96408.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAAGTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAAGTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
QY 121 CGCGTGTGCTGTGACCATGGCCTTGCGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180

RESULT 62

ADA80979
ID ADA80979 standard; cDNA; 1174 BP.
XX
AC ADA80979;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polynucleotide #136.
DE
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
XX US2003082702-A1.
PN
XX
PD 01-MAY-2003.
XX
XX 23-APR-2002; 2002US-00128690.
PF
XX
XX 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-755111/71.
DR
XX P-PSDB; ADA80980.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGCGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCGCGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGSCCTTGGCCGGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGSCCTTGGCCGGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGGCACCGGGCCTGTCACTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGGCACCGGGCCTGTCACTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGAGGTTGCAGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTCAAGAGAGGTTGCAGCTGTTT 300
QY 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGAATGTAA 360
Db 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGAATGTAA 360
QY 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAATCGAGCAAGCAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAATCGAGCAAGCAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTTCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATATCTAT 900
Db 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATATCTAT 900

QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAAGTGAAT	1020
Db	961	GTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTTCAAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTTCAAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCACCTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081	AATTCACCTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 63			
ADA95855			
ID	ADA95855	standard; cDNA; 1174 BP.	
XX	ADA95855;		
AC	ADA95855;		
DT	20-NOV-2003	(first entry)	
XX	Human PRO polynucleotide #136.		
DE	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;		
XX	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;		
KW	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;		
KW	liver; microvascular endothelial cell; glucose; FFA;		
KW	skeletal muscle cell; adipocyte cell; pericyte cell;		
KW	inner ear utricular supporting cell; T-lymphocyte cell;		
KW	endothelial cell tube formation; bone disorder; cartilage disorder;		
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;		
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;		
KW	immune system cell infiltration.		
XX	Homo sapiens.		
OS	US2003082759-A1.		
PN	01-MAY-2003.		
XX	11-APR-2002; 2002US-00121040.		
PD	31-MAR-1997; 97WO-US005230.		
PF	12-JUN-1998; 98WO-US012456.		
XX	14-JUL-1998; 98WO-US014552.		
XX	28-AUG-1998; 98WO-US017888.		
XX	10-SEP-1998; 98WO-US018824.		
XX	14-SEP-1998; 98WO-US019093.		
XX	14-SEP-1998; 98WO-US019094.		
XX	14-SEP-1998; 98WO-US019177.		
XX	16-SEP-1998; 98WO-US019330.		
XX	17-SEP-1998; 98WO-US019437.		
XX	07-OCT-1998; 98WO-US021141.		
XX	29-OCT-1998; 98WO-US022991.		
XX	29-OCT-1998; 98WO-US022992.		
XX	20-NOV-1998; 98WO-US024855.		
XX	01-DEC-1998; 98WO-US025108.		
XX	05-JAN-1999; 99WO-US000106.		
XX	08-MAR-1999; 99WO-US005028.		
XX	10-MAR-1999; 99WO-US005190.		
XX	20-APR-1999; 99WO-US008615.		
XX	14-MAY-1999; 99WO-US010733.		
XX	02-JUN-1999; 99WO-US012252.		
XX	01-SEP-1999; 99WO-US020111.		

PR	08-SEP-1999;	99WO-US020594.
PR	13-SEP-1999;	99WO-US020944.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	05-OCT-1999;	99WO-US023089.
PR	29-NOV-1999;	99WO-US028214.
PR	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030999.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUN-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGCTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
QY	121	CGCGTCTGCTGTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGGTGAAGCA	180
Db	121	CGCGTCTGCTGTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGGTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTCAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTGTACGCGATGTGCAGAGAGTTGCGAGCTGTTT	300
Db	241	TTGCACACCTACCTAAGGAAGAGGAGTGTACGCGATGTGCAGAGAGTTGCGAGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAAATGTGAA	360
Db	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAAATCTGATGAGCAATATGCTTCCCATCTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTCCCAAATCTGATGAGCAATATGCTTCCCATCTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
Db	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGACATGATGGAATCC	540
Db	481	ATGCACCTACTCTTTCTCTAACTCTGGTGAAGTCAATCTGGAGTGACATGATGGAATCC	540
QY	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA	600
Db	541	GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA	600

QY	601	GTATATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTACA	660
Db	601	GTATATATCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT	840
QY	841	TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174

RESULT 65

ID ADB21649 standard; cDNA; 1174 BP.

AC ADB21649;
XX
DT 20-NOV-2003 (first entry)
XX

DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003082765-A1.

PN 01-MAY-2003.

PD 17-MAY-2002; 2002US-00147492.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.

PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786920/74.
DR P-PSDB; ADB21650.

New secreted and transmembrane PRO polypeptide useful for detecting the presence of tumor in a mammal, or modulating the uptake of glucose or free fatty acid by skeletal muscle cells or adipocyte cells.

Claim 2; Fig 271; 638pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PMBC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTTTGGGTGATACGGCGTCTTGGCCACCGGCTGTGAGGAGGTTGAGGAGGTTT 240
Db 181 TTTGACTCGGCTTTGGGTGATACGGCGTCTTGGCCACCGGCTGTGAGGAGGTTGAGGAGGTTT 240
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGACAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGACAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAAACCTCTTCATGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAAACCTCTTCATGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCCACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCCACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGTCCTTTTAAAGATGTCCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGTCCTTTTAAAGATGTCCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCCTCTCGGTGATGGTATGCTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCCTCTCGGTGATGGTATGCTTGGATTGT 840
QY 841 TGTGCACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCACTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
RESULT 66
ACD29300
ID ACD29300 standard; cDNA; 1174 BP.
XX ACD29300;
AC ACD29300;
XX ACD29300;
DT 27-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane polypeptide cDNA #83.
XX
KW Human; secreted and transmembrane protein; PRO; viral infection;
tumour growth; retinal disorder; injury; sight loss;
retinitis pigmentosum; age-related macular degeneration;
sport-related joint problem; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; wound healing; obesity; diabetes; insulinaemia;
kidney disorder; mesangial cell function; Berger disease; nephropathy;
celiac disease; dermatitis; Crohn disease; neuropathy;
cardiac- insufficiency disorder; peripheral neuropathy;
diabetic peripheral neuropathy; autonomic neuropathy;
reduced motility of the gastrointestinal tract;
atony of the urinary bladder; post polio syndrome; Krabbe's disease;
Charcot-Marie-Tooth disease; Fabry's disease; Tangier disease;
Refsum's disease; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003049633-A1.
XX
PD 13-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978585.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0054249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0056364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.

QY 61 GGGAAACAAGATGGCGGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTGAGTTGTGGATGATGGAATTGACCTTAAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTGCTGAGTTGTGGATGATGGAATTGACCTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420
Db 361 TCTGATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGGCATCTTGGTTGC 420
QY 421 CAGAACTCAGCTGCCATTCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAACTCAGCTGCCATTCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTGTTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTGTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAGAGATATCCAGCTTCTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAGAGATATCCAGCTTCTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

Db 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
RESULT 67
ADA77428
ID ADA77428 standard; cDNA; 1174 BP.
XX ADA77428;
AC ADA77428;
XX 20-NOV-2003 (first entry)
XX Human PRO polynucleotide #136.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; PFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

Homo sapiens.

US2003068797-A1.

10-APR-2003.

07-MAY-2002; 2002US-00140921.

31-MAR-1997; 97WO-US005230.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.

29-OCT-1998; 98WO-US022991.

29-OCT-1998; 98WO-US022992.

20-NOV-1998; 98WO-US024855.

01-DEC-1998; 98WO-US025108.

05-JAN-1999; 99WO-US000106.

08-MAR-1999; 99WO-US005028.

10-MAR-1999; 99WO-US005190.

20-APR-1999; 99WO-US008615.

14-MAY-1999; 99WO-US010733.

02-JUN-1999; 99WO-US012252.

01-SEP-1999; 99WO-US020111.

08-SEP-1999; 99WO-US020594.

13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.

15-SEP-1999; 99WO-US021547.

05-OCT-1999; 99WO-US023089.

29-NOV-1999; 99WO-US028214.

30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

22-DEC-1999; 99WO-US030999.

22-DEC-1999; 99WO-US030720.

30-DEC-1999; 99WO-US031243.

Db 421 CAGAATCAGCTGCCATTCTGCTGAACCTGAGACAAGAAACAACCTTAATGTCCCTGATGCCAAAA 480

Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTCTGGAGTGACATGATGGACTCC 540

Qy 541 GCACAGAGCTTCATAAAGCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db 541 GCACAGAGCTTCATAAAGCTCTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660

Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660

Qy 661 AATTGAGAGAAATCATCTTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAAATCATCTTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720

Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780

Qy 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCCTCTCGGTGATGGTATGCTTTGGATTGT 840

Db 781 TCTGGGTGGATTTTAACTACAACTCTTGCTCCTCTCGGTGATGGTATGCTTTGGATTGT 840

Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAAAGCTGATATCTAT 900

Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGATGTTCCCTCTGAGAAAGCTGATATCTAT 900

Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960

Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

Qy 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140

Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 68

ADB18168

ID ADB18168 standard; cDNA; 1174 BP.

AC ADB18168;

XX 20-NOV-2003 (first entry)

DT cDNA encoding human PRO polypeptide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; PFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

OS Homo sapiens.

XX

PN US2003077710-A1.

XX 24-APR-2003.

PD

XX

PF 22-APR-2002; 2002US-00127825.

XX

PR 22-OCT-1998; 98US-0105169P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 30-NOV-1999; 99WO-US028313.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-755065/71.

DR P-PSDB; ADB18169.

XX

PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful

PT in gene therapy, in chromosome and gene mapping, as chromosome markers,

PT in tissue typing, and in identifying chromosomes.

XX

PS Claim 2; Fig 271; 637pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or PFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC the proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence encodes a human PRO polypeptide of the invention. Note: The

CC sequence data for this patent is also available in electronic format from

CC the USPTO website at seqdata.uspto.gov.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

XX

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

Db 1 CGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120

Qy 121 CCGCTGCTGCTGCTGACCAATGGCCTTTGGCCGGAGTTTGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCTTTGGCCGGAGTTTGGGGACCGCTTCGGCTGAAGCA 180

Qy 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGGCACCGGCCCTGTACAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGGCACCGGCCCTGTACAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300

Qy 301 TCAATTTGTGAGTTTGTGGATGATGGAATGCAATTAATCGAATTAATGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATGCAATTAATCGAATTAATGGAATGTGAA 360

Qy 361 TCTGCATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACCTTATGTCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAGAAACAACCTTATGTCCTGATGCCAAA 480

Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGATGGACTCC 540

Qy 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600

Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCCTACA 660

Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720

Qy 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780

Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840

Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG 960

Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATTCTGAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTCTGAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080

Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTTAAGAAATCA 1140

Qy 1141 CTATAAATGCAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAATCTGTG 1174

RESULT 69
ADA86851
ID ADA86851 standard; cDNA; 1174 BP.
XX
AC ADA86851;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
US2003082709-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146791.
XX
PR 17-AUG-1998; 98US-0096895P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786912/74.
DR P-PSDB; ADA86852.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT for preparing a composition for treating e.g., tumor, or for tissue
PT typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the

stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (i) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (ii) encoding (i) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (i) and (ii) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match		100.0%;	Score 1174;	DB 8;	Length 1174;
Best Local Similarity		100.0%;	Pred. No. 0;		
Matches 1174;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CGGACGCTGGGGAAACCCCTTCGAGAAACACAGCAACAGCTGCTGTGACAGAG	60		
DB	1	CGGACGCTGGGGAAACCCCTTCGAGAAACACAGCAACAGCTGCTGTGACAGAG	60		
QY	61	GGGAACAAGATGGCGGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
DB	61	GGGAACAAGATGGCGGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
QY	121	CGGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA	180		
DB	121	CGGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA	180		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCAGGCTGTGACCTACCCC	240		
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCAGGCTGTGACCTACCCC	240		
QY	241	TTGCACACTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGAGGCTGTTT	300		
DB	241	TTGCACACTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGAGGCTGTTT	300		
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360		
DB	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360		
QY	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420		
DB	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420		
QY	421	CAGAAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480		
DB	421	CAGAAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480		
QY	481	ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
DB	481	ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA	600		
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA	600		
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACCGCACCACTTTGGAGCAGGACCTACA	660		

Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAAATTCACAAGCG	720
Db	661	AATTTGAGAGAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGAGAAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGAGAAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
QY	781	TCTGGTGGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
Db	781	TCTGGTGGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCACCTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081	AATTCACCTCCTCATAGAGCTTTTAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTTACTCAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTTACTCAAATCTGTG	1174
RESULT 71			
ADA46342			
ID	ADA46342	standard; cDNA; 1174 BP.	
XX	ADA46342;		
AC	ADA46342;		
XX	20-NOV-2003	(first entry)	
DT	20-NOV-2003	(first entry)	
XX	Novel human secreted and transmembrane protein PRO195 cDNA.		
DE	Human; secreted and transmembrane protein; PRO; gene; ss;		
XX	Tumour necrosis factor alpha release; TNF-alpha release;		
KW	glucose uptake modulator; FFA uptake modulator;		
KW	cell proliferation stimulator; cell differentiation stimulator;		
KW	cell differentiation inhibitor; cytokine release stimulator; tumour;		
KW	lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;		
KW	cervical tumour; liver tumour; chromosome mapping; gene mapping;		
KW	gene therapy; chromosome identification; chromosome marker.		
XX	Homo sapiens.		
OS	US2003054516-A1.		
XX	20-MAR-2003.		
PN	12-APR-2002; 2002US-00121050.		
XX	31-MAR-1997; 97WO-US005230.		
PR	12-JUN-1998; 98WO-US012456.		
PR	14-JUL-1998; 98WO-US014552.		
PR	28-AUG-1998; 98WO-US017888.		
PR	10-SEP-1998; 98WO-US018824.		
PR	14-SEP-1998; 98WO-US019093.		
PR	14-SEP-1998; 98WO-US019094.		

PR	14-SEP-1998;	98WO-US019177.
PR	16-SEP-1998;	98WO-US019330.
PR	17-SEP-1998;	98WO-US019437.
PR	07-OCT-1998;	98WO-US021141.
PR	29-OCT-1998;	98WO-US022991.
PR	29-OCT-1998;	98WO-US022992.
PR	20-NOV-1998;	98WO-US024855.
PR	01-DEC-1998;	98WO-US025108.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	10-MAR-1999;	99WO-US005190.
PR	20-APR-1999;	99WO-US008615.
PR	14-MAY-1999;	99WO-US010733.
PR	02-JUN-1999;	99WO-US012252.
PR	01-SEP-1999;	99WO-US020111.
PR	08-SEP-1999;	99WO-US020594.
PR	13-SEP-1999;	99WO-US020944.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	05-OCT-1999;	99WO-US023089.
PR	29-NOV-1999;	99WO-US028214.
PR	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030999.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.

PR	18-MAY-2001;	2001US-008602016.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.
PR	05-JUN-2001;	2001US-00874503.
PR	14-JUN-2001;	2001US-00882636.
PR	19-JUN-2001;	2001US-00886342.
PR	20-JUN-2001;	2001WO-US019692.
PR	21-JUN-2001;	2001US-00887879.
PR	22-JUN-2001;	2001WO-US020116.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	18-JUL-2001;	2001US-00908827.
PR	06-AUG-2001;	2001US-00924419.
PR	09-AUG-2001;	2001US-00927796.
PR	16-AUG-2001;	2001US-00931836.
PR	19-DEC-2001;	2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-521853/49.
P-PSDB; ADA46343.

New PRO nucleic acid, useful for preparing a composition for treating e.g., tumor.

Claim 2: Fig 271; 200pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

```

Query Match      100.0%;   Score 1174;   DB 8;   Length 1174;
Best Local Similarity 100.0%;   Pred. No. 0;
Matches 1174;   Conservative 0;   Mismatches 0;   Indels 0;   Gaps 0;

```

Qy 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTACGTTGACCTACCCC 240
Db |||||
QY 181 TTTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTACGTTGACCTACCCC 240
Db |||||
QY 241 TTTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTGCAGGCTGTTT 300
Db |||||
QY 241 TTTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTGCAGGCTGTTT 300
Db |||||
QY 301 TCAATTTGTGCTGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Db |||||
QY 301 TCAATTTGTGCTGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Db |||||
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAAATCAGCTGCCATTCCGTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 421 CAGAAATCAGCTGCCATTCCGTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGGAATCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGGAATCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660
Db |||||
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
Db |||||
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
Db |||||
QY 721 CACAGAAATTTCTTGAAGATGGAGAAAAGTATGGCTTTTAAAGATGGCTCTCTCTTAAC 780
Db |||||
QY 721 CACAGAAATTTCTTGAAGATGGAGAAAAGTATGGCTTTTAAAGATGGCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATTTGGATTTGT 840
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCCCTCTCGGTGATGGTATTTGGATTTGT 840
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db |||||
QY 961 GTTGTATGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 961 GTTGTATGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
RESULT 72
ADB28372
ID ADB28372 standard; cDNA; 1174 BP.
XX
AC ADB28372;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082699-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127851.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777202/73.
DR P-PSDB; ADB28373.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of

CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGCGCTTCAGTTGACCTACCCC 240
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATAAATTGGAATGTGAA 360
Db |||||
QY 361 TCTGCATGTACAGAACATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTGC 420
Db |||||
QY 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db |||||
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTGGAGCAGGAGCCTTACA 660
Db |||||
QY 661 AATTTGAGAGAATCATCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG 720
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||

QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATTTCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAAGAAATCA 1140
Db |||||
QY 1141 CTATAAATGCAATTAAGTTACTCAAATCTGTG 1174
Db |||||

RESULT 73
ADB28924
ID ADB28924 standard; cDNA; 1174 BP.

AC ADB28924;
XX 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

Homo sapiens.
US2003082706-A1.
01-MAY-2003.
24-APR-2002; 2002US-00131836.
09-DEC-1999; 99US-0170262P.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforgre L, Desnoyers L, Filvaroff E;
Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-777203/73.
P-PSDB; ADB28925.
XX

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCATGGCCCTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAAGCTAAATGGAATGTGAA 360
DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAAGCTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
DB 421 CAGAATCAGCTGCCATTTCCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGAGCCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGAGCCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGSCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGSCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGCTTTTCAATTTGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGCTTTTCAATTTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
RESULT 74
ADA76876
ID ADA76876 standard; cDNA; 1174 BP.
XX
AC ADA76876;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX OS Homo sapiens.
XX PN US2003059909-A1.
XX PD 27-MAR-2003.
XX PF 10-MAY-2002; 2002US-00143032.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00886342.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-540684/51.
P-PSDB; ADA76877.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 2; Fig 271; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTTTGGGTGATACGGCGCTCTTCCACCAGGCTGTGACCTACCC 240
DB 181 TTTGACTCGGCTTTGGGTGATACGGCGCTCTTCCACCAGGCTGTGACCTACCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCTAAGGAAGAGGAGTTGACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGAGTTTGGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
DB 301 TCAATTGTGAGTTTGGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTCCTAATCTGATGAGCAATATGCTTGCCATCTTGCTGC 420
DB 361 TCTGCATGTACAGAGCATATTCCTAATCTGATGAGCAATATGCTTGCCATCTTGCTGC 420
QY 421 CAGAATCAGCTGCCATTCTGCTGAACCTGAGCAAGAACAACCTTATCTCCCTGATGCCAAA 480
DB 421 CAGAATCAGCTGCCATTCTGCTGAACCTGAGCAAGAACAACCTTATCTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTTCTCTAACTCTGCTGAGGTCACTTCTGGAGTACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTTTCTCTAACTCTGCTGAGGTCACTTCTGGAGTACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGACCTTACA 660
DB 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGACCTTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGTGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCCTCGGTGATGGTATGCTTTGGATTGT 840

DB 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATTTGGATATAGGCCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATTTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATTAAGTTACTCAAATCTGTG 1174
DB 1141 CTATAAAATGCAAAATTAAGTTACTCAAATCTGTG 1174

RESULT 75
ADA88506
ID ADA88506 standard; cDNA; 1174 BP.
XX
AC ADA88506;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.

US2003073213-A1.

17-APR-2003.
17-APR-2002; 2002US-00124819.
31-MAR-1997; 97WO-US005230.
12-JUN-1998; 98WO-US012456.
14-JUL-1998; 98WO-US014552.
28-AUG-1998; 98WO-US017888.
10-SEP-1998; 98WO-US018824.
14-SEP-1998; 98WO-US019093.
14-SEP-1998; 98WO-US019094.
14-SEP-1998; 98WO-US019177.
16-SEP-1998; 98WO-US019330.
17-SEP-1998; 98WO-US019437.
07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 99WO-US000106.
08-MAR-1999; 99WO-US005028.
10-MAR-1999; 99WO-US005190.
20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-743816/70.
DR P-PSDB; ADA88507.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTGACTCGGTCTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
Db |||||

Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCGCTGTGACGTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTGTTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTGTTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTGCCATTTCGCTGAATCTGAGACAAAGAACTTATGTCCCTGATGCCAAA 480

Db 421 CAGAAATCAGCTGCCATTTCGCTGAATCTGAGACAAAGAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db 541 GCACAGAGCTTCATAACCTCTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGGAGGCCCTACA 660

Db 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGGAGGCCCTACA 660

QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGGTGATTTTAACTACAACCTCTTGTCCCTCTCGGTGATGTTGTTGATTTGT 840

Db 781 TCTGGGTGATTTTAACTACAACCTCTTGTCCCTCTCGGTGATGTTGTTGATTTGT 840

QY 841 TGTGCACTGTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGTGATCTAT 900

Db 841 TGTGCACTGTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGTGATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020

QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

QY 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA 1140

Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA 1140

QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 76
ADA97511
ID ADA97511 standard; cDNA; 1174 BP.
XX
AC ADA97511;
XX

DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
XX Homo sapiens.
OS
XX US2003082686-A1.
PN
XX 01-MAY-2003.
PD
XX
PF 19-APR-2002; 2002US-00125926.
XX
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755106/71.
DR P-PSDB; ADA97512.
XX
PT Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 666pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGTGGGGAAACCTTCCGAGAAAACAGCAACAGCTGAGTGTGTGACAGAG 60
Db
QY 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCAATGGCCCTTGGCCGGAGTTCGGGGAACCGCTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCAATGGCCCTTGGCCGGAGTTCGGGGAACCGCTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTACGCCATGTGACGAGAGTTGCGAGGCTGTT 300
Db 241 TTGCACACTACCTTAAGGAAGAGGAGTTGTACGCCATGTGACGAGAGTTGCGAGGCTGTT 300

QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTGCTGTAAGTACGACCAAGCAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGTAAGTACGACCAAGCAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTCTCTAATCTGCTGAGTCACTTCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAATCTGCTGAGTCACTTCTGAGTGACATGATGACTCC 540

QY 541 GCACAGAGCTTCATTAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATTAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660

QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGGTGGAATTTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840
Db 781 TCTGGGTGGAATTTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGGATTTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960

QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATTTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCCCTTAAGAAATCA 1140

QY 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 77
ADB27268
ID ADB27268 standard; cDNA; 1174 BP.
XX
AC ADB27268;
XX
DT 20-NOV-2003 (first entry)
XX cDNA encoding human PRO polypeptide #136.
DE Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX
XX US2003022239-A1.
XX 30-JAN-2003.
XX
XX 12-APR-2002; 2002US-00121049.
XX 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.

PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.

PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 30-OCT-1998; 98WO-US022992.
PR 03-NOV-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.

PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-011557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 20-JAN-1999; 99US-0116533P.
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCTGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGCTCTGGGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGAGAGAGGTTGACGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGAGAGAGGTTGACGGCTGTTT 300
QY 301 TCAATTTGTGATGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTGATGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCACTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCACTTGGTTGC 420
QY 421 CAGAATCAGTGCCTATTCGCTGAATGAGAGCAAGAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGTGCCTATTCGCTGAATGAGAGCAAGAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGTTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGTTTCATTAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGATTTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG 960
QY 961 GTTGTAGATCTAATAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAATAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

QY 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTCGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
RESULT 79
ADA66892
ID ADA66892 standard; cDNA; 1174 BP.
XX
AC ADA66892;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; PFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068793-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123108.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 02-JUN-2000; 2000WO-US014941.
PR 30-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-695925/66.
P-PSDB; ADA66893.

XX
PT
PT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
XX
SQ

Novel secreted and transmembrane PRO polypeptides useful for stimulating release of tumor necrosis factor-alpha from human blood and detecting the presence of a tumor in a mammal.

Claim 2; Fig 271; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumor in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating proliferation or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
Db	1		
QY	61	GGGAAACAAGATGGCGCGCGCGAAGGGAGCCTCTGGGTGAGGACCCCAACTGGGCTCCCG	120
Db	61		
QY	121	CGGCTGCTGCTGTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA	180
Db	121		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTCACTTGAACCTACCCC	240
Db	181		
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTTGCAGCTGTTT	300
Db	241		
QY	301	TCAATTTGTCAGTTTGTGGATGATGAATGACTTAAATCGAACTAAATGGAATGTGAA	360
Db	301		
QY	361	TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC	420
Db	361		

Db 361 TCTGCTATACAGAGCATATTCCTCCATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGATCAGCTGCCATTCGCTGAATGAGACAGAACTTATGCTCCCTGATGCCAAA 480
Db 421 CAGATCAGCTGCCATTCGCTGAATGAGACAGAACTTATGCTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTTAATCTGCTGAGGTCTTCTGGAGTACATGATGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTTAATCTGCTGAGGTCTTCTGGAGTACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCACTGATGAGGTCTTCTCAAGCCGATGACGGAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCACTGATGAGGTCTTCTCAAGCCGATGACGGAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGACCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGACCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACACTCTTGTCTCTCGGTGATGCTTGTGATTTG 840
Db 781 TCTGGTGGATTTTAACTACACTCTTGTCTCTCGGTGATGCTTGTGATTTG 840
QY 841 TGTGCAACTGTTGCTACAGCTCTGGAGCAGTATGCTCCCTCTGAGAGCTGATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTCTGGAGCAGTATGCTCCCTCTGAGAGCTGATCTAT 900
QY 901 GGTGACTTGGATTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960
Db 901 GGTGACTTGGATTTTATGATGAACAAAGCTTAAACAGATATCCAGCTTCTCTCTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATTA 1080
Db 1021 CTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAGTGTAAATAGACATTA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATAGGCTTAAAGATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATAGGCTTAAAGATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 80

ADB22753

ID ADB22753 standard; cDNA; 1174 BP.

XX AC

XX AC

XX AC

DT 20-NOV-2003 (first entry)

XX AC

XX AC

DE Human PRO polynucleotide #136.

XX KW

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

XX US2003077711-A1.

XX 24-APR-2003.

XX 22-APR-2002; 2002US-00127829.

XX 22-OCT-1998; 98US-0105169P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 30-NOV-1999; 99WO-US028313.

XX 18-FEB-2000; 2000WO-US004342.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AB, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755066/71.

XX P-PSDB; ADB22754.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful

XX in gene therapy, as diagnostic markers for the presence of a disease

XX condition, or as therapeutic targets for treating tumors, diabetes,

XX obesity or arthritis.

XX Claim 2; Fig 271; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

XX invention also relates to an antibody which specifically binds to a PRO

XX polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX proliferation or differentiation of chondrocyte cells and a method for

XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

XX polynucleotides are useful in molecular biology, including uses as

XX hybridisation probes, in chromosome and gene mapping, in generating

XX antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX be used in preparing PRO polypeptides by recombinant techniques and in

XX generating either transgenic animals or knock-out animals which are

XX useful in the development and screening of therapeutically useful

XX reagents. The PRO polypeptides or antibodies are used in preparing a

XX medicament for treating a condition responsive to the polypeptides or

XX antibodies, such as tumours, for stimulating and inhibiting proliferation

XX of human microvascular endothelial cells, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating differentiation of adipocyte cells, for stimulating

XX proliferation of or gene expression in pericyte cells, for stimulating

XX the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX cells, for inducing endothelial cell tube formation and for treating

XX various bone and/or cartilage disorders such as sports injuries and

XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX from cartilage are useful for treating sports-related joint problems, PRO

XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX polypeptides are also useful for treating various mammalian haemoglobin-

XX associated disorders such as various thalassaemias and conditions which

XX may benefit from enhanced local immune system cell infiltration. This

XX sequence represents a human PRO polynucleotide of the invention. Note:

XX The sequence data for this patent is also available in electronic format

XX from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1174; DB 8; Length 1174;

XX Best Local Similarity 100.0%; Pred. No. 0;

		Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CGGACGCTGGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60		
Db	1	CGGACGCTGGGGGAAACCCCTTCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60		
QY	61	GGGAACAAGATGGCGGCGCGGAGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120		
Db	61	GGGAACAAGATGGCGGCGCGGAGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120		
QY	121	CCGCTGCTGCTGTGACCATAGGCGCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180		
Db	121	CCGCTGCTGCTGTGACCATAGGCGCTTGGCCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA	180		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240		
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240		
QY	241	TTGCACACCTACCTAAGGAAGAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT	300		
Db	241	TTGCACACCTACCTAAGGAAGAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT	300		
QY	301	TCAATTTGTTCAGTTTGTGGATGATGGAATTGAACTTAAATCGAACTAAATGGAAATGTGAA	360		
Db	301	TCAATTTGTTCAGTTTGTGGATGATGGAATTGAACTTAAATCGAACTAAATGGAAATGTGAA	360		
QY	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
Db	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
QY	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACGAAGAACAACTTATGTCCTGATGCCAAAA	480		
Db	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACGAAGAACAACTTATGTCCTGATGCCAAAA	480		
QY	481	ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGGTCAATTCGAGTGCATGATGGACTCC	540		
Db	481	ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGGTCAATTCGAGTGCATGATGGACTCC	540		
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA	600		
Db	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA	600		
QY	601	GTTATATCCAGTCTAAGCAGAAATCCAGTACGACCAACACATTTGGAGCAGGAGCCTACA	660		
Db	601	GTTATATCCAGTCTAAGCAGAAATCCAGTACGACCAACACATTTGGAGCAGGAGCCTACA	660		
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720		
Db	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720		
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC	780		
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC	780		
QY	781	TCTGGGTGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840		
Db	781	TCTGGGTGATTTTAACTACAACCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT	840		
QY	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900		
Db	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900		
QY	901	GGTACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960		
Db	901	GGTACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960		
QY	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020		
Db	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020		
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080		
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080		

QY	1081	AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCTTAAGAAATCA	1140
Db	1081	AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 81
ADB23526
ID ADB23526 standard; cDNA; 1174 BP.
XX
AC ADB23526;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration.

Homo sapiens.
US2003077712-A1.
24-APR-2003.
22-APR-2002; 2002US-00127835.
20-OCT-1998; 98US-0104987P.
01-SEP-1999; 99WO-US020111.
18-OCT-1999; 99US-00403297.
18-FEB-2000; 2000WO-US004342.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755067/71.
P-PSDB; ADB23527.

New isolated, secreted and transmembrane PRO nucleic acid, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in

generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCATGGCCCTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGGCCACGGGCGCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGGCCACGGGCGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCTAAGGAGAGGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAATAAATGGAATGTGAA 360
DB 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAAATCGAATAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGTGCCTTCTTAACCTGCTGAGTCAATTCGAGTCAATTCCTGATGCCAAA 480
DB 421 CAGAATCAGTGCCTTCTTAACCTGCTGAGTCAATTCGAGTCAATTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAATCTGCTGAGTCAATTCGAGTCAATTCCTGATGCC 540
DB 481 ATGCACCTACTCTTTCTCTAATCTGCTGAGTCAATTCGAGTCAATTCCTGATGCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720

DB 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTCGTTGGATTGT 840
DB 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTCGTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
DB 901 GGTGACTGGAGTTTATGATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCAATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATATAGACATCTAA 1080
DB 1021 CTTGCTCAATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 82
ADA92248
ID ADA92248 standard; cDNA; 1174 BP.
XX
AC ADA92248;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
OS Homo sapiens.
XX
PN US2003082712-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147512.
XX
PR 15-MAY-1998; 98US-0085697P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-786915/74.
P-PSDB; ADA92249.
New PRO nucleic acid, useful for preparing a composition for treating
e.g., tumor or for tissue typing.
Claim 2; Fig 271; 637pp; English.
The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating for stimulating the proliferation of endothelial cells, for detecting the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumor in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes a novel human secreted and transmembrane PRO polypeptide.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CAGATCAGCTGCCATTCGCTGAAGTGAAGCAAGCAAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGATCAGCTGCCATTCGCTGAAGTGAAGCAAGCAAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTTCTTAAGTCTGGTGGGTCATTTCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTTCTTAAGTCTGGTGGGTCATTTCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAAACCCTCTTCATGGACTTTTATTTTCAAGCCGATGACGGAATA 600
Db 541 GCACAGAGCTTCATAAACCCTCTTCATGGACTTTTATTTTCAAGCCGATGACGGAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGACTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGGAGCAGGACTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAAC 780
QY 781 TCTGGGTGATTTTAACTAACAATCTTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGATTTTAACTAACAATCTTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAGAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAGAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCTATAGAGCTTTTAAATGGTTCATTTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCTCTATAGAGCTTTTAAATGGTTCATTTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAATATAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAATATAAGTTACTCAAAATCTGTG 1174

RESULT 83
ADB15311
ID ADB15311 standard; cDNA; 1174 BP.
XX
AC ADB15311;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.
OS US2003087352-A1.
PN 08-MAY-2003.
XX 22-APR-2002; 2002US-00127824.
PF 17-AUG-1998; 98US-0096891P.
XX 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786943/74.
DR P-PSDB; ADB15312.
XX New PRO nucleic acid, useful for producing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 2; Fig 271; 637pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
XX from USPTO at seqdata.uspto.gov/sequence.html.
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||||
QY

Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCGGAGGTTGGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCGGAGGTTGGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATFACGGCGCTTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATFACGGCGCTTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGACAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGACAGGCTGTTT 300
QY 301 TCAATTTGTCAAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAAGTTTGTGGATGATGAAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCCCTTAACCTCTGGTGAGGTTCATTTCTGGAGTGACATGATGGACTCC 480
Db 421 CAGAATCAGCTGCCATTTCCCTTAACCTCTGGTGAGGTTCATTTCTGGAGTGACATGATGGACTCC 480
QY 481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTTCATTTCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTTCATTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGGAAATA 600
Db 541 GCACAGAGCTTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGGAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
Db 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
QY 781 TCTGGGTGGATTTTAACTAACTAACTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTAACTAACTCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAAGCAATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAAGCAATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140

XX PS Claim 2; Fig 271; 660pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX CC a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCG 120

QY 121 CGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

Db 121 CGCTGCTGCTGTGACCATGGCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGCGCTTGTGCCACCGGCGCTGTGAGTACCTACCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGCGCTTGTGCCACCGGCGCTGTGAGTACCTACCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGTTGAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCAGAGAGTTGAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTGGAATGTGAA 360

Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTGCCATTGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480

Db 421 CAGAAATCAGCTGCCATTGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGAGTACTCC 540

Db 481 ATGCACCTACTCTTTCTCTAATCTGGTGAGGTCATTTCTGGAGTGACATGAGTACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600

Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600

QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTGGAGCAGGACCTACA 660

Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTGGAGCAGGACCTACA 660

QY 661 AATTGAGAGAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAAGCG 720

Db 661 AATTGAGAGAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGTTTTTAAGATGCCTCTCTTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGTTTTTAAGATGCCTCTCTTTAAC 780

QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840

Db 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840

QY 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Db 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960

QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTTAAGAAATCA 1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTCAATTGGATATAGGCTTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 85

ADB38011

ID ADB38011 standard; cDNA; 1174 BP.

XX AC ADB38011;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX OS Homo sapiens.

XX FN US2003087347-A1.

XX PD 08-MAY-2003.

XX PF 19-APR-2002; 2002US-00125921.

PR 17-AUG-1998; 98US-0096791P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786938/74.
DR P-PSDB; ADB38012.
DR
XX
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
PT
XX
XX Claim 2; Fig 271; 637pp; English.
PS
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 8; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGACCCCAACTGGGGTCCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGACCCCAACTGGGGTCCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180
DB 121 CCGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTCTTGCACCGGCGCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTCTTGCACCGGCGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTATCGCATGTCTCAGAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTCTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGCTTGC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGCTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGAACCACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGAACCACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCCCTTAACCTCTGAGGTGAGGTCAATCTTGAGTGACATGATGAGTCC 540
Db 481 ATGCACCTACTCTTTTCCCTTAACCTCTGAGGTGAGGTCAATCTTGAGTGACATGATGAGTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGAATTTAACTACAACCTCTGCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGGAATTTAACTACAACCTCTGCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAA 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAA 1020
QY 1021 CTTGCTCATCTCGAAATTTAAGCAATTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1080
Db 1021 CTTGCTCATCTCGAAATTTAAGCAATTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAATATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAATATAAAGTTACTCAAAATCTGTG 1174

RESULT 86
ADB66483
ID ADB66483 standard; cDNA; 1174 BP;
XX
AC ADB66483;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; PFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS US2003082689-A1.
PN 01-MAY-2003.
XX 22-APR-2002; 2002US-00127831.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786905/74.
DR P-PSDB; ADB66484.
DR New PRO nucleic acid, useful for preparing a composition for treating
XX e.g. tumor or for tissue typing.
PS Claim 2; Fig 271; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGGAAGGGGAGCCCTCTGGGTGAGAGACCCCAACTGGGGTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCCGGAAGGGGAGCCCTCTGGGTGAGAGACCCCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGCGCTGTGAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGCGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAAATCGAATAAATGGAATGGAATGAA 360
DB 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAAATCGAATAAATGGAATGGAATGAA 360
QY 361 TCTGCATGTACAGAAAGCATATCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAAGCATATCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
DB 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTTAACCTCTGCTGAGTCAATCTGGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTCTCTTAACCTCTGCTGAGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
DB 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
DB 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTCTTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTAACACTCAACTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
DB 781 TCTGGGTGGATTTAACACTCAACTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
QY 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAAACACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCAATTTTCTTTTAAAAGACAAGTGTAAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAATTTAAGCAATTTTCTTTTAAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 87

ADB89563
ID ADB89563 standard; cDNA; 1174 BP.

XX ADB89563;

DT 04-DEC-2003 (first entry)

XX Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

OS US2003082698-A1.

XX 01-MAY-2003.

XX 22-APR-2002; 2002US-00127850.

XX 20-AUG-1998; 98US-0097218P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 02-MAR-2000; 2000WO-US005841.

PR 30-MAR-2000; 2000WO-US008439.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff B, Gao W;

PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-743896/70.

DR P-PSDB; ADB89564.

XX New PRO nucleic acids and encoded polypeptides, useful in the treatment

PT of cancer.

XX Claim 2; Fig 271; 637pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGCGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

DB 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCC 240

DB 181 TTTGACTCGGTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCC 240

QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300

DB 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTGTGAGTTTGGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGGAATGAA 360

DB 301 TCAATTGTGAGTTTGGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGGAATGAA 360

QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420

DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTGCCATTCGCTGAATGAGCAAGAACTTATGTCCCTGATGCCAAAA 480

DB 421 CAGAAATCAGCTGCCATTCGCTGAATGAGCAAGAACTTATGTCCCTGATGCCAAAA 480

QY 481 ATGCACCTACTCTTTCCCTTAATCTTGGTGGTCAATCTGGAGTGACATGAGTGGACTCC 540

DB 481 ATGCACCTACTCTTTCCCTTAATCTTGGTGGTCAATCTGGAGTGACATGAGTGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600

DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA 600

QY 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACACATTTGGAGCAGGACCTACA 660

DB 601 GTTATATTCAGTCTTAAGCCAGAAATCCAGTACGACACACATTTGGAGCAGGACCTACA 660

QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720

DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTCTTAAAGATGCCCTCTCTTAAC 780

DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTTCTTAAAGATGCCCTCTCTTAAC 780

QY 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGTTGCTTGGATTTGT 840

DB 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGTTGCTTGGATTTGT 840

QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

DB 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020

DB 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTAAAGACAAGTGTATAGACATCTAA 1080

DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTAAAGACAAGTGTATAGACATCTAA 1080

QY 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140

DB 1081 AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140

QY 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

DB 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 88

ADB90295

ID ADB90295 standard; cDNA; 1174 BP.

AC ADB90295;

DT 04-DEC-2003 (first entry)

XX Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
Db	1	CGGACGGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120
QY	121	CGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240
QY	241	TTGCACACCTAACCTAAGGAAGAGGAGTTGTACGGCATGTGACAGAGGTTGAGGCTGTTT	300
Db	241	TTGCACACCTAACCTAAGGAAGAGGAGTTGTACGGCATGTGACAGAGGTTGAGGCTGTTT	300
QY	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAATAAATTGGAATGTGAA	360
Db	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAATAAATTGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCTATCTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCTATCTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAACCACTTATGTCCCTGATGCCAAA	480
Db	421	CAGAATCAGCTGCCATTGCTGAACCTGAGCAAGAACCACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGAGCTCC	540
Db	481	ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGGAGTGACATGATGAGCTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541	GCACAGAGCTTCATAACCTCTTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTATATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA	660
Db	601	GTATATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG	720
Db	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC	780
Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTCTCTCTCGGTGATGCTTGTGGATTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACCTCTCTCTCTCGGTGATGCTTGTGGATTGT	840

Db	781	TCTGGGTGGATTTTAACTACAACCTCTCTCTCGGTGATGCTTGTGGATTGT	840
QY	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAATAAAGTTACTCAAAATCTGTG	1174

RESULT 89

ID ADB39396 standard; cdna; 1174 BP.
XX

AC ADB39396;

DT 04-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO195 cdna.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003082764-A1.

PN 01-MAY-2003.

PD 03-MAY-2002; 2002US-00137868.

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786919/74.
DR P-PSDB; ADB39397.
XX
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX
PS Claim 2; Fig 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumor in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. NO. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAAACCCCTCCGAGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGGCGCGGAGGAGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCGGAGGAGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTT 300
Db |||||
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTT 300
Db |||||
Qy 301 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Db |||||
Qy 361 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAAATCGAATTAATTTGGAATGTGAA 360
Db |||||
Qy 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
Db |||||
Qy 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
Db |||||
Qy 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
Qy 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAGAAACAACTTATGTCCCTGATGCCAAA 480
Db |||||
Qy 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGAGACTCC 540
Db |||||
Qy 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCATTTCTGGAGTGACATGAGACTCC 540
Db |||||
Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
Db |||||
Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
Db |||||
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGAGCTTACA 660
Db |||||
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACACCATTTGGAGCAGGAGCTTACA 660
Db |||||
Qy 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAATTCACAAGCG 720
Db |||||
Qy 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAATTCACAAGCG 720
Db |||||
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db |||||
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db |||||
Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCCTCGGTGATGGTATTGCTTTGGATTGT 840
Db |||||
Qy 841 TGTGCACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
Qy 841 TGTGCACTGTGTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db |||||
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db |||||
Qy 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db |||||
Qy 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db |||||
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db |||||
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db |||||
Qy 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
Db |||||
Qy 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
Db |||||
Qy 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||
Qy 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174
Db |||||

RESULT 90

ADB73835

ID ADB73835 standard; cDNA; 1174 BP.

XX

AC ADB73835;

XX

DT 04-DEC-2003 (first entry)

XX Human PRO polynucleotide sequence #83.
DE
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.
XX
OS Homo sapiens.
XX
XX US2003045462-A1.
PN
XX
PD 06-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00978608.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.

PA
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db |||||
1 CGGACGCGTGGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GCGAACAGATGGCGGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
61 GCGAACAGATGGCGGCGCCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTGACTCGGTCCTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTACCTACCCC 240
Db |||||
181 TTGACTCGGTCCTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTTCAGAGAGTTGCAGGCTGTTT 300
Db |||||
241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTTCAGAGAGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGGGATGATGGAATTCACCTTAAATCGAATAAATGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGGGATGATGGAATTCACCTTAAATCGAATAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAGAAACAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCATCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCATCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCAATACCTCTTCAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 600
Db 541 GCACAGAGCTTCAATACCTCTTCAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGCTTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGTGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTCTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTCTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAGAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAGAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTGATCTAAATCTGAATGATCATGAAGAGAGAGGAGGCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTGATCTAAATCTGAATGATCATGAAGAGAGAGGAGGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCACTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCACTCTGAAATTTAAGCAATTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 91

ID ADB47019 standard; cDNA; 1174 BP.

XX ADB47019;

AC ADB47019;

XX 04-DEC-2003 (first entry)

DT Novel human secreted and transmembrane protein PRO195 cDNA.

DE Human; secreted and transmembrane protein; PRO; gene; ss;

XX

KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
OS
XX
PN US2003082687-A1.
XX
PD 01-MAY-2003.
XX
XX 19-APR-2002; 2002US-00125930.
XX
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786904/74.
DR P-PSDB; ADB47020.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 627pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBM cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db |
61 GGGAAACAAGATGGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
Db |
121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db |
181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGGCAGGCTGTTT 300
Db |
241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCAATGTGAGAGGTTGGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db |
301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |
361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db |
421 CAGAATCAGCTGCCATTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
Db |
481 ATGCACCTACTCTTCTCTAACTCTGCTGAGGTCAATCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600
Db |
541 GCACAGAGCTTCATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db |
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db |
661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAAGCTTTTAAAGATGCTCTCTCTTAAC 780
Db |
721 CACAGGAATTTCTTGAAGATGGAGAAAGTGAAGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAATCTTGTCTCTCGGTGATGATGCTTTGGATTGT 840
Db |
781 TCTGGGTGATTTTAACTACAATCTTGTCTCTCGGTGATGATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
Db |
841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db |
901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGGAAGAGCAGGGCCTTACCTACAAAGTGAAT 1020
Db |
961 GTTGTAGATCTAAACTGAAGATCATGGAAGAGCAGGGCCTTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db |
1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAAGAAATCA 1140
Db |
1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCTTAAAGAAATCA 1140

QY 1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174
Db |
1141 CTATAAATGCAAAATAAGTTACTCAAAATCTGTG 1174
RESULT 92
ADB86626
ID ADB86626 standard; cDNA; 1174 BP.
XX
AC ADB86626;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082697-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127849.
XX
PR 20-OCT-1998; 98US-0104987P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
(GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743895/70.
DR P-PSDB; ADB86627.
XX
XX New secreted and transmembrane PRO polypeptides, useful in the diagnosis
PT and treatment of cancer.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or PFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGSCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGSCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTTCAGAGAGGTTGCGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTTCAGAGAGGTTGCGGCTGTTT 300
QY 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAATCGAATCGAATCGAATCGAATGTA 360
Db 301 TCAATTTGTGAGTTGTGGATGATGGAATTGACTTAATCGAATCGAATCGAATGTA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAATCTGAGTGGTCACTTATGTCCTGATGCGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAATCTGAGTGGTCACTTATGTCCTGATGCGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA 660
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCAGAGCG 720
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCAGAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGTGATGGTATTGCTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGTGATGGTATTGCTTGGATTGT 840
QY 841 TGTGCACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 93
ADB76551

ID ADB76551 standard; cDNA; 1174 BP.

XX ADB76551;

DT 04-DEC-2003 (first entry)

XX Human PRO polynucleotide sequence #83.

DE Human; PRO polypeptide; secreted protein; transmembrane protein;
XX cell death; neuropathy; neuropathy related disease;
KW Charcot-Marie-Tooth disorder; Refsum's disease; Krabbe's disease;
KW chromosome mapping; gene mapping; genetic disorder; septic shock;
KW antibacterial; immunosuppressive; neuroprotective; gene; ss.

OS Homo sapiens.

XX US2003083248-A1.

XX 01-MAY-2003.

PF 16-OCT-2001; 2001US-00978757.

XX 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 11-MAR-1998; 98US-0077649P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 20-MAR-1998; 98US-0078939P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US015264.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-755118/71.
DR P-PSDB; ADB76552.
XX
XX
PT New PRO polypeptides useful for treating peripheral neuropathy,
PT neuropathies associated with systemic disease such as post-polio syndrome
PT or AIDS-associated syndrome.
XX
PS Claim 2; Fig 131; 425pp; English.

The present invention relates to the isolation of novel human PRO polypeptides, and the polynucleotide sequences encoding them. The PRO polypeptides are secreted and transmembrane proteins. The PRO polypeptides are useful for detecting other PRO polypeptides, for linking bioactive molecules to cells expressing PRO polypeptides, for modulating biological activities of cells expressing PRO polypeptides, and for identifying agonists or antagonists. The bioactive molecule maybe a toxin, radiolabel or antibody, and cause cell death. The PRO polypeptides are useful for treating neuropathy and neuropathy related diseases such as Charcot-Marie-Tooth disorder, Refsum's disease, and Krabbe's disease. The polynucleotide sequences encoding PRO polypeptides are useful as hybridisation probes, in chromosome and gene mapping, in the generation

Query Match	100.0%;	Score 1174;	DB 9;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1174;	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

QY	1	CGGACGGCTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
DB	1		
QY	61	GGGAACAAGATGGCGGCGCCGAAGGGAGCCCTCTGGGTGAGGACCCCAACTCGGGCTCCCG	120
DB	61		
QY	121	CCGCTGCTGCTGTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180
DB	121		
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTTGCCACCGGCGCTGTGAGTTGACCTACCCC	240
DB	181		
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT	300
DB	241		
QY	301	TCAATTGTGCTAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA	360
DB	301		
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTTGCCATCTTGGTTGC	420
DB	361		
QY	421	CAGAAATCAGCTGCCATTTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
DB	421		
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATTCGAGTGACATGATGGACTCC	540
DB	481		
QY	541	GCACAGAGCTTCATAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA	600
DB	541		
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA	660
DB	601		
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG	720
DB	661		
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAATGATGGCTTTTTTAAGATGCCCTCTCTCTTAAC	780
DB	721		
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
DB	781		

XX PS Claim 2; Fig 271; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from BMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes

CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGTGACAGAG 60

DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCCCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

DB 61 GGGAAACAAGATGGCGGCCCGAAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180

DB 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGTGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240

DB 181 TTTGACTCGGTCTTGGTGTGATACGGCGCTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTGACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300

DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTGACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTGTGATGTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360

DB 301 TCAATTGTGATGTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTCCTAATCTGTGAGCAATATGCTTGCCATCTTGGTTGC 420

DB 361 TCTGCATGTACAGAAGCATATTCCTAATCTGTGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCGTGAACTGAGACAAGAACTTATGTCCTGTATGCCAAA 480

DB 421 CAGAATCAGCTGCCATTTCGTGAACTGAGACAAGAACTTATGTCCTGTATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540

DB 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

DB 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660

DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660

QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720

DB 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780

DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACCTCTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840

DB 781 TCTGGGTGGATTTTAACTACAACCTCTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840

QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCCCTTAAGAAATCA 1140

DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCCCTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

DB 1141 CTATAAAATGCAAAATAAGTTACTCAAAATCTGTG 1174

RESULT 95

ADB34388

ID ADB34388 standard; cDNA; 1174 BP.

XX

AC ADB34388;

XX

DT 04-DEC-2003 (first entry)

XX

DE Human PRO polynucleotide SEQ ID NO 271.

XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003077717-A1.

XX

PD 24-APR-2003.

XX

PF 24-APR-2002; 2002US-00131818.
XX 07-OCT-1998; 98US-0103328P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
PI
XX WPI: 2003-755072/71.
DR P-PSDB; ADB34389.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGSCCTGTCAAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGSCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACGCGATGTACAGAGAGGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTTACCCTAAGGAAGAGGAGTTGTACGCGATGTACAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCACTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
DB 301 TCAATTTGTCACTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420
DB 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
DB 421 CAGAAATCAGCTGCCATTTCGCTGAATGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTTAACTCTGCTGAGGTCAATCTGAGTGACATGATGGACTCC 540
DB 481 ATGCACCTACTCTTCTTAACTCTGCTGAGGTCAATCTGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCAATAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTTCTGATGATGATGATGATGATGATGAT 720
DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTTCTGATGATGATGATGATGATGATGAT 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTTAAC 780
DB 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCCTCTCTCTTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGATGATGATGATGATGAT 840
DB 781 TCTGGGTGGATTTTAACTACAACTCTTCTCTCTCGGTGATGATGATGATGATGATGATGAT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGIG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGIG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGAATAGACATCTAA 1080
DB 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGAATAGACATCTAA 1080
QY 1081 AATTCACCTCTCATAGAGCTTTTAAATAGGTTTCAATTTGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCACCTCTCATAGAGCTTTTAAATAGGTTTCAATTTGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174
DB 1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174

RESULT 96
ADB35492
ID ADB35492 standard; cDNA; 1174 BP.
XX
AC ADB35492;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polynucleotide SEQ ID NO 271.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077719-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131824.
XX
PR 09-FEB-1999; 99US-0119341P.
PR 01-DEC-1999; 99WO-US028634.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755074/71.
DR P-PSDB; ADB35493.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
XX
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
DB |||||||
1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCG 120
DB |||||||
61 GGGAAACAAGATGGCGGCGCGGAGGAGCCCTCTGGGTGAGGACCCCACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCCGCTCGGCTGAAGCA 180
DB |||||||
121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTCCGGGACCCGCTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTCTTGGGTGATACGGCGCTCTTCCACCGGGCCTGTGAGTTGACCTACCCC 240
DB |||||||
181 TTTGACTCGGCTCTTGGGTGATACGGCGCTCTTCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT 300
DB |||||||
241 TTTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGGATGATGGAATTGAACTTAAATCGAACTAAATTTGGAATGTGAA 360
DB |||||||
301 TCAATTTGTGAGTTTGGATGATGGAATTGAACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420
DB |||||||
361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAACTTATGTCCTGATGCCAAA 480
DB |||||||
421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGGTCATCTTGGAGTGACATGAGACTCC 540
DB |||||||
481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGGTCATCTTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATACCTCTTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAATA 600
DB |||||||
541 GCACAGAGCTTCATACCTCTTTCATGGACCTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCTTACA 660
DB |||||||
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACTTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAATAGAAATTCACAAGCG 720
DB |||||||
661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAATAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB |||||||
721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
DB |||||||
781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840

QY	421	CAGAAATCAGCTGCCATTGCGTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
Db	421		
QY	481	ATGCACCTACTCTTCTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540
Db	481		
QY	541	GCACAGACTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541		
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGGACCAATTTGGAGCAGGAGCCTACA	660
Db	601		
QY	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
Db	661		
QY	721	CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
Db	721		
QY	781	TCGGGTGGATTTTAACTACAACCTCTGTCTCCTCTCGGTGATGGTATTGCTTTGGATTGT	840
Db	781		
QY	841	TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT	900
Db	841		
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960
Db	901		
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCTCTACCTACAAAAGTGAAT	1020
Db	961		
QY	1021	CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
Db	1021		
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081		
QY	1141	CTATAAATGCAATAAAAGTTACTCAATCTGTG	1174
Db	1141		

RESULT 98
ADB34940
ID ADB34940 standard; cDNA; 1174 BP.
XX AC ADB34940;
XX DT
XX DE 04-DEC-2003 (first entry)
XX DE Human PRO polynucleotide SEQ ID NO 271.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX	Homo sapiens.	
OS	US2003077718-A1.	
XX	24-APR-2003.	
PN	24-APR-2002; 2002US-00131823.	
XX	31-MAR-1997; 97WO-US005230.	
PR	12-JUN-1998; 98WO-US012456.	
PR	14-JUL-1998; 98WO-US014552.	
PR	28-AUG-1998; 98WO-US017888.	
PR	10-SEP-1998; 98WO-US018824.	
PR	14-SEP-1998; 98WO-US019093.	
PR	14-SEP-1998; 98WO-US019094.	
PR	14-SEP-1998; 98WO-US019177.	
PR	16-SEP-1998; 98WO-US019330.	
PR	17-SEP-1998; 98WO-US019437.	
PR	07-OCT-1998; 98WO-US021141.	
PR	29-OCT-1998; 98WO-US022991.	
PR	29-OCT-1998; 98WO-US022992.	
PR	20-NOV-1998; 98WO-US024855.	
PR	01-DEC-1998; 98WO-US025108.	
PR	05-JAN-1999; 99WO-US000106.	
PR	08-MAR-1999; 99WO-US005028.	
PR	10-MAR-1999; 99WO-US005190.	
PR	20-APR-1999; 99WO-US008615.	
PR	14-MAY-1999; 99WO-US010733.	
PR	02-JUN-1999; 99WO-US012252.	
PR	01-SEP-1999; 99WO-US020111.	
PR	08-SEP-1999; 99WO-US020594.	
PR	13-SEP-1999; 99WO-US020944.	
PR	15-SEP-1999; 99WO-US021090.	
PR	15-SEP-1999; 99WO-US021547.	
PR	05-OCT-1999; 99WO-US023089.	
PR	29-NOV-1999; 99WO-US028214.	
PR	30-NOV-1999; 99WO-US028313.	
PR	30-NOV-1999; 99WO-US028409.	
PR	01-DEC-1999; 99WO-US028301.	
PR	01-DEC-1999; 99WO-US028634.	
PR	02-DEC-1999; 99WO-US028551.	
PR	02-DEC-1999; 99WO-US028564.	
PR	02-DEC-1999; 99WO-US028565.	
PR	16-DEC-1999; 99WO-US030095.	
PR	20-DEC-1999; 99WO-US030911.	
PR	20-DEC-1999; 99WO-US030999.	
PR	22-DEC-1999; 99WO-US030720.	
PR	30-DEC-1999; 99WO-US031243.	
PR	30-DEC-1999; 99WO-US031274.	
PR	05-JAN-2000; 2000WO-US000219.	
PR	06-JAN-2000; 2000WO-US000277.	
PR	06-JAN-2000; 2000WO-US000376.	
PR	11-FEB-2000; 2000WO-US003565.	
PR	18-FEB-2000; 2000WO-US004341.	
PR	18-FEB-2000; 2000WO-US004342.	
PR	22-FEB-2000; 2000WO-US004414.	
PR	24-FEB-2000; 2000WO-US004914.	
PR	24-FEB-2000; 2000WO-US005004.	
PR	01-MAR-2000; 2000WO-US005601.	
PR	02-MAR-2000; 2000WO-US005746.	
PR	02-MAR-2000; 2000WO-US005841.	
PR	10-MAR-2000; 2000WO-US006319.	
PR	15-MAR-2000; 2000WO-US006884.	
PR	20-MAR-2000; 2000WO-US007377.	
PR	21-MAR-2000; 2000WO-US007532.	
PR	30-MAR-2000; 2000WO-US008439.	
PR	17-MAY-2000; 2000WO-US013705.	
PR	22-MAY-2000; 2000WO-US014042.	
PR	30-MAY-2000; 2000WO-US014941.	
PR	02-JUN-2000; 2000WO-US015264.	
PR	28-JUL-2000; 2000WO-US020710.	
PR	11-AUG-2000; 2000WO-US022031.	

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755073/71.
DR P-PSDB; ADB34941.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.

PS Claim 2; Fig 271; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGAACAAGATGGCGCGCCGAGGGAGCCTCTGCGGAGGAGCCCAACTGGGGCTCCCG 120
Db |||||
QY 61 GGAACAAGATGGCGCGCCGAGGGAGCCTCTGCGGAGGAGCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGTGATACGCGCTTTCGCCACCGGCGCTGTCAGTTGACCTACCCC 240
Db |||||
QY 181 TTTGACTCGGTCTTGGTGATACGCGCTTTCGCCACCGGCGCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
Db |||||
QY 241 TTGCACACCTACCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTATGTCCTGATGCCAAAA 480
Db |||||
QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGAGGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGAGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
Db |||||
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
Db |||||
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCGGTGATGGTATGCTTTGGATTGT 840
Db |||||

Db 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGATGGTATGCTTTGGATTGT 840

QY 841 TGTCGAAGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

Db 841 TGTCGAAGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900

QY 901 GGTCAGTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTG 960

Db 901 GGTCAGTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTG 960

QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCACTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

Db 1021 CTTGCTCACTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080

QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140

Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCTTAAAGAAATCA 1140

QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 99

ADB36044

ID ADB36044 standard; cDNA; 1174 BP.

AC ADB36044;

XX 04-DEC-2003 (first entry)

DE Human PRO polynucleotide SEQ ID NO 271.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

KW liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;

KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.

XX Homo sapiens.

OS US2003077720-A1.

XX 24-APR-2003.

PN 24-APR-2002; 2002US-00131830.

PF 09-DEC-1999; 99US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755075/71.

DR P-PSDB; ADB36045.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,

PT such as lung, colon, breast, prostate, rectal, cervical and/or liver

PT tumors.

XX Claim 2; Fig 271; 637pp; English.

PS The invention relates to isolated human PRO polypeptides (secreted and

XX transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAAAGCTGAGTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAAAGCTGAGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTGGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGGCCACCGGGCCTGTCACTGACCTACCCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGGCCACCGGGCCTGTCACTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATTAATTGGAATGTGAA 360

Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATTAATTGGAATGTGAA 360

QY 361 TCTGCAATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCAATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480

Db 421 CAGAAATCAGCTGCCAATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480

Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGAGACTCC 540

Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGAGACTCC 540

Qy 541 GCACAGAGTTTCATAACCTCTTCATGGACTTTTATCTCAAGCCGATGACGGAATAAATA 600

Db 541 GCACAGAGTTTCATAACCTCTTCATGGACTTTTATCTCAAGCCGATGACGGAATAAATA 600

Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660

Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660

Qy 661 AATTGTGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720

Db 661 AATTGTGAGAAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720

Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Qy 781 TCTGGTGGATTTTAACTACAACCTCTCTCTCGTGGATGGTATTGCTTGGATTGT 840

Db 781 TCTGGTGGATTTTAACTACAACCTCTCTCTCGTGGATGGTATTGCTTGGATTGT 840

Qy 841 TGTGCAACTGTTGCTACAGCTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Db 841 TGTGCAACTGTTGCTACAGCTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

Qy 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960

Db 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960

Qy 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGAGGCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGAGGCTCTACCTACAAAAGTGAAT 1020

Qy 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGCAATTTCTTTTAAAGCAATCTAA 1080

Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGCAATTTCTTTTAAAGCAATCTAA 1080

Qy 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAAGAAATCA 1140

Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAAGAAATCA 1140

Qy 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 100

ADB46439 standard; cDNA; 1174 BP.

AC ADB46439;

XX 04-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003082692-A1.

XX

PN

XX 01-MAY-2003.

PD 22-APR-2002; 2002US-00127842.

XX 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786906/74.

DR P-PSDB; ADB46440.

XX New PRO nucleic acid, useful for preparing a composition for treating

PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 271; 637pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and

CC transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte

CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,

CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

CC the release of a cytokine from PBM cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

CC cells, for stimulating proliferation of endothelial cells, for detecting

CC the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or

CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

CC in assays to identify other proteins or molecules involved in binding

CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

CC and gene mapping, in generation of antisense RNA and DNA, in the

CC preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, in gene therapy, for

CC chromosome identification, as chromosome marker, and for generating

CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

CC detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes

CC a novel human secreted and transmembrane PRO polypeptide.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAAACAGCAACAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGACCCCAACTGGGCTCCG 120

Db 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGACCCCAACTGGGCTCCG 120

Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCCGGGCTGTTCAGTTGACCTACCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCCGGGCTGTTCAGTTGACCTACCC 240

QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCGATGTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATCTAAATGGAATGTGAA 360
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
301 TCAATTTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATCTAAATGGAATGTGAA 360
QY 361 TCTGCAATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
361 TCTGCAATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
421 CAGAATCAGCTGCCATTCCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGGACTCC 540
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
481 ATGCACCTACTCTTTCTCTAACTCTGCTGAGGTCATTTCTGGAGTGACATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATAATA 600
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGT 840
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGCTTTGGATTTGT 840
QY 841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
841 TGTGCAACTGTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAGAGATATCCAGCTTCTTCTTTGTG 960
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAGAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAATAAAGCTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAAGTGAAT 1020
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
961 GTTGTAGATCTAATAAAGCTGAAGATCATGAAGAGCAGGCGCTTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Dd ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 101
ADC43977
ID ADC43977 standard; cdna; 1174 BP.
XX
AC ADC43977;
XX
DT 18-DEC-2003 (first entry)

XX Human cDNA encoding secreted/transmembrane protein, PRO195.
DE
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003054986-A1.
XX
PD 20-MAR-2003.
XX
PF 16-OCT-2001; 2001US-00981915.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078866P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087088P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.
XX

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CCGACGCGTGGGGGAAACCCCTCCGAGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GCGAACAGATGGCGGCGCGGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTGCGGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCCTGTCAAGTACCTACCCC 240
Db |||||
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTCTCAGAGAGGTTGAGGCTGTTT 300
Db |||||

PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-01168978.
PR 07-OCT-1998; 98US-01168978.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99US-0000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99US-0005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99US-0005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99US-010733.
PR 02-JUN-1999; 99US-012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380137.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0028313.
PR 02-DEC-1999; 99US-0028551.

PR 02-DEC-1999; 99US-0028565.
PR 16-DEC-1999; 99US-0030095.
PR 30-DEC-1999; 99US-0031243.
PR 30-DEC-1999; 99US-0031274.
PR 05-JAN-2000; 2000US-0000219.
PR 06-JAN-2000; 2000US-0000277.
PR 06-JAN-2000; 2000US-0000376.
PR 11-FEB-2000; 2000US-0003565.
PR 18-FEB-2000; 2000US-0004341.
PR 24-FEB-2000; 2000US-0005004.
PR 02-MAR-2000; 2000US-0005841.
PR 10-MAR-2000; 2000US-0006319.
PR 21-MAR-2000; 2000US-0007532.
PR 30-MAR-2000; 2000US-0008439.
PR 17-MAY-2000; 2000US-0013705.
PR 22-MAY-2000; 2000US-0014042.
PR 30-MAY-2000; 2000US-0014941.
PR 02-JUN-2000; 2000US-0015264.
PR 28-JUL-2000; 2000US-0020710.
PR 24-AUG-2000; 2000US-0023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000US-0032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000US-0034956.
PR 28-FEB-2001; 2001US-0006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001US-0009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-0017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-0017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-0019692.
PR 29-JUN-2001; 2001US-0021066.
PR 09-JUL-2001; 2001US-0021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
|||
Db 1 CGGACGCGTGGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGACAGAG 60
|||
Qy 61 GGGAAACAAGATGGCGGCGCGGAGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
|||
Db 61 GGGAAACAAGATGGCGGCGCGGAGAGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
|||
Qy 121 CCGCTGCTGCTGCTGACCAATGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180
|||
Db 121 CCGCTGCTGCTGCTGACCAATGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA 180
|||
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTGACCTACCCC 240
|||
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTGACCTACCCC 240
|||
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
|||
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
|||
Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
|||
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
|||

QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAATCAGTCCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db |||||
QY 421 CAGAATCAGTCCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db |||||
QY 481 ATGCACCTACTCTTTCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAAACCTCTTCTCATGGACTTTTATCTTCAAGCCGATGACGCAAAAAATA 600
Db |||||
QY 541 GCACAGAGCTTCATAAACCTCTTCTCATGGACTTTTATCTTCAAGCCGATGACGCAAAAAATA 600
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAAGCG 720
Db |||||
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAAGCG 720
Db |||||
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db |||||
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTTCTCCTCTCGGTGATGTATTTGGATTGT 840
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTTCTCCTCTCGGTGATGTATTTGGATTGT 840
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAGCAAGATATCCAGCTTCTTCTCTGTG 960
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAGCAAGATATCCAGCTTCTTCTCTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
Db |||||
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTTAA 1080
Db |||||
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTTAA 1080
Db |||||
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAAATGCAATATAAGTTTACTCAAATCTGTG 1174
Db |||||
QY 1141 CTATAAAATGCAATATAAGTTTACTCAAATCTGTG 1174
Db |||||

RESULT 103
ADC63701
ID ADC63701 standard; cdna; 1174 BP.
XX
AC ADC63701;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cdna encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosstatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulneryary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
KW

XX OS Homo sapiens.
XX PN US2003054405-A1.
XX PD 20-MAR-2003.
XX PF 24-OCT-2001; 2001US-00999833.
XX PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-007886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.

PR	06-MAY-1998;	98US-0084441P.	PR	30-DEC-1999;	99WO-US031274.
PR	07-MAY-1998;	98US-0084598P.	PR	05-JAN-2000;	2000WO-US000219.
PR	07-MAY-1998;	98US-0084600P.	PR	06-JAN-2000;	2000WO-US000277.
PR	07-MAY-1998;	98US-0084627P.	PR	06-JAN-2000;	2000WO-US000376.
PR	07-MAY-1998;	98US-0084637P.	PR	11-FEB-2000;	2000WO-US003565.
PR	07-MAY-1998;	98US-0084639P.	PR	18-FEB-2000;	2000WO-US004341.
PR	07-MAY-1998;	98US-0084640P.	PR	24-FEB-2000;	2000WO-US005004.
PR	07-MAY-1998;	98US-0084643P.	PR	02-MAR-2000;	2000WO-US005841.
PR	13-MAY-1998;	98US-0085323P.	PR	10-MAR-2000;	2000WO-US006319.
PR	13-MAY-1998;	98US-0085338P.	PR	21-MAR-2000;	2000WO-US007532.
PR	13-MAY-1998;	98US-0085339P.	PR	30-MAR-2000;	2000WO-US008439.
PR	15-MAY-1998;	98US-0085573P.	PR	17-MAY-2000;	2000WO-US013705.
PR	15-MAY-1998;	98US-0085579P.	PR	22-MAY-2000;	2000WO-US014042.
PR	15-MAY-1998;	98US-0085580P.	PR	30-MAY-2000;	2000WO-US014941.
PR	15-MAY-1998;	98US-0085582P.	PR	02-JUN-2000;	2000WO-US015264.
PR	15-MAY-1998;	98US-0085689P.	PR	28-JUL-2000;	2000WO-US020710.
PR	15-MAY-1998;	98US-0085697P.	PR	24-AUG-2000;	2000WO-US023328.
PR	15-MAY-1998;	98US-0085700P.	PR	08-NOV-2000;	2000US-00709238.
PR	15-MAY-1998;	98US-0085704P.	PR	27-NOV-2000;	2000US-00723749.
PR	18-MAY-1998;	98US-0086023P.	PR	01-DEC-2000;	2000WO-US032678.
PR	22-MAY-1998;	98US-0086392P.	PR	20-DEC-2000;	2000US-00747259.
PR	22-MAY-1998;	98US-0086414P.	PR	20-DEC-2000;	2000WO-US034956.
PR	22-MAY-1998;	98US-0086430P.	PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAY-1998;	98US-0086486P.	PR	22-MAR-2001;	2001US-00816744.
PR	28-MAY-1998;	98US-0087098P.	PR	22-MAR-2001;	2001US-00816920.
PR	28-MAY-1998;	98US-0087106P.	PR	22-MAR-2001;	2001WO-US009552.
PR	28-MAY-1998;	98US-0087208P.	PR	10-MAY-2001;	2001US-00854208.
PR	26-JUN-1998;	98US-00105413.	PR	10-MAY-2001;	2001US-00854280.
PR	26-JUN-1998;	98US-0090863P.	PR	25-MAY-2001;	2001WO-US017092.
PR	26-JUN-1998;	98US-0091010P.	PR	01-JUN-2001;	2001US-00872035.
PR	01-JUL-1998;	98US-0091359P.	PR	01-JUN-2001;	2001WO-US017800.
PR	30-JUL-1998;	98US-0094651P.	PR	05-JUN-2001;	2001US-00874503.
PR	11-SEP-1998;	98US-0100038P.	PR	14-JUN-2001;	2001US-00882636.
PR	07-OCT-1998;	98US-00168978.	PR	19-JUN-2001;	2001US-00886342.
PR	07-OCT-1998;	98WO-US021141.	PR	20-JUN-2001;	2001WO-US019692.
PR	02-NOV-1998;	98US-00184216.	PR	29-JUN-2001;	2001WO-US021066.
PR	06-NOV-1998;	98US-00187368.	PR	09-JUL-2001;	2001WO-US021735.
PR	20-NOV-1998;	98US-0109304P.	PR	30-JUL-2001;	2001US-00918585.
PR	20-NOV-1998;	98WO-US024855.	XX		
PR	07-DEC-1998;	98US-00202054.	PA	(GETH) GENENTECH INC.	
PR	22-DEC-1998;	98US-00218517.	XX		
PR	22-DEC-1998;	98US-0113296P.	Query Match 100.0%; Score 1174; DB 9; Length 1174;		
PR	23-DEC-1998;	98US-0113621P.	Best Local Similarity 100.0%; Pred. No. 0;		
PR	05-JAN-1999;	99WO-US000106.	Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
PR	05-MAR-1999;	99US-00254465.			
PR	08-MAR-1999;	99WO-US005028.	QY	1	CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60
PR	10-MAR-1999;	99US-00265686.	Db	1	CGGACGCGTGGGGAAACCCCTTCGAGAGAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60
PR	10-MAR-1999;	99WO-US005190.	QY	61	GGGAACAAGATGGCGCGCCGCGGAGGAGCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
PR	12-MAR-1999;	99US-00267213.	Db	61	GGGAACAAGATGGCGCGCCGCGGAGGAGCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
PR	12-MAR-1999;	99US-0123957P.	QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
PR	29-MAR-1999;	99US-0126773P.	Db	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
PR	12-APR-1999;	99US-00284291.	QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGCGCTTCAGTTGACCTACCCC 240
PR	21-APR-1999;	99US-0130232P.	Db	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTCCACCGGCGCTTCAGTTGACCTACCCC 240
PR	26-APR-1999;	99US-0131022P.	QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
PR	28-APR-1999;	99US-0131445P.	Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
PR	14-MAY-1999;	99US-00311832.	QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATAAATGGAATGTGAA 360
PR	14-MAY-1999;	99US-0134287P.	Db	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAATAAATGGAATGTGAA 360
PR	14-MAY-1999;	99WO-US010733.	QY	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
PR	02-JUN-1999;	99WO-US012252.	Db	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
PR	16-JUN-1999;	99US-0139557P.			
PR	23-JUN-1999;	99US-0141037P.			
PR	07-JUL-1999;	99US-0142680P.			
PR	26-JUL-1999;	99US-0145698P.			
PR	28-JUL-1999;	99US-0146222P.			
PR	25-AUG-1999;	99US-00380137.			
PR	25-AUG-1999;	99US-00380138.			
PR	25-AUG-1999;	99US-00380142.			
PR	29-OCT-1999;	99US-0162506P.			
PR	30-NOV-1999;	99WO-US028313.			
PR	02-DEC-1999;	99WO-US028551.			
PR	02-DEC-1999;	99WO-US028565.			
PR	16-DEC-1999;	99WO-US030095.			
PR	30-DEC-1999;	99WO-US031243.			

QY 421 CAGAATCAGCTGCCATTGGCTGAAGTGAACAAGAACAACTTATGTCCCTGATGCCAAA 480
DB |||||||
421 CAGAATCAGCTGCCATTGGCTGAAGTGAACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGTGCCTCC 540
DB |||||||
481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGTGCCTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600
DB |||||||
541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
DB |||||||
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB |||||||
661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
DB |||||||
721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGAATTTAACTACAACTCTGTCTCGGTGATGGTATGCTTTGGATTTGT 840
DB |||||||
781 TCTGGGTGAATTTAACTACAACTCTGTCTCGGTGATGGTATGCTTTGGATTTGT 840
QY 841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB |||||||
841 TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB |||||||
901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAAAGCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB |||||||
961 GTTGTAGATCTAAAAGCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
DB |||||||
1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
DB |||||||
1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
DB |||||||
1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 104
ADC66801
ID ADC66801 standard; cDNA; 1174 BP.
XX
AC ADC66801;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
DE
XX
KW vulnary; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amyotrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.

XX
PN US2003060406-A1.
XX
PD 27-MAR-2003.
XX
PF 30-JUL-2001; 2001US-00918585.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 26-JUN-1998; 98US-00105413.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-APR-1999; 99US-00284291.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380142.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR

PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-596568/56.
DR P-PSDB; ADC66802.

XX Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them, useful for treating wound healing, tissue growth and
PT muscle generation and regeneration, amyotrophic lateral sclerosis or
PT neuropathy.

XX Claim 2; SEQ ID NO 329; 472pp; English.

PS The invention describes an isolated secreted and transmembrane PRO
XX polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615
CC is useful in biotechnological and medical research, as well as in various
CC industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703,
CC PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO772, PRO853,
CC PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful
CC therapeutically in vivo for lessening the effects of viral infection.
CC PRO200 is useful for the treatment of wound healing, tissue growth and
CC muscle generation and regeneration. PRO337 is useful for treating
CC amyotrophic lateral sclerosis, neuropathy, AIDS-associated neuropathy or
CC diabetic peripheral neuropathy. A polynucleotide (II) encoding (I) is
CC useful for generating transgenic animals or knockout animals which are
CC useful in the development and screening of therapeutically useful
CC reagents, as probes for generating a pool of sequences for identifying
CC related PRO coding sequences, and to construct hybridisation probes for
CC mapping the gene which encodes the PRO and for the genetic analysis of
CC individuals with genetic disorders, for recombinantly expressing (I) and
CC for chromosome identification. (I) is useful as molecular marker for
CC protein electrophoresis purposes, and as therapeutic agents. (I) is also
CC useful for screening compounds to identify those that mimic the PRO
CC polypeptide (agonists) or prevent the effect of the PRO polypeptide
CC (antagonists). (I) and (II) are useful for tissue typing. PRO antibodies
CC are useful for immunohistochemical staining and/or assay of sample
CC fluids. Anti-PRO antibodies are useful in diagnostic assays for PRO e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a human secreted and transmembrane PRO
XX protein.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAAAACAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAAAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCGGCGGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCACTGGCCCTTGGCCGGAGGTTTGGGGACCCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCACTGGCCCTTGGCCGGAGGTTTGGGGACCCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGCGCTGTCACTGACCTACCCC 240
DB 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGCGCTGTCACTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAAGCTGTTT 300
DB 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGATGTCAAGAGGTTGCAAGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGGAATTGACTTAAATCGAACTAAATTTGAATGTAA 360
DB 301 TCAATTTGTCAGTTTGTGGATGGAATTGACTTAAATCGAACTAAATTTGAATGTAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTTCGTGTAATCTGAGACAAGAACTTATGTCCTGATGCCAAA 480
DB 421 CAGAAATCAGCTGCCATTTCGTGTAATCTGAGACAAGAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTTAACTCTGAGGAGGTTGATCGCATGTCAAGAGGTTGCAAGCTCC 540
DB 481 ATGCACCTACTCTTCTTAACTCTGAGGAGGTTGATCGCATGTCAAGAGGTTGCAAGCTCC 540
QY 541 GCACAGAGCTTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACCGGAAAATA 600
DB 541 GCACAGAGCTTCATAAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACCGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGAATTTTAACTACAACCTTTGTCCTCTCGGTGATGGTATGCTTTGGATTGT 840
DB 781 TCTGGGTGGAATTTTAACTACAACCTTTGTCCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGTAAACAGATATCCAGCTTCTTCTTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAAGTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080

Db 1021 CTGTCTCATCTCGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTGTAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAGAAATCA 1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAGAAATCA 1140

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 105

ADC68925

ID ADC68925 standard; cDNA; 1174 BP.

XX AC ADC68925;

XX DT 18-DEC-2003 (first entry)

XX DE Human cDNA encoding secreted/transmembrane protein, PRO195.

XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;

KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;

KW vulneryary; auditory; tumour growth; retinal disorder;

KW sports-related joint problem; articular cartilage defects;

KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX OS Homo sapiens.

XX PN US2003064407-A1.

XX PD 03-APR-2003.

XX PF 24-OCT-2001; 2001US-00999834.

XX PR 17-OCT-1997; 97US-0062250P.

PR 03-NOV-1997; 97US-0064249P.

PR 13-NOV-1997; 97US-0065311P.

PR 21-NOV-1997; 97US-0066364P.

PR 10-MAR-1998; 98US-0077450P.

PR 11-MAR-1998; 98US-0077632P.

PR 11-MAR-1998; 98US-0077641P.

PR 11-MAR-1998; 98US-0077649P.

PR 12-MAR-1998; 98US-0077791P.

PR 13-MAR-1998; 98US-0078004P.

PR 17-MAR-1998; 98US-00040220.

PR 20-MAR-1998; 98US-0078886P.

PR 20-MAR-1998; 98US-0078910P.

PR 20-MAR-1998; 98US-0078936P.

PR 20-MAR-1998; 98US-0078939P.

PR 25-MAR-1998; 98US-0079294P.

PR 26-MAR-1998; 98US-0079656P.

PR 27-MAR-1998; 98US-0079663P.

PR 27-MAR-1998; 98US-0079664P.

PR 27-MAR-1998; 98US-0079689P.

PR 27-MAR-1998; 98US-0079728P.

PR 27-MAR-1998; 98US-0079786P.

PR 30-MAR-1998; 98US-0079920P.

PR 30-MAR-1998; 98US-0079923P.

PR 31-MAR-1998; 98US-0080105P.

PR 31-MAR-1998; 98US-0080107P.

PR 31-MAR-1998; 98US-0080165P.

PR 31-MAR-1998; 98US-0080194P.

PR 01-APR-1998; 98US-0080327P.

PR 01-APR-1998; 98US-0080328P.

PR 01-APR-1998; 98US-0080333P.

PR 01-APR-1998; 98US-0080334P.

PR 08-APR-1998; 98US-0081049P.

PR 08-APR-1998; 98US-0081070P.

PR 08-APR-1998; 98US-0081071P.

PR 09-APR-1998; 98US-0081195P.

PR 09-APR-1998; 98US-0081203P.

PR 09-APR-1998; 98US-0081229P.

PR 15-APR-1998; 98US-0081817P.

PR 15-APR-1998; 98US-0081819P.

PR 15-APR-1998; 98US-0081838P.

PR 15-APR-1998; 98US-0081952P.

PR 15-APR-1998; 98US-0081955P.

PR 21-APR-1998; 98US-0082568P.

PR 21-APR-1998; 98US-0082569P.

PR 22-APR-1998; 98US-0082700P.

PR 22-APR-1998; 98US-0082704P.

PR 22-APR-1998; 98US-0082797P.

PR 22-APR-1998; 98US-0082804P.

PR 23-APR-1998; 98US-0082796P.

PR 27-APR-1998; 98US-0083336P.

PR 28-APR-1998; 98US-0083322P.

PR 29-APR-1998; 98US-0083392P.

PR 29-APR-1998; 98US-0083495P.

PR 29-APR-1998; 98US-0083496P.

PR 29-APR-1998; 98US-0083499P.

PR 29-APR-1998; 98US-0083500P.

PR 29-APR-1998; 98US-0083545P.

PR 29-APR-1998; 98US-0083554P.

PR 29-APR-1998; 98US-0083558P.

PR 29-APR-1998; 98US-0083559P.

PR 30-APR-1998; 98US-0083742P.

PR 05-MAY-1998; 98US-0084366P.

PR 06-MAY-1998; 98US-0084414P.

PR 06-MAY-1998; 98US-0084441P.

PR 07-MAY-1998; 98US-0084598P.

PR 07-MAY-1998; 98US-0084600P.

PR 07-MAY-1998; 98US-0084627P.

PR 07-MAY-1998; 98US-0084637P.

PR 07-MAY-1998; 98US-0084639P.

PR 07-MAY-1998; 98US-0084640P.

PR 07-MAY-1998; 98US-0084643P.

PR 13-MAY-1998; 98US-0085323P.

PR 13-MAY-1998; 98US-0085338P.

PR 13-MAY-1998; 98US-0085339P.

PR 15-MAY-1998; 98US-0085573P.

PR 15-MAY-1998; 98US-0085579P.

PR 15-MAY-1998; 98US-0085580P.

PR 15-MAY-1998; 98US-0085582P.

PR 15-MAY-1998; 98US-0085689P.

PR 15-MAY-1998; 98US-0085697P.

PR 15-MAY-1998; 98US-0085700P.

PR 15-MAY-1998; 98US-0085704P.

PR 18-MAY-1998; 98US-0086023P.

PR 22-MAY-1998; 98US-0086392P.

PR 22-MAY-1998; 98US-0086414P.

PR 22-MAY-1998; 98US-0086430P.

PR 22-MAY-1998; 98US-0086486P.

PR 28-MAY-1998; 98US-0087098P.

PR 28-MAY-1998; 98US-0087106P.

PR 28-MAY-1998; 98US-0087208P.

PR 26-JUN-1998; 98US-00105413.

PR 26-JUN-1998; 98US-0090863P.

PR 26-JUN-1998; 98US-0091010P.

PR 01-JUL-1998; 98US-0091359P.

PR 30-JUL-1998; 98US-0094651P.

PR 11-SEP-1998; 98US-0100038P.

PR 07-OCT-1998; 98US-00168978.

PR 07-OCT-1998; 98WO-US021141.

PR 02-NOV-1998; 98US-00184216.

PR 06-NOV-1998; 98US-00187368.

PR 20-NOV-1998; 98US-0109304P.

PR 20-NOV-1998; 98WO-US024855.

PR 07-DEC-1998; 98US-00202054.

PR 22-DEC-1998; 98US-00218517.

PR 22-DEC-1998; 98US-0113296P.

PR 23-DEC-1998; 98US-0113621P.

PR 05-JAN-1999; 99WO-US000106.

PR 05-MAR-1999; 99US-00254465.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99US-00265686.

PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380142.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000US-00709238.
PR 27-NOV-2000; 2000US-00723749.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001US-00816744.
PR 22-MAR-2001; 2001US-00816920.
PR 22-MAR-2001; 2001WO-US009552.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.

(GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAAACAGCAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGAGCCTCTGGGTGAGAACCAACTGGGGCTCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGAGCCTCTGGGTGAGAACCAACTGGGGCTCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAACATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAACATATTTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAATTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAAACAATTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACITTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGGACITTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACCATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCTCTCTTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGAATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTTAAGAAATCA 1140

Db	1081	AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Qy	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
RESULT 106			
ADC62985	ID ADC62985 standard; cDNA; 1174 BP.		
XX	AC	ADC62985;	
XX	DT	18-DEC-2003 (first entry)	
XX	DE	Human cDNA encoding secreted/transmembrane protein, PRO195.	
XX	KW	Human; ss; gene; secreted protein; transmembrane protein; PRO;	
KW	KW	cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;	
KW	KW	vulnery; auditory; tumour growth; retinal disorder;	
KW	KW	sports-related joint problem; articular cartilage defects;	
KW	XX	osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.	
OS	XX	Homo sapiens.	
XX	PN	US2003068648-A1.	
XX	PD	10-APR-2003.	
XX	PF	25-OCT-2001; 2001US-00013921.	
XX	PR	17-OCT-1997; 97US-0062250P.	
PR	PR	03-NOV-1997; 97US-0064249P.	
PR	PR	13-NOV-1997; 97US-0065311P.	
PR	PR	21-NOV-1997; 97US-0066364P.	
PR	PR	10-MAR-1998; 98US-0077450P.	
PR	PR	11-MAR-1998; 98US-0077632P.	
PR	PR	11-MAR-1998; 98US-0077641P.	
PR	PR	11-MAR-1998; 98US-0077649P.	
PR	PR	12-MAR-1998; 98US-0077791P.	
PR	PR	13-MAR-1998; 98US-0078004P.	
PR	PR	20-MAR-1998; 98US-0078886P.	
PR	PR	20-MAR-1998; 98US-0078910P.	
PR	PR	20-MAR-1998; 98US-0078936P.	
PR	PR	20-MAR-1998; 98US-0078939P.	
PR	PR	25-MAR-1998; 98US-0079294P.	
PR	PR	26-MAR-1998; 98US-0079656P.	
PR	PR	27-MAR-1998; 98US-0079663P.	
PR	PR	27-MAR-1998; 98US-0079664P.	
PR	PR	27-MAR-1998; 98US-0079689P.	
PR	PR	27-MAR-1998; 98US-0079728P.	
PR	PR	27-MAR-1998; 98US-0079786P.	
PR	PR	30-MAR-1998; 98US-0079923P.	
PR	PR	30-MAR-1998; 98US-0079923P.	
PR	PR	31-MAR-1998; 98US-0080105P.	
PR	PR	31-MAR-1998; 98US-0080107P.	
PR	PR	31-MAR-1998; 98US-0080165P.	
PR	PR	31-MAR-1998; 98US-0080194P.	
PR	PR	01-APR-1998; 98US-0080327P.	
PR	PR	01-APR-1998; 98US-0080328P.	
PR	PR	01-APR-1998; 98US-0080333P.	
PR	PR	01-APR-1998; 98US-0080334P.	
PR	PR	08-APR-1998; 98US-0081049P.	
PR	PR	08-APR-1998; 98US-0081070P.	
PR	PR	08-APR-1998; 98US-0081071P.	
PR	PR	09-APR-1998; 98US-0081195P.	
PR	PR	09-APR-1998; 98US-0081203P.	
PR	PR	09-APR-1998; 98US-0081229P.	
PR	PR	15-APR-1998; 98US-0081817P.	
PR	PR	15-APR-1998; 98US-0081819P.	
PR	PR	15-APR-1998; 98US-0081838P.	
PR	PR	15-APR-1998; 98US-0081952P.	
PR	PR	15-APR-1998; 98US-0081955P.	

PR	21-APR-1998;	98US-0082568P.
PR	21-APR-1998;	98US-0082569P.
PR	22-APR-1998;	98US-0082700P.
PR	22-APR-1998;	98US-0082704P.
PR	22-APR-1998;	98US-0082797P.
PR	22-APR-1998;	98US-0082804P.
PR	23-APR-1998;	98US-0082796P.
PR	27-APR-1998;	98US-0083336P.
PR	28-APR-1998;	98US-0083322P.
PR	29-APR-1998;	98US-0083392P.
PR	29-APR-1998;	98US-0083495P.
PR	29-APR-1998;	98US-0083496P.
PR	29-APR-1998;	98US-0083499P.
PR	29-APR-1998;	98US-0083500P.
PR	29-APR-1998;	98US-0083545P.
PR	29-APR-1998;	98US-0083554P.
PR	29-APR-1998;	98US-0083558P.
PR	29-APR-1998;	98US-0083559P.
PR	30-APR-1998;	98US-0083742P.
PR	05-MAY-1998;	98US-0084366P.
PR	06-MAY-1998;	98US-0084414P.
PR	06-MAY-1998;	98US-0084441P.
PR	07-MAY-1998;	98US-0084598P.
PR	07-MAY-1998;	98US-0084600P.
PR	07-MAY-1998;	98US-0084627P.
PR	07-MAY-1998;	98US-0084637P.
PR	07-MAY-1998;	98US-0084639P.
PR	07-MAY-1998;	98US-0084640P.
PR	07-MAY-1998;	98US-0084643P.
PR	13-MAY-1998;	98US-0085323P.
PR	13-MAY-1998;	98US-0085339P.
PR	15-MAY-1998;	98US-0085573P.
PR	15-MAY-1998;	98US-0085579P.
PR	15-MAY-1998;	98US-0085580P.
PR	15-MAY-1998;	98US-0085582P.
PR	15-MAY-1998;	98US-0085689P.
PR	15-MAY-1998;	98US-0085697P.
PR	15-MAY-1998;	98US-0085700P.
PR	15-MAY-1998;	98US-0085704P.
PR	18-MAY-1998;	98US-0086023P.
PR	22-MAY-1998;	98US-0086392P.
PR	22-MAY-1998;	98US-0086414P.
PR	22-MAY-1998;	98US-0086430P.
PR	22-MAY-1998;	98US-0086486P.
PR	28-MAY-1998;	98US-0087098P.
PR	28-MAY-1998;	98US-0087106P.
PR	28-MAY-1998;	98US-0087208P.
PR	26-JUN-1998;	98US-0090863P.
PR	26-JUN-1998;	98US-0091010P.
PR	01-JUL-1998;	98US-0091359P.
PR	30-JUL-1998;	98US-0094651P.
PR	11-SEP-1998;	98US-0100038P.
PR	07-OCT-1998;	98WO-US021141.
PR	20-NOV-1998;	98US-0109304P.
PR	20-NOV-1998;	98WO-US024855.
PR	22-DEC-1998;	98US-0113296P.
PR	23-DEC-1998;	98US-0113621P.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	10-MAR-1999;	99WO-US005190.
PR	12-MAR-1999;	99US-0123957P.
PR	29-MAR-1999;	99US-0126773P.
PR	21-APR-1999;	99US-0130232P.
PR	26-APR-1999;	99US-0131022P.
PR	28-APR-1999;	99US-0131445P.
PR	14-MAY-1999;	99US-0134287P.
PR	14-MAY-1999;	99WO-US010733.
PR	02-JUN-1999;	99WO-US012252.
PR	16-JUN-1999;	99US-0139557P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH) GENENTECH INC.

Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
Stewart TA, Tumas D, Williams PM, Wood WI;

WPI; 2003-695924/66.
P-PSDB; ADC62986.

New isolated secreted and transmembrane PRO polypeptides, useful in the preparation of a medicament for treating a condition responsive to the polypeptide, and as therapeutic agents e.g. vaccines.

Claim 2; SEQ ID NO 329; 467pp; English.

The invention relates to an isolated PRO polypeptide (secreted or transmembrane protein) having at least 80% amino acid sequence identity to an amino acid sequence chosen from 94 fully defined sequences as given in the specification (including PRO lacking its associated signal peptide), a PRO extracellular domain with or without its associated signal peptide). Also included are nucleic acids encoding the PRO proteins mentioned above, a vector comprising a PRO nucleic acid), a host cell comprising the vector and producing PRO, a chimaeric molecule comprising PRO fused to a heterologous amino acid sequence, and an anti-PRO antibody. PRO337 polypeptide is useful for detecting a PRO4993 polypeptide in a sample suspected of containing PRO4993 polypeptide. Similarly, PRO4993 polypeptide is useful for detecting PRO337 polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
|||||
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGCTGTGACAGAG 60
|||||

QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCAATGTACAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCAATGTACAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTCCATCTTGGTTGC 420
Db 361 TCTGCAATGTACAGAAAGCATATTTCCCAATCTGATGAGCAATATGCTTCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTAATTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTAATTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGAATCC 540
Db 481 ATGCACCTACTCTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGAATCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACATACTCTTCTCTCTCGGTGATGGTATTCCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACATACTCTTCTCTCTCGGTGATGGTATTCCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAGAAATCA 1140
Db 1081 AATTCACACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCTTAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
|||||

Db	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
RESULT 107			
ADC68050			
ID	ADC68050	standard; cDNA; 1174 BP.	
XX	AC	ADC68050;	
XX	DT	18-DEC-2003 (first entry)	
XX	DE	Human cDNA encoding secreted/transmembrane protein, PRO195.	
XX	KW	Human; ss; gene; secreted protein; transmembrane protein; PRO;	
KW		cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;	
KW		vulnerary; auditory; tumour growth; retinal disorder;	
KW		sports-related joint problem; articular cartilage defects;	
KW		osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.	
XX	OS	Homo sapiens.	
XX	PN	US2003069178-A1.	
XX	PD	10-APR-2003.	
XX	PF	16-OCT-2001; 2001US-00978423.	
XX	PR	17-OCT-1997; 97US-0062250P.	
PR		03-NOV-1997; 97US-0064249P.	
PR		13-NOV-1997; 97US-0065311P.	
PR		21-NOV-1997; 97US-0066364P.	
PR		10-MAR-1998; 98US-0077450P.	
PR		11-MAR-1998; 98US-0077632P.	
PR		11-MAR-1998; 98US-0077641P.	
PR		12-MAR-1998; 98US-0077791P.	
PR		13-MAR-1998; 98US-0078004P.	
PR		20-MAR-1998; 98US-0078886P.	
PR		20-MAR-1998; 98US-0078910P.	
PR		20-MAR-1998; 98US-0078936P.	
PR		20-MAR-1998; 98US-0078939P.	
PR		25-MAR-1998; 98US-0079294P.	
PR		26-MAR-1998; 98US-0079656P.	
PR		27-MAR-1998; 98US-0079663P.	
PR		27-MAR-1998; 98US-0079689P.	
PR		27-MAR-1998; 98US-0079728P.	
PR		27-MAR-1998; 98US-0079786P.	
PR		30-MAR-1998; 98US-0079920P.	
PR		30-MAR-1998; 98US-0079923P.	
PR		31-MAR-1998; 98US-0080105P.	
PR		31-MAR-1998; 98US-0080194P.	
PR		01-APR-1998; 98US-0080327P.	
PR		01-APR-1998; 98US-0080328P.	
PR		01-APR-1998; 98US-0080333P.	
PR		01-APR-1998; 98US-0080334P.	
PR		08-APR-1998; 98US-0081049P.	
PR		08-APR-1998; 98US-0081070P.	
PR		08-APR-1998; 98US-0081071P.	
PR		09-APR-1998; 98US-0081195P.	
PR		09-APR-1998; 98US-0081203P.	
PR		09-APR-1998; 98US-0081229P.	
PR		15-APR-1998; 98US-0081817P.	
PR		15-APR-1998; 98US-0081819P.	
PR		15-APR-1998; 98US-0081838P.	
PR		15-APR-1998; 98US-0081952P.	
PR		15-APR-1998; 98US-0081955P.	
PR		21-APR-1998; 98US-0082568P.	
PR		21-APR-1998; 98US-0082569P.	
PR		22-APR-1998; 98US-0082700P.	
PR		22-APR-1998; 98US-0082704P.	
PR		22-APR-1998; 98US-0082797P.	
PR		22-APR-1998; 98US-0082804P.	
PR		23-APR-1998; 98US-0082796P.	
PR		27-APR-1998; 98US-0083336P.	
PR		28-APR-1998; 98US-0083322P.	
PR		29-APR-1998; 98US-0083392P.	
PR		29-APR-1998; 98US-0083495P.	
PR		29-APR-1998; 98US-0083496P.	
PR		29-APR-1998; 98US-0083499P.	
PR		29-APR-1998; 98US-0083500P.	
PR		29-APR-1998; 98US-0083545P.	
PR		29-APR-1998; 98US-0083554P.	
PR		29-APR-1998; 98US-0083559P.	
PR		30-APR-1998; 98US-0083742P.	
PR		05-MAY-1998; 98US-0084366P.	
PR		06-MAY-1998; 98US-0084414P.	
PR		06-MAY-1998; 98US-0084441P.	
PR		07-MAY-1998; 98US-0084598P.	
PR		07-MAY-1998; 98US-0084600P.	
PR		07-MAY-1998; 98US-0084627P.	
PR		07-MAY-1998; 98US-0084637P.	
PR		07-MAY-1998; 98US-0084639P.	
PR		07-MAY-1998; 98US-0084640P.	
PR		07-MAY-1998; 98US-0084643P.	
PR		13-MAY-1998; 98US-0085323P.	
PR		13-MAY-1998; 98US-0085338P.	
PR		13-MAY-1998; 98US-0085339P.	
PR		15-MAY-1998; 98US-0085573P.	
PR		15-MAY-1998; 98US-0085579P.	
PR		15-MAY-1998; 98US-0085580P.	
PR		15-MAY-1998; 98US-0085582P.	
PR		15-MAY-1998; 98US-0085689P.	
PR		15-MAY-1998; 98US-0085697P.	
PR		15-MAY-1998; 98US-0085700P.	
PR		15-MAY-1998; 98US-0085704P.	
PR		22-MAY-1998; 98US-0086392P.	
PR		22-MAY-1998; 98US-0086414P.	
PR		22-MAY-1998; 98US-0086430P.	
PR		22-MAY-1998; 98US-0086486P.	
PR		28-MAY-1998; 98US-0087098P.	
PR		28-MAY-1998; 98US-0087106P.	
PR		28-MAY-1998; 98US-0087208P.	
PR		26-JUN-1998; 98US-0090863P.	
PR		26-JUN-1998; 98US-0091010P.	
PR		01-JUL-1998; 98US-0091359P.	
PR		30-JUL-1998; 98US-0094651P.	
PR		11-SEP-1998; 98US-0100038P.	
PR		07-OCT-1998; 98WO-US021141.	
PR		20-NOV-1998; 98US-0109304P.	
PR		20-NOV-1998; 98WO-US024855.	
PR		22-DEC-1998; 98US-0113296P.	
PR		23-DEC-1998; 98US-0113621P.	
PR		05-JAN-1999; 99WO-US000106.	
PR		08-MAR-1999; 99WO-US005028.	
PR		10-MAR-1999; 99WO-US005190.	
PR		12-MAR-1999; 99US-0123957P.	
PR		29-MAR-1999; 99US-0126773P.	
PR		21-APR-1999; 99US-0130232P.	
PR		26-APR-1999; 99US-0131022P.	
PR		28-APR-1999; 99US-0131445P.	
PR		14-MAY-1999; 99US-0134287P.	
PR		14-MAY-1999; 99WO-US010733.	
PR		02-JUN-1999; 99WO-US012252.	
PR		16-JUN-1999; 99US-0139557P.	
PR		23-JUN-1999; 99US-0141037P.	
PR		07-JUL-1999; 99US-0142680P.	
PR		26-JUL-1999; 99US-0145698P.	
PR		28-JUL-1999; 99US-0146222P.	
PR		29-OCT-1999; 99US-0162506P.	
PR		30-NOV-1999; 99WO-US028313.	
PR		02-DEC-1999; 99WO-US028551.	
PR		16-DEC-1999; 99WO-US028565.	
PR		16-DEC-1999; 99WO-US030095.	

```
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
XX
PA (GETH ) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
XX WPI; 2003-657582/62.
DR P-PSDB; ADC68051.
XX
XX Novel secreted and transmembrane polypeptides, designated PRO
PT polypeptides, and polynucleotides encoding them useful for treating
PT kidney diseases, bone, cartilage and retinal disorders.
XX
XX Claim 2; SEQ ID NO 329; 468pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide), a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid), a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCGCGAAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGGCTGAAGCA 180
```

```
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGCCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCGATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTTGGTTGC 420
QY 421 CAGATCAGCTGCCATTTCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGATCAGCTGCCATTTCGTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCATTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCACTTTGGAGCAGGACCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCACTTTGGAGCAGGACCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC 780
QY 781 TCTGGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTAACAATCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTACTCAATCTGTG 1174
RESULT 108
```

ADC41370
ID ADC41370 standard; cDNA; 1174 BP.
XX AC ADC41370;
XX DT 18-DEC-2003 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytotostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulneryary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX OS Homo sapiens.
XX PN US2003072745-A1.
XX PD 17-APR-2003.
XX PF 25-OCT-2001; 2001US-00013929.
XX PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079932P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 15-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.

PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-008441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.


```
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 22-MAR-2001; 2001WO-US009552.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 30-JUL-2001; 2001US-00918585.
XX
PA (GETH ) GENENTECH INC.
XX
PI Ashkenazi A, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX
DR WPI; 2003-743806/70.
DR P-PSDB; ADC41371.
XX
PT Novel isolated secreted and transmembrane PRO polypeptides, useful in the
PT preparation of a medicament for treating a condition responsive to the
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 2; SEQ ID NO 329; 466pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
DB 1 CGGACGGGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB 61 GGGAAACAAGATGGCGGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTGCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTGTACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCCTGTGAGTTGACCTACCCC 240
```

```
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGACAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGACAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTTGACTTAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGATGTACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAAATCAGCTGCCATTTCGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 480
Db 421 CAGAAATCAGCTGCCATTTCGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 480
QY 481 ATGCACCTACTCTTTCCCTCAATCTGCTGAGGTGAGTGAAGTGAAGTGAAGTGAAGTGAAGT 540
Db 481 ATGCACCTACTCTTTCCCTCAATCTGCTGAGGTGAGTGAAGTGAAGTGAAGTGAAGTGAAGT 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGCTACACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGCTACACA 660
QY 661 AATTGGAGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGGAGAGAAATCATCTCTAAGCAAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGATTTGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGATTTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
```

RESULT 109
ADC67425
ID ADC67425 standard; cDNA; 1174 BP.
XX
AC ADC67425;

XX
DT 18-DEC-2003 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW vulnery; virucide; neuroprotective; cytostatic; gene therapy;
KW tumour cell proliferation inhibitor;
KW secreted and transmembrane protein; PRO; viral infection; wound healing;
KW tissue growth; muscle generation; muscle regeneration;
KW amytrophic lateral sclerosis; neuropathy; AIDS-associated neuropathy;
KW diabetic peripheral neuropathy; chromosome identification; antagonist;
KW tissue typing; immunohistochemical staining; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003073131-A1.
XX
PD 17-APR-2003.
XX
PF 25-OCT-2001; 2001US-00016177.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.

PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98WO-US021141.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-0134287P.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 16-JUN-1999; 99US-0139557P.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0142680P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.

PR	06-JAN-2000;	2000WO-US0000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	10-MAR-2000;	2000WO-US006319.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	24-AUG-2000;	2000WO-US023328.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001WO-US006520.
PR	22-MAR-2001;	2001WO-US009552.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	30-JUL-2001;	2001US-00918585.

(GETH) GENENTECH INC.

XX PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-743810/70.
DR P-PSDB; ADC67426.

Novel isolated secreted and transmembrane PRO polypeptides, useful in the preparation of a medicament for treating a condition responsive to the polypeptide, and as therapeutic agents e.g. vaccines.

PS Claim 2; SEQ ID NO 329; 464pp; English.

The invention describes an isolated secreted and transmembrane PRO polypeptide (I). PRO polypeptide such as PRO213, PRO700, PRO320 or PRO615 is useful in biotechnological and medical research, as well as in various industrial applications. PRO polypeptide such as PRO300, PRO866, PRO703, PRO708, PRO320, PRO351, PRO352, PRO381, PRO615, PRO618, PRO772, PRO853, PRO860 or PRO846 is useful for therapeutic purposes. PRO363 is useful therapeutically in vivo for lessening the effects of viral infection. PRO200 is useful for the treatment of wound healing, tissue growth and muscle generation and regeneration. PRO337 is useful for treating

Query Match	100.0%	Score 1174;	DB 9;	Length 1174;
Best Local Similarity	100.0%	Pred.No. 0;		
Matches 1174;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	1	CGGACCGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACCGCTGGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCGCCGGAAGGGAGACCTCTGGGTGAGACCCCAACTGGGGTCCCCG	120
DB	61	GGGAACAAGATGGCGGCGCCGGAAGGGAGACCTCTGGGTGAGACCCCAACTGGGGTCCCCG	120

RESULT 110
ADC62361
ID ADC62361 standard; cDNA; 1174 BP.
XX
XX
AC ADC62361;
XX
XX
DT 18-DEC-2003 (first entry)
XX
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.

XX Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnery; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX Homo sapiens.
OS
XX US2003073624-A1.
PN
XX
PD
XX 17-APR-2003.
PD
XX 15-OCT-2001; 2001US-00978193.
PF
XX 17-OCT-1997; 97US-0062250P.
XX 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080107P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR 22-APR-1998; 98US-0082797P.
PR 23-APR-1998; 98US-0082804P.
PR 27-APR-1998; 98US-0082796P.
PR 28-APR-1998; 98US-0083336P.
PR 29-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR

PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-008441P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 26-JUN-1998; 98US-0091010P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98US-0021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-00202054.
PR 07-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-0000106.
PR 05-MAR-1999; 98US-00254465.
PR 08-MAR-1999; 98US-0005028.
PR 10-MAR-1999; 98US-00265686.
PR 10-MAR-1999; 98US-0005190.
PR 12-MAR-1999; 98US-00267213.
PR 12-MAR-1999; 98US-0123957P.
PR 29-MAR-1999; 98US-0126773P.
PR 12-APR-1999; 98US-00284291.
PR 21-APR-1999; 98US-0130232P.
PR 26-APR-1999; 98US-0131022P.
PR 28-APR-1999; 98US-0131445P.
PR 14-MAY-1999; 98US-00311832.
PR 14-MAY-1999; 98US-0134287P.
PR 14-MAY-1999; 98US-0010733.
PR 02-JUN-1999; 98US-0012252.
PR 16-JUN-1999; 98US-0139557P.
PR 23-JUN-1999; 98US-0141037P.
PR 07-JUL-1999; 98US-0142680P.
PR 26-JUL-1999; 98US-0145698P.
PR 28-JUL-1999; 98US-0146222P.
PR 25-AUG-1999; 98US-00380137.
PR 25-AUG-1999; 98US-00380138.
PR 25-AUG-1999; 98US-00380142.
PR 29-OCT-1999; 98US-0162506P.
PR

KW	sports-related joint problem; articular cartilage defects;	PR	05-MAY-1998;	98US-0084366P.
KW	osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.	PR	06-MAY-1998;	98US-0084414P.
XX		PR	06-MAY-1998;	98US-0084441P.
OS	Homo sapiens.	PR	07-MAY-1998;	98US-0084598P.
XX		PR	07-MAY-1998;	98US-0084600P.
PN	US2003104998-A1.	PR	07-MAY-1998;	98US-0084627P.
XX		PR	07-MAY-1998;	98US-0084637P.
PD		PR	07-MAY-1998;	98US-0084639P.
XX		PR	07-MAY-1998;	98US-0084640P.
PF		PR	07-MAY-1998;	98US-0084643P.
XX		PR	13-MAY-1998;	98US-0085323P.
PR		PR	13-MAY-1998;	98US-0085338P.
PR	17-OCT-1997;	PR	13-MAY-1998;	98US-0085339P.
PR	03-NOV-1997;	PR	15-MAY-1998;	98US-0085573P.
PR	13-NOV-1997;	PR	15-MAY-1998;	98US-0085579P.
PR	21-NOV-1997;	PR	15-MAY-1998;	98US-0085580P.
PR	10-MAR-1998;	PR	15-MAY-1998;	98US-0085582P.
PR	11-MAR-1998;	PR	15-MAY-1998;	98US-0085689P.
PR	11-MAR-1998;	PR	15-MAY-1998;	98US-0085697P.
PR	12-MAR-1998;	PR	15-MAY-1998;	98US-0085700P.
PR	13-MAR-1998;	PR	15-MAY-1998;	98US-0085704P.
PR	17-MAR-1998;	PR	18-MAY-1998;	98US-0086023P.
PR	20-MAR-1998;	PR	22-MAY-1998;	98US-0086392P.
PR	20-MAR-1998;	PR	22-MAY-1998;	98US-0086414P.
PR	20-MAR-1998;	PR	22-MAY-1998;	98US-0086430P.
PR	20-MAR-1998;	PR	22-MAY-1998;	98US-0086486P.
PR	25-MAR-1998;	PR	28-MAY-1998;	98US-0087098P.
PR	26-MAR-1998;	PR	28-MAY-1998;	98US-0087106P.
PR	27-MAR-1998;	PR	28-MAY-1998;	98US-0087208P.
PR	27-MAR-1998;	PR	26-JUN-1998;	98US-00105413.
PR	27-MAR-1998;	PR	26-JUN-1998;	98US-0090863P.
PR	30-MAR-1998;	PR	26-JUN-1998;	98US-0091010P.
PR	30-MAR-1998;	PR	01-JUL-1998;	98US-0091359P.
PR	31-MAR-1998;	PR	30-JUL-1998;	98US-0094651P.
PR	31-MAR-1998;	PR	11-SEP-1998;	98US-0100038P.
PR	31-MAR-1998;	PR	07-OCT-1998;	98US-00168978.
PR	31-MAR-1998;	PR	07-OCT-1998;	98WO-US021141.
PR	31-MAR-1998;	PR	02-NOV-1998;	98US-00184216.
PR	31-MAR-1998;	PR	06-NOV-1998;	98US-00187368.
PR	01-APR-1998;	PR	20-NOV-1998;	98US-0109304P.
PR	01-APR-1998;	PR	20-NOV-1998;	98WO-US024855.
PR	01-APR-1998;	PR	07-DEC-1998;	98US-00202054.
PR	01-APR-1998;	PR	22-DEC-1998;	98US-00218517.
PR	08-APR-1998;	PR	22-DEC-1998;	98US-0113296P.
PR	08-APR-1998;	PR	23-DEC-1998;	98US-0113621P.
PR	09-APR-1998;	PR	05-JAN-1999;	99WO-US000106.
PR	09-APR-1998;	PR	05-MAR-1999;	99US-00254465.
PR	09-APR-1998;	PR	08-MAR-1999;	99WO-US005028.
PR	15-APR-1998;	PR	10-MAR-1999;	99US-00265686.
PR	15-APR-1998;	PR	10-MAR-1999;	99WO-US005190.
PR	15-APR-1998;	PR	12-MAR-1999;	99US-00267213.
PR	15-APR-1998;	PR	12-MAR-1999;	99US-0123957P.
PR	15-APR-1998;	PR	29-MAR-1999;	99US-0126773P.
PR	15-APR-1998;	PR	12-APR-1999;	99US-00284291.
PR	21-APR-1998;	PR	21-APR-1999;	99US-0130232P.
PR	21-APR-1998;	PR	26-APR-1999;	99US-0131022P.
PR	22-APR-1998;	PR	28-APR-1999;	99US-0131445P.
PR	22-APR-1998;	PR	14-MAY-1999;	99US-00311832.
PR	22-APR-1998;	PR	14-MAY-1999;	99US-0134287P.
PR	23-APR-1998;	PR	14-MAY-1999;	99WO-US010733.
PR	27-APR-1998;	PR	02-JUN-1999;	99WO-US012252.
PR	28-APR-1998;	PR	16-JUN-1999;	99US-0139557P.
PR	29-APR-1998;	PR	23-JUN-1999;	99US-0141037P.
PR	29-APR-1998;	PR	07-JUL-1999;	99US-0142680P.
PR	29-APR-1998;	PR	26-JUL-1999;	99US-0145698P.
PR	29-APR-1998;	PR	28-JUL-1999;	99US-0146222P.
PR	29-APR-1998;	PR	25-AUG-1999;	99US-00380137.
PR	29-APR-1998;	PR	25-AUG-1999;	99US-00380138.
PR	29-APR-1998;	PR	25-AUG-1999;	99US-00380142.
PR	29-APR-1998;	PR	29-OCT-1999;	99US-0162506P.
PR	29-APR-1998;	PR	30-NOV-1999;	99WO-US028313.
PR	29-APR-1998;	PR	02-DEC-1999;	99WO-US028551.
PR	30-APR-1998;	PR	02-DEC-1999;	99WO-US028565.

endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping;
gene therapy; chromosome identification; chromosome marker; gene; ss.
Homo sapiens.
US2003092106-A1.
15-MAY-2003.
24-APR-2002; 2002US-00131822.
19-AUG-1998; 98US-0097141P.
02-JUN-1999; 99WO-US012252.
25-AUG-1999; 99US-00380137.
30-MAR-2000; 2000WO-US008439.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801171/75.
P-PSDB; ADCS0313.
New secreted and transmembrane nucleic acid useful for treating
inflammation, organ failure, atherosclerosis, cardiac injury,
infertility, birth defects, premature aging, acquired immunodeficiency
syndrome or cancer.
Claim 2; Fig 271; 637pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
cells, for stimulating differentiation of adipocyte cells, for
stimulating proliferation of or gene expression in pericyte cells, for
stimulating the proliferation of inner ear utricular supporting cells or
T-lymphocyte cells, for inducing endothelial cell tube formation and for
treating various bone and/or cartilage disorders such as sports injuries
and arthritis. PRO polypeptides which stimulate the release of
proteoglycans from cartilage are useful for treating sports-related joint
problems, articular cartilage defects, osteoarthritis and rheumatoid
arthritis. PRO polypeptides are also useful for treating various
mammalian haemoglobin-associated disorders such as various thalassaemias
and conditions which may benefit from enhanced local immune system cell
infiltration. This sequence represents a human PRO polynucleotide of the
invention. Note: The sequence data for this patent is also available in
electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match		100.0%;	Score 1174;	DB 9;	Length 1174;
Best Local Similarity		100.0%;	Pred. No. 0;		
Matches 1174;		Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;
QY	1	CGGACGCGTGGGGGAAACCCCTTCGAGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60		
DB	1	CGGACGCGTGGGGGAAACCCCTTCGAGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG	60		
QY	61	GGGAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
DB	61	GGGAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG	120		
QY	121	CCGCTGCTGCTGCTGACCATNGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180		
DB	121	CCGCTGCTGCTGCTGACCATNGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA	180		
QY	181	TTTGACTCGGTCTTGGGTGATACCGGCTCTTGGCCACCGGGCTGTCACTGACCTACCCC	240		
DB	181	TTTGACTCGGTCTTGGGTGATACCGGCTCTTGGCCACCGGGCTGTCACTGACCTACCCC	240		
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT	300		
DB	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT	300		
QY	301	TCAATTTGTCAAGTTTGTGGATGATGGAATGACTTAAATCGAACTGGAATGTGAA	360		
DB	301	TCAATTTGTCAAGTTTGTGGATGATGGAATGACTTAAATCGAACTGGAATGTGAA	360		
QY	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
DB	361	TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420		
QY	421	CAGAATCAGCTGCCATTGCGTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCCAAA	480		
DB	421	CAGAATCAGCTGCCATTGCGTGAACCTGAGCAAGAAACAACTTATGTCCCTGATGCCAAA	480		
QY	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
DB	481	ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC	540		
QY	541	GCACAGAGCTTCATAACCTCTTCAAGCCGATGTTTATCTTCAAGCCGATGACGGAATAA	600		
DB	541	GCACAGAGCTTCATAACCTCTTCAAGCCGATGTTTATCTTCAAGCCGATGACGGAATAA	600		
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA	660		
DB	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA	660		
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG	720		
DB	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG	720		
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTAAC	780		
DB	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTAAC	780		
QY	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840		
DB	781	TCTGGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840		
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900		
DB	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900		
QY	901	GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960		
DB	901	GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG	960		
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020		
DB	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT	1020		
QY	1021	CTTGCTCATCTTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA	1080		

Db 1021 CTTGCTCATCTGAAATTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Qy 1081 AATTCCACTCCTCATAGAGCTTTTAAATAGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATAGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
Qy 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 113

ADCV71859
ID ADCV71859 standard; cDNA; 1174 BP.

XX
AC ADCV71859;

XX
DT 18-DEC-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX
OS Homo sapiens.

XX
PN US2003092107-A1.

XX
PD 15-MAY-2003.

XX
PF 24-APR-2002; 2002US-00131828.

XX
PR 07-OCT-1998; 98US-0103315P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX
PA (GETH) GENENTECH INC.

XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX
DR WPI; 2003-801172/75.

XX
DR P-PSDB; ADCV71860.

PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.

XX
PS Claim 2; Fig 271; 637pp; English.

XX
CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGCGCGCGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTTCGGGGACCGCTTCGGCTGAAGCA 180

Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTCAGTTGACCTACCCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTCAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTTT 300

Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGAA 360

Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTGGAATGAA 360

Qy 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

Qy 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAATTATGTCCTGATGCCAAAA 480

Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAATTATGTCCTGATGCCAAAA 480

Qy 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGGTCAATTCGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTCCTTAACCTCTGGTGAGGTCAATTCGGAGTGACATGATGGACTCC 540

Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db 181 TTTGACTCGGTCCTTGGGTGATACGGCGCTTGCCACCGGGCCTGTCAGTTGACCTACCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCAGAGAGGTTGCAGGCTGTT 300
Qy 301 TCAATTTGTGAGTTGTGATGATGGAATGGAATGACTTAAATCGAATCGAATCGAATGGAATGGAATGGA 360
Db 301 TCAATTTGTGAGTTGTGATGATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGA 360
Qy 361 TCTGCATGTACAGAAGCATATNTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATNTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTCCGTGAACCTGAGACAAAGCAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCCGTGAACCTGAGACAAAGCAACTTATGTCCCTGATGCCAAAA 480
Qy 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Qy 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Qy 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATGCTTTGGATTGT 840
Qy 841 TGTGCAACTGTGTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGTCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Qy 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Qy 1081 AATTCCTCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Db 1081 AATTCCTCTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
Qy 1141 CTATAAAATGCAAAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAATCTGTG 1174

RESULT 115
ID ADC52845
XX ADC52845 standard; cDNA; 1174 BP.
AC ADC52845;

XX 18-DEC-2003 (first entry)
DT Novel human secreted and transmembrane protein cDNA Seq ID271.
XX human; PRO; membrane bound protein; membrane bound receptor;
DE cell proliferation; cell migration; cell differentiation;
XX mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
OS US2003087365-A1.
XX 08-MAY-2003.
PD 23-APR-2002; 2002US-00128689.
PF 31-MAR-1997; 97WO-US005230.
XX 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godwoski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-801150/75.
P-PSDB; ADC52846.

New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.

Claim 2; SEQ ID NO 271; 637pp; English.

This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides and hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
and receptors may be of use as pharmaceutical and diagnostic agents, such
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors

CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytosolic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGGTGGGGGAAACCCCTTCCGAGAGAAACAGCAACAAGCTGAGTGTGTGACAGAG 60
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 CGGACGGGTGGGGGAAACCCCTTCCGAGAGAAACAGCAACAAGCTGAGTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGCGGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
61 GGGAAACAAGATGGCGCGCGCGGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCACTGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
121 CCGCTGCTGCTGCTGACCACTGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
181 TTTGACTCGGTCTTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTTGCAGGCTGTTT 300
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
301 TCAATTTGTGCTGTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGGTGAACAGCAAGAACAACTTATGTCCTGATGCCAAA 480
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
421 CAGAATCAGCTGCCATTTCGGTGAACAGCAAGAACAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
481 ATGCACCTACTCTTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAAACCTCTTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAATA 600
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
541 GCACAGAGCTTCATAAACCTCTTTCATGGAATTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
841 TGTGCAACTGTTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCGCTTAAGAAATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTTCATTTGGATATAGGCGCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAGTTTACTCAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAGTTTACTCAATCTGTG 1174

RESULT 116

ADCS7199
ID ADCS7199 standard; cDNA; 1174 BP.

AC ADCS7199;

XX 18-DEC-2003 (first entry)

DE Novel human secreted and transmembrane protein cDNA Seq ID271.

XX human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuro peptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.

XX US2003087366-A1.

XX 08-MAY-2003.

XX 23-APR-2002; 2002US-00128694.

XX 02-MAR-2000; 2000WO-US005841.

XX 30-MAY-2000; 2000WO-US014941.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-801151/75.

XX P-PSDB; ADC57200.

XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.

XX Claim 2; SEQ ID NO 271; 637pp; English.

XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic

CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

XX Query Match 100.0%; Score 1174; DB 9; Length 1174;

XX Best Local Similarity 100.0%; Pred. No. 0;

XX Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGACCCGCTTCGGCTGAAGCA 180

QY 181 TTTCACTCGGTCTTGGGTGATACGGCGCTTTCGCCACGGGCGCTGTGAGTTGACCTACCCC 240

Db 181 TTTCACTCGGTCTTGGGTGATACGGCGCTTTCGCCACGGGCGCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300

QY 301 TCRAATTTGTGAGTTTGTGATGATGGAATTCGAACTTAAATCGAACTAAATTTGGAATGTGA 360

Db 301 TCRAATTTGTGAGTTTGTGATGATGGAATTCGAACTTAAATCGAACTAAATTTGGAATGTGA 360

QY 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGTTGGCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGTTGGCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 480

Db 421 CAGAATCAGCTGCCATTTCGCTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAAGTTCATCTGGAGTGACATGAGCTCC 540

Db 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAAGTTCATCTGGAGTGACATGAGCTCC 540

QY 541 GCACAGAGCTTCATAACCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600

Db 541 GCACAGAGCTTCATAACCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCATTCATTTGGAGGAGGCTTACA 660

Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCATTCATTTGGAGGAGGCTTACA 660

QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTCTTGAAGTGAAGAAAGTGTGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTCTTGAAGTGAAGAAAGTGTGCTTTTAAAGATGCCTCTCTCTTAAC 780

QY	781	TCTGGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGGTATTGCTTTGGATTGT	840
Db	781	TCTGGGTGGATTTTAACTACAACTCTTGTCCCTCGGTGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG	960
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAAGTGAAT	1020
QY	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAAAGACAAGTGTAATAGACATCTAA	1080
Db	1021	CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAAAGACAAGTGTAATAGACATCTAA	1080
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCCTCATAGAGCTTTTAAAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTACTCAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTACTCAAATCTGTG	1174

RESULT 117

ADC60390
ID ADC60390 standard; cDNA; 1174 BP.

XX
AC ADC60390;

XX
DT 18-DEC-2003 (first entry)

XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.

KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; PFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX
OS Homo sapiens.

XX
PN US2003087367-A1.

XX
PD 08-MAY-2003.

XX
PF 24-APR-2002; 2002US-00131825.

XX
PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR	20-NOV-1998;	98WO-US024855.
PR	01-DEC-1998;	98WO-US025108.
PR	05-JAN-1999;	99WO-US000106.
PR	08-MAR-1999;	99WO-US005028.
PR	10-MAR-1999;	99WO-US005190.
PR	10-MAR-1999;	2000WO-US006319.
PR	20-APR-1999;	99WO-US008615.
PR	14-MAY-1999;	99WO-US010733.
PR	02-JUN-1999;	99WO-US012252.
PR	01-SEP-1999;	99WO-US020111.
PR	08-SEP-1999;	99WO-US020594.
PR	13-SEP-1999;	99WO-US020944.
PR	15-SEP-1999;	99WO-US021090.
PR	15-SEP-1999;	99WO-US021547.
PR	05-OCT-1999;	99WO-US023089.
PR	29-NOV-1999;	99WO-US028214.
PR	30-NOV-1999;	99WO-US028313.
PR	30-NOV-1999;	99WO-US028409.
PR	01-DEC-1999;	99WO-US028301.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US028551.
PR	02-DEC-1999;	99WO-US028564.
PR	02-DEC-1999;	99WO-US028565.
PR	16-DEC-1999;	99WO-US030095.
PR	20-DEC-1999;	99WO-US030911.
PR	20-DEC-1999;	99WO-US030999.
PR	22-DEC-1999;	99WO-US030720.
PR	30-DEC-1999;	99WO-US031243.
PR	30-DEC-1999;	99WO-US031274.
PR	05-JAN-2000;	2000WO-US000219.
PR	06-JAN-2000;	2000WO-US000277.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004341.
PR	18-FEB-2000;	2000WO-US004342.
PR	22-FEB-2000;	2000WO-US004414.
PR	24-FEB-2000;	2000WO-US004914.
PR	24-FEB-2000;	2000WO-US005004.
PR	01-MAR-2000;	2000WO-US005601.
PR	02-MAR-2000;	2000WO-US005746.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006884.
PR	20-MAR-2000;	2000WO-US007377.
PR	21-MAR-2000;	2000WO-US007532.
PR	30-MAR-2000;	2000WO-US008439.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	28-JUL-2000;	2000WO-US020710.
PR	11-AUG-2000;	2000WO-US022031.
PR	23-AUG-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	20-DEC-2000;	2000US-00747259.
PR	20-DEC-2000;	2000WO-US034956.
PR	28-FEB-2001;	2001US-00796498.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	09-MAR-2001;	2001US-00802706.
PR	14-MAR-2001;	2001US-00808689.
PR	22-MAR-2001;	2001US-00816744.
PR	05-APR-2001;	2001US-00828366.
PR	10-MAY-2001;	2001US-00854208.
PR	10-MAY-2001;	2001US-00854280.
PR	18-MAY-2001;	2001US-00860216.
PR	25-MAY-2001;	2001US-00866028.
PR	25-MAY-2001;	2001US-00866034.
PR	25-MAY-2001;	2001WO-US017092.
PR	01-JUN-2001;	2001US-00872035.
PR	01-JUN-2001;	2001WO-US017800.

PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801152/75.
DR P-PSDB; ADC60391.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 2; Fig 27i; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGACAAGATGGCGGCCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGACAAGATGGCGGCCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCTTGGCCGGAGGTTCGGGGACCGCTTCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGGTGATACGGCGCTTTGCCACCGGGCCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGATGTTCAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTAATTAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAAGTTTGTGGATGATGGAATTAATTAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTATGTTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAATGAGCAAGAACTATGTTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTTAACCTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCCGATGACGGAAAAATA 600
QY 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAGAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCCTTAAGAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCCTTAAGAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 118

ADC50865

ID ADC50865 standard; cDNA; 1174 BP.

XX

AC ADC50865;

XX

DT 18-DEC-2003 (first entry)

XX

DE Novel human secreted and transmembrane protein PRO195 cDNA.

XX

KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;

KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;

KW rectum; kidney; cervix; liver; microvascular endothelial cell;

KW glucose uptake modulator; FFA uptake modulator; cell proliferation;

KW cell differentiation; skeletal muscle cell; adipocyte cell;

KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;

KW immune system cell infiltration; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker; gene; ss.

XX

OS Homo sapiens.

XX

PN US2003087361-A1.

XX

PD 08-MAY-2003.

XX

PF 22-APR-2002; 2002US-00127841.

XX

PR 09-SEP-1998; 98US-0099536P.

PR 01-SEP-1999; 99WO-US020111.

PR 18-OCT-1999; 99US-00403297.

PR 18-FEB-2000; 2000WO-US004342.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Pilvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-801146/75.

DR P-PSDB; ADC50866.

XX

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide

PT and for manufacturing a medicament for diagnosing or treating tumor.

XX

PS Claim 2; Fig 271; 637pp; English.

XX

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte

CC cells, for stimulating differentiation of adipocyte cells, for

CC stimulating proliferation of or gene expression in pericyte cells, for

CC stimulating the proliferation of inner ear utricular supporting cells or

CC T-lymphocyte cells, for inducing endothelial cell tube formation and for

CC treating various bone and/or cartilage disorders such as sports injuries

CC and arthritis. PRO polypeptides which stimulate the release of

CC proteoglycans from cartilage are useful for treating sports-related joint

CC problems, articular cartilage defects, osteoarthritis and rheumatoid

CC arthritis. PRO polypeptides are also useful for treating various

CC mammalian haemoglobin-associated disorders such as various thalassaemias

CC and conditions which may benefit from enhanced local immune system cell

CC infiltration. This sequence represents a human PRO polynucleotide of the

CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGGACGCGTGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAACCCCTTCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60

Qy 61 GGGAAACAAGATGGCGCGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCG 120

Db 61 GGGAAACAAGATGGCGCGCGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCG 120

Qy 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180

Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180

Qy 181 TTTGACTCGGCTTTGGGTGATACGGCGCTTGGCCCGGCTGTCCAGTTGACCTACCCC 240

Db 181 TTTGACTCGGCTTTGGGTGATACGGCGCTTGGCCCGGCTGTCCAGTTGACCTACCCC 240

Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGATGAGCAATATGCTGCTTGGTTC 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGATGAGCAATATGCTGCTTGGTTC 300

Qy 301 TCAATTGTGTCAGTTTGGGTGATGAGTAAATGAACTTAAATCGAACTAAATTTGAATGTGAA 360

Db 301 TCAATTGTGTCAGTTTGGGTGATGAGTAAATGAACTTAAATCGAACTAAATTTGAATGTGAA 360

Qy 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTGCTTGGTTC 420

Db 361 TCTGCATGTACAGAGCATATTTCCCAATCTGATGAGCAATATGCTGCTTGGTTC 420

Qy 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGCAACAAGAACTTATGCTCCCTGATGCCAAATA 480

Db 421 CAGAATCAGCTGCCATTCGCTGAACCTGAGCAACAAGAACTTATGCTCCCTGATGCCAAATA 480

Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGGTCAATCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGGTCAATCTGGAGTGACATGATGGACTCC 540

Qy 541 GCACAGAGCTTCATACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600

Db 541 GCACAGAGCTTCATACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600

Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660

Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGACCACTTTGGAGCAGGAGCTTACA 660

Qy 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTTCAAGCG 720

Db 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAATGAGAAATTTCAAGCG 720

Qy 721 CACAGGAATTTTCTTGAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 721 CACAGGAATTTTCTTGAGATGGAGAAAGTGGCTTTTAAAGATGCCTCTCTCTTAAC 780

Db 421 CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAAGAACTTATGTCCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTCTTAACCTCTGGTGAAGTCAATCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTCTTAACCTCTGGTGAAGTCAATCTGGAGTGACATGAGACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600
Qy 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGCTTACA 660
Qy 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGAGCTTTTAAAGATGCCCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGAGAAAGTATGAGCTTTTAAAGATGCCCTCTCTTAAC 780
Qy 781 TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGTTATGCTTGGATTTGT 840
Db 781 TCTGGTGGATTTAACTACAACTCTTGTCTCTCGGTGATGTTATGCTTGGATTTGT 840
Qy 841 TGTGCAACTGTGCTACAGCTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGCTACAGCTGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGATTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Qy 961 GTTGTAGATCTAAAAGTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAAGTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Qy 1081 AATCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140
Db 1081 AATCCACTCTCATAGAGCTTTTAAATGTTTCAATGATATAGGCTTTAAGAAATCA 1140
Qy 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAATCTGTG 1174

RESULT 120
ADC54490
ID ADC54490 standard; cDNA; 1174 BP.
XX AC ADC54490;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein cDNA Seq ID271.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuro peptide; hormone; cell receptor;
KW receptor-ligand interaction; cytosstatic; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003087363-A1.
XX XX
XX 08-MAY-2003.

XX 23-APR-2002; 2002US-00128687.
XX 10-SEP-1998; 98US-0099816P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801148/75.
DR P-PSDB; ADC54491.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
PT
XX Claim 2; SEQ ID NO 271; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuro peptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.
XX SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAACAGCAACAGCTGAGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCGCGAAGGGAGGCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCGCGAAGGGAGGCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGGCCCTGTGAGTTCAGCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGGCCCTGTGAGTTCAGCTACCCC 240
Qy 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAGGCTGTTT 300
Qy 301 TCAATTTGTGCTGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360

Best Local Similarity 100.0%; Pred. No. 0;			
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CGGACGCTGGGGAAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGTGACAGAG	60
Db	1	CGGACGCTGGGGAAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGCAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
Db	61	GGGAACAAGATGGCGCGCCGCAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGACCAATGSCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
Db	121	CCGCTGCTGCTGACCAATGSCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC	240
Db	181	TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATCTCAGAGAGGTTGCAGGCTGTTT	300
Db	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATCTCAGAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTTGGAATGTAA	360
Db	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTTGGAATGTAA	360
QY	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
QY	421	CAGAAATCAGCTGCCATTTCGCTGAATGAGCAAGAAACAACTTATGTCCCTGATGCCAAAA	480
Db	421	CAGAAATCAGCTGCCATTTCGCTGAATGAGCAAGAAACAACTTATGTCCCTGATGCCAAAA	480
QY	481	ATGCACCTACTTTCTCTTAATCTGAGTGGTCACTTCTGGAGTGACATGATGGAATCC	540
Db	481	ATGCACCTACTTTCTCTTAATCTGAGTGGTCACTTCTGGAGTGACATGATGGAATCC	540
QY	541	GCACAGAGCTTCATAAACCCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAATA	600
Db	541	GCACAGAGCTTCATAAACCCTTCTCATGAGCTTTTATCTTCAAGCCGATGACGGAATAATA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCAATTTGGAGCAGGAGCTACA	660
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCAATTTGGAGCAGGAGCTACA	660
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG	720
Db	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCCTCTCTCTAAC	780
Db	721	CACAGGAATTTCTTGAAGATGGAGAAAGTGGCTTTTAAAGATGCCCTCTCTCTAAC	780
QY	781	TCTGGTGGATTTTAACTACAACCTTCTGCTCTCGGTGATGGTATGCTTTGGATTGT	840
Db	781	TCTGGTGGATTTTAACTACAACCTTCTGCTCTCGGTGATGGTATGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GCTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG	960
Db	901	GCTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTGTG	960
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080

Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCTTTAAGAAATCA	1140
Db	1081	AATTCACCTCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCTTTAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTTACTCAAAATCTGTG	1174
RESULT 124			
ADC58422			
ID	ADC58422	standard; cDNA; 1174 BP.	
XX	ADC58422;		
DT	18-DEC-2003	(first entry)	
XX	Novel human secreted and transmembrane protein cDNA Seq ID271.		
DB	human; PRO; membrane bound protein; membrane bound receptor;		
XX	cell proliferation; cell migration; cell differentiation;		
KW	mitogenic factor; survival factor; cytotoxic factor;		
KW	differentiation factor; neuroepithelial; hormone; cell receptor;		
KW	receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.		
OS	Homo sapiens.		
XX	US2003087346-A1.		
PN	08-MAY-2003.		
XX	17-APR-2002; 2002US-00124815.		
PD	09-DEC-1999; 99US-0170262P.		
XX	01-DEC-2000; 2000WO-US032678.		
PR	19-DEC-2001; 2001US-00028072.		
XX	(GETH) GENENTECH INC.		
PA	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;		
XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;		
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;		
XX	WPI; 2003-801137/75.		
DR	P-PSDB; ADC58423.		
XX	Isolated nucleic acid for use in industrial applications has at least 80		
PT	percent nucleic acid sequence identity to nucleotide sequence that		
PT	encodes amino acid sequence selected from amino acid sequence group.		
XX	Claim 2; SEQ ID NO 271; 637pp; English.		
PS	This invention relates to novel nucleic acids encoding human PRO secreted		
XX	and transmembrane proteins. Extracellular proteins play important roles		
CC	in the formation, differentiation and maintenance of multicellular		
CC	organisms. The fate of many individual cells (for example proliferation,		
CC	migration or differentiation) is typically governed by information		
CC	received from other cells and the immediate environment. The information		
CC	is often transmitted by secreted polypeptides (for example mitogenic		
CC	factors, survival factors, cytotoxic factors, differentiation factors,		
CC	neuropeptides and hormones) which are received and interpreted by diverse		
CC	cell receptors or membrane bound proteins. These membrane bound proteins		
CC	and receptors may be of use as pharmaceutical and diagnostic agents, such		
CC	as in the blocking of receptor-ligand interactions. The current invention		
CC	provides the amino acid sequences of novel human membrane bound receptors		
CC	and proteins, along with the cDNA sequences encoding them. The novel		
CC	proteins of the invention may have cytostatic activities through the		
CC	stimulation of chondrocytes. The nucleic acids of the invention may be		
CC	useful for the manufacture of a medicament for diagnosing or treating a		
CC	tumour in a mammal. In addition, they may be useful for measuring or		
CC	detecting the expression of a tumour associated gene. The present		

CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGTGAGTGTGACAGAG 60
DB 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAAACAGCAACAGTGAGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB 61 GGGAAACAAGATGGCGCGCCGAGAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGACCACTGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCACTGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTGGGTGATACGGCGCTCTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
DB 181 TTTGACTCGGTCTGGGTGATACGGCGCTCTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCATGTCTAGAGAGTTGCAGGCTGTTT 300
DB 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCATGTCTAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGATGATGGAATTGACTTAAATCGAATAAATGGAATGTGAA 360
DB 301 TCAATTTGTGAGTTTGTGATGATGGAATTGACTTAAATCGAATAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAAA 480
DB 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAGAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGAGACTCC 540
DB 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGTCAATCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGAGGAGCCTACA 660
DB 601 GTTATATCCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGAGGAGCCTACA 660
QY 661 AATTTGAGAGAAATCATCTCTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTTGAGAGAAATCATCTCTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
DB 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
QY 781 TCTGGGTGGAATTTTAACTACAACCTTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
DB 781 TCTGGGTGGAATTTTAACTACAACCTTTGTCTCTCGGTGATGGTATTGCTTGGATTGT 840
QY 841 TGTGCACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB 841 TGTGCACTGTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGATTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
DB 901 GGTGACTTGGATTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960

QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
DB 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAATATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAATATAAAGTTACTCAAAATCTGTG 1174

RESULT 125

ADD03096

ID ADD03096 standard; cDNA; 1174 BP.

XX ADD03096;

AC ADD03096;

XX 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.
Human; secreted and transmembrane protein; PRO; secreted polypeptide;
transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
rectum; kidney; cervix; liver; microvascular endothelial cell;
glucose uptake modulator; FFA uptake modulator; cell proliferation;
cell differentiation; skeletal muscle cell; adipocyte cell;
pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
immune system cell infiltration; chromosome mapping; gene mapping; ss.
gene therapy; chromosome identification; chromosome marker; gene; ss.

OS Homo sapiens.

XX US2003092104-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131817.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801169/75.
DR P-PSDB; ADD03097.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||

QY 61 GGGAAACAAGATGGCGGCGCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCC 120
|||
Db 61 GGGAAACAAGATGGCGGCGCGCGAAGGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCC 120
|||

QY 121 CCGCTGCTGCTGCTGACCATGSCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180
|||
Db 121 CCGCTGCTGCTGCTGACCATGSCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180
|||

QY 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTTCAGTTGACCTACCCC 240
|||
Db 181 TTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTTCAGTTGACCTACCCC 240
|||

Db 1 CGGACGGTGGGGAAACCCCTTCGAGAAACACAGCAAGCTGAGCTGCTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGTGAGGACCCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGTGAGGACCCCAACTGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGTGATACGGCGTCTTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGTGATACGGCGTCTTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGACGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGGTTGACGCTGTTT 300
Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAACTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCTATCTGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCTATCTGTTGC 420
Qy 421 CAGAATCAGCTGCGCAATTCGCTGAATCGAGCAAGCAACATATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCGCAATTCGCTGAATCGAGCAAGCAACATATGTCCCTGATGCCAAA 480
Qy 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCATTTCTGAGTGACATGATGACTCC 540
Qy 541 GCACAGAGCTTCAFAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCAFAACCTCTTCAATGGAATTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCTACA 660
Qy 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAATGATGGCTTTTAAAGATGCCTCTCTCTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAATGATGGCTTTTAAAGATGCCTCTCTCTAAC 780
Qy 781 TCTGGTGGAATTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840
Db 781 TCTGGTGGAATTTAACTACAACTCTTGTCTCTCGGTGATGATGCTTTGGATTTGT 840
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTTTGTG 960
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080
Qy 1081 AATTCACCTCTCATAGAGCTTTTAAAGATGTTTCTTTGATATAGGCTTAAAGAAATCA 1140

Db 1081 AATTCACCTCTCATAGAGCTTTTAAAGATGTTTCTTTGATATAGGCTTAAAGAAATCA 1140
Qy 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
RESULT 127
ADC69507
ID ADC69507 standard; cDNA; 1174 BP.
XX
AC ADC69507;
XX
DT 01-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152375.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844453/78.
DR P-PSDB; ADC69508.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
acids, useful for the diagnosis, prevention and/or treatment of tumors,
such as lung, colon, breast, prostate, rectal, cervical and/or liver
tumors.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or

antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence encodes a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at segdata.uspto.gov.

Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGTGGGGAAACCCCTTCGAGAAAACAGCAACCAAGCTGAGCTGTGACAGAG	60
DB	1	CGGACGGTGGGGAAACCCCTTCGAGAAAACAGCAACCAAGCTGAGCTGTGACAGAG	60
QY	61	GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
DB	61	GGGAAACAAGATGGCGGCGCCGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTACCCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTACCCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGATGTCAGAGAGGTTCAGGCTGTTT	300
DB	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGATGTCAGAGAGGTTCAGGCTGTTT	300
QY	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
DB	301	TCAATTTGTCAAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA	360
QY	361	CTGCACTGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCACTCTGGTTGC	420
DB	361	CTGCACTGTACAGAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCACTCTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACCTTATGTCCCTGATGCCAAA	480
DB	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACCTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTCTCTAATCTCGGTGAGTCACTCTGGAGTGACATGAGTCC	540
DB	481	ATGCACCTACTCTTCTCTAATCTCGGTGAGTCACTCTGGAGTGACATGAGTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA	660
DB	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCAATTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTAAC	780

Db	721	CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTAAC	780
QY	781	TCCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGTTGGATTGT	840
Db	781	TCCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTGTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG	960
Db	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG	960
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTTAAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTTAAAGCATTTTCTTTTAAAGACAAAGTGTATAGACATCTAA	1080
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081	AATTCCACTCCTCATAGAGCTTTTAAATGGTTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 128
ADC48396

ID ADC48396 standard; cDNA; 1174 BP.

XX

AC ADC48396;

XX

DT 01-JAN-2004 (first entry)

XX

Human PRO polynucleotide #136.

DE

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

liver; microvascular endothelial cell; glucose; FFA;

skeletal muscle cell; adipocyte cell; pericyte cell;

inner ear utricular supporting cell; T-lymphocyte cell;

endothelial cell tube formation; bone disorder; cartilage disorder;

sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

immune system cell infiltration.

XX

OS Homo sapiens.

XX

PN US2003194773-A1.

XX

PD 16-OCT-2003.

XX

PF 21-MAY-2002; 2002US-00152391.

XX

PR 09-DEC-1999; 99US-0170262P.

PR 30-MAY-2000; 2000WO-US014941.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX

PA (GETH) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

DR WPI; 2003-844455/78.

DR P-PSDB; ADC48397.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumor necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCCGAAGGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCTGTGAGTTGACCTACCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACGGGCTGTGAGTTGACCTACCC 240
QY 241 TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
Db 241 TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCAATATCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAGCAATATCCCAATCTGTATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAATCTGCTGAGGTCTATCTGGAGTGACATGATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAATCTGCTGAGGTCTATCTGGAGTGACATGATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTTTAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTCTCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGCCCTTAAGAAATCA 1140
QY 1141 CTATATAAATGCAATATAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATATAAATGCAATATAAGTTACTCAAAATCTGTG 1174

RESULT 129
ADD09925
ID ADD09925 standard; cDNA; 1174 BP.
XX
AC ADD09925;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.
OS Homo sapiens.
XX US2003194776-A1.
PN 16-OCT-2003.
XX 29-MAY-2002; 2002US-00157785.
XX 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-852596/79.
DR P-PSDB; ADD09926.
XX New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.
XX Claim 2; Fig 271; 637pp; English.
PS The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
|||||

Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGTGTCTGTCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGTGTCTGTCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTTGGTGATACGGCGTCTTGGCACCGGGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTTGGTGATACGGCGTCTTGGCACCGGGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGAAATGACTTAAATCGAACTAAATTCGAATGTAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGAAATGACTTAAATCGAACTAAATTCGAATGTAA 360
QY 361 TCTGCAATGACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCAATGACAGAAAGCATATTCCTCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTTCCCTCAATCTGTTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCCCTCAATCTGTTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTCAAGCCGATGACGGAATAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660
QY 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC 780
QY 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGTTGCTTTGGATTTGT 840
Db 781 TCTGGTGGATTTAACTACAACCTTGTCTCTCGGTGATGTTGCTTTGGATTTGT 840
QY 841 TGTGCAACTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTGTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
QY 961 GTTGTGATGATCTAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTGATGATCTAAACCTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140

CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGGCTGGGGGAAACCCCTCCGAGAAAACAGCAACAGCTGAGCTGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGCTCCCG 120

QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCATGTTCAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTAGCATGTTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGATTTGTGATGATGGAATTTGAACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGATTTGTGATGATGGAATTTGAACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAATCAGCTGCCATTTCCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTTCCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATTTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGGTCAATTTGGAGTGACATGAGACTCC 540

QY 541 GCACAGAGCTTCATAACCTCTTCAAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCAAGCTTTTATCTTCAAGCCGATGACGGAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGACCACCATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGACCACCATTTGGAGCAGGAGCTTACA 660

QY 661 AATTTGAGAGAATCATCTCTAAGCAAAAATGTCCTATCTGCAATGAGAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAAATGTCCTATCTGCAATGAGAATTCACAAGCG 720

QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 130
ADD04500
ID ADD04500 standard; cDNA; 1174 BP.
XX
AC ADD04500;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003087354-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127827.
XX
PR 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801139/75.
DR P-PSDB; ADD04501.
XX
PS New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
PT
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful

OY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB |||||||
OY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB |||||||
OY 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
DB |||||||
OY 781 TCTGGGTGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
DB |||||||
OY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB |||||||
OY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB |||||||
OY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
DB |||||||
OY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
DB |||||||
OY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB |||||||
OY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB |||||||
OY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
DB |||||||
OY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA 1080
DB |||||||
OY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
DB |||||||
OY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCTTAAGAAATCA 1140
DB |||||||
OY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
DB |||||||
OY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
DB |||||||

RESULT 131
ADC80456
ID ADC80456 standard; cDNA; 1174 BP.
AC ADC80456;
XX
DT 01-JAN-2004 (first entry)
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX
OS Homo sapiens.
XX
PN US2003092103-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131815.
XX
PR 22-DEC-1998; 98US-0113511P.
PR 01-DEC-1999; 99WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801168/75.
DR P-PSDB; ADC80457.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAGAAACAGCAACAGCTGCTGTGACAGAG 60
DB |||||||
OY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAGAAACAGCAACAGCTGCTGTGACAGAG 60
DB |||||||
OY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB |||||||
OY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGTCCCG 120
DB |||||||
OY 121 CCGTGTCTGCTGTGACCATGGCCTTGGCCGAGAGTTTCGGGGACCGCTTCGGCTGAAGCA 180
DB |||||||
OY 121 CCGTGTCTGCTGTGACCATGGCCTTGGCCGAGAGTTTCGGGGACCGCTTCGGCTGAAGCA 180
DB |||||||
OY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTCACTTACCTACCCC 240
DB |||||||
OY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTCACTTACCTACCCC 240
DB |||||||
OY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
DB |||||||
OY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGCAGGCTGTTT 300
DB |||||||

XX	Sequence	1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
SQ	Query Match	100.0%; Score 1174; DB 9; Length 1174;
	Best Local Similarity	100.0%; Pred. No. 0;
	Matches 1174; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	1	CGGACGCGTGGGGAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG 60
DB	1	CGGACGCGTGGGGAACCCCTTCGAGAAAAACAGCAAAAGCTGAGCTGCTGTGACAGAG 60
QY	61	GGGAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
DB	61	GGGAACAAGATGGCGGCGCCGGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY	121	CCGCTGCTGCTGACCATGCGCTTGGCGGAGGTTTGGCGGACCCGCTTCGGCTGAAGCA 180
DB	121	CCGCTGCTGCTGACCATGCGCTTGGCGGAGGTTTGGCGGACCCGCTTCGGCTGAAGCA 180
QY	181	TTTGACTCGGTCCTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC 240
DB	181	TTTGACTCGGTCCTGGGTGATACGGCGTCTTGCCACCGGCGCTGTGAGTTGACCTACCCC 240
QY	241	TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCGAGCTGTTT 300
DB	241	TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCGAGCTGTTT 300
QY	301	TCAATTTGTGAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360
DB	301	TCAATTTGTGAGTTTGTGGATGATGGAATGACTTAAATCGAACTAAATGGAATGTGAA 360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
DB	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGTTGC 420
QY	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTATGTCCCTGATGCCAAA 480
DB	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTATGTCCCTGATGCCAAA 480
QY	481	ATGCACCTACTCTTCTCTTAACCTCTGAGTGGTCAATTCGAGTGACATGATGACTCC 540
DB	481	ATGCACCTACTCTTCTCTTAACCTCTGAGTGGTCAATTCGAGTGACATGATGACTCC 540
QY	541	GCACAGAGCTTCAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGGAAAATA 600
DB	541	GCACAGAGCTTCAACCTCTTCAATGAGCTTTTATCTTCAAGCCGATGACGGGAAAATA 600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCAACACATTTGGAGCAGGAGCTACA 660
DB	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCAACACATTTGGAGCAGGAGCTACA 660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
DB	721	CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY	781	TCTGGGTGATTTTAACTAACAATCTTGTCTCTCGGTGATGATGCTTTTGGATTGT 840
DB	781	TCTGGGTGATTTTAACTAACAATCTTGTCTCTCGGTGATGATGCTTTTGGATTGT 840
QY	841	TGTGCAACTGTTGTGACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
DB	841	TGTGCAACTGTTGTGACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY	961	GTTGTTAGATCTAAACTGAAGATCATGAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
DB	961	GTTGTTAGATCTAAACTGAAGATCATGAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020

DB	961	GTTGTTAGATCTAAACTGAAGATCATGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY	1021	CTTGCTCATCTCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
DB	1021	CTTGCTCATCTCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY	1081	AATTCCACTCCTCATAGAGCTTTTAAATGTTTCTTTCATTTGATATAGGCTTAAAGAAATCA 1140
DB	1081	AATTCCACTCCTCATAGAGCTTTTAAATGTTTCTTTCATTTGATATAGGCTTAAAGAAATCA 1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
DB	1141	CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
RESULT 134		
ADC47844		
ID	ADC47844	standard; cDNA; 1174 BP.
XX	AC	ADC47844;
XX	DT	01-JAN-2004 (first entry)
XX	DE	Human PRO polynucleotide #136.
XX	KW	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW		tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW		cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW		liver; microvascular endothelial cell; glucose; FFA;
KW		skeletal muscle cell; adipocyte cell; pericyte cell;
KW		inner ear utricular supporting cell; T-lymphocyte cell;
KW		endothelial cell tube formation; bone disorder; cartilage disorder;
KW		sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW		rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW		immune system cell infiltration.
XX	OS	Homo sapiens.
OS		US2003194771-A1.
PN	XX	16-OCT-2003.
PD	XX	21-MAY-2002; 2002US-00152377.
XX	PF	09-DEC-1999; 99US-0170262P.
XX	PR	01-DEC-2000; 2000WO-US032678.
PR	PR	19-DEC-2001; 2001US-00028072.
XX	XX	(GETH) GENENTECH INC.
PA	XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI	XX	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Gurney SL, Smith V;
PI	XX	Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	DR	WPI; 2003-844454/78.
DR	DR	P-PSDB; ADC47845.
XX	PT	New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT	PT	for detecting a tumor, stimulating the release of proteoglycans from
PT	PT	cartilage and stimulating the proliferation of endothelial cells.
XX	PS	Claim 2; Fig 271; 637pp; English.
XX	CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	CC	invention also relates to an antibody which specifically binds to a PRO
CC	CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	CC	proliferation or differentiation of chondrocyte cells and a method for
CC	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	CC	polynucleotides are useful in molecular biology, including uses as
CC	CC	hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGGCGCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGGCGCGCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
QY	121	CGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
DB	121	CGCTGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTGAGTTCACCTACCCC	240
DB	181	TTTGACTCGGCTTGGGTGATACGGCGTCTTGCCACCGGGCGCTGTGAGTTCACCTACCCC	240
QY	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT	300
DB	241	TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTCAAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTGTGAGTTGTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGAA	360
DB	301	TCAATTGTGAGTTGTGGATGATGGAAATGACTTAAATCGAACTAAATGGAAATGAA	360
QY	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420
DB	361	TCTGCATGTACAGAGCATATTCCTCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC	420
QY	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
DB	421	CAGAAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGTCACTTCTGGAGTACATGATGGACTCC	540
DB	481	ATGCACCTACTCTTTCTCTTAACCTCTGCTGAGTCACTTCTGGAGTACATGATGGACTCC	540
QY	541	GCACAGAGCTTCATAACCTTTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA	600
DB	541	GCACAGAGCTTCATAACCTTTTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA	600
QY	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGAGCAGGAGCCTACA	660
DB	601	GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAACATTTGAGCAGGAGCCTACA	660

QY	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAAC	780
DB	721	CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAAC	780
QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCCGTCGATGGTATTGCTTTGGATTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCCGTCGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTTGTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAAAGCTAAACAGATATCCAGCTTCTTCTCTGTG	960
QY	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
DB	1021	CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
DB	1081	AATTCCACTCTCTCATAGAGCTTTTAAATGGTTTTCATTGGATATAGGCCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174
DB	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174

RESULT 135
ADC79904

ID ADC79904 standard; cDNA; 1174 BP.

XX ADC79904;

DT 01-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO195 cDNA.

DE Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; ss.

OS Homo sapiens.

XX US2003087358-A1.

XX 08-MAY-2003.

XX 22-APR-2002; 2002US-00127833.

XX 01-SEP-1998; 98US-0098750P.

XX 01-SEP-1999; 99WO-US020111.

XX 18-OCT-1999; 99US-00403297.

XX 18-FEB-2000; 2000WO-US004342.

PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-801143/75.
DR P-PSDB; ADC79905.
XX
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
PT
XX
PS Claim 2; Fig 271; 637pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage defects, osteoarthritis and rheumatoid
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db |||||
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db |||||
QY 121 CCGCTGCTGCTGCTGACCAATGGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGGCCACCGGCGCTGTGAGTTGACCTACCCC 240
Db |||||

QY 241 TTGCACACCTACCTTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGTTGCAGGCTGTTT 300
Db |||||
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGAA 360
Db |||||
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTCCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACATTATGTCCCTGATGCCAAAA 480
Db |||||
QY 481 ATGCACCTACTCTTCTTAACTCTGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db |||||
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGGAGCTTACA 660
Db |||||
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAAGCG 720
Db |||||
QY 721 CACAGGAAATTTCTTGAAGATGGAGAAAGTCAAGTGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db |||||
QY 841 TGTGCACTGTTGTCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCACTTCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db |||||

RESULT 136
ADD11256
ID ADD11256 standard; cDNA; 1174 BP.
XX ADD11256;
AC
XX
DT 01-JAN-2004 (first entry)

Db 901 GGTGACTGGAGTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTGTG 960
QY 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTGGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 138
ADD41086
ID ADD41086 standard; cDNA; 1174 BP.
XX
AC ADD41086;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX

OS Homo sapiens.
XX
PN US2003203438-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146786.
XX
PR 24-NOV-1997; 97US-0066511P.
PR 16-SEP-1998; 98WO-US019330.
PR 25-AUG-1999; 99US-00380139.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875645/81.
DR P-PSDB; ADD41087.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 271; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAAACAGCAACAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAAGGGAGCCTCTGGGTGAGGACCAACTGGGGTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCCGAGGTTCCGGGACCGCTTCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGGAATTAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGGAATTAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCGTGAACCTGAGACAAGAAACAACCTTATGTCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTGCGTGAACCTGAGACAAGAAACAACCTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
Db 541 GCACAGAGCTTCAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCCACCACTTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTAGCCACCACTTTGGAGCAGGAGCTACA 660

Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGATGCTCTCTCTTAAC 780
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGGTGATGATTTGCTTTTGGATTGT 840
Db 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCTCGGTGATGATTTGCTTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAACAGCGGCTCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAACAGCGGCTCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCACTCTCATAGAGCTTTTAAATGTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCACTCTCATAGAGCTTTTAAATGTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA 1140
Db 1081 AATTCCACTCTCATAGAGCTTTTAAATGTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA 1140
QY 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 139
ADD52225
ID ADD52225 standard; cDNA; 1174 BP.
XX
AC ADD52225;
XX
DT 15-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194769-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152374.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852593/79.
DR P-PSDB; ADD52226.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for detection of tumors, modulating the uptake of glucose
PT or free fatty acids and stimulating the release of proteoglycans from
PT cartilage.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAGCTGAGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCGCGGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGGCCTGTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTGTCCACCGGGCCTGTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGCAGGCTGTT 300

Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTAGAGAGGTTGCAGGCTGTTT 300
Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAAGTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAAGTAAATTTGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420
Qy 421 CAGAATCAGCTGCCATTCGCTGAATCTGAGACAAGAACAACTTATGCTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAATCTGAGACAAGAACAACTTATGCTCCCTGATGCCAAAA 480
Qy 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGAGACTCC 540
Qy 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Qy 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAAATCCAGTACGCCACACATTTGGAGCAGGAGCTTACA 660
Qy 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTCTAAGCAAAAATGCTCTATCTGCAATGAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Qy 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGTTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTTGGATTGTTGT 840
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Qy 961 GTTGTAGATCTAAAAGCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAAGCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Qy 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAAGAAATCA 1140
Qy 1141 CTATAAATGCAAAATAAAGTTTACTCAAATCTGTG 1174
Db 1141 CTATAAATGCAAAATAAAGTTTACTCAAATCTGTG 1174

RESULT 140
ADD52965
ID ADD52965 standard; cdna; 1174 BP.
XX
AC ADD52965;
XX
DT 15-JAN-2004 (first entry)
XX
DE cdna encoding human PRO polypeptide #136.
XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX
PN US2003194792-A1.
XX 16-OCT-2003.
PF 15-APR-2002; 2002US-00123156.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.

Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAATAGAAATTCACAAGCG 720
Qy 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCTCTCTCTTAAC 780
Qy 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATTTGGATTGT 840
Qy 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATATCTAT 900
Qy 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960
Qy 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCCTCTACCTACAAAGTGAAT 1020
Qy 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGCAAGTGTATAGACATCTAA 1080
Qy 1081 AATTCACCTCCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Qy 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAATGCAATAAAGTTACTCAAAATCTGTG 1174

RESULT 141
ADD53517
ID ADD53517 standard; cDNA; 1174 BP.
XX
AC ADD53517;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203437-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146728.
XX
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUN-1999; 99WO-US012252.
PR 01-DEC-2000; 2000US-00380137.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-875644/81.
DR P-PSDB; ADD53518.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; SEQ ID NO 271; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the release of proteoglycans from cartilage, for
CC cells, for stimulating the proliferation of inner ear utricular supporting cells,
CC stimulating the proliferation of T-lymphocyte cells, for stimulating
CC for stimulating the proliferation of BMC cells, for inhibiting the binding of
CC the release of a cytokine from BMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACAGCAACAGCTGCTGTGACAGAG 60
Qy 61 GGGAAACAAGATGGCGCGCCGAGGAGGAGCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGAGGAGCTCTGGGTGAGGACCCAACTGGGCTCCCG 120
Qy 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180
Qy 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTCGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Qy 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTTCAGAGAGTTGAGGCTGTTT 300
Qy 301 TCAATTTGTCAGTTTGTGGATGATGGAATTAATCGAATTAATGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATTAATCGAATTAATGGAATGTGAA 360
Qy 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAAATCAGCTGCCATTGCTGAACTGAGACAAGAAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACCTCTGCTCTCGGTGATGCTATGCTTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACCTCTGCTCTCGGTGATGCTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCCTTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCFAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAAGAAATCA 1140
Db 1081 AATTCACCTCCTCFAGAGCTTTTAAATGGTTTCAATGGATATAGGCCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 142
ADD37049
ID ADD37049 standard; cDNA; 1174 BP.
AC ADD37049;
XX ADD37049;
DT 15-JAN-2004 (first entry)
DE Human secreted/transmembrane PRO polypeptide cDNA #4.
XX ss; gene; human; secreted protein; transmembrane protein;
KW cardiovascular disorder; endothelial disorder; angiogenic disorder;
KW myocardial infarction; cardiac hypertrophy; trauma; cancer;
KW age-related macular degeneration; angiogenesis;
KW endothelial cell apoptosis; smooth muscle cell growth;
KW endothelial cell tube formation.
XX Homo sapiens.
OS

PN US2003105012-A1.
XX 05-JUN-2003.
PD 16-AUG-2002; 2002US-00223088.
PF 15-SEP-2000; 2000US-0232887P.
PR 20-JUN-2001; 2001WO-US019692.
PR 09-JUL-2001; 2001WO-US021735.
PR 20-FEB-2002; 2002US-00081056.
XX (GETH) GENENTECH INC.
PA Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
XX Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Stephan JF;
PI Watanabe CK, Williams PM, Wood WI, Ye W;
XX WPI; 2003-829354/77.
DR P-PSDB; ADD37050.
XX New isolated nucleic acids encoding a secreted and transmembrane
PT polypeptide for treating a cardiovascular, endothelial, or angiogenic
PT disorder in a mammal, such as cancer or age-related macular degeneration.
XX Claim 2; SEQ ID NO 7; 492pp; English.

XX The invention relates to an isolated nucleic acid encoding a secreted and
CC transmembrane polypeptide (PRO). The nucleic acid, a polypeptide encoded
CC by the nucleic acid, or an agonist or antagonist, is used to treat a
CC cardiovascular, endothelial, or angiogenic disorder in a mammal,
CC preferably a human. The human may have suffered a myocardial infarction
CC or has cardiac hypertrophy, trauma, a cancer, or age-related macular
CC degeneration. The cardiac hypertrophy is characterised by the presence of
CC an elevated level of PGP-2 alpha. A PRO polypeptide, given in the
CC specification, or an agonist is used to inhibit or stimulate endothelial
CC cell growth in a mammal. PRO21 or an agonist is used to induce cardiac
CC hypertrophy. PRO1376 or PRO1449 is used to stimulate angiogenesis.
CC PRO4302 or an agonist is used to induce endothelial cell apoptosis. A PRO
CC polypeptide, given in the specification, or an agonist is used to
CC stimulate or inhibit smooth muscle cell growth, or to induce endothelial
CC cell tube formation. The present sequence represents a cDNA encoding a
CC PRO polypeptide of the invention.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGCTGTGACAGAG 60
Db 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAAAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGGCCGCGAAGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCGAGGTTCCGGGACCCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGTGGATGATGGAATGACTTAATCGAACTAAATGGAATGTGAA 360

||||| 1 CGGACGCGTGGGGAAACCCCTTCGAGAAACACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCCGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCTCTTGCCACCGGCCCTGTGAGTTGAGCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCTCTTGCCACCGGCCCTGTGAGTTGAGCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTTT 300
QY 301 TCAATTTGTCAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
Db 301 TCAATTTGTCAGTTTGGATGATGGAATTGACTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATGCTTGCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATGCTTGCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTCTAACTCTGTGAGGTCAATCTGAGTGACATGATGACTCC 540
Db 481 ATGCACCTACTCTTCTCTAACTCTGTGAGGTCAATCTGAGTGACATGATGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAATAAATA 600
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAATCATCTTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGTGCCTCTCTCTTAAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGCTTTTAAAGTGCCTCTCTCTTAAAC 780
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGATTTGATTTGT 840
Db 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGGTGATGATGATTTGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTTAAACAGATATCCAGCTTCTTCTCTTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAGCAGGGCTCTACCTACAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGAATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAAGAAATCA 1140
|||||

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTTACTCAAAATCTGTG 1174
RESULT 144
ADD02472
ID ADD02472 standard; cDNA; 1174 BP.
XX
AC ADD02472;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203431-A1.
XX
PD 30-OCT-2003.
XX
PF 24-APR-2002; 2002US-00131820.
XX
PR 28-OCT-1998; 98US-0106030P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-875638/81.
DR P-PSDB; ADD02473.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.
PT
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG	60
Db	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG	60
Qy	61	GGGAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG	120
Db	61	GGGAACAAGATGGCGGCGCGGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGTCCCG	120
Qy	121	CGGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGGTTGGGCTGAAGCA	180
Db	121	CGGCTGCTGCTGACCATGGCCCTTGGCGGAGGTTCCGGGACCGGTTGGGCTGAAGCA	180
Qy	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCC	240
Db	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCC	240
Qy	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTTT	300
Db	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGGTTGCAGGCTGTTT	300
Qy	301	TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGAATGTGAA	360
Db	301	TCAATTTGTGAGTTTGTGGATGATGGAATTGACTTAAATCGAATTAATTTGAATGTGAA	360
Qy	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
Db	361	TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
Qy	421	CAGAAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
Db	421	CAGAAATCAGCTGCCATTCCGTGAACCTGAGACAAGAACTTATGTCCCTGATGCCAAA	480
Qy	481	ATGCACCTACTCTTCTCTTAACCTCTGGTGAGGTCATTTCTGGAGTGACATGAGCTCC	540
Db	481	ATGCACCTACTCTTCTCTTAACCTCTGGTGAGGTCATTTCTGGAGTGACATGAGCTCC	540
Qy	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Db	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
Qy	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA	660
Db	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCTTACA	660
Qy	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAGCG	720
Db	661	AATTTGAGAGAAATCATCTCTAAGCAAAATGTCTCTATCTGCAATGAGAAATTCACAGCG	720

Qy	721	CACAGGAATTTTCTTGAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC	780
Db	721	CACAGGAATTTTCTTGAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTTAAC	780
Qy	781	TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT	840
Db	781	TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTGGATTGT	840
Qy	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Db	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
Qy	901	GGTGAATGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
Db	901	GGTGAATGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
Qy	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
Db	961	GTTGTTAGATCTAAACCTGAAGATCATGAAGAGCAGGGCCCTCTACCTACAAAAGTGAAT	1020
Qy	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
Db	1021	CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
Qy	1081	AATTCCTCTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Db	1081	AATTCCTCTCTCATAGAGCTTTTAAATGGTTTCATTTGGATATAGGCCCTTAAGAAATCA	1140
Qy	1141	CTATAAATGCAAAATAAAGTTACTCAAATCTGTG	1174
Db	1141	CTATAAATGCAAAATAAAGTTACTCAAATCTGTG	1174

RESULT 145

ADD01906
ID ADD01906 standard; cDNA; 1174 BP.

XX ADD01906;

XX 15-JAN-2004 (first entry)

XX Human PRO polynucleotide #136.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
XX liver; microvascular endothelial cell; glucose; FFA;
XX skeletal muscle cell; adipocyte cell; pericyte cell;
XX inner ear utricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

XX Homo sapiens.

XX US2003203430-A1.

XX 30-OCT-2003.

XX 23-APR-2002; 2002US-00128685.

XX 11-AUG-1998; 98US-0096143P.

XX 02-JUN-1999; 99WO-US012252.

XX 30-MAR-2000; 2000US-00380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875637/81.
XX P-PSDB; ADD01907.
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 2; Fig 271; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180
QY 181 TTTGACTCGGCTTGGGTGATACGGGCTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGCTTGGGTGATACGGGCTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGAGGAGTTGTACGCATGTGACAGAGGTTGAGGCTGTTT 300
Db 241 TTGCACACCTACCTAAGGAAGAGAGGAGTTGTACGCATGTGACAGAGGTTGAGGCTGTTT 300
QY 301 TCAATTGTGCTGCTGCTGATGATGGAATGACTTAAATCGAACTAAATGGAAATGTGAA 360

Db 301 TCAATTGTGCTGCTGCTGATGATGGAATGACTTAAATCGAACTAAATGGAAATGTGAA 360
QY 361 TCTGCAATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTCCCATCTTGGTTC 420
Db 361 TCTGCAATGTACAGAAGCATATTCCCAATCTGTATGAGCAATATGCTTCCCATCTTGGTTC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGCAAGCAACAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAACTGAGCAAGCAACAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTTAACCTCTGGTGAGGTCAATCTCGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTCTTAACCTCTGGTGAGGTCAATCTCGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCAACCTCTTCATGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTACA 660
QY 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGATCATCTCTAAGCAAAATGTCTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCCTCTCTCTTAAC 780
QY 781 TCTGGGTGGATTTAACTACAACCTCTGCTCTCTCGGTGATGGTATGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTAACTACAACCTCTGCTCTCTCGGTGATGGTATGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCAATTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCTTAAAGAAATCA 1140
Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTCATTGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
RESULT 146
ADD54088
ID ADD54088 standard; cDNA; 1174 BP.
XX
AC ADD54088;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO195 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX

OS Homo sapiens.

XX US2003203432-A1.

XX 30-OCT-2003.

XX 10-MAY-2002; 2002US-00142886.

XX 05-JUN-2000; 2000US-0209832P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-875639/81.

DR P-PSDB; ADD54089.

XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.

XX Claim 2; SEQ ID NO 271; 637pp; English.

PS
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

SQ
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGTGTGTGACAGAG 60

Db 1 CGGACCGGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGTGTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGGCGCGCAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120

Db 61 GGGAAACAAGATGGCGGCGCGCAAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGTCCCG 120
QY 121 CCGTGTCTGTCTGACCAATGSCCTTGGCCGGAGGTTCCGGGACCCTTCCGGTGAAGCA 180
Db 121 CCGTGTCTGTCTGACCAATGSCCTTGGCCGGAGGTTCCGGGACCCTTCCGGTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTCCACCGGGCCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAAGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGGTTGCAAGCTGTTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGATGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360
Db 301 TCAATTTGTGAGTTTGTGGATGATGAATTTGACTTAAATCGAACTAAATTTGGAATGTAA 360
QY 361 TCTGCAATGACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db 361 TCTGCAATGACAGAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
Db 421 CAGAATCAGCTGCCATTCGCTGAACTGAGACAAGAACAACTTATGTCCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTTCTCTAACTCTGGTGGAGTCAATCTGGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACCTCTTCATGGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCATTTGGAGCAGGACCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCAACCATTTGGAGCAGGACCTTACA 660
QY 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db 661 AATTTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
Db 721 CACAGGAATTTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
QY 781 TCTGGTGGATTTTAACTAAGTCTTGTCTCTCGGTGATGGTATTGCTTGGATTTGT 840
Db 781 TCTGGTGGATTTTAACTAAGTCTTGTCTCTCGGTGATGGTATTGCTTGGATTTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATTTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCCCTTAAGAAATCA 1140
Db 1081 AATTCACCTCCTCATAGAGCTTTTAAATGGTTTTCATTTGATATAGGCCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

Db 1141 CTATAAATGCAATAAAGTTACTCAAACTCTGTG 1174
RESULT 147
ADE49363
ID ADE49363 standard; cDNA; 1174 BP.
XX
AC ADE49363;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytosolic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003096744-A1.
XX
PD 22-MAY-2003.
XX
PF 28-JAN-2002; 2002US-00978187.
XX
PR 17-OCT-1997; 97US-0062250P.
PR 03-NOV-1997; 97US-0064249P.
PR 13-NOV-1997; 97US-0065311P.
PR 21-NOV-1997; 97US-0066364P.
PR 10-MAR-1998; 98US-0077450P.
PR 11-MAR-1998; 98US-0077632P.
PR 11-MAR-1998; 98US-0077641P.
PR 11-MAR-1998; 98US-0077649P.
PR 12-MAR-1998; 98US-0077791P.
PR 13-MAR-1998; 98US-0078004P.
PR 17-MAR-1998; 98US-00040220.
PR 20-MAR-1998; 98US-0078886P.
PR 20-MAR-1998; 98US-0078910P.
PR 20-MAR-1998; 98US-0078936P.
PR 20-MAR-1998; 98US-0078939P.
PR 25-MAR-1998; 98US-0079294P.
PR 26-MAR-1998; 98US-0079656P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079664P.
PR 27-MAR-1998; 98US-0079689P.
PR 27-MAR-1998; 98US-0079728P.
PR 27-MAR-1998; 98US-0079786P.
PR 30-MAR-1998; 98US-0079920P.
PR 30-MAR-1998; 98US-0079923P.
PR 31-MAR-1998; 98US-0080105P.
PR 31-MAR-1998; 98US-0080165P.
PR 31-MAR-1998; 98US-0080194P.
PR 01-APR-1998; 98US-0080327P.
PR 01-APR-1998; 98US-0080328P.
PR 01-APR-1998; 98US-0080333P.
PR 01-APR-1998; 98US-0080334P.
PR 08-APR-1998; 98US-0081049P.
PR 08-APR-1998; 98US-0081070P.
PR 08-APR-1998; 98US-0081071P.
PR 09-APR-1998; 98US-0081195P.
PR 09-APR-1998; 98US-0081203P.
PR 09-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081819P.
PR 15-APR-1998; 98US-0081838P.
PR 15-APR-1998; 98US-0081952P.
PR 15-APR-1998; 98US-0081955P.
PR 21-APR-1998; 98US-0082568P.
PR 21-APR-1998; 98US-0082569P.
PR 22-APR-1998; 98US-0082700P.
PR 22-APR-1998; 98US-0082704P.
PR

PR 22-APR-1998; 98US-0082797P.
PR 22-APR-1998; 98US-0082804P.
PR 23-APR-1998; 98US-0082796P.
PR 27-APR-1998; 98US-0083336P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083392P.
PR 29-APR-1998; 98US-0083495P.
PR 29-APR-1998; 98US-0083496P.
PR 29-APR-1998; 98US-0083499P.
PR 29-APR-1998; 98US-0083500P.
PR 29-APR-1998; 98US-0083545P.
PR 29-APR-1998; 98US-0083554P.
PR 29-APR-1998; 98US-0083558P.
PR 29-APR-1998; 98US-0083559P.
PR 30-APR-1998; 98US-0083742P.
PR 05-MAY-1998; 98US-0084366P.
PR 06-MAY-1998; 98US-0084414P.
PR 06-MAY-1998; 98US-0084414P.
PR 07-MAY-1998; 98US-0084598P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 07-MAY-1998; 98US-0084639P.
PR 07-MAY-1998; 98US-0084640P.
PR 07-MAY-1998; 98US-0084643P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085573P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085580P.
PR 15-MAY-1998; 98US-0085582P.
PR 15-MAY-1998; 98US-0085689P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085700P.
PR 15-MAY-1998; 98US-0085704P.
PR 18-MAY-1998; 98US-0086023P.
PR 22-MAY-1998; 98US-0086392P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 22-MAY-1998; 98US-0086486P.
PR 28-MAY-1998; 98US-0087098P.
PR 28-MAY-1998; 98US-0087106P.
PR 28-MAY-1998; 98US-0087208P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091359P.
PR 30-JUL-1998; 98US-0094651P.
PR 11-SEP-1998; 98US-0100038P.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 02-NOV-1998; 98US-00184216.
PR 06-NOV-1998; 98US-00187368.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 05-MAR-1999; 99US-00254465.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99US-00265686.
PR 10-MAR-1999; 99WO-US005190.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 29-MAR-1999; 99US-0126773P.
PR 12-APR-1999; 99US-00284291.
PR 21-APR-1999; 99US-0130232P.
PR 26-APR-1999; 99US-0131022P.
PR 28-APR-1999; 99US-0131445P.
PR 14-MAY-1999; 99US-00311832.
PR

PR	14-MAY-1999;	99US-0134287P.	
PR	14-MAY-1999;	99WO-US010733.	
PR	02-JUN-1999;	99WO-US012252.	
PR	16-JUN-1999;	99US-0139557P.	
PR	23-JUN-1999;	99US-0141037P.	
PR	07-JUL-1999;	99US-0142680P.	
PR	26-JUL-1999;	99US-0145698P.	
PR	28-JUL-1999;	99US-0146222P.	
PR	25-AUG-1999;	99US-00380137.	
PR	25-AUG-1999;	99US-00380138.	
PR	25-AUG-1999;	99US-00380142.	
PR	29-OCT-1999;	99US-0162506P.	
PR	30-NOV-1999;	99WO-US028313.	
PR	02-DEC-1999;	99WO-US028551.	
PR	02-DEC-1999;	99WO-US028565.	
PR	16-DEC-1999;	99WO-US030095.	
PR	30-DEC-1999;	99WO-US031243.	
PR	30-DEC-1999;	99WO-US031274.	
PR	05-JAN-2000;	2000WO-US000219.	
PR	06-JAN-2000;	2000WO-US000277.	
PR	06-JAN-2000;	2000WO-US000376.	
PR	11-FEB-2000;	2000WO-US0003565.	
PR	18-FEB-2000;	2000WO-US004341.	
PR	24-FEB-2000;	2000WO-US005004.	
PR	02-MAR-2000;	2000WO-US005841.	
PR	10-MAR-2000;	2000WO-US006319.	
PR	21-MAR-2000;	2000WO-US007532.	
PR	30-MAR-2000;	2000WO-US008439.	
PR	17-MAY-2000;	2000WO-US013705.	
PR	22-MAY-2000;	2000WO-US014042.	
PR	30-MAY-2000;	2000WO-US014941.	
PR	02-JUN-2000;	2000WO-US015264.	
PR	28-JUL-2000;	2000WO-US020710.	
PR	24-AUG-2000;	2000WO-US023328.	
PR	08-NOV-2000;	2000US-00709238.	
PR	27-NOV-2000;	2000US-00723749.	
PR	01-DEC-2000;	2000WO-US032678.	
PR	20-DEC-2000;	2000US-00747259.	
PR	20-DEC-2000;	2000WO-US034956.	
PR	28-FEB-2001;	2001WO-US006520.	
PR	22-MAR-2001;	2001US-00816744.	
PR	22-MAR-2001;	2001US-00816920.	
PR	22-MAR-2001;	2001WO-US009552.	
PR	10-MAY-2001;	2001US-00872035.	
PR	01-JUN-2001;	2001WO-US017800.	
PR	05-JUN-2001;	2001US-00874503.	
PR	14-JUN-2001;	2001US-00882636.	
PR	19-JUN-2001;	2001US-00886342.	
PR	20-JUN-2001;	2001WO-US019692.	
PR	29-JUN-2001;	2001WO-US021066.	
PR	09-JUL-2001;	2001WO-US021735.	
PR	30-JUL-2001;	2001US-00918585.	
XX			
PA	(GETH) GENENTECH INC.		
XX			
PI	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;		
	Query Match 100.0%; Score 1174; DB 9; Length 1174;		
	Best Local Similarity 100.0%; Pred. No. 0;		
	Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60		
Dd	1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60		
QY	61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120		
Dd	61 GGGAAACAAGATGGCGGCCCGAAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120		
QY	121 CCGCTGCTGCTGCTACCATGGCCCTTGGCGGGAGGTTCCGGGGACCGCTTCGGCTGAAGCA 180		

Db	121 CCGCTGCTGCTGCTGACCAATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180	
QY	181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGACGTGACCTACCC 240	
Dd	181 TTTGACTCGGTCTTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTGACGTGACCTACCC 240	
QY	241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT 300	
Dd	241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGACAGAGGTTGACGGCTGTTT 300	
QY	301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360	
Dd	301 TCAATTTGTCAGTTTGTGGATGATGGAATTTGACTTAAATCGAACTAAATTTGGAATGTGAA 360	
QY	361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420	
Dd	361 TCTGCATGTACAGAAGCATATTTCCCAATCTGATGAGCAATATGCTTGCCATCTTTGGTTGC 420	
QY	421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGACAACAACTTATGTCCCTGATGCCAAAA 480	
Dd	421 CAGAATCAGCTGCCATTTCGCTGAATGAGACAAGACAACAACTTATGTCCCTGATGCCAAAA 480	
QY	481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTCAATTTGGAGTGACATGAGGACTCC 540	
Dd	481 ATGCACCTACTCTTTCCCTTAACCTCTGGTGAGGTCAATTTGGAGTGACATGAGGACTCC 540	
QY	541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTCAAGCCGATGACCGGAAAAATA 600	
Dd	541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTCAAGCCGATGACCGGAAAAATA 600	
QY	601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660	
Dd	601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACCACATTTGGAGCAGGAGCCTACA 660	
QY	661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720	
Dd	661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720	
QY	721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTTAAC 780	
Dd	721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTTAAC 780	
QY	781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840	
Dd	781 TCTGGGTGGATTTTAACTACAACCTCTGTCTCTCGGTGATGGTATTGCTTTGGATTGT 840	
QY	841 TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900	
Dd	841 TGTCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900	
QY	901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960	
Dd	901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTTGTG 960	
QY	961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAAGTGAAT 1020	
Dd	961 GTTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAAGTGAAT 1020	
QY	1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080	
Dd	1021 CTTGCTCATTTCTGAATTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA 1080	
QY	1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTTCATTGGATATAGGCTTTAAGAAATCA 1140	
Dd	1081 AATTCCACTCCTCATAGAGCTTTTAAATGTTTTCATTGGATATAGGCTTTAAGAAATCA 1140	
QY	1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174	
Dd	1141 CTATAAAATGCAAAATAAGTTACTCAAATCTGTG 1174	

RESULT 148

ADD92405
ID ADD92405 standard; cDNA; 1174 BP.
XX
AC ADD92405;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199030-A1.
XX
PD 23-OCT-2003.
XX
XX 28-MAY-2002; 2002US-00156841.
PF
XX 03-MAR-2000; 2000US-0187202P.
PR
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-900159/82.
DR P-PSDB; ADD92406.
DR
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 271; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
Db 1 CGGACGCGTGGGGGAAACCCCTTCCGAGAAACAGCAACAGCTGAGCTGTGTGACAGAG 60
QY 61 GGGAAACAAGATGGGGCGCCGAGAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGGGCGCCGAGAGGGGAGCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGCTCTGGGTGATACGGCGCTCTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
Db 181 TTTGACTCGGCTCTGGGTGATACGGCGCTCTGCCACCGGGCCCTGTCAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT 300
Db 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGGTTGCAGGCTGTTT 300
QY 301 TCAATTTGTGCTGCTGATGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGCTGCTGATGATGGAATGACTTAAATCGAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420
Db 361 TCTGCATGTACAGAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTGC 420
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGAACTGAGACAAGAACAACTTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTTAACTCTGGTGGGTCACTTCTGGAGTGACATGAGACTCC 540
Db 481 ATGCACCTACTCTTCTTAACTCTGGTGGGTCACTTCTGGAGTGACATGAGACTCC 540
QY 541 GCACAGAGCTTCATAACTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAACTCTTCACTGAGCTTTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCATTTGGAGCAGGAGCCTACA 660
QY 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAAATGAGAAATTCACAAGCG 720
Db 661 AATTGAGAGAAATCATCTTAAGCAAAATGTCTATCTGCAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
QY 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTGGATTGT 840
Db 781 TCTGGTGGATTTTAACTACAACTCTTGTCTCTCGGTGATGGTATGCTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT 900

PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900165/82.
P-PSDB: ADD91302.

Two hundred and seventy five nucleic acids encoding PRO polypeptides, useful for treating pericyte-associated tumors, diabetes and various bone and/or cartilage disorders, e.g. arthritis.

Claim 2: SEO ID NO 271; 636pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing antibodies for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiating of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1174 BP: 325 A: 250 C: 275 G: 324 T: 0 U: 0 Other: 0

Query Match	100.0%;	Score 1174;	DB 9;	Length 1174;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1174:	Conservative	0;	Mismatches	0;
			Indels	0;
			Gaps	0;

1 CGACCGCGTGGGGAAACCCCTTCCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAAACCCCTTCCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60

61 GGGAA CAAGATGGCGGCGCCGAA GGGAGCCTCTCGGTGAGGACCACTGGGCTCCCG 120

67 GGGAAC AAGATGCGCGCGCCGAAGGGAGCCTCTGGTGAGGACCAACTGGGCTCCCG 120

121 CCGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAGCA 180

121 CCGGTGGTGGTGTGAACATGGCCCTGGAGGTTGGGACCGGCTTCGGCTGAAGCA 180

Q17 181 TTTTGAATCCCTCTTGGGTGATACGGCGTCTTTGCCACCGGGCTGTCA GTTGA CCTACCCC 240

RESULT 150
ADE03915
ID ADE03915 standard; cDNA; 1174 BP
XX AC ADE03915;

181	DB	TTTTGACTCGGTCTTTGGGTGATACGGCGTCTTTGCCACGGGCCCTGTCTCAGTTGACCTACCCC	240
241	QY	TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGACAGGCTGTTT	300
241	DB	TTGACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTCTCAGAGAGGTTGACAGGCTGTTT	300
301	QY	TCAAATTTGTTCAGTTTGTGGATGATGGAATTGACTTTAAATCGAACTAAATTTGGAATGTGAA	360
301	DB	TCAAATTTGTTCAGTTTGTGGATGATGGAATTGACTTTAAATCGAACTAAATTTGGAATGTGAA	360
361	QY	TCTGCATGTACAGAAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTTGGTTGC	420
361	DB	TCTGCATGTACAGAAAGCATATTTCCCAATCTGTATGAGCAATATGCTTGCCATCTTTGGTTGC	420
421	QY	CAGAAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480
421	DB	CAGAAATCAGCTGCCATTTCGCTGAACCTGAGACAAGAACAACTTATGTCCCTGATGCCAAAA	480
481	QY	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC	540
481	DB	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCACTTCTGGAGTGACATGATGGACTCC	540
541	QY	GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA	600
541	DB	GCACAGAGCTTCATAACCTCTTCATGGACTTTTTTATCTTCAAGCCGATGACGGAAAAATA	600
601	QY	GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA	660
601	DB	GTTATATTTCCAGTCTAAGCCAGAAATCCAGTACGCCACACATTTGGAGCAGGAGCCTACA	660
661	QY	AATTTGAGAGAAATCATCTCTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
661	DB	AATTTGAGAGAAATCATCTCTAAGCAAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG	720
721	QY	CACAGGAATTTCTTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
721	DB	CACAGGAATTTCTTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTCTTAAC	780
781	QY	TCTGGGTGGATTTTAACTACAACTCTGTCCTCTCGGTGATGGTATTGCTTTGGATTGT	840
781	DB	TCTGGGTGGATTTTAACTACAACTCTGTCCTCTCGGTGATGGTATTGCTTTGGATTGT	840
841	QY	TGTGCAACTGTTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
841	DB	TGTGCAACTGTTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT	900
901	QY	GCTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTTG	960
901	DB	GCTGACTTGGAGTTTATGAATGAACAAAAGCTTAAACAGATATCCAGCTTCTCTCTTG	960
961	QY	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAAGTGAAT	1020
961	DB	GTTGTTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCTTACCTACAAAAGTGAAT	1020
1021	QY	CTTGCTCATTTCTGAAATTTAAGCATTTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA	1080
1021	DB	CTTGCTCATTTCTGAAATTTAAGCATTTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA	1080
1081	QY	AATTCACACTCCTCATAGAGCTTTTAAAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA	1140
1081	DB	AATTCACACTCCTCATAGAGCTTTTAAAAATGGTTTCAATTGGATATAGGCCCTTAAGAAATCA	1140
1141	QY	CTATAAAAATGCAAAATAAGTTACTCAAATCTGTG	1174
1141	DB	CTATAAAAATGCAAAATAAGTTACTCAAATCTGTG	1174

RESULT 150
ADE03915
ID ADE03
XX
AC ADE03

XX 29-JAN-2004 (first entry)
XX Human PRO polynucleotide #136.
DE
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199057-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123213.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900167/82.
P-PSDB; ADE03916.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,
useful for treating pericyte-associated tumors, diabetes and various bone
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 271; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGACAGAG 60
DB 1 CGGACGCTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGACAGAG 60
QY 61 GGGAAACAGATGGCGGCGCGGAGGGAGCCCTCTGGTGAGGACCCCACTGGGCTCCCG 120
DB 61 GGGAAACAGATGGCGGCGCGGAGGGAGCCCTCTGGTGAGGACCCCACTGGGCTCCCG 120
QY 121 CCGCTGCTGCTGACCATGSCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCA 180
DB 121 CCGCTGCTGCTGACCATGSCCTTGGCCGGAGGTTGGGGACCGCTTGGCTGAAGCA 180
QY 181 TTTGACTCGTCTTGGTGATACGGCGCTTGGCCACCGGGCCTGTGAGTTGACCTACCC 240
DB 181 TTTGACTCGTCTTGGTGATACGGCGCTTGGCCACCGGGCCTGTGAGTTGACCTACCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTT 300
DB 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACCGCATGTGACAGAGGTTGAGGCTGTT 300
QY 301 TCAATTTGTGAGTTTGTGGATGAGGAAATGACCTTAAATCGAACTAAATGGAATGTGAA 360
DB 301 TCAATTTGTGAGTTTGTGGATGAGGAAATGACCTTAAATCGAACTAAATGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
DB 361 TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
QY 421 CAGAATCAGTGCCATTTCGCTGAATGAGACAAGAACTTATGTCCTGATGCCAAA 480
DB 421 CAGAATCAGTGCCATTTCGCTGAATGAGACAAGAACTTATGTCCTGATGCCAAA 480
QY 481 ATGCACCTACTCTTCTCTAATCTGGTGAGGTTGAGTGTGAGTGACATGAGTCTCC 540
DB 481 ATGCACCTACTCTTCTCTAATCTGGTGAGGTTGAGTGTGAGTGACATGAGTCTCC 540
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600
DB 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGAGCCTACA 660
DB 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCACACATTTGGAGCAGAGCCTACA 660
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
DB 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTGCTGCTGCTGCTGCTGCTTAAAC 780
DB 721 CACAGGAATTTCTTGAAGATGAGAAAGTGTGCTGCTGCTGCTGCTGCTTAAAC 780
QY 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTGT 840
DB 781 TCTGGGTGATTTTAACTACAACTCTTGTCTCTCGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGATATCTAT 900
DB 841 TGTGCAACTGTTGCTACAGCTGTGAGCAGTATGTTCCCTCTGAGAACTGATATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
DB 901 GGTGACTTGGAGTTTATGAATGAACAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960
QY 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
DB 961 GTTGTAGATCTAAACCTGAAGATCATGAAGAGCAGGCGCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
DB 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTATAGACATCTAA 1080
QY 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
DB 1081 AATTCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA 1140
QY 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
DB 1141 CTATAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 151

ID ADE32212 standard; cdna; 1174 BP.

AC ADE32212;

DT 29-JAN-2004 (first entry)

DE Novel human secreted and transmembrane protein PRO195 cdna.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW glucose uptake modulator; FFA uptake modulator;

KW cell proliferation stimulator; cell differentiation stimulator;

KW cell differentiation inhibitor; cytokine release stimulator; tumour;

KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.

OS Homo sapiens.

XX US2003194765-A1.

PD 16-OCT-2003.

XX 09-MAY-2002; 2002US-00142889.

PR 03-MAR-2000; 2000US-0187202P.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

PA (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899784/82.
DR P-PSDB; ADE32213.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; SEQ ID NO 271; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACCGCTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGCTGTGACAGAG 60
Db |||||
QY 61 GGGAAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCACTGGGGCTCCCG 120
Db |||||
QY 121 CCGTGTGCTGTGACCATGGCCCTTGGCCGGAGGTTCCGGGACCGCTTCGGGTGAAGCA 180
Db |||||
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTTTGCCACCGGGCCTGTGAGTTGACCTACCCC 240
Db |||||
QY 241 TTGCACACCTACCCCTAAGGAGAGGAGTTGTACGCATGTGACAGAGGTTGACGGCTGTT 300
Db |||||
QY 301 TCAATTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAAGTAAATGGAATGTGAA 360
Db |||||

QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGTGATGAGCAATATGCTTGCCATCTTGGTTGC 420
Db |||||
QY 421 CAGAATCAGCTGCCATTGCTGAACTGAGAGCAAGAACAACTTATGTCCTCGATGCCAAA 480
Db |||||
QY 481 ATGCACCTACTCTTTCTCTAACTCTGGTGAGGTTCATCTGGAGTGACATGATGGACTCC 540
Db |||||
QY 541 GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGAAAAATA 600
Db |||||
QY 601 GTTATATCCAGTCTAAGCCAGAAATCCAGTACGCCACCACATTTGGAGCAGAGCCTACA 660
Db |||||
QY 661 AATTGAGAGAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
Db |||||
QY 721 CACAGGAATTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTCTTAAC 780
Db |||||
QY 781 TCTGGTGGATTTTAACTACAACCTCTTGTCTCTCGTGATGGTATTGCTTTGGATTGT 840
Db |||||
QY 841 TGTGCACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db |||||
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTTGTG 960
Db |||||
QY 961 GTTGTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db |||||
QY 1021 CTTGCTCAATCTGAAATTTAAGCATTTTCTTTTAAAGACAAAGTGTAAATAGACATCTAA 1080
Db |||||
QY 1081 AATTCCACTCCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCCCTTAAGAAATCA 1140
Db |||||
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db |||||
CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 152
ADE22144
ID ADE22144 standard; cDNA; 1174 BP.
XX
AC ADE22144;
XX
DT 29-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #136.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003199056-A1.

PN 23-OCT-2003.

XX 15-APR-2002; 2002US-00123212.

PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.

PR 11-FEB-2000; 2000WO-US003565.

PR 18-FEB-2000; 2000WO-US004341.

PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.

PR 01-MAR-2000; 2000WO-US005601.

PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.

PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.

PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900166/82.
DR P-PSDB; ADE22145.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 271; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems. PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
DB	1	CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAGCTGAGCTGCTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGCGCCGAGGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGTGACCATGGCCCTTGGCCGAGGCTCGGGACCGCTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGTGACCATGGCCCTTGGCCGAGGCTCGGGACCGCTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTACCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTCACTTGACCTACCC	240
QY	241	TTTGACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGACAGAGGTTGCAGGCTGTTT	300
DB	241	TTTGACACCTACCCCTAAGGAAGAGGAGTTGTACGATGTGACAGAGGTTGCAGGCTGTTT	300
QY	301	TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTGGAATGTGAA	360
DB	301	TCAATTGTGTCAGTTTGTGGATGATGGAATTGACTTAATCGAATAAATTGGAATGTGAA	360
QY	361	TCTGATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
DB	361	TCTGATGTACAGAAGCATATCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
QY	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACACTTATGTCCCTGATGCCAAA	480
DB	421	CAGAATCAGCTGCCATTCGCTGAACCTGAGACAAGAACACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCTTAACTCTGGTGAGGTCATCTGGAGTGACATGGAATGCTCC	540
DB	481	ATGCACCTACTCTTTCTTAACTCTGGTGAGGTCATCTGGAGTGACATGGAATGCTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA	600
QY	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA	660
DB	601	GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGAGCCTACA	660
QY	661	AATTTGAGAGAATCATCTCTAAGCAAAAATGCTCTATCTGCAAAATGAGAATTCACAAGCG	720
DB	661	AATTTGAGAGAATCATCTCTAAGCAAAAATGCTCTATCTGCAAAATGAGAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTTGAAGATGAGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTTGAAGATGAGAGAAAGTATGGCTTTTAAAGATGCCTCTCTTAAC	780

QY	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCCCTCTCGGTGATGGTATGCTTTGGATTGT	840
DB	781	TCTGGGTGGATTTTAACTACAACCTCTTGTCCCTCTCGGTGATGGTATGCTTTGGATTGT	840
QY	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
DB	841	TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGAGTATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCATTTCTGAAATTTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
DB	1021	CTTGCTCATTTCTGAAATTTTAAGCATTTTCTTTTAAAGACAAGTGAATAGACATCTAA	1080
QY	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAGAAATCA	1140
DB	1081	AATTCCACTCTCATAGAGCTTTTAAATGGTTTCATTTGATATAGGCTTAAGAAATCA	1140
QY	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174
DB	1141	CTATAAATGCAATAAAGTTACTCAATCTGTG	1174

RESULT 153

ADD79368

ID ADD79368 standard; cDNA; 1174 BP.

XX ADD79368;

DT 29-JAN-2004 (first entry)

XX cDNA encoding human PRO polypeptide #136.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

XX Homo sapiens.

XX US2003203428-A1.

XX 30-OCT-2003.

XX 22-APR-2002; 2002US-00127852.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-875635/81.

XX P-PSDB; ADD79369.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic

PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX

PS Claim 2; Fig 271; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CGGACGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGTGTGACAGAG	60
DB	1	CGGACGCTGGGGAAACCCCTCCGAGAAACACAGCAACAGCTGAGCTGTGTGACAGAG	60
QY	61	GGGAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
DB	61	GGGAACAAGATGGCGCGCCGAGGGAGCCTCTGGGTGAGGACCCCACTGGGGCTCCCG	120
QY	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA	180
DB	121	CCGCTGCTGCTGCTGACCATGGCCCTTGGCCGGAGGTTTGGGGACCGCTTCGGCTGAAGCA	180
QY	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240
DB	181	TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC	240
QY	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGGCATGTCAGAGAGGTTGAGGCTGTTT	300
DB	241	TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGGCATGTCAGAGAGGTTGAGGCTGTTT	300
QY	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360
DB	301	TCAATTTGTCAGTTTGTGGATGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA	360
QY	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420
DB	361	TCTGCATGTACAGAAGCATATTCCCAATCTGATGAGCAATATGCTTGCCATCTTGGTTGC	420

QY	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGACAACACTTATGTCCCTGATGCCAAA	480
DB	421	CAGAATCAGCTGCCATTGCTGAACTGAGACAAGACAACACTTATGTCCCTGATGCCAAA	480
QY	481	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGGGACTCC	540
DB	481	ATGCACCTACTCTTTCCCTCTAACTCTGGTGAGGTCAATCTGGAGTGACATGGGACTCC	540
QY	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA	600
DB	541	GCACAGAGCTTCATAACCTCTTCATGGACTTTTATCTTCAAGCCGATGACGGAATAA	600
QY	601	GTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTTGGAGCAGGACTACA	660
DB	601	GTATATTCAGTCTAAGCCAGAAATCCAGTACGACCAACACATTTGGAGCAGGACTACA	660
QY	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
DB	661	AATTTGAGAGATCATCTCTAAGCAAAATGCTCTATCTGCAAAATGAGAAATTCACAAGCG	720
QY	721	CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
DB	721	CACAGGAATTTCTTGAAGATGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAC	780
QY	781	TCTGGGTGATTTTAACTCAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
DB	781	TCTGGGTGATTTTAACTCAACTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTGT	840
QY	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT	900
DB	841	TGTGCAACTGTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAGCTGATCTAT	900
QY	901	GGTGACTTGGAGTTTATGAATGAAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
DB	901	GGTGACTTGGAGTTTATGAATGAAACAAAGCTAAACAGATATCCAGCTTCTTCTTGTG	960
QY	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
DB	961	GTTGTTAGATCTAAAACCTGAAGATCATGAAGAAGCAGGCGCTCTACCTACAAAAGTGAAT	1020
QY	1021	CTTGCTCACTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
DB	1021	CTTGCTCACTCTGAAATTTAAGCAATTTTCTTTTAAAGACAAGTGTAATAGACATCTAA	1080
QY	1081	AATCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
DB	1081	AATCCACTCTCATAGAGCTTTTAAATGGTTTCAATGGATATAGGCTTAAAGAAATCA	1140
QY	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174
DB	1141	CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG	1174

RESULT 154

ADE35417

ID ADE35417 standard; cDNA; 1174 BP.

XX

AC ADE35417;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human cDNA encoding secreted/transmembrane protein, PRO195.

XX

KW Human; ss; gene; secreted protein; transmembrane protein; PRO;

KW cytototoxic; ophthalmological; antiarthritic; osteopathic; antirheumatic;

KW vulnary; auditory; tumour growth; retinal disorder;

KW sports-related joint problem; articular cartilage defects;

KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

XX

OS Homo sapiens.

XX

PN US2003203434-A1.

XX 30-OCT-2003.

XX 18-OCT-2001; 2001US-00145088.

XX 15-MAY-1998; 98US-0085689P.

PR 08-MAR-1999; 99WO-US005028.

PR 28-APR-1999; 99US-0131445P.

PR 25-AUG-1999; 99US-00380138.

PR 18-FEB-2000; 2000WO-US004341.

PR 30-JUL-2001; 2001US-00918585.

XX (GETH) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;

XX Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;

PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;

PI Stewart TA, Tumas D, Williams PM, Wood WI;

XX WPI; 2003-875641/81.

DR P-PSDB; ADE35418.

XX

PT New genes, and its encoded secreted and transmembrane polypeptides,

PT useful for treating e.g. lung or breast tumors, osteoarthritis,

PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,

PT hypoinsulinemia or wounds.

XX

PS Claim 2; SEQ ID NO 329; 462pp; English.

XX

CC The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 94 fully defined sequences as given

CC in the specification (including PRO lacking its associated signal

CC peptide, a PRO extracellular domain with or without its associated signal

CC peptide). Also included are nucleic acids encoding the PRO proteins

CC mentioned above, a vector comprising a PRO nucleic acid), a host cell

CC comprising the vector and producing PRO, a chimaeric molecule comprising

CC PRO fused to a heterologous amino acid sequence, and an anti-PRO

CC antibody. PRO337 polypeptide is useful for detecting a PRO4993

CC polypeptide in a sample suspected of containing PRO4993 polypeptide.

CC Similarly, PRO4993 polypeptide is useful for detecting PRO337

CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting

CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a

CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive

CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule

CC causes death of the cell. PRO337 polypeptide is useful for linking a

CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,

CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule

CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is

CC useful for linking a bioactive molecule to a cell expressing PRO725,

CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337

CC polypeptide is useful for modulating at least one biological activity of

CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337

CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the

CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,

CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for

CC modulating the biological activity of the cell expressing PRO1559

CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-

CC PRO739 polypeptide is useful for modulating the biological activity of

CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The

CC polypeptides are useful for inhibiting tumour growth, retinal disorders,

CC sports-related joint problems, articular cartilage defects,

CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in

CC mammals. The present sequence encodes a PRO protein.

XX

SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60

Db 1 CGGACGCGTGGGGAACCCCTTCCGAGAAAAACAGCAACAAAGCTGAGCTGCTGTGACAGAG 60

QY 61 GGGAAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

Db 61 GGGAAACAAGATGGCGCGCCGGAAGGGAGCCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120

QY 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180

Db 121 CCGCTGCTGCTGTGACCATGGCCCTTGGCGGAGGTTTCGGGACCGCTTCGGCTGAAGCA 180

QY 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240

Db 181 TTTGACTCGGTCTTGGGTGATACGGCGCTCTTGCCACCGGGCCCTGTGAGTTGACCTACCCC 240

QY 241 TTGCACACCTACCTAACCTTAAGGAAGAGGAGTTTACGCGCATGTTCAGAGAGGTTGCAGGCTGTTT 300

Db 241 TTGCACACCTACCTAACCTTAAGGAAGAGGAGTTTACGCGCATGTTCAGAGAGGTTGCAGGCTGTTT 300

QY 301 TCAATTTGTGAGTTGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

Db 301 TCAATTTGTGAGTTGATGGAATTGACTTAAATCGAACTAAATTTGGAATGTGAA 360

QY 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTAGAGCAATATGCTTGCCATCTTGGTTGC 420

Db 361 TCTGCATGTACAGAAGCATATTTCCCAATCTGTAGAGCAATATGCTTGCCATCTTGGTTGC 420

QY 421 CAGATCAGCTGCCATTGCTGAACTGAGACAAAGAACAACTTATGTCCCTGATGCCAAA 480

Db 421 CAGATCAGCTGCCATTGCTGAACTGAGACAAAGAACAACTTATGTCCCTGATGCCAAA 480

QY 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGTTCATTTCTGGAGTGACATGATGGACTCC 540

Db 481 ATGCACCTACTCTTTTCTTAACTCTGGTGAGTTCATTTCTGGAGTGACATGATGGACTCC 540

QY 541 GCACAGAGCTTCATAACCTTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

Db 541 GCACAGAGCTTCATAACCTTTTCATGGACTTTTATCTTCAAGCCGATGACGGAAAAATA 600

QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGACCTACA 660

Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCACTTTGGAGCAGGACCTACA 660

QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720

QY 721 CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780

Db 721 CACAGGAATTTTCTTGAAGATGAGAGAAAGTGATGGCTTTTAAAGATGCCTCTCTTAAC 780

QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGTCTCTCGGTGATGGTATTGCTTTGGATTTGT 840

QY 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

Db 841 TGTGCACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900

QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960

Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTCTTGTG 960

QY 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020

Db 961 GTTGTGTAGATCTAAAACTGAAGATCATGAAGAAGCAGGGCCCTCTACCTACAAAAGTGAAT 1020

QY 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

Db 1021 CTTGCTCATTCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080

QY 1081 AATTCCACTCCTCATAGAGCTTTTAAAAATGGTTTCAATTGGATATAGGCCTTAAGAAATCA 1140

Db 1081 AATTCCACTCCTCATAGAGCTTTTAAATGCTTTTCATTGGATATAGGCCTTAAGAAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAAATCTGTG 1174

RESULT 155
ADE16531
ID ADE16531 standard; cDNA; 1174 BP.
XX
AC ADE16531;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX
KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytoskeletal; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.
XX
OS Homo sapiens.
XX
PN US2003203435-A1.
XX
PD 30-OCT-2003.
XX
PF 18-OCT-2001; 2001US-00145092.
XX
XX 30-APR-1998; 98US-0083742P.
PR 08-MAR-1999; 99WO-US005028.
PR 23-JUN-1999; 99US-0141037P.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.

XX (GETH) GENENTECH INC.
XX
XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875642/81.
DR P-PSDB; ADE16532.
XX
PT New genes, and its encoded secreted and transmembrane polypeptides,
PT useful for treating e.g. lung or breast tumors, osteoarthritis,
PT rheumatoid arthritis, obesity, diabetes, hyperinsulinemia,
PT hypoinsulinemia or wounds.

XX Claim 2; SEQ ID NO 329; 452pp; English.
PS
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive

CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.

XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;
Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGAAACCCCTCCGAGAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCGCGGAGGGAGCCCTCTGGGTGAGGACCCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGCGCTTGGCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGGCCACCGGGCTGTGAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGACAGGCTGTTT 300
Db 241 TTGCACACCTACCTAAGGAAGAGGAGTTGTACGCATGTGAGAGAGTTGACAGGCTGTTT 300
QY 301 TCAATTTGTGCTGCTGATGATGGAATTGACTTAATCAACTAAATTTGGAATGTGAA 360
Db 301 TCAATTTGTGCTGCTGATGATGGAATTGACTTAATCAACTAAATTTGGAATGTGAA 360
QY 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420
Db 361 TCTGCATGTACAGAAAGCATATTCCCAATCTGATGAGCAATATGCTTGCATCTTGGTTC 420
QY 421 CAGAATCAGCTGCCATTGCTGATGAGCAAGAAACAATTATGTCCTGATGCCAAAA 480
Db 421 CAGAATCAGCTGCCATTGCTGATGAGCAAGAAACAATTATGTCCTGATGCCAAAA 480
QY 481 ATGCACCTACTCTTCTCCTAATCTGAGGTGAGTCAATCTGAGTGACATGATGGACTCC 540
Db 481 ATGCACCTACTCTTCTCCTAATCTGAGGTGAGTCAATCTGAGTGACATGATGGACTCC 540
QY 541 GCACAGAGCTTCATAAACCTCTTTCATGGAGTCTTATCTTCAAGCCGATGACGGAAAAATA 600
Db 541 GCACAGAGCTTCATAAACCTCTTTCATGGAGTCTTATCTTCAAGCCGATGACGGAAAAATA 600
QY 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
Db 601 GTTATATTCAGTCTAAGCCAGAAATCCAGTACGCCACCAATTTGGAGCAGGAGCTTACA 660
QY 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAATGAGAAATTCACAAGCG 720

Db 661 AATTGAGAGAAATCATCTCTAAGCAAAATGTCCTATCTGCAAAATGAGAAATTCACAAGCG 720
QY 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
Db 721 CACAGGAATTTCTTGAAGATGGAGAAAGTGATGGCTTTTAAAGATGCCCTCTCTTAAAC 780
QY 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATTGCTTTGGATTGT 840
Db 781 TCTGGGTGGATTTTAACTACAACCTCTTGCTCTCGGTGATGGTATTGCTTTGGATTGT 840
QY 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
Db 841 TGTGCAACTGTTGCTACAGCTGTGGAGCAGTATGTTCCCTCTGAGAAAGCTGAGTATCTAT 900
QY 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
Db 901 GGTGACTTGGAGTTTATGAATGAACAAAAGCTAAACAGATATCCAGCTTCTTCTTGTG 960
QY 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
Db 961 GTTGTAGATCTAAACTGAAGATCATGAAGAAGCAGGGCCTCTACCTACAAAAGTGAAT 1020
QY 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
Db 1021 CTTGCTCATCTGAAATTTAAGCATTTTCTTTTAAAGACAAGTGTAAATAGACATCTAA 1080
QY 1081 AANTCCACTCCTCATAGAGCTTTTAAATAGTTTTCATTGGATATAGCCCTTAAGAATCA 1140
Db 1081 AANTCCACTCCTCATAGAGCTTTTAAATAGTTTTCATTGGATATAGCCCTTAAGAATCA 1140
QY 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174
Db 1141 CTATAAAATGCAAAATAAAGTTACTCAAATCTGTG 1174

RESULT 156
ADD73146
ID ADD73146 standard; cDNA; 1174 BP.

XX AC ADD73146;
XX DT 29-JAN-2004 (first entry)
XX DE Human cDNA encoding secreted/transmembrane protein, PRO195.
XX KW Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW cytostatic; ophthalmological; antiarthritic; osteopathic; antirheumatic;
KW vulnary; auditory; tumour growth; retinal disorder;
KW sports-related joint problem; articular cartilage defects;
KW osteoarthritis; rheumatoid arthritis; wound healing; hearing loss.

OS Homo sapiens.
XX US2003203436-A1.
XX 30-OCT-2003.
XX PF 18-OCT-2001; 2001US-00145129.
XX PR 22-MAY-1998; 98US-0086414P.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-APR-1999; 99US-00284291.
PR 25-AUG-1999; 99US-00380138.
PR 18-FEB-2000; 2000WO-US004341.
PR 30-JUL-2001; 2001US-00918585.

XX (GETH) GENENTECH INC.
PA Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
XX Ferrara N, Filvarcoff E, Fong S, Gao W, Gerber H, Gerritsen ME;
PI Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI

PI Kljavin IJ, Kuo SS, Napier MA, Pan J, Paoni NF, Roy MA, Shelton DL;
PI Stewart TA, Tumas D, Williams PM, Wood WI;
XX WPI; 2003-875643/81.
DR P-PSDB; ADD73147.
XX New PRO genes and encoded secreted and transmembrane polypeptides, useful
PT for treating e.g. lung or breast tumors, osteoarthritis, rheumatoid
PT arthritis, obesity, diabetes, hyperinsulinemia, hypoinsulinemia or
PT wounds.
XX Claim 2; SEQ ID NO 329; 453pp; English.
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 94 fully defined sequences as given
CC in the specification (including PRO lacking its associated signal
CC peptide, a PRO extracellular domain with or without its associated signal
CC peptide). Also included are nucleic acids encoding the PRO proteins
CC mentioned above, a vector comprising a PRO nucleic acid, a host cell
CC comprising the vector and producing PRO, a chimaeric molecule comprising
CC PRO fused to a heterologous amino acid sequence, and an anti-PRO
CC antibody. PRO337 polypeptide is useful for detecting a PRO4993
CC polypeptide in a sample suspected of containing PRO4993 polypeptide.
CC Similarly, PRO4993 polypeptide is useful for detecting PRO337
CC polypeptide. PRO725, PRO700 or PRO739 polypeptide is useful for detecting
CC PRO1559 polypeptide, and PRO1559 polypeptide is useful for detecting a
CC PRO725, PRO700 or PRO739. PRO4993 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO337 polypeptide. The bioactive
CC molecule is the toxin, radiolabel, or an antibody. The bioactive molecule
CC causes death of the cell. PRO337 polypeptide is useful for linking a
CC bioactive molecule to a cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide are useful for linking a bioactive molecule
CC to a cell expressing PRO1559 polypeptide; and PRO1559 polypeptide is
CC useful for linking a bioactive molecule to a cell expressing PRO725,
CC PRO700 or PRO739 polypeptide. PRO4993 polypeptide or anti-PRO337
CC polypeptide is useful for modulating at least one biological activity of
CC the cell expressing PRO337 polypeptide, where the cell is killed. PRO337
CC polypeptide or anti-PRO4993 polypeptide is useful for modulating the
CC biological activity of the cell expressing PRO4993 polypeptide; PRO725,
CC PRO700 or PRO739 polypeptide or an anti-PRO1559 polypeptide is useful for
CC modulating the biological activity of the cell expressing PRO1559
CC polypeptide; and PRO1559 polypeptide or anti-PRO725, anti-PRO700 or anti-
CC PRO739 polypeptide is useful for modulating the biological activity of
CC the cell expressing PRO725, PRO700 or PRO739 polypeptide. The
CC polypeptides are useful for inhibiting tumour growth, retinal disorders,
CC sports-related joint problems, articular cartilage defects,
CC osteoarthritis or rheumatoid arthritis, wound healing and hearing loss in
CC mammals. The present sequence encodes a PRO protein.
XX
SQ Sequence 1174 BP; 325 A; 250 C; 275 G; 324 T; 0 U; 0 Other;

Query Match 100.0%; Score 1174; DB 9; Length 1174;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1174; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
Db 1 CGGACGCGTGGGGGAAACCCCTTCGAGAAAACAGCAACAAGCTGAGCTGCTGTGACAGAG 60
QY 61 GGGAAACAAGATGGCGCGCCGAGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
Db 61 GGGAAACAAGATGGCGCGCCGAGAGGGAGCCTCTGGGTGAGGACCCAACTGGGGCTCCCG 120
QY 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
Db 121 CCGCTGCTGCTGCTGACCATGGCCTTGGCCGGAGGTTCCGGGACCGCTTCGGCTGAAGCA 180
QY 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
Db 181 TTTGACTCGGTCTTGGGTGATACGGCGTCTTGCCACCGGGCCTGTCAAGTTGACCTACCCC 240
QY 241 TTGCACACCTACCCCTAAGGAAGAGGAGTTGTACGCATGTACAGAGAGGTTGCAGGCTGTTT 300

